{"items": "712", "sentiment_score_definition": "x <= -0.35: Bearish; -0.35 < x <= -0.15: Somewhat-Bearish; -0.15 < x < 0.15: Neutral; 0.15 <= x < 0.35: Somewhat_Bullish; x >= 0.35: Bullish", "relevance_score_definition": "0 < x <= 1, with a higher score indicating higher relevance.", "feed": [{"title": "Behind the Scenes of Moderna's Latest Options Trends - Moderna  ( NASDAQ:MRNA ) ", "url": "https://www.benzinga.com/insights/options/24/01/36683205/behind-the-scenes-of-modernas-latest-options-trends", "time_published": "20240118T180308", "authors": ["Benzinga Insights"], "summary": "Whales with a lot of money to spend have taken a noticeably bearish stance on Moderna. Looking at options history for Moderna MRNA we detected 8 trades. If we consider the specifics of each trade, it is accurate to state that 37% of the investors opened trades with bullish expectations and 62% ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}, {"topic": "Earnings", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.16895, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.688777", "ticker_sentiment_score": "0.239933", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Alphabet, Electronic Arts And 2 Other Stocks Insiders Are Selling - Electronic Arts  ( NASDAQ:EA ) , Automatic Data Processing  ( NASDAQ:ADP ) ", "url": "https://www.benzinga.com/news/24/01/36675664/alphabet-electronic-arts-and-2-other-stocks-insiders-are-selling", "time_published": "20240118T124021", "authors": ["Avi Kapoor"], "summary": "The Nasdaq 100 closed lower by over 90 points on Wednesday. Investors, meanwhile, focused on some notable insider trades. When insiders sell shares, it could be a preplanned sale, or could indicate their concern in the company's prospects or that they view the stock as being overpriced.", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/01/18/alphabet_-_logo.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.104081, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.391311", "ticker_sentiment_score": "0.005376", "ticker_sentiment_label": "Neutral"}, {"ticker": "EA", "relevance_score": "0.391311", "ticker_sentiment_score": "0.197828", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.391311", "ticker_sentiment_score": "0.169491", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ADP", "relevance_score": "0.391311", "ticker_sentiment_score": "0.209148", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JPM", "relevance_score": "0.081552", "ticker_sentiment_score": "0.095806", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Things That Could Help 2023 Loser-Stock Moderna Roar Higher in 2024", "url": "https://www.fool.com/investing/2024/01/18/3-things-that-could-help-2023-loser-stock-moderna/", "time_published": "20240118T100000", "authors": ["Adria Cimino"], "summary": "Moderna may be heading for a new era of growth.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F761439%2Fgettyimages-876388422.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.905476"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.955357"}], "overall_sentiment_score": 0.108911, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.669232", "ticker_sentiment_score": "0.309141", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.059636", "ticker_sentiment_score": "0.13532", "ticker_sentiment_label": "Neutral"}]}, {"title": "Zacks Industry Outlook Highlights Shopify, Upwork and Uber", "url": "https://www.zacks.com/stock/news/2211835/zacks-industry-outlook-highlights-shopify-upwork-and-uber", "time_published": "20240118T092600", "authors": ["Zacks Investment Research"], "summary": "Shopify, Upwork and Uber have been highlighted in this Industry Outlook article.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/58/1179.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.682689"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.962106"}, {"topic": "Earnings", "relevance_score": "0.999998"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.185504, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SHOP", "relevance_score": "0.151539", "ticker_sentiment_score": "0.086596", "ticker_sentiment_label": "Neutral"}, {"ticker": "ETSY", "relevance_score": "0.021778", "ticker_sentiment_score": "0.005333", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIDU", "relevance_score": "0.021778", "ticker_sentiment_score": "0.005333", "ticker_sentiment_label": "Neutral"}, {"ticker": "TRVG", "relevance_score": "0.021778", "ticker_sentiment_score": "0.005333", "ticker_sentiment_label": "Neutral"}, {"ticker": "UPWK", "relevance_score": "0.1301", "ticker_sentiment_score": "0.177563", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DBX", "relevance_score": "0.043539", "ticker_sentiment_score": "0.155022", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.021778", "ticker_sentiment_score": "0.224931", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "UBER", "relevance_score": "0.151539", "ticker_sentiment_score": "0.051105", "ticker_sentiment_label": "Neutral"}]}, {"title": "Genetic sequence of coronavirus was submitted to US database two weeks before China's official disclosure, documents show", "url": "https://www.cnn.com/2024/01/17/health/coronavirus-sequence-database/index.html", "time_published": "20240118T020125", "authors": ["Katherine Dillinger"], "summary": "The genetic sequence of SARS-CoV-2, the virus that causes Covid-19, was submitted to a National Institutes of Health database two weeks before its release by the Chinese government, according to documents that were shared with US lawmakers and released Wednesday.", "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/231002105813-01-nobel-prize-100223-medicine.jpg?c=16x9&q=h_144,w_256,c_fill", "source": "CNN", "category_within_source": "Economy", "source_domain": "www.cnn.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.002401, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.044634", "ticker_sentiment_score": "0.041055", "ticker_sentiment_label": "Neutral"}, {"ticker": "WBD", "relevance_score": "0.089129", "ticker_sentiment_score": "-0.155514", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Genetic sequence of coronavirus was submitted to US database two weeks before China's official disclosure, documents show", "url": "https://us.cnn.com/2024/01/17/health/coronavirus-sequence-database", "time_published": "20240118T020100", "authors": ["Katherine Dillinger"], "summary": "Genetic sequence of coronavirus was submitted to US database two weeks before China's official disclosure ... ...", "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/231002105813-01-nobel-prize-100223-medicine.jpg?c=16x9&q=h_144,w_256,c_fill", "source": "CNN", "category_within_source": "Economy", "source_domain": "us.cnn.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.002401, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.044634", "ticker_sentiment_score": "0.041055", "ticker_sentiment_label": "Neutral"}, {"ticker": "WBD", "relevance_score": "0.089129", "ticker_sentiment_score": "-0.155514", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Moderna  ( MRNA )  Falls More Steeply Than Broader Market: What Investors Need to Know", "url": "https://www.zacks.com/stock/news/2211749/moderna-mrna-falls-more-steeply-than-broader-market-what-investors-need-to-know", "time_published": "20240117T225017", "authors": ["Zacks Equity Research"], "summary": "Moderna (MRNA) closed at $100.35 in the latest trading session, marking a -1.77% move from the prior day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default133.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.684621"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.206506, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.510588", "ticker_sentiment_score": "0.243111", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "3 Picks from the Attractive Internet Services Industry", "url": "https://www.zacks.com/commentary/2211328/3-picks-from-the-attractive-internet-services-industry", "time_published": "20240117T210700", "authors": ["Sejuti Banerjea"], "summary": "Steadying interest rates and a stronger-than-expected economy are contributing to positive sentiments regarding the very broad-based Internet - Services industry. Valuation improvements are creating opportunities.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/charts/d2/59594.jpg?v=1668670507", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.682689"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.980922"}, {"topic": "Earnings", "relevance_score": "0.999999"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.187713, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SHOP", "relevance_score": "0.173177", "ticker_sentiment_score": "0.116248", "ticker_sentiment_label": "Neutral"}, {"ticker": "ETSY", "relevance_score": "0.021817", "ticker_sentiment_score": "-0.032243", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIDU", "relevance_score": "0.021817", "ticker_sentiment_score": "-0.032243", "ticker_sentiment_label": "Neutral"}, {"ticker": "TRVG", "relevance_score": "0.021817", "ticker_sentiment_score": "-0.032243", "ticker_sentiment_label": "Neutral"}, {"ticker": "UPWK", "relevance_score": "0.151812", "ticker_sentiment_score": "0.216888", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DBX", "relevance_score": "0.043618", "ticker_sentiment_score": "0.093866", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.021817", "ticker_sentiment_score": "0.1813", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "UBER", "relevance_score": "0.173177", "ticker_sentiment_score": "0.094193", "ticker_sentiment_label": "Neutral"}]}, {"title": "Peering Into Moderna's Recent Short Interest - Moderna  ( NASDAQ:MRNA ) ", "url": "https://www.benzinga.com/short-sellers/24/01/36665986/peering-into-modernas-recent-short-interest", "time_published": "20240117T190024", "authors": ["Benzinga Insights"], "summary": "Moderna's MRNA short percent of float has risen 10.47% since its last report. The company recently reported that it has 24.19 million shares sold short, which is 8.44% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.7 days to cover their ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.26961, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.224903", "ticker_sentiment_score": "0.158881", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "3 Struggling Businesses Investors Shouldn't Gamble on This Year", "url": "https://www.fool.com/investing/2024/01/17/3-struggling-businesses-investors-shouldnt-gamble/", "time_published": "20240117T151500", "authors": ["David Jagielski"], "summary": "These stocks all crashed heavily in 2023, and there is no reason to expect things will get a whole lot better this year.", "banner_image": "https://g.foolcdn.com/editorial/images/761245/business-people-looking-at-a-tablet.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.999186"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.161647"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.0, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.310843", "ticker_sentiment_score": "-0.032871", "ticker_sentiment_label": "Neutral"}, {"ticker": "LUMN", "relevance_score": "0.158519", "ticker_sentiment_score": "-0.1385", "ticker_sentiment_label": "Neutral"}, {"ticker": "PLUG", "relevance_score": "0.310843", "ticker_sentiment_score": "0.284132", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Jim Cramer Says Hold Onto This Biotech Stock: 'I Don't Understand Why It's So Inexpensive' - Becton Dickinson  ( NYSE:BDX ) , Amphastar Pharma  ( NASDAQ:AMPH ) ", "url": "https://www.benzinga.com/trading-ideas/long-ideas/24/01/36653800/jim-cramer-says-hold-onto-this-biotech-stock-i-dont-understand-why-its-so-inexpensive", "time_published": "20240117T132244", "authors": ["Avi Kapoor"], "summary": "On CNBC's \"Mad Money Lightning Round,\" Jim Cramer said he would back Moderna, Inc. MRNA here. \"I think that Stephane Bancel is the real deal,\" he added. Cramer recommended holding onto BioNTech SE BNTX. \"I don't understand why it's so inexpensive,\" he noted. When asked about Amphastar ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/01/17/jim_cramer_chart_shutter.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Real Estate & Construction", "relevance_score": "0.25"}], "overall_sentiment_score": 0.002425, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LMT", "relevance_score": "0.454174", "ticker_sentiment_score": "-0.210132", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PAAS", "relevance_score": "0.454174", "ticker_sentiment_score": "-0.152171", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "BDX", "relevance_score": "0.454174", "ticker_sentiment_score": "-0.130012", "ticker_sentiment_label": "Neutral"}, {"ticker": "STWD", "relevance_score": "0.454174", "ticker_sentiment_score": "-0.113612", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMPH", "relevance_score": "0.454174", "ticker_sentiment_score": "-0.130012", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.454174", "ticker_sentiment_score": "-0.257643", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "BNTX", "relevance_score": "0.454174", "ticker_sentiment_score": "-0.046966", "ticker_sentiment_label": "Neutral"}]}, {"title": "The Best Stock to Invest $1,000 in Right Now", "url": "https://www.fool.com/investing/2024/01/17/the-best-stock-to-invest-1000-in-right-now/", "time_published": "20240117T105000", "authors": ["Keith Speights"], "summary": "This stock has what it takes to be a big winner.", "banner_image": "https://g.foolcdn.com/editorial/images/761362/happy-stock-investor-holding-smartphone.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.99676"}, {"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.20789, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GS", "relevance_score": "0.060694", "ticker_sentiment_score": "0.103004", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.060694", "ticker_sentiment_score": "0.15826", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.121037", "ticker_sentiment_score": "0.238791", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Stock market today: US futures slide amid rate jitters, China gloom", "url": "https://markets.businessinsider.com/news/stocks/stock-market-today-us-futures-slide-amid-rate-jitters-china-gloom-2024-1", "time_published": "20240117T102800", "authors": ["Anil Varma"], "summary": "\u2022 US stock futures declined Wednesday, taking a cue from sharp declines in Asian and European equities. \u2022 Investor sentiment remained weak after the latest economic reports from China failed to cheer the market. \u2022 The dollar held near a one-month high as bets for imminent rate cuts by the ...", "banner_image": null, "source": "Business Insider", "category_within_source": "GoogleRSS", "source_domain": "markets.businessinsider.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.918141"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}], "overall_sentiment_score": -0.189053, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.126784", "ticker_sentiment_score": "-0.07122", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMCR", "relevance_score": "0.126784", "ticker_sentiment_score": "-0.07122", "ticker_sentiment_label": "Neutral"}, {"ticker": "ENPH", "relevance_score": "0.126784", "ticker_sentiment_score": "-0.07122", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:EUR", "relevance_score": "0.126784", "ticker_sentiment_score": "-0.07122", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:USD", "relevance_score": "0.367865", "ticker_sentiment_score": "-0.171031", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.126784", "ticker_sentiment_score": "-0.07122", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:ETH", "relevance_score": "0.126784", "ticker_sentiment_score": "-0.07122", "ticker_sentiment_label": "Neutral"}]}, {"title": "Class Action Settlements Enter 'Era Of Heightened Risks And Higher Stakes'", "url": "https://www.forbes.com/sites/cfo/2024/01/16/class-action-settlements-enter-era-of-heightened-risks-and-higher-stakes/", "time_published": "20240116T191537", "authors": ["Megan Poinski"], "summary": "This is the published version of Forbes' CFO newsletter, which offers the latest news for chief finance officers and other leaders focused on the budget. Sign up here to get it delivered to your inbox every Tuesday.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65a6bbe39008cad5671cb833/0x0.jpg?format=jpg&crop=3594,2022,x0,y185,safe&height=900&width=1600&fit=bounds", "source": "Forbes", "category_within_source": "n/a", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}, {"topic": "Blockchain", "relevance_score": "0.769861"}, {"topic": "Economy - Monetary", "relevance_score": "0.769861"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.998333"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.875462"}], "overall_sentiment_score": 0.072568, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MASI", "relevance_score": "0.091977", "ticker_sentiment_score": "0.044684", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.091977", "ticker_sentiment_score": "0.054784", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.03072", "ticker_sentiment_score": "0.047138", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNH", "relevance_score": "0.03072", "ticker_sentiment_score": "0.049455", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.03072", "ticker_sentiment_score": "0.058027", "ticker_sentiment_label": "Neutral"}]}, {"title": "Merck  ( MRK )  Keytruda Ok'd by FDA for Expanded Cervical Cancer Use", "url": "https://www.zacks.com/stock/news/2210152/merck-mrk-keytruda-okd-by-fda-for-expanded-cervical-cancer-use", "time_published": "20240115T143000", "authors": ["Zacks Equity Research"], "summary": "FDA approves Merck's (MRK) Keytruda plus chemoradiotherapy (CRT) for patients with FIGO 2014 Stage III-IVA cervical cancer based on data from the phase KEYNOTE-A18 study.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/08/595.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.838487"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.116433, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "FUSN", "relevance_score": "0.316439", "ticker_sentiment_score": "0.023179", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.064973", "ticker_sentiment_score": "0.009134", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.129516", "ticker_sentiment_score": "0.052545", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.193207", "ticker_sentiment_score": "0.045776", "ticker_sentiment_label": "Neutral"}]}, {"title": "Salon CES 2024 : la plateforme mondiale qui d\u00e9finit notre avenir", "url": "https://www.prnewswire.com/news-releases/salon-ces-2024--la-plateforme-mondiale-qui-definit-notre-avenir-302034370.html", "time_published": "20240115T045500", "authors": ["Consumer Technology Association"], "summary": "LAS VEGAS, 15 janvier 2024 /PRNewswire/ -- Le salon CES\u00ae 2024 s'est achev\u00e9 aujourd'hui, apr\u00e8s une semaine exaltante qui a d\u00e9fini le parcours technologique pour l'ann\u00e9e \u00e0 venir.", "banner_image": "https://mma.prnewswire.com/media/2212991/CES_CTA_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.006951, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SNEJF", "relevance_score": "0.017928", "ticker_sentiment_score": "0.006167", "ticker_sentiment_label": "Neutral"}, {"ticker": "PCAR", "relevance_score": "0.017928", "ticker_sentiment_score": "0.006167", "ticker_sentiment_label": "Neutral"}, {"ticker": "DASTF", "relevance_score": "0.017928", "ticker_sentiment_score": "-0.027073", "ticker_sentiment_label": "Neutral"}, {"ticker": "BBY", "relevance_score": "0.017928", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PCRFF", "relevance_score": "0.017928", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "RMD", "relevance_score": "0.017928", "ticker_sentiment_score": "-0.027073", "ticker_sentiment_label": "Neutral"}, {"ticker": "MCLE", "relevance_score": "0.017928", "ticker_sentiment_score": "-0.027073", "ticker_sentiment_label": "Neutral"}, {"ticker": "LRLCF", "relevance_score": "0.017928", "ticker_sentiment_score": "0.019388", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.017928", "ticker_sentiment_score": "-0.027073", "ticker_sentiment_label": "Neutral"}]}, {"title": "S Hotel Jamaica nombrado Mejor Resort Caribe\u00f1o Todo Incluido en los 10Best Readers' Choice Travel Awards", "url": "https://www.prnewswire.com/news-releases/s-hotel-jamaica-nombrado-mejor-resort-caribeno-todo-incluido-en-los-10best-readers-choice-travel-awards-302034111.html", "time_published": "20240113T221400", "authors": ["S Hotel Jamaica"], "summary": "MONTEGO BAY, Jamaica, 13 de enero de 2024 /PRNewswire/ -- Jamaica recibi\u00f3 hoy un importante galard\u00f3n internacional cuando S Hotel en Montego Bay obtuvo el codiciado t\u00edtulo de Mejor Resort Caribe\u00f1o Todo Incluido en los 10Best Readers' Choice Awards de USA Today de 2024.", "banner_image": "https://mma.prnewswire.com/media/2317832/S_Hotel_Jamaica_2019_S_Hotel_Main_Pool.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.009361, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.051886", "ticker_sentiment_score": "-0.040877", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Red Flags That Could Sink Pfizer in 2024", "url": "https://www.fool.com/investing/2024/01/13/2-red-flags-that-could-sink-pfizer-in-2024/", "time_published": "20240113T100500", "authors": ["Adria Cimino"], "summary": "Pfizer shares dropped more than 40% last year.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F760968%2Fgettyimages-1276837766.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Earnings", "relevance_score": "0.998682"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.062998, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.050148", "ticker_sentiment_score": "-0.146231", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.050148", "ticker_sentiment_score": "-0.133893", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.767901", "ticker_sentiment_score": "0.068293", "ticker_sentiment_label": "Neutral"}]}, {"title": "CES 2024: The Global Platform Defining Our Future", "url": "https://www.prnewswire.com/in/news-releases/ces-2024-the-global-platform-defining-our-future-864500861.html", "time_published": "20240113T005400", "authors": ["Consumer Technology Association"], "summary": "Tech Execs and Global Leaders Choose CES for AI, Accessibility, Digital Health and Mobility LAS VEGAS, Jan. 13, 2024 /PRNewswire/ -- CES\u00ae 2024 closes today, after an exhilarating week that set the technology narrative for the year ahead.", "banner_image": "https://mma.prnewswire.com/media/2212991/CES_CTA_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.322765, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SNEJF", "relevance_score": "0.025139", "ticker_sentiment_score": "0.106072", "ticker_sentiment_label": "Neutral"}, {"ticker": "PCAR", "relevance_score": "0.025139", "ticker_sentiment_score": "0.106072", "ticker_sentiment_label": "Neutral"}, {"ticker": "DASTF", "relevance_score": "0.025139", "ticker_sentiment_score": "0.122363", "ticker_sentiment_label": "Neutral"}, {"ticker": "QCOM", "relevance_score": "0.025139", "ticker_sentiment_score": "0.085264", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESLOF", "relevance_score": "0.025139", "ticker_sentiment_score": "0.122363", "ticker_sentiment_label": "Neutral"}, {"ticker": "BBY", "relevance_score": "0.025139", "ticker_sentiment_score": "0.085264", "ticker_sentiment_label": "Neutral"}, {"ticker": "PCRFF", "relevance_score": "0.025139", "ticker_sentiment_score": "0.027687", "ticker_sentiment_label": "Neutral"}, {"ticker": "RMD", "relevance_score": "0.025139", "ticker_sentiment_score": "0.122363", "ticker_sentiment_label": "Neutral"}, {"ticker": "LRLCF", "relevance_score": "0.050254", "ticker_sentiment_score": "0.255437", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.025139", "ticker_sentiment_score": "0.122363", "ticker_sentiment_label": "Neutral"}, {"ticker": "ELV", "relevance_score": "0.025139", "ticker_sentiment_score": "0.085264", "ticker_sentiment_label": "Neutral"}, {"ticker": "WMT", "relevance_score": "0.050254", "ticker_sentiment_score": "0.078381", "ticker_sentiment_label": "Neutral"}]}, {"title": "Kia Europe renueva el patrocinio exclusivo del Campeonato League of Legends EMEA - PR Newswire", "url": "https://www.prnewswire.com/news-releases/kia-europe-renueva-el-patrocinio-exclusivo-del-campeonato-league-of-legends-emea-302033678.html", "time_published": "20240112T145700", "authors": [], "summary": "Kia Europe renueva el patrocinio exclusivo del Campeonato League of Legends EMEA PR ...", "banner_image": null, "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Real Estate & Construction", "relevance_score": "0.5"}, {"topic": "Life Sciences", "relevance_score": "0.5"}], "overall_sentiment_score": -0.204072, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.035608", "ticker_sentiment_score": "-0.014624", "ticker_sentiment_label": "Neutral"}, {"ticker": "VTR", "relevance_score": "0.035608", "ticker_sentiment_score": "-0.092601", "ticker_sentiment_label": "Neutral"}, {"ticker": "KIMTF", "relevance_score": "0.035608", "ticker_sentiment_score": "-0.092601", "ticker_sentiment_label": "Neutral"}]}, {"title": "How to Find Strong Medical Stocks Slated for Positive Earnings Surprises", "url": "https://www.zacks.com/stock/news/2209409/how-to-find-strong-medical-stocks-slated-for-positive-earnings-surprises", "time_published": "20240112T135005", "authors": ["Zacks Equity Research"], "summary": "The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default44.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999937"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.353285, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.341857", "ticker_sentiment_score": "0.304664", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.404563", "ticker_sentiment_score": "0.342224", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Conference - CytomX Therapeutics  ( NASDAQ:CTMX ) ", "url": "https://www.benzinga.com/pressreleases/24/01/g36609305/cytomx-therapeutics-to-present-at-the-b-riley-securities-virtual-annual-oncology-conference", "time_published": "20240112T130000", "authors": ["Globe Newswire"], "summary": "SOUTH SAN FRANCISCO, Calif., Jan. 12, 2024 ( GLOBE NEWSWIRE ) -- CytomX Therapeutics, Inc. CTMX, a leader in the field of conditionally activated, localized biologics, today announced that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will participate in a fireside ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}], "overall_sentiment_score": 0.038723, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.095138", "ticker_sentiment_score": "0.022799", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.188928", "ticker_sentiment_score": "0.033129", "ticker_sentiment_label": "Neutral"}, {"ticker": "CTMX", "relevance_score": "0.28008", "ticker_sentiment_score": "0.032022", "ticker_sentiment_label": "Neutral"}]}, {"title": "CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Conference", "url": "https://www.globenewswire.com/news-release/2024/01/12/2808578/37704/en/CytomX-Therapeutics-to-Present-at-the-B-Riley-Securities-Virtual-Annual-Oncology-Conference.html", "time_published": "20240112T130000", "authors": ["CytomX Therapeutics Inc."], "summary": "SOUTH SAN FRANCISCO, Calif., Jan. 12, 2024 ( GLOBE NEWSWIRE ) -- CytomX Therapeutics, Inc. ( Nasdaq: CTMX ) , a leader in the field of conditionally activated, localized biologics, today announced that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will participate in ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/c252869d-a4c1-4e56-88e8-d80b85d20c35", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.055859, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.105604", "ticker_sentiment_score": "0.024792", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.209365", "ticker_sentiment_score": "0.037617", "ticker_sentiment_label": "Neutral"}, {"ticker": "CTMX", "relevance_score": "0.209365", "ticker_sentiment_score": "-0.014718", "ticker_sentiment_label": "Neutral"}]}, {"title": "Human trial for deadly Nipah virus vaccine begins at Oxford; Here's what you need to know", "url": "https://www.financialexpress.com/healthcare/news-healthcare/human-trial-for-deadly-nipah-virus-vaccine-begins-at-oxford-heres-what-you-need-to-know/3362833/", "time_published": "20240112T071022", "authors": ["Sushmita Panda"], "summary": "Human trial for deadly Nipah virus vaccine begins at Oxford. Here's what you need to know The Financial Express ...", "banner_image": "https://www.financialexpress.com/wp-content/uploads/2024/01/ch1159595.jpg", "source": "The Financial Express", "category_within_source": "n/a", "source_domain": "www.financialexpress.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.198526, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.063763", "ticker_sentiment_score": "-0.16721", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "AZN", "relevance_score": "0.127119", "ticker_sentiment_score": "-0.096747", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biotech Stock Roundup: REGN Down on Eylea Update, MRNA Gains on Preliminary Results", "url": "https://www.zacks.com/stock/news/2208960/biotech-stock-roundup-regn-down-on-eylea-update-mrna-gains-on-preliminary-results", "time_published": "20240111T152800", "authors": ["Zacks Equity Research"], "summary": "Preliminary Q4 and 2023 results from Regeneron (REGN) and Moderna (MRNA) were key highlights this week in the biotech sector.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ab/2180.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.989041"}], "overall_sentiment_score": 0.156779, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "EXEL", "relevance_score": "0.220475", "ticker_sentiment_score": "0.057037", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.220475", "ticker_sentiment_score": "0.132471", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.074345", "ticker_sentiment_score": "-0.034075", "ticker_sentiment_label": "Neutral"}, {"ticker": "SRPT", "relevance_score": "0.111315", "ticker_sentiment_score": "0.148748", "ticker_sentiment_label": "Neutral"}]}, {"title": "Oxford University Kicks off Human Study for AstraZeneca's COVID-19 Vaccine Technology in Nipah Virus Defense - AstraZeneca  ( NASDAQ:AZN ) ", "url": "https://www.benzinga.com/general/biotech/24/01/36594595/oxford-university-kicks-off-human-study-for-astrazenecas-covid-19-vaccine-technology-in-nipah-vir", "time_published": "20240111T143318", "authors": ["Vandana Singh"], "summary": "Oxford Vaccine Group, part of the University's Pandemic Sciences Institute, has commenced the first-in-human trial of the ChAdOx1 NipahB vaccine, targeting the deadly Nipah virus. The trial involves 51 participants aged 18 to 55.", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Photo-by-Paul-McManus-from-Pixabay.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": -0.346627, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.247838", "ticker_sentiment_score": "-0.096253", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.364275", "ticker_sentiment_score": "0.153943", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Can satellite cities help solve Africa's urbanisation challenges?", "url": "https://www.economist.com/middle-east-and-africa/2024/01/11/can-satellite-cities-help-solve-africas-urbanisation-challenges", "time_published": "20240111T135726", "authors": ["The Economist"], "summary": "F but the well-off, living in an African city can be dispiriting. Home is often a cramped shack in a fetid slum. Getting to work, if there is any, means navigating rutted streets and manic traffic. Unlit alleys give cover to ne'er-do-wells, making the trudge home even more hazardous.", "banner_image": "https://www.economist.com/cdn-cgi/image/width=1424,quality=80,format=auto/content-assets/images/20240113_MAP005.jpg", "source": "The Economist", "category_within_source": "BusinessGoogleRSS", "source_domain": "www.economist.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.089371, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.025272", "ticker_sentiment_score": "0.090921", "ticker_sentiment_label": "Neutral"}, {"ticker": "UONE", "relevance_score": "0.025272", "ticker_sentiment_score": "-0.079844", "ticker_sentiment_label": "Neutral"}, {"ticker": "SZIHF", "relevance_score": "0.050519", "ticker_sentiment_score": "0.055061", "ticker_sentiment_label": "Neutral"}]}, {"title": "60% Of This Year's Top Stocks Are In This Sector  ( It's Not Tech ) ", "url": "https://www.investors.com/etfs-and-funds/etfs/sp500-this-years-top-stocks-are-in-this-sector-not-tech/", "time_published": "20240111T130000", "authors": ["Investor's Business Daily", "MATT KRANTZ"], "summary": "Just when it looked like technology stocks took over the S&P 500 - another sector is on the rise. Health care stocks, like Viatris ( VTRS ) , Catalent ( CTLT ) and Moderna ( MRNA ) , are dominating the ranks of top-performing stocks this year so far, says an Investor's Business Daily analysis of ...", "banner_image": "https://www.investors.com/wp-content/uploads/2022/11/Stock-doctormoney-01-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.99246"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.242038, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JNPR", "relevance_score": "0.123209", "ticker_sentiment_score": "0.074964", "ticker_sentiment_label": "Neutral"}, {"ticker": "CTLT", "relevance_score": "0.123209", "ticker_sentiment_score": "0.192664", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VTRS", "relevance_score": "0.243498", "ticker_sentiment_score": "0.201769", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LLY", "relevance_score": "0.183895", "ticker_sentiment_score": "0.180302", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SPGI", "relevance_score": "0.06179", "ticker_sentiment_score": "0.164515", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.183895", "ticker_sentiment_score": "0.111881", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNH", "relevance_score": "0.123209", "ticker_sentiment_score": "0.141481", "ticker_sentiment_label": "Neutral"}]}, {"title": "The Best Places to Invest $100,000 in 2024", "url": "https://www.fool.com/investing/2024/01/11/the-best-places-to-invest-100000-in-2024/", "time_published": "20240111T104500", "authors": ["Adria Cimino"], "summary": "Right now looks like a great time to invest in growth stocks.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F760828%2Fgettyimages-man-smiles-on-phone-at-computer.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.999922"}, {"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.399311, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "CHWY", "relevance_score": "0.131164", "ticker_sentiment_score": "0.255516", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AAPL", "relevance_score": "0.087663", "ticker_sentiment_score": "0.245485", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TDOC", "relevance_score": "0.043898", "ticker_sentiment_score": "0.134285", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.131164", "ticker_sentiment_score": "0.255516", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DNA", "relevance_score": "0.043898", "ticker_sentiment_score": "0.134285", "ticker_sentiment_label": "Neutral"}]}, {"title": "Moderna  ( MRNA )  Stock Drops Despite Market Gains: Important Facts to Note", "url": "https://www.zacks.com/stock/news/2208530/moderna-mrna-stock-drops-despite-market-gains-important-facts-to-note", "time_published": "20240110T225017", "authors": ["Zacks Equity Research"], "summary": "The latest trading day saw Moderna (MRNA) settling at $109.46, representing a -0.65% change from its previous close.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default165.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.650727"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.193806, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.655824", "ticker_sentiment_score": "0.283307", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Smart Money Is Betting Big In MRNA Options - Moderna  ( NASDAQ:MRNA ) ", "url": "https://www.benzinga.com/markets/options/24/01/36580514/smart-money-is-betting-big-in-mrna-options", "time_published": "20240110T171602", "authors": ["Benzinga Insights"], "summary": "Whales with a lot of money to spend have taken a noticeably bearish stance on Moderna. Looking at options history for Moderna MRNA we detected 12 trades. If we consider the specifics of each trade, it is accurate to state that 8% of the investors opened trades with bullish expectations and 91% ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.980922"}, {"topic": "Earnings", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.149599, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.798255", "ticker_sentiment_score": "0.226989", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Elis announces the signing of an agreement for the acquisition of Moderna Holding BV in the Netherlands", "url": "https://www.globenewswire.com/news-release/2024/01/10/2806796/0/en/Elis-announces-the-signing-of-an-agreement-for-the-acquisition-of-Moderna-Holding-BV-in-the-Netherlands.html", "time_published": "20240110T060000", "authors": ["Elis"], "summary": "Elis announces the signing of an agreement for the acquisition of Moderna Holding BV in the Netherlands Saint-Cloud, 10 January 2024 - Elis, the global leader in circular services at work, today announces the signing of an agreement to acquire 100% of Moderna Holding BV ( \u00ab Moderna \u00bb ) in the ...", "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/02f69c9d-981a-47be-82df-2302782ee4ff", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.35969, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.781591", "ticker_sentiment_score": "0.571749", "ticker_sentiment_label": "Bullish"}]}, {"title": "PRISM MarketView Honors National Biotechnology Month with a Spotlight on Emerging Biotech Innovators", "url": "https://www.benzinga.com/pressreleases/24/01/g36564507/prism-marketview-honors-national-biotechnology-month-with-a-spotlight-on-emerging-biotech-innovato", "time_published": "20240109T200203", "authors": ["Globe Newswire"], "summary": "NEW YORK, Jan. 09, 2024 ( GLOBE NEWSWIRE ) -- In celebration of National Biotechnology Month, PRISM MarketView acknowledges the significant advancements in biotechnology since its establishment by President Clinton in 2000.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.236641, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.064623", "ticker_sentiment_score": "0.059348", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.064623", "ticker_sentiment_score": "0.059348", "ticker_sentiment_label": "Neutral"}]}, {"title": "2024 Marks a New Era Of Pharmaceutical Innovation - Moderna  ( NASDAQ:MRNA ) ", "url": "https://www.benzinga.com/markets/penny-stocks/24/01/36563119/2024-marks-a-new-era-of-pharmaceutical-innovation", "time_published": "20240109T184050", "authors": ["Upwallstreet"], "summary": "With Covid-19 finally fading into history, the Covid-19 heroes, namely Moderna Inc MRNA and Pfizer Inc PFE were forced to redefine their business focus last year, and so, they turned to fighting cancer, the one battle that pharma never seems to win.", "banner_image": "https://cdn.benzinga.com/files/medical-banner-with-doctor-wearing-equipment.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": -0.069305, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.347492", "ticker_sentiment_score": "-0.223935", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PFE", "relevance_score": "0.17813", "ticker_sentiment_score": "-0.241466", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Moderna  ( MRNA )  Issues 2023 Preliminary Results, Stock Up 4%", "url": "https://www.zacks.com/stock/news/2207654/moderna-mrna-issues-2023-preliminary-results-stock-up-4", "time_published": "20240109T181500", "authors": ["Zacks Equity Research"], "summary": "Moderna (MRNA) reports unaudited product sales of around $6.7 billion for 2023, meeting its previously issued guidance. Share price rises following the announcement.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.928139"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.061261, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.64962", "ticker_sentiment_score": "0.15185", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVO", "relevance_score": "0.184598", "ticker_sentiment_score": "0.119388", "ticker_sentiment_label": "Neutral"}, {"ticker": "CTMX", "relevance_score": "0.273807", "ticker_sentiment_score": "-0.022647", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biotech ETFs Stage Solid Comeback at the Start of 2024", "url": "https://www.zacks.com/stock/news/2207551/biotech-etfs-stage-solid-comeback-at-the-start-of-2024", "time_published": "20240109T160500", "authors": ["Sweta Killa"], "summary": "The biotech space staged a strong comeback at the start of 2024, driven by multi-billion dollar deals, upbeat clinical results and cutting-edge medical advances like CRISPR gene-editing hitting prime-time.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7b/850.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.999999"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.147642, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVO", "relevance_score": "0.133346", "ticker_sentiment_score": "0.162037", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.089129", "ticker_sentiment_score": "0.084886", "ticker_sentiment_label": "Neutral"}, {"ticker": "KRTX", "relevance_score": "0.089129", "ticker_sentiment_score": "0.058856", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.089129", "ticker_sentiment_score": "0.084886", "ticker_sentiment_label": "Neutral"}, {"ticker": "RYZB", "relevance_score": "0.089129", "ticker_sentiment_score": "0.058856", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.089129", "ticker_sentiment_score": "0.058856", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.133346", "ticker_sentiment_score": "0.06769", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.089129", "ticker_sentiment_score": "0.058856", "ticker_sentiment_label": "Neutral"}, {"ticker": "GRCL", "relevance_score": "0.089129", "ticker_sentiment_score": "0.058856", "ticker_sentiment_label": "Neutral"}, {"ticker": "HARP", "relevance_score": "0.089129", "ticker_sentiment_score": "0.084886", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.133346", "ticker_sentiment_score": "0.162037", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.133346", "ticker_sentiment_score": "0.071668", "ticker_sentiment_label": "Neutral"}, {"ticker": "OMGA", "relevance_score": "0.089129", "ticker_sentiment_score": "0.140918", "ticker_sentiment_label": "Neutral"}]}, {"title": "$1000 Invested In This Stock 5 Years Ago Would Be Worth $6,700 Today - Moderna  ( NASDAQ:MRNA ) ", "url": "https://www.benzinga.com/news/24/01/36557394/1000-invested-in-this-stock-5-years-ago-would-be-worth-6-700-today", "time_published": "20240109T143023", "authors": ["Benzinga Insights"], "summary": "Moderna MRNA has outperformed the market over the past 5 years by 33.78% on an annualized basis producing an average annual return of 46.67%. Currently, Moderna has a market capitalization of $43.33 billion.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_3.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.983605", "ticker_sentiment_score": "0.387251", "ticker_sentiment_label": "Bullish"}]}, {"title": "DEAN BANKS APPOINTED CEO OF INDIGO AG AND CEO-PARTNER OF FLAGSHIP PIONEERING - PR Newswire", "url": "https://www.prnewswire.com/news-releases/dean-banks-appointed-ceo-of-indigo-ag-and-ceo-partner-of-flagship-pioneering-302029919.html", "time_published": "20240109T134400", "authors": [], "summary": "DEAN BANKS APPOINTED CEO OF INDIGO AG AND CEO-PARTNER OF FLAGSHIP PIONEERING PR ...", "banner_image": null, "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.980922"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.108179"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.422198, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.047046", "ticker_sentiment_score": "0.111687", "ticker_sentiment_label": "Neutral"}, {"ticker": "MCRB", "relevance_score": "0.047046", "ticker_sentiment_score": "0.112682", "ticker_sentiment_label": "Neutral"}, {"ticker": "FHTX", "relevance_score": "0.047046", "ticker_sentiment_score": "0.112682", "ticker_sentiment_label": "Neutral"}, {"ticker": "DNLI", "relevance_score": "0.047046", "ticker_sentiment_score": "0.112682", "ticker_sentiment_label": "Neutral"}, {"ticker": "SANA", "relevance_score": "0.047046", "ticker_sentiment_score": "0.112682", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXXRF", "relevance_score": "0.023533", "ticker_sentiment_score": "0.074338", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.070517", "ticker_sentiment_score": "0.09948", "ticker_sentiment_label": "Neutral"}, {"ticker": "OMGA", "relevance_score": "0.047046", "ticker_sentiment_score": "0.112682", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSN", "relevance_score": "0.047046", "ticker_sentiment_score": "0.148563", "ticker_sentiment_label": "Neutral"}]}, {"title": "Better Growth Investment: Ginkgo Bioworks vs. Shiba Inu", "url": "https://www.fool.com/investing/2024/01/09/better-growth-investment-ginkgo-bioworks-vs-shiba/", "time_published": "20240109T125700", "authors": ["Alex Carchidi"], "summary": "Both of these investments need to prove that they can actually grow.", "banner_image": "https://g.foolcdn.com/editorial/images/759677/investor-sitting-with-laptop-and-dog.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Blockchain", "relevance_score": "0.451494"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.210206, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.050572", "ticker_sentiment_score": "0.076428", "ticker_sentiment_label": "Neutral"}, {"ticker": "DNA", "relevance_score": "0.200273", "ticker_sentiment_score": "0.185511", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVO", "relevance_score": "0.050572", "ticker_sentiment_score": "0.076428", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.050572", "ticker_sentiment_score": "0.076428", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:SHIB", "relevance_score": "0.342939", "ticker_sentiment_score": "0.190441", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Want to Win in the Stock Market? Be Average.", "url": "https://www.fool.com/investing/2024/01/09/want-to-win-in-the-stock-market-be-average/", "time_published": "20240109T103000", "authors": ["Adria Cimino"], "summary": "Start with companies that have proven themselves.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F760525%2Fgettyimages-1323758599.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.999896"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": 0.357023, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "LTRCF", "relevance_score": "0.061315", "ticker_sentiment_score": "0.171433", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVAX", "relevance_score": "0.061315", "ticker_sentiment_score": "0.104012", "ticker_sentiment_label": "Neutral"}, {"ticker": "KO", "relevance_score": "0.122269", "ticker_sentiment_score": "0.187826", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.061315", "ticker_sentiment_score": "0.104012", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.122269", "ticker_sentiment_score": "0.187826", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "3 Turnaround Stocks With 151% to 600% Upside in 2024, According to Select Wall Street Analysts", "url": "https://www.fool.com/investing/2024/01/09/3-turnaround-stocks-with-151-to-600-upside-in-2024/", "time_published": "20240109T102100", "authors": ["Sean Williams"], "summary": "High-water price targets from select analysts imply triple-digit gains in the new year for three former highfliers.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F760447%2Fwall-street-sign-invest-retire-stock-market-broker-hedge-fund-institutional-getty.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.977154"}, {"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.200011, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BABA", "relevance_score": "0.035086", "ticker_sentiment_score": "0.04154", "ticker_sentiment_label": "Neutral"}, {"ticker": "EVR", "relevance_score": "0.035086", "ticker_sentiment_score": "0.184428", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WOOF", "relevance_score": "0.339978", "ticker_sentiment_score": "0.430809", "ticker_sentiment_label": "Bullish"}, {"ticker": "NVAX", "relevance_score": "0.371523", "ticker_sentiment_score": "0.06013", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.035086", "ticker_sentiment_score": "0.057443", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.035086", "ticker_sentiment_score": "0.057443", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.035086", "ticker_sentiment_score": "0.057443", "ticker_sentiment_label": "Neutral"}]}, {"title": "Moderna Stock Is Trading Higher Monday: What's Going On? - Moderna  ( NASDAQ:MRNA ) ", "url": "https://www.benzinga.com/news/24/01/36544349/moderna-stock-is-trading-higher-monday-whats-going-on", "time_published": "20240108T205316", "authors": ["Adam Eckert"], "summary": "Moderna Inc MRNA shares are rising Monday after the company provided updates at a JPMorgan conference. What Happened: Moderna announced a series of business updates and progress on the company's pipeline of mRNA medicines at the 42nd annual JPMorgan Healthcare Conference on Monday.", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/vaccine-6557412-1920.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.182013, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.978075", "ticker_sentiment_score": "0.335563", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JPM", "relevance_score": "0.323078", "ticker_sentiment_score": "0.24918", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Moderna sales beat estimates at $6.7 bn last year on rising vaccine share", "url": "https://www.business-standard.com/companies/news/moderna-sales-beat-estimates-at-6-7-bn-last-year-on-rising-vaccine-share-124010900007_1.html", "time_published": "20240108T184021", "authors": ["Bloomberg"], "summary": "Moderna Inc.'s sales for 2023 modestly beat analyst estimates as it eked out a bigger US market share for Covid shots, though the biotech giant reiterated a downbeat outlook for the year ahead.", "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2021-06/29/full/1624962564-5734.jpg?im=FeatureCrop,size=(826,465)", "source": "Business Standard", "category_within_source": "GoogleRSS", "source_domain": "www.business-standard.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Earnings", "relevance_score": "0.929393"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": -0.060203, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.463192", "ticker_sentiment_score": "-0.172095", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "GSK", "relevance_score": "0.07031", "ticker_sentiment_score": "0.016222", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.07031", "ticker_sentiment_score": "0.106509", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.140076", "ticker_sentiment_score": "-0.118495", "ticker_sentiment_label": "Neutral"}]}, {"title": "How To Buy Hot And Promising - But Uncertain - Biotech Stocks", "url": "https://www.investors.com/research/how-to-find-the-best-stocks-to-buy/xbi-etf-how-to-buy-hot-and-promising-but-uncertain-biotech-stocks/", "time_published": "20240108T173400", "authors": ["Investor's Business Daily", "MATTHEW GALGANI"], "summary": "A mix of choppy or nonexistent earnings alongside the promise of game-changing breakthroughs make biotech stocks a challenge for investors. The SPDR S&P Biotech ETF ( XBI ) , now on the IBD Leaderboard watchlist, offers an alternative to betting on a single biotech name.", "banner_image": "https://www.investors.com/wp-content/uploads/2024/01/Stock-petridishmolecule-01-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.972476"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.268824, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.083541", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARWR", "relevance_score": "0.166169", "ticker_sentiment_score": "0.070153", "ticker_sentiment_label": "Neutral"}, {"ticker": "BSX", "relevance_score": "0.166169", "ticker_sentiment_score": "0.200529", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.166169", "ticker_sentiment_score": "0.200529", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "KRTX", "relevance_score": "0.246999", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.400052", "ticker_sentiment_score": "0.433085", "ticker_sentiment_label": "Bullish"}, {"ticker": "MRNA", "relevance_score": "0.166169", "ticker_sentiment_score": "0.070153", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.246999", "ticker_sentiment_score": "0.430266", "ticker_sentiment_label": "Bullish"}, {"ticker": "BMY", "relevance_score": "0.166169", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Jim Cramer's top 10 things to watch in the stock market Monday", "url": "https://www.cnbc.com/2024/01/08/jim-cramers-top-10-things-to-watch-in-the-stock-market-monday.html", "time_published": "20240108T142357", "authors": ["Jim Cramer"], "summary": "Wall Street looks to bounce back after first down week in the past 10.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107200467-1677528554270-NUP_200782_00122.jpg?v=1695324179&w=1920&h=1080", "source": "CNBC", "category_within_source": "Top News", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.999174"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Real Estate & Construction", "relevance_score": "0.2"}], "overall_sentiment_score": 0.147161, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "C", "relevance_score": "0.068502", "ticker_sentiment_score": "-0.033365", "ticker_sentiment_label": "Neutral"}, {"ticker": "BSX", "relevance_score": "0.068502", "ticker_sentiment_score": "0.046261", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.068502", "ticker_sentiment_score": "0.046261", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.136499", "ticker_sentiment_score": "0.073744", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAL", "relevance_score": "0.068502", "ticker_sentiment_score": "0.052143", "ticker_sentiment_label": "Neutral"}, {"ticker": "FSLR", "relevance_score": "0.068502", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MA", "relevance_score": "0.068502", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PHM", "relevance_score": "0.068502", "ticker_sentiment_score": "-0.033365", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.136499", "ticker_sentiment_score": "0.096173", "ticker_sentiment_label": "Neutral"}, {"ticker": "AXP", "relevance_score": "0.068502", "ticker_sentiment_score": "0.110373", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.068502", "ticker_sentiment_score": "0.046261", "ticker_sentiment_label": "Neutral"}, {"ticker": "AXNX", "relevance_score": "0.068502", "ticker_sentiment_score": "0.046261", "ticker_sentiment_label": "Neutral"}, {"ticker": "BA", "relevance_score": "0.269033", "ticker_sentiment_score": "0.187397", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.068502", "ticker_sentiment_score": "0.035442", "ticker_sentiment_label": "Neutral"}]}, {"title": "Moderna Covid vaccine sales plunge by two-thirds in 2023, but meet company's $6 billion forecast", "url": "https://www.cnbc.com/2024/01/08/moderna-covid-vaccine-sales-plunge-in-2023-but-meet-company-forecast.html", "time_published": "20240108T120001", "authors": ["Annika Kim Constantino"], "summary": "Moderna's sales show the steep drop in demand for Covid products as cases and public concern about the virus dwindled front their pandemic peaks.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107261604-1687528288611-gettyimages-1239618774-npekiaridis_vaccines-4.jpeg?v=1704681354&w=1920&h=1080", "source": "CNBC", "category_within_source": "Top News", "source_domain": "www.cnbc.com", "topics": [{"topic": "Earnings", "relevance_score": "0.918141"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.033788, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.518708", "ticker_sentiment_score": "-0.055861", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.112008", "ticker_sentiment_score": "-0.196709", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Flagship Pioneering Debuts Enabling Technologies Initiative", "url": "https://www.prnewswire.com/news-releases/flagship-pioneering-debuts-enabling-technologies-initiative-302027740.html", "time_published": "20240108T113000", "authors": ["Flagship Pioneering"], "summary": "CAMBRIDGE, Mass., Jan. 8, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced the formation of a new strategic initiative to foster enabling technologies for the life sciences and biotech sectors.", "banner_image": "https://mma.prnewswire.com/media/2156098/Flagship_Pioneering_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.367516, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "SSNLF", "relevance_score": "0.285526", "ticker_sentiment_score": "0.264803", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MCRB", "relevance_score": "0.145145", "ticker_sentiment_score": "0.150788", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FHTX", "relevance_score": "0.145145", "ticker_sentiment_score": "0.150788", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DNLI", "relevance_score": "0.145145", "ticker_sentiment_score": "0.150788", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SANA", "relevance_score": "0.145145", "ticker_sentiment_score": "0.150788", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TMO", "relevance_score": "0.072876", "ticker_sentiment_score": "0.108797", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.145145", "ticker_sentiment_score": "0.150788", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "OMGA", "relevance_score": "0.145145", "ticker_sentiment_score": "0.150788", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Flagship Pioneering and Samsung Announce Collaboration to Advance Groundbreaking Technologies in Translational Science and Medicine", "url": "https://www.prnewswire.com/news-releases/flagship-pioneering-and-samsung-announce-collaboration-to-advance-groundbreaking-technologies-in-translational-science-and-medicine-302027591.html", "time_published": "20240108T113000", "authors": ["Flagship Pioneering"], "summary": "Flagship Pioneering and Samsung Announce Collaboration to Advance Groundbreaking Technologies in Translational ... PR ...", "banner_image": "https://mma.prnewswire.com/media/2156098/Flagship_Pioneering_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.929393"}], "overall_sentiment_score": 0.40623, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "SSNLF", "relevance_score": "0.828466", "ticker_sentiment_score": "0.610252", "ticker_sentiment_label": "Bullish"}, {"ticker": "MCRB", "relevance_score": "0.127795", "ticker_sentiment_score": "0.141102", "ticker_sentiment_label": "Neutral"}, {"ticker": "FHTX", "relevance_score": "0.127795", "ticker_sentiment_score": "0.141102", "ticker_sentiment_label": "Neutral"}, {"ticker": "DNLI", "relevance_score": "0.127795", "ticker_sentiment_score": "0.141102", "ticker_sentiment_label": "Neutral"}, {"ticker": "SANA", "relevance_score": "0.127795", "ticker_sentiment_score": "0.141102", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.127795", "ticker_sentiment_score": "0.141102", "ticker_sentiment_label": "Neutral"}, {"ticker": "OMGA", "relevance_score": "0.127795", "ticker_sentiment_score": "0.141102", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSOI", "relevance_score": "0.064104", "ticker_sentiment_score": "0.248578", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Is It Time to Buy the S&P 500's 4 Worst-Performing Stocks This Year?", "url": "https://www.fool.com/investing/2024/01/08/is-it-time-to-buy-the-sp-500s-4-worst-performing-s/", "time_published": "20240108T112000", "authors": ["Billy Duberstein"], "summary": "These four names span different sectors, but all underperformed in 2023. Is it time to be a contrarian and pick up bargains on the discount aisle?", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F760405%2Fbusiness-analyst-trader-stocks-trends-1.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.962106"}, {"topic": "Earnings", "relevance_score": "0.99737"}], "overall_sentiment_score": 0.122637, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.197413", "ticker_sentiment_score": "-0.001624", "ticker_sentiment_label": "Neutral"}, {"ticker": "DG", "relevance_score": "0.099476", "ticker_sentiment_score": "0.125963", "ticker_sentiment_label": "Neutral"}]}, {"title": "Covid Hospitalizations And Deaths See Double-Digit Spike After Holiday - Amid Surge In Respiratory Illnesses", "url": "https://www.forbes.com/sites/ariannajohnson/2024/01/05/covid-hospitalizations-and-deaths-see-double-digit-spike-after-holiday---amid-surge-in-respiratory-illnesses/", "time_published": "20240105T223706", "authors": ["Arianna Johnson"], "summary": "Hospitalizations for Covid spiked 20% in the week after Christmas, according to new data from Centers for Disease Control and Prevention, along with an increase in Covid deaths, and flu hospitalizations and deaths, solidifying what experts predicted to be a \"severe\" season for respiratory ...", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65988430ca1edae871826c97/0x0.jpg?format=jpg&crop=5120,2880,x0,y0,safe&height=900&width=1600&fit=bounds", "source": "Forbes", "category_within_source": "n/a", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.054818, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVAX", "relevance_score": "0.064623", "ticker_sentiment_score": "0.056276", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.064623", "ticker_sentiment_score": "0.056276", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.064623", "ticker_sentiment_score": "0.056276", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.064623", "ticker_sentiment_score": "0.056276", "ticker_sentiment_label": "Neutral"}]}, {"title": "S&P 500 Notches First Losing Week Since October Amid Tech Selloff", "url": "https://www.forbes.com/sites/dereksaul/2024/01/05/sp-500-notches-first-losing-week-since-october-amid-tech-selloff/", "time_published": "20240105T210007", "authors": ["Derek Saul"], "summary": "The stock market kicked off 2024 on a rough note, as major indexes broke their historic winning streaks, with losses concentrated in the biggest stocks responsible for much of last year's strong gains. Despite notching modest gains Friday, all three of the top indexes closed down for the week.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/6598687ba22e618bcf0569c8/0x0.jpg?format=jpg&crop=2402,1350,x0,y0,safe&height=900&width=1600&fit=bounds", "source": "Forbes", "category_within_source": "n/a", "source_domain": "www.forbes.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.995973"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": -0.090774, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.167904", "ticker_sentiment_score": "0.268719", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NFLX", "relevance_score": "0.084423", "ticker_sentiment_score": "-0.149058", "ticker_sentiment_label": "Neutral"}, {"ticker": "AVGO", "relevance_score": "0.084423", "ticker_sentiment_score": "-0.149058", "ticker_sentiment_label": "Neutral"}]}, {"title": "Healthcare Champions Kick Off 2024 - Moderna  ( NASDAQ:MRNA ) ", "url": "https://www.benzinga.com/general/24/01/36514593/healthcare-champions-kick-off-2024", "time_published": "20240105T180623", "authors": ["Upwallstreet"], "summary": "Surprisingly, it is not Big Tech that kicked off 2024 but healtchare champions. Moderna Inc MRNA shares rose after Oppenheimer upgraded the stock due to the Covid-19 vaccine star possibly marketing as many as five products by 2026.", "banner_image": "https://cdn.benzinga.com/files/medical-banner-with-doctor-wearing-goggles_1.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}, {"topic": "Earnings", "relevance_score": "0.938238"}], "overall_sentiment_score": 0.117668, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.410059", "ticker_sentiment_score": "0.205317", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WBA", "relevance_score": "0.142565", "ticker_sentiment_score": "-0.011521", "ticker_sentiment_label": "Neutral"}]}, {"title": "Dry January Investing: Trading Pints For Portfolio Growth - Merck & Co  ( NYSE:MRK ) , Eli Lilly  ( NYSE:LLY ) ", "url": "https://www.benzinga.com/markets/equities/24/01/36513620/dry-january-investing-trading-pints-for-portfolio-growth", "time_published": "20240105T172022", "authors": ["Neil Dennis"], "summary": "Around 15% of Americans said they were planning to participate this year in Dry January - a month of abstinence from alcohol - according to a survey by Morning Consult. Most cite the health benefits from taking a break from the bottle, but it has its financial benefits too.", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/wall-street-beer-shutter.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.997405"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": 0.214335, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.143843", "ticker_sentiment_score": "0.294132", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "STZ", "relevance_score": "0.143843", "ticker_sentiment_score": "0.072032", "ticker_sentiment_label": "Neutral"}, {"ticker": "TAP", "relevance_score": "0.143843", "ticker_sentiment_score": "0.072032", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.143843", "ticker_sentiment_score": "0.339557", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.143843", "ticker_sentiment_score": "0.115142", "ticker_sentiment_label": "Neutral"}]}, {"title": "Dow Jones Turns Higher After Jobs Report; Apple Stock Battles Near Long-Term Support Level", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-holds-near-highs-after-jobs-report-apple-stock-battles-near-long-term-support-level/", "time_published": "20240105T155100", "authors": ["Investor's Business Daily", "KEN SHREVE"], "summary": "Dow Jones Turns Higher After Jobs Report. Apple Stock Battles Near Long-Term Support Level Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2018/05/Stock-dow-04-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.999975"}, {"topic": "Earnings", "relevance_score": "0.650727"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}], "overall_sentiment_score": 0.251066, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SHOP", "relevance_score": "0.119532", "ticker_sentiment_score": "0.273956", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AAPL", "relevance_score": "0.178459", "ticker_sentiment_score": "0.280895", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "COST", "relevance_score": "0.119532", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRWD", "relevance_score": "0.119532", "ticker_sentiment_score": "0.054076", "ticker_sentiment_label": "Neutral"}, {"ticker": "CVX", "relevance_score": "0.119532", "ticker_sentiment_score": "-0.035079", "ticker_sentiment_label": "Neutral"}, {"ticker": "VZ", "relevance_score": "0.178459", "ticker_sentiment_score": "0.262564", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNOW", "relevance_score": "0.119532", "ticker_sentiment_score": "0.273956", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CAT", "relevance_score": "0.178459", "ticker_sentiment_score": "0.262564", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ZS", "relevance_score": "0.178459", "ticker_sentiment_score": "0.068079", "ticker_sentiment_label": "Neutral"}, {"ticker": "HD", "relevance_score": "0.178459", "ticker_sentiment_score": "0.262564", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.119532", "ticker_sentiment_score": "0.373876", "ticker_sentiment_label": "Bullish"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.178459", "ticker_sentiment_score": "0.206156", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Short Sellers' Nightmare: $195B Evaporates In 2023's Market Surge - Apple  ( NASDAQ:AAPL ) , Coinbase Glb  ( NASDAQ:COIN ) ", "url": "https://www.benzinga.com/markets/equities/24/01/36510120/short-sellers-nightmare-195b-evaporates-in-2023s-market-surge", "time_published": "20240105T142522", "authors": ["Neil Dennis"], "summary": "In a year when equity markets rallied strongly, short sellers - traders who position for losses on assets - had an extremely tough time in 2023. Data published on Friday by S3 Partners showed that short sellers in the U.S. and Canada were down $194.9 billion in 2023 - down 20.4% on an average ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/bear-chart-shutter3.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.99246"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.576289"}, {"topic": "Finance", "relevance_score": "0.333333"}, {"topic": "Blockchain", "relevance_score": "0.310843"}], "overall_sentiment_score": -0.019588, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.188193", "ticker_sentiment_score": "-0.042676", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.188193", "ticker_sentiment_score": "-0.435133", "ticker_sentiment_label": "Bearish"}, {"ticker": "MRNA", "relevance_score": "0.188193", "ticker_sentiment_score": "-0.042676", "ticker_sentiment_label": "Neutral"}, {"ticker": "COIN", "relevance_score": "0.188193", "ticker_sentiment_score": "-0.289687", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "FRC", "relevance_score": "0.094762", "ticker_sentiment_score": "-0.272366", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PFE", "relevance_score": "0.188193", "ticker_sentiment_score": "-0.042676", "ticker_sentiment_label": "Neutral"}]}, {"title": "It's Been An Abysmal Two Years. But Biotech Is Looking Up.", "url": "https://www.investors.com/news/technology/biotech-stocks-pharma-heat-up-in-2024-as-buyouts-obesity-ai-drive-excitement/", "time_published": "20240105T140000", "authors": ["Investor's Business Daily", "ALLISON GATLIN"], "summary": "Biotech Stocks, Pharma Heat Up In 2024 As Buyouts, Obesity And AI Drive Excitement Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2024/01/A1-010824-biotech-Gash.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}], "overall_sentiment_score": 0.12567, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVO", "relevance_score": "0.035679", "ticker_sentiment_score": "0.069333", "ticker_sentiment_label": "Neutral"}, {"ticker": "NBIX", "relevance_score": "0.02379", "ticker_sentiment_score": "0.14181", "ticker_sentiment_label": "Neutral"}, {"ticker": "KRTX", "relevance_score": "0.035679", "ticker_sentiment_score": "0.037838", "ticker_sentiment_label": "Neutral"}, {"ticker": "IONS", "relevance_score": "0.02379", "ticker_sentiment_score": "0.084592", "ticker_sentiment_label": "Neutral"}, {"ticker": "RYZB", "relevance_score": "0.02379", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.02379", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARWR", "relevance_score": "0.02379", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALEC", "relevance_score": "0.09495", "ticker_sentiment_score": "0.150269", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LLY", "relevance_score": "0.153696", "ticker_sentiment_score": "0.053027", "ticker_sentiment_label": "Neutral"}, {"ticker": "VERV", "relevance_score": "0.02379", "ticker_sentiment_score": "0.006781", "ticker_sentiment_label": "Neutral"}, {"ticker": "OMGA", "relevance_score": "0.02379", "ticker_sentiment_score": "0.079056", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTLA", "relevance_score": "0.02379", "ticker_sentiment_score": "-0.008781", "ticker_sentiment_label": "Neutral"}, {"ticker": "BHVN", "relevance_score": "0.02379", "ticker_sentiment_score": "-0.001871", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.02379", "ticker_sentiment_score": "0.067127", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.035679", "ticker_sentiment_score": "0.017905", "ticker_sentiment_label": "Neutral"}, {"ticker": "CPRX", "relevance_score": "0.02379", "ticker_sentiment_score": "0.14181", "ticker_sentiment_label": "Neutral"}, {"ticker": "BEAM", "relevance_score": "0.02379", "ticker_sentiment_score": "0.057997", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.02379", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GRCL", "relevance_score": "0.02379", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLNN", "relevance_score": "0.02379", "ticker_sentiment_score": "-0.020246", "ticker_sentiment_label": "Neutral"}, {"ticker": "GPCR", "relevance_score": "0.035679", "ticker_sentiment_score": "0.08972", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMPH", "relevance_score": "0.02379", "ticker_sentiment_score": "0.14181", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARGX", "relevance_score": "0.011896", "ticker_sentiment_score": "-0.115274", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.02379", "ticker_sentiment_score": "0.067127", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.02379", "ticker_sentiment_score": "-0.042606", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.035679", "ticker_sentiment_score": "0.064761", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.059429", "ticker_sentiment_score": "0.106048", "ticker_sentiment_label": "Neutral"}]}, {"title": "7 Stocks Are Taking Off Already - And The Year Just Started", "url": "https://www.investors.com/etfs-and-funds/sectors/sp500-stocks-are-taking-off-already-and-the-year-just-started/", "time_published": "20240105T130000", "authors": ["MATT KRANTZ", "Investor's Business Daily"], "summary": "The calendar just flipped to 2024 - and investors already have their favorite S&P 500 stocks. And none of them are the Big Tech giants that dominated in 2023.", "banner_image": "https://www.investors.com/wp-content/uploads/2021/04/Stock-cranesmoney-01-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}], "overall_sentiment_score": 0.227189, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.276909", "ticker_sentiment_score": "0.332128", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.521465", "ticker_sentiment_score": "0.232629", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SPGI", "relevance_score": "0.09402", "ticker_sentiment_score": "0.162601", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Moderna  ( MRNA )  Ascends While Market Falls: Some Facts to Note", "url": "https://www.zacks.com/stock/news/2205931/moderna-mrna-ascends-while-market-falls-some-facts-to-note", "time_published": "20240104T225018", "authors": ["Zacks Equity Research"], "summary": "Moderna (MRNA) closed the most recent trading day at $108.66, moving +0.07% from the previous trading session.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default166.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.77141"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.180549, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.520773", "ticker_sentiment_score": "0.246643", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Market Whales and Their Recent Bets on MRNA Options - Moderna  ( NASDAQ:MRNA ) ", "url": "https://www.benzinga.com/markets/options/24/01/36492030/market-whales-and-their-recent-bets-on-mrna-options", "time_published": "20240104T151635", "authors": ["Benzinga Insights"], "summary": "Financial giants have made a conspicuous bullish move on Moderna. Our analysis of options history for Moderna MRNA revealed 8 unusual trades. Delving into the details, we found 62% of traders were bullish, while 37% showed bearish tendencies.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}, {"topic": "Earnings", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.210288, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.753715", "ticker_sentiment_score": "0.205096", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Biotech Stock Roundup: VYGR Gains From NVS Deal, AGIO Up on Study Data & More", "url": "https://www.zacks.com/stock/news/2205605/biotech-stock-roundup-vygr-gains-from-nvs-deal-agio-up-on-study-data-more", "time_published": "20240104T140500", "authors": ["Zacks Equity Research"], "summary": "Collaboration news from Voyager (VYGR) and study updates from Agios (AGIO) are the key highlights this week.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ba/1149.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.149302, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CORT", "relevance_score": "0.135094", "ticker_sentiment_score": "-0.154914", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "AGIO", "relevance_score": "0.090304", "ticker_sentiment_score": "0.177909", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.045224", "ticker_sentiment_score": "0.060652", "ticker_sentiment_label": "Neutral"}, {"ticker": "VYGR", "relevance_score": "0.090304", "ticker_sentiment_score": "0.113168", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.135094", "ticker_sentiment_score": "0.063145", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Healthcare Stocks That Turned $1,000 Into $2,400  ( or More ) ", "url": "https://www.fool.com/investing/2024/01/04/2-healthcare-stocks-that-turned-1000-into-2400-or/", "time_published": "20240104T133000", "authors": ["Prosper Junior Bakiny"], "summary": "These innovative biotechs likely aren't done rewarding their shareholders.", "banner_image": "https://g.foolcdn.com/editorial/images/758458/physician-giving-medicine-to-elderly-patient.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}, {"topic": "Earnings", "relevance_score": "0.891286"}], "overall_sentiment_score": 0.284231, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.444487", "ticker_sentiment_score": "0.337611", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NTLA", "relevance_score": "0.052226", "ticker_sentiment_score": "0.136906", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.052226", "ticker_sentiment_score": "0.184991", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Time to Buy Moderna-Heavy ETFs on Vaccine Optimism?", "url": "https://www.zacks.com/stock/news/2205496/time-to-buy-moderna-heavy-etfs-on-vaccine-optimism", "time_published": "20240104T130000", "authors": ["Sanghamitra Saha"], "summary": "Shares of Moderna witnessed a significant increase of more than 13% on Jan 2, 2024, driven by Oppenheimer's decision to upgrade the stock to \"outperform,\" as quoted on CNBC.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/6f/3484.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.744043"}], "overall_sentiment_score": 0.110374, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.777664", "ticker_sentiment_score": "0.281025", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "CytomX Therapeutics Outlines 2024 Company Priorities and Milestones", "url": "https://www.globenewswire.com/news-release/2024/01/04/2803919/37704/en/CytomX-Therapeutics-Outlines-2024-Company-Priorities-and-Milestones.html", "time_published": "20240104T130000", "authors": ["CytomX Therapeutics Inc."], "summary": "- CX-904 ( EGFRxCD3 T-cell engager ) initial Phase 1a dose escalation data anticipated in the 2nd half of ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/c252869d-a4c1-4e56-88e8-d80b85d20c35", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.083791, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.074518", "ticker_sentiment_score": "0.045805", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.166679", "ticker_sentiment_score": "0.060408", "ticker_sentiment_label": "Neutral"}, {"ticker": "CTMX", "relevance_score": "0.111574", "ticker_sentiment_score": "0.072076", "ticker_sentiment_label": "Neutral"}]}, {"title": "CytomX Therapeutics Outlines 2024 Company Priorities and Milestones - CytomX Therapeutics  ( NASDAQ:CTMX ) ", "url": "https://www.benzinga.com/pressreleases/24/01/g36488030/cytomx-therapeutics-outlines-2024-company-priorities-and-milestones", "time_published": "20240104T130000", "authors": ["Globe Newswire"], "summary": "- CX-904 ( EGFRxCD3 T-cell engager ) initial Phase 1a dose escalation data anticipated in the 2nd half of 2024 - - IND application filed for conditionally activated EpCAM-directed ADC ( CX-2051 ) with Phase 1 initiation in EpCAM positive tumors expected in the 1st half of 2024 -", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.081327, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.072655", "ticker_sentiment_score": "0.046793", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.180325", "ticker_sentiment_score": "0.070017", "ticker_sentiment_label": "Neutral"}, {"ticker": "CTMX", "relevance_score": "0.126784", "ticker_sentiment_score": "0.038576", "ticker_sentiment_label": "Neutral"}]}, {"title": "American stocks loiter near an all-time high", "url": "https://www.economist.com/finance-and-economics/2024/01/04/american-stocks-loiter-near-an-all-time-high", "time_published": "20240104T104210", "authors": ["The Economist"], "summary": "Their performance this year will depend on the real economy ...", "banner_image": "https://www.economist.com/cdn-cgi/image/width=1424,quality=80,format=auto/content-assets/images/20240106_FNC873.png", "source": "The Economist", "category_within_source": "Finance", "source_domain": "www.economist.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.682689"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.113318, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.054483", "ticker_sentiment_score": "0.039017", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.054483", "ticker_sentiment_score": "0.039017", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.054483", "ticker_sentiment_score": "0.039017", "ticker_sentiment_label": "Neutral"}]}, {"title": "America's stocks loiter near an all-time high", "url": "https://www.economist.com/finance-and-economics/2024/01/04/americas-stocks-loiter-near-an-all-time-high", "time_published": "20240104T104210", "authors": ["The Economist"], "summary": "I first trading day of the year. The stockmarket opens a whisker away from an all-time high. American equities have soared over the past 12 months, up by around 25%, with a handful of technology giants leading the charge.", "banner_image": "https://www.economist.com/cdn-cgi/image/width=1424,quality=80,format=auto/content-assets/images/20240106_FNC873.png", "source": "The Economist", "category_within_source": "BusinessGoogleRSS", "source_domain": "www.economist.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.682689"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.113318, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.054483", "ticker_sentiment_score": "0.039017", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.054483", "ticker_sentiment_score": "0.039017", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.054483", "ticker_sentiment_score": "0.039017", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Moderna  ( MRNA )  Stock Price Was Up 13% on Tuesday", "url": "https://www.zacks.com/stock/news/2205244/why-moderna-mrna-stock-price-was-up-13-on-tuesday", "time_published": "20240103T185600", "authors": ["Zacks Equity Research"], "summary": "Moderna (MRNA) surges after analysts at Oppenheimer upgraded its rating in anticipation of the company marketing five products by 2026.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/34/973.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.682689"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.12862, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CTMX", "relevance_score": "0.222022", "ticker_sentiment_score": "0.086244", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.570165", "ticker_sentiment_score": "0.270732", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SRPT", "relevance_score": "0.089797", "ticker_sentiment_score": "0.052721", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.04497", "ticker_sentiment_score": "0.045947", "ticker_sentiment_label": "Neutral"}]}, {"title": "Moderna  ( MRNA )  Moves 13.1% Higher: Will This Strength Last?", "url": "https://www.zacks.com/stock/news/2204987/moderna-mrna-moves-131-higher-will-this-strength-last", "time_published": "20240103T143100", "authors": ["Zacks Equity Research"], "summary": "Moderna (MRNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default128.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.961735"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.263459, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.59972", "ticker_sentiment_score": "0.43261", "ticker_sentiment_label": "Bullish"}, {"ticker": "EXAS", "relevance_score": "0.516656", "ticker_sentiment_score": "-0.085466", "ticker_sentiment_label": "Neutral"}]}, {"title": "Company News for Jan 3, 2024", "url": "https://www.zacks.com/stock/news/2204970/company-news-for-jan-3-2024", "time_published": "20240103T142300", "authors": ["Zacks Equity Research"], "summary": "Companies in The News Are: ...", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/db/3160.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.059231, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.70749", "ticker_sentiment_score": "0.316494", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVDA", "relevance_score": "0.70749", "ticker_sentiment_score": "-0.532212", "ticker_sentiment_label": "Bearish"}, {"ticker": "RCL", "relevance_score": "0.70749", "ticker_sentiment_score": "-0.532766", "ticker_sentiment_label": "Bearish"}]}, {"title": "US Stocks Set To Open Weaker As Traders Eye Key Main Street Events: Analyst Sees Buying Opportunity On 'Stunning' Earnings Expectations - Invesco QQQ Trust, Series 1  ( NASDAQ:QQQ ) , SPDR S&P 500  ( ARCA:SPY ) ", "url": "https://www.benzinga.com/news/earnings/24/01/36466738/us-stocks-set-to-open-weaker-as-traders-eye-key-main-street-events-analyst-sees-buying-opportunity-", "time_published": "20240103T122844", "authors": ["Shanthi Rexaline"], "summary": "The negative sentiment observed in the stock market at the beginning of the year appears to persist, with index futures pointing to a lower opening on Wednesday. Several market-moving catalysts, including the release of the Fed minutes, a Federal Reserve speech, and JOLTS data, could influence ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/data-charts.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.576289"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.998682"}, {"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.0218, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CALM", "relevance_score": "0.110717", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "RGP", "relevance_score": "0.110717", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SZIHF", "relevance_score": "0.055492", "ticker_sentiment_score": "0.202946", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IVZ", "relevance_score": "0.055492", "ticker_sentiment_score": "0.06309", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.110717", "ticker_sentiment_score": "0.183932", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VZ", "relevance_score": "0.110717", "ticker_sentiment_score": "0.254998", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Value Stocks Shine in Year's First Trading Day in Big Reversal From 2023", "url": "https://www.barrons.com/amp/articles/value-stocks-rise-6d8b367b", "time_published": "20240102T212200", "authors": ["Andrew Bary"], "summary": "Value Stock Shine in Year's First Trading Day in Big Reversal From ...", "banner_image": "https://images.barrons.com/im-41734267/social", "source": "Barrons", "category_within_source": "n/a", "source_domain": "www.barrons.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.967321"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.34052, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PEP", "relevance_score": "0.206685", "ticker_sentiment_score": "0.245021", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BCS", "relevance_score": "0.104228", "ticker_sentiment_score": "0.164843", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.104228", "ticker_sentiment_score": "0.164843", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "UBER", "relevance_score": "0.104228", "ticker_sentiment_score": "0.164843", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.206685", "ticker_sentiment_score": "0.245021", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Why Longboard Pharmaceuticals Shares Are Trading Higher By Around 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session - Akso Health Group  ( NASDAQ:AHG ) , Aditxt  ( NASDAQ:ADTX ) ", "url": "https://www.benzinga.com/news/24/01/36457165/why-longboard-pharmaceuticals-shares-are-trading-higher-by-around-200-here-are-other-stocks-moving-i", "time_published": "20240102T183524", "authors": ["Avi Kapoor"], "summary": "Shares of Longboard Pharmaceuticals, Inc. LBPH rose sharply during Tuesday's session after the company released topline data from the PACIFIC Phase 1b/2a study evaluating bexicaserin ( LP352 ) for seizures associated with a broad range of Developmental and Epileptic Encephalopathies ( DEEs ) .", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/01/02/image21_0.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Blockchain", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.858979"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Real Estate & Construction", "relevance_score": "0.166667"}], "overall_sentiment_score": 0.104777, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AHG", "relevance_score": "0.093653", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSTR", "relevance_score": "0.093653", "ticker_sentiment_score": "0.21635", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GDRX", "relevance_score": "0.093653", "ticker_sentiment_score": "-0.071898", "ticker_sentiment_label": "Neutral"}, {"ticker": "FLJ", "relevance_score": "0.093653", "ticker_sentiment_score": "-0.057651", "ticker_sentiment_label": "Neutral"}, {"ticker": "PGEN", "relevance_score": "0.093653", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VSTE", "relevance_score": "0.093653", "ticker_sentiment_score": "-0.521725", "ticker_sentiment_label": "Bearish"}, {"ticker": "VYGR", "relevance_score": "0.093653", "ticker_sentiment_score": "0.038336", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIDU", "relevance_score": "0.046907", "ticker_sentiment_score": "0.065952", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIVN", "relevance_score": "0.093653", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AWON", "relevance_score": "0.046907", "ticker_sentiment_score": "0.054136", "ticker_sentiment_label": "Neutral"}, {"ticker": "LBPH", "relevance_score": "0.140076", "ticker_sentiment_score": "0.057288", "ticker_sentiment_label": "Neutral"}, {"ticker": "TBLT", "relevance_score": "0.093653", "ticker_sentiment_score": "-0.39546", "ticker_sentiment_label": "Bearish"}, {"ticker": "KNSA", "relevance_score": "0.093653", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PRTC", "relevance_score": "0.093653", "ticker_sentiment_score": "-0.39546", "ticker_sentiment_label": "Bearish"}, {"ticker": "LYEL", "relevance_score": "0.093653", "ticker_sentiment_score": "0.360512", "ticker_sentiment_label": "Bullish"}, {"ticker": "AOSL", "relevance_score": "0.093653", "ticker_sentiment_score": "0.182082", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HLTH", "relevance_score": "0.093653", "ticker_sentiment_score": "0.083427", "ticker_sentiment_label": "Neutral"}, {"ticker": "UP", "relevance_score": "0.046907", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CGA", "relevance_score": "0.093653", "ticker_sentiment_score": "-0.054074", "ticker_sentiment_label": "Neutral"}, {"ticker": "MOBX", "relevance_score": "0.093653", "ticker_sentiment_score": "-0.39546", "ticker_sentiment_label": "Bearish"}, {"ticker": "BTCS", "relevance_score": "0.093653", "ticker_sentiment_score": "0.39546", "ticker_sentiment_label": "Bullish"}, {"ticker": "AUR", "relevance_score": "0.093653", "ticker_sentiment_score": "-0.04127", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLSK", "relevance_score": "0.093653", "ticker_sentiment_score": "0.442999", "ticker_sentiment_label": "Bullish"}, {"ticker": "DOGZ", "relevance_score": "0.093653", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MNKD", "relevance_score": "0.140076", "ticker_sentiment_score": "0.066921", "ticker_sentiment_label": "Neutral"}, {"ticker": "RNXT", "relevance_score": "0.093653", "ticker_sentiment_score": "-0.089952", "ticker_sentiment_label": "Neutral"}, {"ticker": "MARA", "relevance_score": "0.093653", "ticker_sentiment_score": "0.39546", "ticker_sentiment_label": "Bullish"}, {"ticker": "YY", "relevance_score": "0.093653", "ticker_sentiment_score": "0.071134", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARBK", "relevance_score": "0.093653", "ticker_sentiment_score": "0.227973", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HUT", "relevance_score": "0.093653", "ticker_sentiment_score": "0.442999", "ticker_sentiment_label": "Bullish"}, {"ticker": "SNTG", "relevance_score": "0.093653", "ticker_sentiment_score": "-0.054074", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMPX", "relevance_score": "0.093653", "ticker_sentiment_score": "-0.39546", "ticker_sentiment_label": "Bearish"}, {"ticker": "SNGX", "relevance_score": "0.140076", "ticker_sentiment_score": "0.288809", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VTNR", "relevance_score": "0.093653", "ticker_sentiment_score": "0.006463", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNES", "relevance_score": "0.140076", "ticker_sentiment_score": "0.255841", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ALLO", "relevance_score": "0.093653", "ticker_sentiment_score": "0.360512", "ticker_sentiment_label": "Bullish"}, {"ticker": "CORT", "relevance_score": "0.093653", "ticker_sentiment_score": "-0.013839", "ticker_sentiment_label": "Neutral"}, {"ticker": "SXTC", "relevance_score": "0.093653", "ticker_sentiment_score": "-0.015833", "ticker_sentiment_label": "Neutral"}, {"ticker": "KORE", "relevance_score": "0.093653", "ticker_sentiment_score": "-0.054074", "ticker_sentiment_label": "Neutral"}, {"ticker": "LMDX", "relevance_score": "0.140076", "ticker_sentiment_score": "-0.173252", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "AVXL", "relevance_score": "0.093653", "ticker_sentiment_score": "-0.144194", "ticker_sentiment_label": "Neutral"}, {"ticker": "BROG", "relevance_score": "0.140076", "ticker_sentiment_score": "-0.204472", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ADTX", "relevance_score": "0.093653", "ticker_sentiment_score": "-0.054074", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIOT", "relevance_score": "0.093653", "ticker_sentiment_score": "0.275679", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.093653", "ticker_sentiment_score": "0.332948", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BTDR", "relevance_score": "0.093653", "ticker_sentiment_score": "-0.350973", "ticker_sentiment_label": "Bearish"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.275867", "ticker_sentiment_score": "0.621848", "ticker_sentiment_label": "Bullish"}]}, {"title": "Moderna stock pops after Oppenheimer says Covid shot maker could launch more products over next two years", "url": "https://www.cnbc.com/2024/01/02/moderna-stock-jumps-after-oppenheimer-upgrade-on-pipeline-potential.html", "time_published": "20240102T183210", "authors": ["Annika Kim Constantino"], "summary": "The upgrade follows a dismal 2023 for Moderna, whose only commercially available product is its Covid shot.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107261603-1687528289059-gettyimages-1237672961-widak-covid19s220112_npv5n.jpeg?v=1696417201&w=1920&h=1080", "source": "CNBC", "category_within_source": "Business", "source_domain": "www.cnbc.com", "topics": [{"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.022032, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.538782", "ticker_sentiment_score": "0.013588", "ticker_sentiment_label": "Neutral"}]}, {"title": "Travel Updates: Gatwick Hikes Drop-Off Fee", "url": "https://www.forbes.com/uk/advisor/travel-insurance/2024/01/02/travel-latest-news/", "time_published": "20240102T180148", "authors": ["Kevin Pratt"], "summary": "2 January: Minimum Charge To Rise 20% To \u00a36 For 10 Minutes Gatwick Airport is increasing its minimum drop-off charge by 20% from 5 January, when it will increase from \u00a35 to \u00a36. The minimum charge covers the first 10 minutes and must be paid by midnight the day after the visit.", "banner_image": "https://thumbor.forbes.com/thumbor/fit-in/x/https://www.forbes.com/uk/advisor/wp-content/uploads/2022/02/ET-Ski-Resort-Map.jpg", "source": "Forbes", "category_within_source": "n/a", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Economy - Fiscal", "relevance_score": "0.576289"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}], "overall_sentiment_score": 0.007163, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DRTGF", "relevance_score": "0.000901", "ticker_sentiment_score": "-0.050149", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.000901", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.000901", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAL", "relevance_score": "0.001803", "ticker_sentiment_score": "0.060776", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.004506", "ticker_sentiment_score": "0.034618", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.002704", "ticker_sentiment_score": "0.054221", "ticker_sentiment_label": "Neutral"}, {"ticker": "SHTDF", "relevance_score": "0.000901", "ticker_sentiment_score": "0.124796", "ticker_sentiment_label": "Neutral"}, {"ticker": "MA", "relevance_score": "0.000901", "ticker_sentiment_score": "0.01804", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.004506", "ticker_sentiment_score": "0.034618", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSSMY", "relevance_score": "0.000901", "ticker_sentiment_score": "-0.150718", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "YUGVF", "relevance_score": "0.001803", "ticker_sentiment_score": "0.049842", "ticker_sentiment_label": "Neutral"}, {"ticker": "AXP", "relevance_score": "0.000901", "ticker_sentiment_score": "0.01804", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.004506", "ticker_sentiment_score": "0.034618", "ticker_sentiment_label": "Neutral"}, {"ticker": "RYAOF", "relevance_score": "0.003605", "ticker_sentiment_score": "-0.032104", "ticker_sentiment_label": "Neutral"}, {"ticker": "UBER", "relevance_score": "0.000901", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "What's Going On With Pfizer Stock? - Pfizer  ( NYSE:PFE ) ", "url": "https://www.benzinga.com/news/24/01/36456287/whats-going-on-with-pfizer-stock", "time_published": "20240102T174805", "authors": ["Erica Kollmann"], "summary": "Pfizer, Inc. PFE shares are trading higher on the first trading day of 2024 after the stock lost more than 40% in 2023. Here's a look at what's going on. Pfizer shares may be moving in sympathy with fellow drug-maker, Moderna, Inc. MRNA which is up nearly 15% Tuesday.", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/01/02/virus-4030721_1280.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.299663, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.391923", "ticker_sentiment_score": "0.662163", "ticker_sentiment_label": "Bullish"}, {"ticker": "PFE", "relevance_score": "0.927326", "ticker_sentiment_score": "0.631211", "ticker_sentiment_label": "Bullish"}]}, {"title": "Moderna Analyst Projects Transformation Into 'Five-Product Commercial Company' By 2026 - Moderna  ( NASDAQ:MRNA ) ", "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/01/36453042/moderna-analyst-projects-transformation-into-five-product-commercial-company-by-202", "time_published": "20240102T162147", "authors": ["Priya Nigam"], "summary": "Moderna Inc MRNA is back in focus as it is making advancements in cancer treatment. Moderna is likely to become a \"five-product commercial company\" by 2026, according to Oppenheimer. The Moderna Analyst: Hartaj Singh upgraded the rating for Moderna to Outperform, while raising the price target ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/01/02/moderna_shutter.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.178055, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.972323", "ticker_sentiment_score": "0.034597", "ticker_sentiment_label": "Neutral"}]}, {"title": "Moderna's stock soars after Oppenheimer upgrades to buy", "url": "https://www.marketwatch.com/story/modernas-stock-soars-10-to-lead-s-p-500-gainers-as-oppenheimer-upgrades-to-buy-f822bb42", "time_published": "20240102T154600", "authors": ["Ciara Linnane"], "summary": "Moderna's stock started the year with a bang thanks to an analyst upgrade.", "banner_image": "https://images.mktw.net/im-56518205?width=700&height=422", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.133008, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.533842", "ticker_sentiment_score": "0.171502", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.191929", "ticker_sentiment_score": "0.118352", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.191929", "ticker_sentiment_score": "0.118352", "ticker_sentiment_label": "Neutral"}]}, {"title": "Moderna Stock Is Moving Higher: What's Going On? - Moderna  ( NASDAQ:MRNA ) ", "url": "https://www.benzinga.com/news/24/01/36453571/moderna-stock-is-moving-higher-whats-going-on", "time_published": "20240102T154429", "authors": ["Adam Eckert"], "summary": "Moderna Inc MRNA shares are trading higher Tuesday following positive analyst coverage from Oppenheimer. What Happened: Oppenheimer analyst Hartaj Singh upgraded Moderna from Perform to Outperform on Tuesday and announced a price target of $142.", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/01/02/vaccine-6557409_1920.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.227218, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.885652", "ticker_sentiment_score": "0.506005", "ticker_sentiment_label": "Bullish"}]}, {"title": "Xinhua Silk Road: Xinhua-Yushu Wild Cordyceps Sinensis Price Index lanzado en Pek\u00edn", "url": "https://www.prnewswire.com/news-releases/xinhua-silk-road-xinhua-yushu-wild-cordyceps-sinensis-price-index-lanzado-en-pekin-302024456.html", "time_published": "20240102T120200", "authors": ["Xinhua Silk Road"], "summary": "PEK\u00cdN, 2 de enero de 2024 /PRNewswire/ -- El Xinhua-Yushu Wild Cordyceps Sinensis Price Index fue lanzado oficialmente el 27 de diciembre en Pek\u00edn, capital de China, lo que indica el desarrollo acelerado de la industria de cordyceps sinensis silvestre hacia una nueva etapa digital, informativa y ...", "banner_image": "https://www.prnewswire.com/content/dam/prnewswire/common/newsletter-signup.png", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.0231, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.067158", "ticker_sentiment_score": "-0.041065", "ticker_sentiment_label": "Neutral"}]}, {"title": "Zika Never Ended", "url": "https://www.theatlantic.com/ideas/archive/2024/01/zika-virus-never-ended-covid-pandemic/676922/", "time_published": "20240102T120000", "authors": ["Olga Khazan"], "summary": "In 2015, a horror movie came to life. The mosquitoes that swarm almost all tropical climates began infecting people with a strange new virus. In most, Zika caused no symptoms, or a mild rash and fever. But if it happened to infect a pregnant woman, her baby could be born with severe birth defects.", "banner_image": "https://cdn.theatlantic.com/thumbor/rcbb6OfLfGYxUgkuihJI94N3jEI=/0x0:2000x1125/960x540/media/img/mt/2023/12/Zika5/original.jpg", "source": "The Atlantic", "category_within_source": "n/a", "source_domain": "www.theatlantic.com", "topics": [{"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": -0.228222, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.025406", "ticker_sentiment_score": "-0.007547", "ticker_sentiment_label": "Neutral"}, {"ticker": "NYT", "relevance_score": "0.025406", "ticker_sentiment_score": "-0.087939", "ticker_sentiment_label": "Neutral"}]}, {"title": "Xinhua Silk Road: Presentaci\u00f3n del \"\u00cdndice de Precios del Cordyceps sinensis Silvestre de Xinhua-Yushu\" en Pek\u00edn", "url": "https://www.prnewswire.com/news-releases/xinhua-silk-road-presentacion-del-indice-de-precios-del-cordyceps-sinensis-silvestre-de-xinhua-yushu-en-pekin-891335793.html", "time_published": "20240102T115800", "authors": ["Xinhua Silk Road"], "summary": "PEK\u00cdN, 2 de enero de 2024 /PRNewswire/ -- El 27 de diciembre se public\u00f3 oficialmente en Pek\u00edn, capital de China, el \"\u00cdndice de Precios del Cordyceps sinensis Silvestre de Xinhua-Yushu\", lo que indica el acelerado desarrollo de la industria del Cordyceps sinensis silvestre y su evoluci\u00f3n hacia un ...", "banner_image": "https://mma.prnewswire.com/media/2309318/image.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.009265, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.067347", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why the Market Dipped But Moderna  ( MRNA )  Gained Today", "url": "https://www.zacks.com/stock/news/2203915/why-the-market-dipped-but-moderna-mrna-gained-today", "time_published": "20231229T225018", "authors": ["Zacks Equity Research"], "summary": "In the latest trading session, Moderna (MRNA) closed at $99.45, marking a +0.67% move from the previous day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default121.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.839681"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.236353, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.568148", "ticker_sentiment_score": "0.312151", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "2023 Will Go Down As The Year Pharma Showed Its Determination To Beat Cancer - AstraZeneca  ( NASDAQ:AZN ) ", "url": "https://www.benzinga.com/markets/penny-stocks/23/12/36431167/2023-will-go-down-as-the-year-pharma-showed-its-determination-to-beat-cancer", "time_published": "20231229T174858", "authors": ["Upwallstreet"], "summary": "During the last week of 2023, AstraZeneca PLC AZN agreed to acquire Chinese cancer therapy developer Gracell Biotechnologies Inc. as it continues its efforts to tap pharma innovations from China's biotech industry.", "banner_image": "https://cdn.benzinga.com/files/7774_0.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": -0.113696, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SGEN", "relevance_score": "0.052685", "ticker_sentiment_score": "-0.057229", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.356317", "ticker_sentiment_score": "-0.326566", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "AZN", "relevance_score": "0.402941", "ticker_sentiment_score": "-0.025176", "ticker_sentiment_label": "Neutral"}, {"ticker": "GRCL", "relevance_score": "0.052685", "ticker_sentiment_score": "-0.081067", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.572194", "ticker_sentiment_score": "-0.069952", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stocks are going out with a bang: The market is on pace for a record. The Nasdaq is having its best year since '03 | Business", "url": "https://www.cnn.com/2023/12/29/investing/stock-market-record-winners-and-losers-2023/index.html", "time_published": "20231229T143500", "authors": ["Nicole Goodkind"], "summary": "Stocks are going out with a bang: The market is on pace for a record. The Nasdaq is having its best year since ...", "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/2023-12-15t215744z-840851908-rc2wx4a0c5qc-rtrmadp-3-usa-stocks.JPG?c=16x9&q=w_800,c_fill", "source": "CNN", "category_within_source": "Markets", "source_domain": "www.cnn.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.576289"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.063439, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ENPH", "relevance_score": "0.096283", "ticker_sentiment_score": "-0.196513", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "META", "relevance_score": "0.096283", "ticker_sentiment_score": "0.165763", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVDA", "relevance_score": "0.143987", "ticker_sentiment_score": "0.197374", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DG", "relevance_score": "0.096283", "ticker_sentiment_score": "-0.166733", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "DLTR", "relevance_score": "0.04823", "ticker_sentiment_score": "0.013016", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.04823", "ticker_sentiment_score": "-0.148842", "ticker_sentiment_label": "Neutral"}, {"ticker": "DUOL", "relevance_score": "0.143987", "ticker_sentiment_score": "0.197483", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.096283", "ticker_sentiment_score": "-0.170334", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MSFT", "relevance_score": "0.04823", "ticker_sentiment_score": "0.315222", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TSLA", "relevance_score": "0.143987", "ticker_sentiment_score": "0.197374", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WBD", "relevance_score": "0.04823", "ticker_sentiment_score": "-0.051085", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANF", "relevance_score": "0.096283", "ticker_sentiment_score": "0.232735", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.143987", "ticker_sentiment_score": "-0.235041", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "WMT", "relevance_score": "0.04823", "ticker_sentiment_score": "0.013016", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stocks are sliding on final trading day of 2023. But the Nasdaq is still on pace for its best year since '03 | Business", "url": "https://www.cnn.com/2023/12/29/investing/stock-market-record-winners-and-losers-2023", "time_published": "20231229T143500", "authors": ["Nicole Goodkind"], "summary": "Stocks are going out with a bang: The market is on pace for a record. The Nasdaq is having its best year since ...", "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/2023-12-15t215744z-840851908-rc2wx4a0c5qc-rtrmadp-3-usa-stocks.JPG?c=16x9&q=w_800,c_fill", "source": "CNN", "category_within_source": "Markets", "source_domain": "www.cnn.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.576289"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.0487, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ENPH", "relevance_score": "0.090645", "ticker_sentiment_score": "-0.193783", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "META", "relevance_score": "0.090645", "ticker_sentiment_score": "0.163106", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVDA", "relevance_score": "0.135602", "ticker_sentiment_score": "0.190892", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DG", "relevance_score": "0.090645", "ticker_sentiment_score": "-0.164427", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "DLTR", "relevance_score": "0.045396", "ticker_sentiment_score": "0.013003", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.045396", "ticker_sentiment_score": "-0.148123", "ticker_sentiment_label": "Neutral"}, {"ticker": "DUOL", "relevance_score": "0.135602", "ticker_sentiment_score": "0.191228", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.090645", "ticker_sentiment_score": "-0.167479", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MSFT", "relevance_score": "0.045396", "ticker_sentiment_score": "0.314438", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TSLA", "relevance_score": "0.135602", "ticker_sentiment_score": "0.190892", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WBD", "relevance_score": "0.045396", "ticker_sentiment_score": "-0.052031", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANF", "relevance_score": "0.090645", "ticker_sentiment_score": "0.229492", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.135602", "ticker_sentiment_score": "-0.227433", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "WMT", "relevance_score": "0.045396", "ticker_sentiment_score": "0.013003", "ticker_sentiment_label": "Neutral"}]}, {"title": "Moderna Stock Is Climbing Thanks to Merck, But Is It Still a Buy?", "url": "https://www.fool.com/investing/2023/12/29/moderna-stock-is-climbing-thanks-to-merck-but-is/", "time_published": "20231229T141500", "authors": ["Alex Carchidi"], "summary": "The pair's collaboration is making waves, and there's more to come.", "banner_image": "https://g.foolcdn.com/editorial/images/759362/scientists-talking-about-antiviral-drug-in-laboratory.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.796627"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.929393"}], "overall_sentiment_score": 0.009858, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.201523", "ticker_sentiment_score": "0.279514", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Biotech Stock Roundup: BMY's KRTX and RYZB Acquisition, CYTK Surges on Study Data", "url": "https://www.zacks.com/stock/news/2203052/biotech-stock-roundup-bmys-krtx-and-ryzb-acquisition-cytk-surges-on-study-data", "time_published": "20231228T133900", "authors": ["Ekta Bagri"], "summary": "Bristol Myers (BMY) and Cytokinetics (CYTK) are in the news on acquisition announcements and study updates, respectively.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/57/40404.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.189775, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "KRTX", "relevance_score": "0.085324", "ticker_sentiment_score": "0.12637", "ticker_sentiment_label": "Neutral"}, {"ticker": "RYZB", "relevance_score": "0.127682", "ticker_sentiment_score": "0.205625", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CYTK", "relevance_score": "0.169676", "ticker_sentiment_score": "0.127713", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.127682", "ticker_sentiment_score": "0.112789", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.169676", "ticker_sentiment_score": "0.100268", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stock Market News for Dec 28, 2023", "url": "https://www.zacks.com/stock/news/2203035/stock-market-news-for-dec-28-2023", "time_published": "20231228T131600", "authors": ["Zacks Equity Research"], "summary": "Wall Street closed higher on Wednesday, with the S&P 500, the Dow and the Nasdaq notching their longest winning streak since 2017.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/db/3160.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}, {"topic": "Economy - Macro", "relevance_score": "0.451494"}], "overall_sentiment_score": -0.103539, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.184598", "ticker_sentiment_score": "0.163151", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FOREX:USD", "relevance_score": "0.273807", "ticker_sentiment_score": "-0.246071", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Operation Warp Speed, but for Everything Government Does", "url": "https://www.theatlantic.com/ideas/archive/2023/12/operation-warp-speed-trump-lessons/676913/", "time_published": "20231228T110000", "authors": ["Gary Hamel", "Michele Zanini"], "summary": "The U.S. government can achieve great things quickly when it has to. In November 2020, the Food and Drug Administration granted emergency-use authorization to the Pfizer-BioNTech vaccine for COVID-19. Seven days later, a competing vaccine from Moderna was approved.", "banner_image": "https://cdn.theatlantic.com/thumbor/3fadt4VPZL2RPFOirVUKwBg2rTU=/0x0:2000x1125/960x540/media/img/mt/2023/12/operation_warp_speed/original.jpg", "source": "The Atlantic", "category_within_source": "n/a", "source_domain": "www.theatlantic.com", "topics": [{"topic": "Energy & Transportation", "relevance_score": "0.5"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.125986, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "FDX", "relevance_score": "0.021659", "ticker_sentiment_score": "-0.013083", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.021659", "ticker_sentiment_score": "0.118938", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.021659", "ticker_sentiment_score": "0.118938", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.021659", "ticker_sentiment_score": "0.118938", "ticker_sentiment_label": "Neutral"}]}, {"title": "Upwork Stock: Covid Highflier Dusts Off Its Wings, Nears Breakout", "url": "https://www.investors.com/research/the-new-america/upwork-stock-covid-highflier-dusts-off-its-wings-nears-breakout/", "time_published": "20231227T130000", "authors": ["JED GRAHAM", "Investor's Business Daily"], "summary": "Upwork Stock: Covid Highflier Nails Soft Landing, Nears Breakout Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2023/12/wNAclients010124.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.459462"}, {"topic": "Earnings", "relevance_score": "0.967645"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.223932, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.05749", "ticker_sentiment_score": "0.114968", "ticker_sentiment_label": "Neutral"}, {"ticker": "FVRR", "relevance_score": "0.05749", "ticker_sentiment_score": "0.215", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RHI", "relevance_score": "0.05749", "ticker_sentiment_score": "0.09896", "ticker_sentiment_label": "Neutral"}, {"ticker": "COUR", "relevance_score": "0.028764", "ticker_sentiment_score": "0.117387", "ticker_sentiment_label": "Neutral"}, {"ticker": "UPWK", "relevance_score": "0.632647", "ticker_sentiment_score": "0.314131", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABNB", "relevance_score": "0.05749", "ticker_sentiment_score": "0.114968", "ticker_sentiment_label": "Neutral"}, {"ticker": "DBX", "relevance_score": "0.05749", "ticker_sentiment_score": "0.114968", "ticker_sentiment_label": "Neutral"}, {"ticker": "CCORF", "relevance_score": "0.05749", "ticker_sentiment_score": "0.227002", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.05749", "ticker_sentiment_score": "0.114968", "ticker_sentiment_label": "Neutral"}, {"ticker": "UDMY", "relevance_score": "0.028764", "ticker_sentiment_score": "0.117387", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Monster Stocks to Buy Without Any Hesitation", "url": "https://www.fool.com/investing/2023/12/27/3-monster-stocks-to-buy-without-any-hesitation/", "time_published": "20231227T105000", "authors": ["Keith Speights"], "summary": "These are easy choices for investors seeking market-beating long-term gains.", "banner_image": "https://g.foolcdn.com/editorial/images/759343/hands-behind-head-young-man.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.268385, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.054857", "ticker_sentiment_score": "0.164172", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.109455", "ticker_sentiment_score": "0.08296", "ticker_sentiment_label": "Neutral"}, {"ticker": "MELI", "relevance_score": "0.269181", "ticker_sentiment_score": "0.337638", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.054857", "ticker_sentiment_score": "0.134994", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.508593", "ticker_sentiment_score": "0.345767", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WMT", "relevance_score": "0.054857", "ticker_sentiment_score": "-0.012001", "ticker_sentiment_label": "Neutral"}]}, {"title": "S&P 500 Notches Fresh 2-Year High: How 2023's Rally Compares To Recent Years", "url": "https://www.forbes.com/sites/dereksaul/2023/12/26/sp-500-notches-fresh-2-year-high-how-2023s-rally-compares-to-recent-years/", "time_published": "20231226T211755", "authors": ["Derek Saul"], "summary": "Major stock indexes gained again Tuesday, marching toward a strong, but far from historic, year for investors. as the Dow Jones Industrial Average registered its highest closing price ever and the S&P 500 and Nasdaq Composite closed at their highest prices since January 2022.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/658b41cd66901b707bc19db8/0x0.jpg?format=jpg&crop=1450,815,x0,y0,safe&height=900&width=1600&fit=bounds", "source": "Forbes", "category_within_source": "n/a", "source_domain": "www.forbes.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.14529, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.080458", "ticker_sentiment_score": "-0.016847", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.080458", "ticker_sentiment_score": "-0.016847", "ticker_sentiment_label": "Neutral"}]}, {"title": "Investors Lose $426 Billion On These 8 Giant Losers This Year", "url": "https://www.investors.com/etfs-and-funds/sectors/sp500-investors-lose-billions-on-these-giant-losers-this-year-2023/", "time_published": "20231226T130000", "authors": ["MATT KRANTZ", "Investor's Business Daily"], "summary": "Investors scored big-time on the biggest S&P 500 stocks this year. But those who picked the wrong stocks suffered mightily. Investors lost $462 billion holding just eight stocks dropping the most market value this year, including ailing vaccine maker Pfizer ( PFE ) , struggling oil giant Chevron ...", "banner_image": "https://www.investors.com/wp-content/uploads/2020/09/Stock-sadinvestors-03-shutt.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.022152, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.212425", "ticker_sentiment_score": "0.074915", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.142565", "ticker_sentiment_score": "0.154439", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CVX", "relevance_score": "0.212425", "ticker_sentiment_score": "-0.057835", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.142565", "ticker_sentiment_score": "-0.041371", "ticker_sentiment_label": "Neutral"}, {"ticker": "XOM", "relevance_score": "0.07157", "ticker_sentiment_score": "-0.071879", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPGI", "relevance_score": "0.07157", "ticker_sentiment_score": "-0.032605", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.142565", "ticker_sentiment_score": "0.213747", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.346642", "ticker_sentiment_score": "0.121081", "ticker_sentiment_label": "Neutral"}]}, {"title": "Should You Buy This Year's Worst-Performing S&P 500 Stocks for 2024?", "url": "https://www.fool.com/investing/2023/12/25/should-you-buy-this-years-worst-performing-sp-500/", "time_published": "20231225T105200", "authors": ["Keith Speights"], "summary": "Some of this year's underperformers could have brighter futures.", "banner_image": "https://g.foolcdn.com/editorial/images/758911/young-man-worried-laptop.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.158519"}], "overall_sentiment_score": -0.056204, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ENPH", "relevance_score": "0.185781", "ticker_sentiment_score": "-0.197349", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "DG", "relevance_score": "0.245959", "ticker_sentiment_score": "0.019689", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.416516", "ticker_sentiment_score": "-0.253772", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "DLTR", "relevance_score": "0.062434", "ticker_sentiment_score": "0.09628", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.245959", "ticker_sentiment_score": "-0.074275", "ticker_sentiment_label": "Neutral"}, {"ticker": "WMT", "relevance_score": "0.062434", "ticker_sentiment_score": "0.09628", "ticker_sentiment_label": "Neutral"}]}, {"title": "S&P 500, Nasdaq 100 Aim For 8th Week Of Gains As Fed's Inflation Gauge Cools: What's Driving Markets Friday? - Ansys  ( NASDAQ:ANSS ) ", "url": "https://www.benzinga.com/analyst-ratings/analyst-color/23/12/36367344/s-p-500-nasdaq-100-aim-for-8th-week-of-gains-as-feds-inflation-gauge-cools-whats-dr", "time_published": "20231222T180424", "authors": ["Piero Cingari"], "summary": "The S&P 500 and Nasdaq 100 indices are on the verge of achieving an impressive eight consecutive weeks of gains following a more significant decline than expected in the Federal Reserve's favored inflation gauge in November, the Personal Consumption Expenditures ( PCE ) price index.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/Wall-Street-sign_8.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.857896"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.295112, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "KRTX", "relevance_score": "0.262052", "ticker_sentiment_score": "0.429985", "ticker_sentiment_label": "Bullish"}, {"ticker": "NKE", "relevance_score": "0.176502", "ticker_sentiment_score": "-0.187282", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ANSS", "relevance_score": "0.176502", "ticker_sentiment_score": "0.141083", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.176502", "ticker_sentiment_score": "0.333732", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.176502", "ticker_sentiment_score": "0.391717", "ticker_sentiment_label": "Bullish"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.176502", "ticker_sentiment_score": "0.230175", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Here are the big health sector themes to watch next year", "url": "https://www.cnbc.com/2023/12/22/health-sector-themes-to-watch-in-2024.html", "time_published": "20231222T134109", "authors": ["Bertha Coombs"], "summary": "The health-care sector has seen a big rebound this month, and analysts say some beaten-down names will continue to have positive momentum in 2024.", "banner_image": "https://image.cnbcfm.com/api/v1/image/106886059-16215272662021-05-20t161326z_1086106208_rc2sjn9cwi51_rtrmadp_0_pharmaceuticals-easteurope.jpeg?v=1621527339&w=1920&h=1080", "source": "CNBC", "category_within_source": "Business", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}, {"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "IPO", "relevance_score": "0.310843"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.77141"}, {"topic": "Earnings", "relevance_score": "0.614606"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.144638, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CVS", "relevance_score": "0.050679", "ticker_sentiment_score": "0.116952", "ticker_sentiment_label": "Neutral"}, {"ticker": "HUM", "relevance_score": "0.101154", "ticker_sentiment_score": "0.215236", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BAC", "relevance_score": "0.025352", "ticker_sentiment_score": "0.362517", "ticker_sentiment_label": "Bullish"}, {"ticker": "JPM", "relevance_score": "0.025352", "ticker_sentiment_score": "0.033066", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.025352", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.025352", "ticker_sentiment_score": "0.054743", "ticker_sentiment_label": "Neutral"}, {"ticker": "AVTR", "relevance_score": "0.025352", "ticker_sentiment_score": "0.1296", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.025352", "ticker_sentiment_score": "-0.087163", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNH", "relevance_score": "0.025352", "ticker_sentiment_score": "0.110094", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABT", "relevance_score": "0.025352", "ticker_sentiment_score": "0.075078", "ticker_sentiment_label": "Neutral"}, {"ticker": "PODD", "relevance_score": "0.050679", "ticker_sentiment_score": "0.083415", "ticker_sentiment_label": "Neutral"}, {"ticker": "QGEN", "relevance_score": "0.025352", "ticker_sentiment_score": "0.1296", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.025352", "ticker_sentiment_score": "-0.087163", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.050679", "ticker_sentiment_score": "0.083415", "ticker_sentiment_label": "Neutral"}]}, {"title": "This Is What Whales Are Betting On Moderna - Moderna  ( NASDAQ:MRNA ) ", "url": "https://www.benzinga.com/markets/options/23/12/36351754/this-is-what-whales-are-betting-on-moderna", "time_published": "20231221T203107", "authors": ["Benzinga Insights"], "summary": "Whales with a lot of money to spend have taken a noticeably bearish stance on Moderna. Looking at options history for Moderna MRNA we detected 21 trades. If we consider the specifics of each trade, it is accurate to state that 19% of the investors opened trades with bullish expectations and 80% ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.962106"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.096169, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.866386", "ticker_sentiment_score": "0.222727", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JPM", "relevance_score": "0.099476", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "What to Know About the New Fast-Spreading Covid-19 Strain", "url": "https://www.barrons.com/amp/articles/what-know-about-jn-1-new-covid-strain-342dab5b", "time_published": "20231221T170900", "authors": ["Josh Nathan-Kazis"], "summary": "What to Know About JN.1, the New Fast-Spreading Covid-19 Strain ...", "banner_image": "https://images.barrons.com/im-689951/social", "source": "Barrons", "category_within_source": "n/a", "source_domain": "www.barrons.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": -0.11328, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NYT", "relevance_score": "0.054483", "ticker_sentiment_score": "-0.01698", "ticker_sentiment_label": "Neutral"}, {"ticker": "C", "relevance_score": "0.054483", "ticker_sentiment_score": "-0.021997", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVAX", "relevance_score": "0.054483", "ticker_sentiment_score": "0.024001", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.215415", "ticker_sentiment_score": "0.091532", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.267413", "ticker_sentiment_score": "0.065433", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biotech Stock Roundup: CGEN Up on GILD Deal, MRNA Gains on Study Data & More", "url": "https://www.zacks.com/stock/news/2201158/biotech-stock-roundup-cgen-up-on-gild-deal-mrna-gains-on-study-data-more", "time_published": "20231221T163900", "authors": ["Zacks Equity Research"], "summary": "Compugen (CGEN) and Moderna (MRNA) are in the news on collaboration and study updates, respectively.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/86/1981.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.918141"}], "overall_sentiment_score": 0.079368, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CGEN", "relevance_score": "0.392948", "ticker_sentiment_score": "0.207093", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.136113", "ticker_sentiment_score": "0.05447", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.310843", "ticker_sentiment_score": "0.156311", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BLUE", "relevance_score": "0.136113", "ticker_sentiment_score": "0.065648", "ticker_sentiment_label": "Neutral"}]}, {"title": "CytomX Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference - CytomX Therapeutics  ( NASDAQ:CTMX ) ", "url": "https://www.benzinga.com/pressreleases/23/12/g36341721/cytomx-therapeutics-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference", "time_published": "20231221T130000", "authors": ["Globe Newswire"], "summary": "SOUTH SAN FRANCISCO, Calif., Dec. 21, 2023 ( GLOBE NEWSWIRE ) -- CytomX Therapeutics, Inc. CTMX, a leader in the field of conditionally activated, localized biologics, today announced that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will present at the 42nd Annual ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.0, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.09402", "ticker_sentiment_score": "-0.023668", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.186738", "ticker_sentiment_score": "-0.0341", "ticker_sentiment_label": "Neutral"}, {"ticker": "CTMX", "relevance_score": "0.186738", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "CytomX Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference", "url": "https://www.globenewswire.com/news-release/2023/12/21/2799945/37704/en/CytomX-Therapeutics-to-Present-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html", "time_published": "20231221T130000", "authors": ["CytomX Therapeutics Inc."], "summary": "SOUTH SAN FRANCISCO, Calif., Dec. 21, 2023 ( GLOBE NEWSWIRE ) -- CytomX Therapeutics, Inc. ( Nasdaq: CTMX ) , a leader in the field of conditionally activated, localized biologics, today announced that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will present at the ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/c252869d-a4c1-4e56-88e8-d80b85d20c35", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.0, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.101582", "ticker_sentiment_score": "-0.02539", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.201523", "ticker_sentiment_score": "-0.037842", "ticker_sentiment_label": "Neutral"}, {"ticker": "CTMX", "relevance_score": "0.201523", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is It Time to Buy the S&P 500's 4 Worst-Performing Stocks This Year?", "url": "https://www.fool.com/investing/2023/12/20/is-it-time-to-buy-the-sp-500s-4-worst-performing-s/", "time_published": "20231220T132817", "authors": ["Jon Quast"], "summary": "One retail chain may have the clearest path to market-beating upside from here.", "banner_image": "https://media.ycharts.com/charts/1ee61ff0e2b938a2a4d6f888f6e532ea.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.990999"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.999822"}], "overall_sentiment_score": 0.041067, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ENPH", "relevance_score": "0.073886", "ticker_sentiment_score": "-0.053381", "ticker_sentiment_label": "Neutral"}, {"ticker": "DG", "relevance_score": "0.219147", "ticker_sentiment_score": "0.049516", "ticker_sentiment_label": "Neutral"}, {"ticker": "SEDG", "relevance_score": "0.036983", "ticker_sentiment_score": "-0.050525", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.073886", "ticker_sentiment_score": "0.042827", "ticker_sentiment_label": "Neutral"}, {"ticker": "GNRC", "relevance_score": "0.073886", "ticker_sentiment_score": "0.042827", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALGN", "relevance_score": "0.036983", "ticker_sentiment_score": "-0.093085", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.219147", "ticker_sentiment_score": "0.030687", "ticker_sentiment_label": "Neutral"}]}, {"title": "Weight loss drugs, Alzheimer's treatments and gene editing: Enormous firsts defined 2023 in pharma", "url": "https://www.cnbc.com/2023/12/20/weight-loss-drugs-covid-downturn-pharma-had-a-year-full-of-firsts.html", "time_published": "20231220T120001", "authors": ["Annika Kim Constantino"], "summary": "Wall Street turned its focus to a handful of newer treatments in different disease areas in 2023, including weight loss medications and a new Alzheimer's drug.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107347356-1702499004188-gettyimages-1839792823-roy-notitle231211_np5rX.jpeg?v=1702499083&w=1920&h=1080", "source": "CNBC", "category_within_source": "Business", "source_domain": "www.cnbc.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Earnings", "relevance_score": "0.938793"}], "overall_sentiment_score": 0.016958, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.053992", "ticker_sentiment_score": "0.045817", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.08091", "ticker_sentiment_score": "-0.013704", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.053992", "ticker_sentiment_score": "-0.015961", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.027011", "ticker_sentiment_score": "0.172126", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.053992", "ticker_sentiment_score": "-0.091089", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.107736", "ticker_sentiment_score": "0.068154", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.08091", "ticker_sentiment_score": "0.132047", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.08091", "ticker_sentiment_score": "0.05643", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.053992", "ticker_sentiment_score": "-0.015961", "ticker_sentiment_label": "Neutral"}]}, {"title": "Hello, Goodbye: Incentives Draw A Battery Maker, Sweeten A Steel Sale", "url": "https://www.forbes.com/sites/cfo/2023/12/19/hello-goodbye-incentives-draw-a-battery-maker-sweeten-a-steel-sale/", "time_published": "20231219T172330", "authors": ["Megan Poinski"], "summary": "This is the published version of Forbes' CFO newsletter, which offers the latest news for chief finance officers and other leaders focused on the budget. Sign up here to get it delivered to your inbox every Tuesday.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/6581d0d5750640c59222b798/0x0.jpg?format=jpg&crop=2134,1202,x0,y200,safe&height=900&width=1600&fit=bounds", "source": "Forbes", "category_within_source": "n/a", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.890401"}, {"topic": "Financial Markets", "relevance_score": "0.999956"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.917436"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.070026, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.02275", "ticker_sentiment_score": "-0.028523", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.02275", "ticker_sentiment_score": "0.03695", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.135857", "ticker_sentiment_score": "0.116378", "ticker_sentiment_label": "Neutral"}, {"ticker": "OXY", "relevance_score": "0.02275", "ticker_sentiment_score": "0.055802", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.090816", "ticker_sentiment_score": "-0.128404", "ticker_sentiment_label": "Neutral"}, {"ticker": "NISTF", "relevance_score": "0.02275", "ticker_sentiment_score": "0.081743", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGEN", "relevance_score": "0.045482", "ticker_sentiment_score": "-0.004988", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.02275", "ticker_sentiment_score": "-0.128006", "ticker_sentiment_label": "Neutral"}, {"ticker": "PXD", "relevance_score": "0.02275", "ticker_sentiment_score": "0.055802", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.045482", "ticker_sentiment_score": "-0.004988", "ticker_sentiment_label": "Neutral"}]}, {"title": "$100 Invested In This Stock 5 Years Ago Would Be Worth $500 Today - Moderna  ( NASDAQ:MRNA ) ", "url": "https://www.benzinga.com/news/23/12/36286302/100-invested-in-this-stock-5-years-ago-would-be-worth-500-today", "time_published": "20231218T163020", "authors": ["Benzinga Insights"], "summary": "Moderna MRNA has outperformed the market over the past 5 years by 27.73% on an annualized basis producing an average annual return of 42.13%. Currently, Moderna has a market capitalization of $32.61 billion.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_3.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.983605", "ticker_sentiment_score": "0.387251", "ticker_sentiment_label": "Bullish"}]}, {"title": "Bonus: Tracey Franklin", "url": "https://www.economist.com/news/2023/12/18/bonus-tracey-franklin", "time_published": "20231218T161214", "authors": ["The Economist"], "summary": "Tracey Franklin, chief human resources officer at vaccine and biotech company Moderna, tells Andrew Palmer what turbocharged growth taught her about hiring, teamwork and company culture. This is a subscriber-only episode.", "banner_image": "https://www.economist.com/img/b/1280/720/90/media-assets/image/20231125_PDP511.jpg", "source": "The Economist", "category_within_source": "BusinessGoogleRSS", "source_domain": "www.economist.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.360189, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.323078", "ticker_sentiment_score": "0.21187", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "3 Stocks Down 30% or More This Year That Wall Street Expects to Skyrocket in 2024", "url": "https://www.fool.com/investing/2023/12/18/stocks-down-wall-street-expects-skyrocket-2024/", "time_published": "20231218T105000", "authors": ["Keith Speights"], "summary": "Analysts think these beaten-down stocks could rebound strongly in the new year.", "banner_image": "https://g.foolcdn.com/editorial/images/758417/woman-with-fingers-crossed-laptop.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.16711, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.432291", "ticker_sentiment_score": "0.310115", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.056943", "ticker_sentiment_score": "-0.137961", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.479683", "ticker_sentiment_score": "0.237914", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Moderna Just Took a Step Closer to Its Product Launch Goal. Is the Stock a Buy?", "url": "https://www.fool.com/investing/2023/12/18/moderna-a-step-closer-to-goal-is-it-a-buy/", "time_published": "20231218T100000", "authors": ["Adria Cimino"], "summary": "Moderna's personalized cancer vaccine candidate just delivered excellent clinical trial results.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F758523%2Fgettyimages-1213513544.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.744043"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.962106"}], "overall_sentiment_score": 0.026781, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.605266", "ticker_sentiment_score": "0.14229", "ticker_sentiment_label": "Neutral"}]}, {"title": "AI: a blessing or curse for humanity? | FT Tech", "url": "https://www.ft.com/video/1c199563-e2cd-4817-990f-79972f3828fb", "time_published": "20231218T040241", "authors": [], "summary": "You can enable subtitles ( captions ) in the video player We're now able to get machines to do things that look like what humans can do. You can ask them anything and they'll give you a very intelligent answer. It might be that just a few other changes to the AI systems would actually ...", "banner_image": "https://www.ft.com/__origami/service/image/v2/images/raw/https%3A%2F%2Fnext-video-editor-images.s3.ap-northeast-1.amazonaws.com%2F0b65cf8e-18c9-4ecd-bed2-89d905edf26e?source=next-opengraph&fit=scale-down&width=900", "source": "Financial Times", "category_within_source": "GoogleRSS", "source_domain": "www.ft.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.136297, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.03478", "ticker_sentiment_score": "0.052691", "ticker_sentiment_label": "Neutral"}]}, {"title": "Contaminated Vaccines: FDA Reportedly Finds Cleaning And Expiry Lapses At Moderna's Massachusetts Facility - Merck & Co  ( NYSE:MRK ) , Moderna  ( NASDAQ:MRNA ) ", "url": "https://www.benzinga.com/markets/equities/23/12/36272737/contaminated-vaccines-fda-reportedly-finds-cleaning-and-expiry-lapses-at-modernas-massachusetts-", "time_published": "20231216T195823", "authors": ["Nabaparna Bhattacharya"], "summary": "The U.S. Food and Drug Administration ( FDA ) identified several quality control issues at the primary manufacturing facility of Moderna Inc. MRNA during a September inspection.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/16/shutterstock_2021925674.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.062553, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.626443", "ticker_sentiment_score": "0.139688", "ticker_sentiment_label": "Neutral"}]}, {"title": "Barron's Weekend Stock Picks: Nokia, Roku, Nvidia And Moderna's Latest Cancer Treatment Trial - Moderna  ( NASDAQ:MRNA ) , Amazon.com  ( NASDAQ:AMZN ) ", "url": "https://www.benzinga.com/news/23/12/36270466/barrons-weekend-stock-picks-nokia-roku-nvidia-and-modernas-latest-cancer-treatment-trial", "time_published": "20231216T152618", "authors": ["Justin Chan"], "summary": "Benzinga reviews this weekend's top stories covered by Barron's. Here are the articles investors need to read. In \"Sell Nokia Stock, Citi Says. It Remains 'a Value Trap,'\" Emily Dattilo writes that Nokia Oyj's NOK stock dropped after a downgrade due to expected reduced sales, highlighting the ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/16/shutterstock_1783441619.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.54554"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.112843, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVDA", "relevance_score": "0.399204", "ticker_sentiment_score": "0.459628", "ticker_sentiment_label": "Bullish"}, {"ticker": "ROKU", "relevance_score": "0.399204", "ticker_sentiment_score": "-0.271094", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "C", "relevance_score": "0.138464", "ticker_sentiment_score": "-0.221265", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "NOK", "relevance_score": "0.399204", "ticker_sentiment_score": "-0.454512", "ticker_sentiment_label": "Bearish"}, {"ticker": "MRNA", "relevance_score": "0.399204", "ticker_sentiment_score": "0.128171", "ticker_sentiment_label": "Neutral"}]}, {"title": "There's Still Time To Legally Cut Your 2023 Tax Bill - Here's How", "url": "https://www.investors.com/etfs-and-funds/personal-finance/pay-less-tax-to-legally-cut-your-2023-tax-bill-heres-how/", "time_published": "20231215T175600", "authors": ["ADAM SHELL", "Investor's Business Daily"], "summary": "Pay Less Tax Legally In 2023. Here's How Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2023/12/Stock-rippingpapertaxform-01-shutt.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.990999"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.259445, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ENPH", "relevance_score": "0.055109", "ticker_sentiment_score": "0.039124", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.082582", "ticker_sentiment_score": "0.041115", "ticker_sentiment_label": "Neutral"}, {"ticker": "SCHW", "relevance_score": "0.109956", "ticker_sentiment_score": "0.092296", "ticker_sentiment_label": "Neutral"}, {"ticker": "SEDG", "relevance_score": "0.055109", "ticker_sentiment_score": "0.039124", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.055109", "ticker_sentiment_score": "0.039124", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:USD", "relevance_score": "0.027571", "ticker_sentiment_score": "0.255716", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "FDA Expands Merck's  ( MRK )  Welireg Label in Renal Cell Carcinoma", "url": "https://www.zacks.com/stock/news/2198921/fda-expands-mercks-mrk-welireg-label-in-renal-cell-carcinoma", "time_published": "20231215T173200", "authors": ["Zacks Equity Research"], "summary": "Per Merck (MRK), the latest FDA approval to Welireg marks the first time a new treatment has been approved in a novel therapeutic class in advanced renal cell carcinoma since 2015.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ef/472.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.682689"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.09686, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.256719", "ticker_sentiment_score": "-0.017999", "ticker_sentiment_label": "Neutral"}, {"ticker": "GLPG", "relevance_score": "0.30569", "ticker_sentiment_score": "0.080967", "ticker_sentiment_label": "Neutral"}, {"ticker": "OCUP", "relevance_score": "0.104228", "ticker_sentiment_score": "0.052553", "ticker_sentiment_label": "Neutral"}]}, {"title": "Moderna  ( MRNA )  Soars on Upbeat Data From Cancer Therapy Study", "url": "https://www.zacks.com/stock/news/2198897/moderna-mrna-soars-on-upbeat-data-from-cancer-therapy-study", "time_published": "20231215T172700", "authors": ["Zacks Equity Research"], "summary": "Three-year follow up data from a mid-stage study shows that treatment with Moderna (MRNA)/Merck's cancer combination therapy reduces recurrence/death risk in certain melanoma patients by half.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/db/3160.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.769861"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.019405, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.514619", "ticker_sentiment_score": "-0.019422", "ticker_sentiment_label": "Neutral"}, {"ticker": "GLPG", "relevance_score": "0.324495", "ticker_sentiment_score": "0.084811", "ticker_sentiment_label": "Neutral"}, {"ticker": "OCUP", "relevance_score": "0.110973", "ticker_sentiment_score": "0.053649", "ticker_sentiment_label": "Neutral"}]}, {"title": "Market Surges To 2023 Highs As Fed Pivots Toward Rate Cuts: Weekly Review", "url": "https://www.investors.com/news/stock-market-rally-surges-to-2023-highs-as-fed-pivots-toward-rate-cuts-weekly-review/", "time_published": "20231215T155400", "authors": ["Investor's Business Daily", "IBD STAFF"], "summary": "The stock market rally raced higher in a powerful, broad advance as the Federal Reserve signaled it could cut rates three times in 2024. The Dow Jones hit a record high while the S&P 500, Nasdaq composite, S&P MidCap 400 and small-cap Russell 2023 all set 2023 bests. Treasury yields plunged.", "banner_image": "https://www.investors.com/wp-content/uploads/2021/03/LSSECRETS-peak-040221.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.142857"}, {"topic": "Energy & Transportation", "relevance_score": "0.142857"}, {"topic": "Technology", "relevance_score": "0.142857"}, {"topic": "Finance", "relevance_score": "0.142857"}, {"topic": "Economy - Monetary", "relevance_score": "0.972193"}, {"topic": "Retail & Wholesale", "relevance_score": "0.142857"}, {"topic": "Financial Markets", "relevance_score": "0.980716"}, {"topic": "Manufacturing", "relevance_score": "0.142857"}, {"topic": "Earnings", "relevance_score": "0.992549"}, {"topic": "Real Estate & Construction", "relevance_score": "0.142857"}], "overall_sentiment_score": -0.065812, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVDA", "relevance_score": "0.059935", "ticker_sentiment_score": "0.086", "ticker_sentiment_label": "Neutral"}, {"ticker": "BRK-A", "relevance_score": "0.029989", "ticker_sentiment_score": "-0.028872", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.119532", "ticker_sentiment_score": "-0.108167", "ticker_sentiment_label": "Neutral"}, {"ticker": "ORCL", "relevance_score": "0.178459", "ticker_sentiment_score": "-0.007668", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.059935", "ticker_sentiment_score": "-0.441897", "ticker_sentiment_label": "Bearish"}, {"ticker": "OXY", "relevance_score": "0.089797", "ticker_sentiment_score": "-0.031906", "ticker_sentiment_label": "Neutral"}, {"ticker": "COST", "relevance_score": "0.119532", "ticker_sentiment_score": "0.106769", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.029989", "ticker_sentiment_score": "0.217562", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LEN", "relevance_score": "0.059935", "ticker_sentiment_score": "-0.003011", "ticker_sentiment_label": "Neutral"}, {"ticker": "INTC", "relevance_score": "0.1491", "ticker_sentiment_score": "0.10867", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADBE", "relevance_score": "0.178459", "ticker_sentiment_score": "0.058147", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.059935", "ticker_sentiment_score": "-0.141007", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.059935", "ticker_sentiment_score": "-0.2386", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "The Pain Continues For Bedraggled Pharma Heavyweight Pfizer", "url": "https://www.investors.com/news/technology/pfizer-stock-suffers-another-price-target-cut-as-the-pain-continues/", "time_published": "20231215T144000", "authors": ["Investor's Business Daily", "ALLISON GATLIN"], "summary": "Pfizer Stock Suffers Another Price Target Cut As The Pain Continues Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2020/11/Stock-Pfizer-04-shutt.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.769861"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.995077"}], "overall_sentiment_score": -0.144693, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.154455", "ticker_sentiment_score": "-0.393069", "ticker_sentiment_label": "Bearish"}, {"ticker": "PFE", "relevance_score": "0.827318", "ticker_sentiment_score": "-0.310448", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Pharma Stock Roundup: PFE Issues Weak 2024 View, AZN to Buy Icosavax & More", "url": "https://www.zacks.com/stock/news/2198513/pharma-stock-roundup-pfe-issues-weak-2024-view-azn-to-buy-icosavax-more", "time_published": "20231215T133400", "authors": ["Kinjel Shah"], "summary": "Pfizer (PFE) issues a disappointing outlook for 2024. AstraZeneca (AZN) announces that it is buying vaccine company, Icosavax.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/52/873.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.938793"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.156532, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.271489", "ticker_sentiment_score": "0.219964", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LLY", "relevance_score": "0.079", "ticker_sentiment_score": "-0.064902", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.079", "ticker_sentiment_score": "-0.065918", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGEN", "relevance_score": "0.195814", "ticker_sentiment_score": "0.070548", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.195814", "ticker_sentiment_score": "-0.045716", "ticker_sentiment_label": "Neutral"}, {"ticker": "ICVX", "relevance_score": "0.157227", "ticker_sentiment_score": "0.105049", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.344606", "ticker_sentiment_score": "0.047034", "ticker_sentiment_label": "Neutral"}]}, {"title": "Daily: Pope Francis Calls For Regulation Of AI", "url": "https://www.forbes.com/sites/forbesdaily/2023/12/15/forbes-daily-pope-francis-calls-for-regulation-of-ai/", "time_published": "20231215T130808", "authors": ["Danielle Chemtob"], "summary": "This is a published version of the Forbes Daily newsletter, you can sign-up to get Forbes Daily in your inbox here. There's plenty of discussion about how younger generations are transforming the workplace, but the fastest-growing demographic in the workforce is actually people 75 and older, ...", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/657c4eabf820a73144c2709e/0x0.jpg?format=jpg&crop=4464,2511,x0,y230,safe&height=900&width=1600&fit=bounds", "source": "Forbes", "category_within_source": "n/a", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.058114, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.023957", "ticker_sentiment_score": "0.136231", "ticker_sentiment_label": "Neutral"}, {"ticker": "MAT", "relevance_score": "0.047892", "ticker_sentiment_score": "0.053694", "ticker_sentiment_label": "Neutral"}, {"ticker": "NYT", "relevance_score": "0.023957", "ticker_sentiment_score": "-0.108418", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.023957", "ticker_sentiment_score": "0.152425", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HD", "relevance_score": "0.023957", "ticker_sentiment_score": "0.152425", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.023957", "ticker_sentiment_score": "-0.132576", "ticker_sentiment_label": "Neutral"}, {"ticker": "CEIX", "relevance_score": "0.023957", "ticker_sentiment_score": "0.006259", "ticker_sentiment_label": "Neutral"}, {"ticker": "DUOL", "relevance_score": "0.047892", "ticker_sentiment_score": "0.23686", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BA", "relevance_score": "0.023957", "ticker_sentiment_score": "0.152425", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "SNL's New Kings of Bizarro Buddy Comedy", "url": "https://www.theatlantic.com/magazine/archive/2024/01/please-dont-destroy-snl-foggy-mountain-movie/676144/", "time_published": "20231215T120000", "authors": ["David Sims"], "summary": "The Bizarro Buddy Comedy of SNL's Please Don't Destroy The Atlantic ...", "banner_image": "https://cdn.theatlantic.com/thumbor/Y9PO-zyCepJTdE5hM7lnF_-mvaE=/0x0:2000x1125/960x540/media/img/2023/12/0124_Sims_copy/original.png", "source": "The Atlantic", "category_within_source": "n/a", "source_domain": "www.theatlantic.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.127418, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.029184", "ticker_sentiment_score": "0.005883", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.029184", "ticker_sentiment_score": "0.005883", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 No-Brainer Healthcare Stocks to Buy Right Now", "url": "https://www.fool.com/investing/2023/12/15/3-no-brainer-healthcare-stocks-to-buy-right-now/", "time_published": "20231215T100000", "authors": ["Adria Cimino"], "summary": "These players have what it takes to boost your portfolio over time.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F758186%2Folder-woman-laptop.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.990786"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.413559"}], "overall_sentiment_score": 0.271986, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.499254", "ticker_sentiment_score": "0.225713", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.399506", "ticker_sentiment_score": "0.205006", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABT", "relevance_score": "0.11894", "ticker_sentiment_score": "0.066386", "ticker_sentiment_label": "Neutral"}]}, {"title": "Fear & Greed Index Remains In 'Greed' Zone Following Economic Reports; Dow Records New High - Darden Restaurants  ( NYSE:DRI ) , Moderna  ( NASDAQ:MRNA ) ", "url": "https://www.benzinga.com/news/earnings/23/12/36251742/fear-greed-index-remains-in-greed-zone-following-economic-reports-dow-records-new-high", "time_published": "20231215T065814", "authors": ["Avi Kapoor"], "summary": "The CNN Money Fear and Greed index showed some easing in overall market sentiment, but the index remained in the \"Greed\" zone on Thursday. U.S. stocks closed higher on Thursday, with the 10-year Treasury falling below 4%.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/14/image13_0.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}], "overall_sentiment_score": -0.131278, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "WBD", "relevance_score": "0.116348", "ticker_sentiment_score": "-0.197485", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "DRI", "relevance_score": "0.230235", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "RCAT", "relevance_score": "0.230235", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.230235", "ticker_sentiment_score": "0.230315", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "COST, PFE, MRNA, LEN, TSLA: Why These 5 Stocks Are Trending Today - Costco Wholesale  ( NASDAQ:COST ) , Lennar  ( NYSE:LEN ) ", "url": "https://www.benzinga.com/news/23/12/36250606/costco-pfizer-moderna-lennar-corp-tesla-why-these-5-stocks-are-on-investors-radars-today", "time_published": "20231215T023458", "authors": ["Benzinga Neuro"], "summary": "The stock market witnessed a notable surge today, with the Dow Jones rising 0.43% to 37,248.35 and the S&P 500 gaining 0.26% to 4,719.55. The Nasdaq also ended Thursday in the green appreciating 0.19% to 14,761.56.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/Stocks-Photo-by-Jirapong-Manustrong-on-S_8.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.998356"}, {"topic": "Earnings", "relevance_score": "0.614606"}, {"topic": "Real Estate & Construction", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.232534, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SSTK", "relevance_score": "0.110462", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGEN", "relevance_score": "0.110462", "ticker_sentiment_score": "0.202633", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LEN", "relevance_score": "0.110462", "ticker_sentiment_score": "0.212937", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.110462", "ticker_sentiment_score": "-0.040981", "ticker_sentiment_label": "Neutral"}, {"ticker": "UBER", "relevance_score": "0.218817", "ticker_sentiment_score": "0.130902", "ticker_sentiment_label": "Neutral"}]}, {"title": "Moderna CEO Highlights Promising Cancer Vaccine Data: 'Think About The Number Of Lives That Can Be Impacted' - Moderna  ( NASDAQ:MRNA ) ", "url": "https://www.benzinga.com/news/23/12/36246521/moderna-ceo-highlights-promising-cancer-vaccine-data-think-about-the-number-of-lives-that-can-be-imp", "time_published": "20231214T210325", "authors": ["Erica Kollmann"], "summary": "Moderna, Inc. MRNA CEO St\u00e9phane Bancel appeared on CNBC's \"Squawk Box\" Thursday to discuss the company's promising new cancer vaccine developed in partnership with Merck & Company, Inc. MRK.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/14/50714712987_c540b01ef5_k.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.071018, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.699089", "ticker_sentiment_score": "-0.436498", "ticker_sentiment_label": "Bearish"}, {"ticker": "PFE", "relevance_score": "0.269776", "ticker_sentiment_score": "-0.187431", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Dow Jones Pares Gains Amid 'Goldilocks' Set Up; Moderna Soars On Cancer Vaccine", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-at-new-high-amid-goldilocks-set-up-moderna-soars-on-cancer-vaccine/", "time_published": "20231214T202800", "authors": ["VIDYA RAMAKRISHNAN", "Investor's Business Daily"], "summary": "Dow Jones Pares Gains Amid 'Goldilocks' Set Up. Moderna Soars On Cancer Vaccine Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2017/03/silo_retail_033017_adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "0.999696"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.576289"}, {"topic": "Real Estate & Construction", "relevance_score": "0.166667"}], "overall_sentiment_score": 0.021818, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.125134", "ticker_sentiment_score": "0.107586", "ticker_sentiment_label": "Neutral"}, {"ticker": "COST", "relevance_score": "0.125134", "ticker_sentiment_score": "-0.231671", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "LEN", "relevance_score": "0.125134", "ticker_sentiment_score": "0.031232", "ticker_sentiment_label": "Neutral"}, {"ticker": "JBL", "relevance_score": "0.186738", "ticker_sentiment_score": "0.004618", "ticker_sentiment_label": "Neutral"}, {"ticker": "INTC", "relevance_score": "0.125134", "ticker_sentiment_score": "0.107586", "ticker_sentiment_label": "Neutral"}, {"ticker": "SMCI", "relevance_score": "0.125134", "ticker_sentiment_score": "-0.092156", "ticker_sentiment_label": "Neutral"}, {"ticker": "TEX", "relevance_score": "0.062761", "ticker_sentiment_score": "-0.093412", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAT", "relevance_score": "0.125134", "ticker_sentiment_score": "0.107586", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADBE", "relevance_score": "0.125134", "ticker_sentiment_score": "-0.044531", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.125134", "ticker_sentiment_score": "0.107586", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.125134", "ticker_sentiment_score": "0.019708", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNH", "relevance_score": "0.125134", "ticker_sentiment_score": "0.107586", "ticker_sentiment_label": "Neutral"}]}, {"title": "Nasdaq Turns Lower; US Retail Sales Top Estimates - Amtech Systems  ( NASDAQ:ASYS ) , Cepton  ( NASDAQ:CPTN ) ", "url": "https://www.benzinga.com/news/earnings/23/12/36245135/nasdaq-turns-lower-us-retail-sales-top-estimates", "time_published": "20231214T192309", "authors": ["Avi Kapoor"], "summary": "U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite turning lower on Thursday. The Dow traded up 0.04% to 37,105.00 while the NASDAQ fell 0.44% to 14,669.25. The S&P 500 also fell, dropping, 0.10% to 4,702.57. Real estate shares rose by 3% on Thursday.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/14/image32.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": -0.004852, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "OXY", "relevance_score": "0.06179", "ticker_sentiment_score": "0.111024", "ticker_sentiment_label": "Neutral"}, {"ticker": "ASYS", "relevance_score": "0.123209", "ticker_sentiment_score": "0.200021", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VCIG", "relevance_score": "0.123209", "ticker_sentiment_score": "0.193667", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RPHM", "relevance_score": "0.123209", "ticker_sentiment_score": "0.035064", "ticker_sentiment_label": "Neutral"}, {"ticker": "CPTN", "relevance_score": "0.183895", "ticker_sentiment_score": "-0.333062", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "FRGT", "relevance_score": "0.123209", "ticker_sentiment_score": "0.329248", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.123209", "ticker_sentiment_score": "0.148002", "ticker_sentiment_label": "Neutral"}]}, {"title": "US Stocks Eye 7-Day Winning Streak As Mortgage Rates Fall Below 7%, Yields Tumble: What's Driving Markets Thursday? - Align Tech  ( NASDAQ:ALGN ) ", "url": "https://www.benzinga.com/markets/cryptocurrency/23/12/36244595/us-stocks-eye-7-day-winning-streak-as-mortgage-rates-fall-below-7-yields-tumble-whats-driv", "time_published": "20231214T185822", "authors": ["Piero Cingari"], "summary": "It's shaping up to be a positive Thursday on Wall Street, with risk sentiment remaining robust after the Federal Reserve effectively opened the door to rate cuts in 2024. The S&P 500 is poised to record its seventh consecutive green session, closing in at just 1.5% away from its all-time highs.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/Bull-Stock-chart_4.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Financial Markets", "relevance_score": "0.986564"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Real Estate & Construction", "relevance_score": "0.2"}], "overall_sentiment_score": 0.107593, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ENPH", "relevance_score": "0.130571", "ticker_sentiment_score": "0.115317", "ticker_sentiment_label": "Neutral"}, {"ticker": "LCID", "relevance_score": "0.130571", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TPIC", "relevance_score": "0.130571", "ticker_sentiment_score": "0.23273", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FSLR", "relevance_score": "0.130571", "ticker_sentiment_score": "0.115317", "ticker_sentiment_label": "Neutral"}, {"ticker": "SEDG", "relevance_score": "0.130571", "ticker_sentiment_score": "0.115317", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.065506", "ticker_sentiment_score": "-0.176403", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "APLS", "relevance_score": "0.130571", "ticker_sentiment_score": "-0.207821", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ALGN", "relevance_score": "0.130571", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.130571", "ticker_sentiment_score": "0.066812", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.130571", "ticker_sentiment_score": "-0.039564", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:EUR", "relevance_score": "0.065506", "ticker_sentiment_score": "-0.168368", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "FOREX:USD", "relevance_score": "0.130571", "ticker_sentiment_score": "-0.082927", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.130571", "ticker_sentiment_score": "0.330725", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Moderna Stock Soars After Cancer Vaccine's Strong Test Results", "url": "https://www.forbes.com/sites/jamesfarrell/2023/12/14/moderna-stock-soars-after-cancer-vaccines-strong-test-results/", "time_published": "20231214T163508", "authors": ["James Farrell"], "summary": "Moderna's new mRNA vaccine reduces the chance of relapse or death of skin cancer by half when paired with Merck's immunotherapy drug Keytruda, new data shows, marking a step forward in the developing field of mRNA technology and sending Moderna's stock soaring Thursday morning.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/657b2e714d4d9431412ee712/0x0.jpg?format=jpg&crop=2832,1593,x0,y147,safe&height=900&width=1600&fit=bounds", "source": "Forbes", "category_within_source": "n/a", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": -0.176986, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.402941", "ticker_sentiment_score": "-0.169424", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Dow Jones Hits Another High As Rally Continues; Moderna Soars On Cancer Drug News", "url": "https://www.investors.com/market-trend/stock-market-today/stock-market-keeps-rally-going-moderna-soars-on-cancer-drug-news/", "time_published": "20231214T160100", "authors": ["Investor's Business Daily", "KIMBERLEY KOENIG"], "summary": "Stock Market Keeps Rally Going. Moderna Soars On Cancer Drug News Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2023/12/Stock-dowjones-02-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.142857"}, {"topic": "Energy & Transportation", "relevance_score": "0.142857"}, {"topic": "Technology", "relevance_score": "0.142857"}, {"topic": "Finance", "relevance_score": "0.142857"}, {"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Retail & Wholesale", "relevance_score": "0.142857"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.142857"}, {"topic": "Earnings", "relevance_score": "0.988787"}, {"topic": "Real Estate & Construction", "relevance_score": "0.142857"}], "overall_sentiment_score": 0.152985, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALK", "relevance_score": "0.099683", "ticker_sentiment_score": "0.176834", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "COST", "relevance_score": "0.099683", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LEN", "relevance_score": "0.099683", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "JBL", "relevance_score": "0.099683", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.049939", "ticker_sentiment_score": "0.07599", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADBE", "relevance_score": "0.149038", "ticker_sentiment_score": "0.136492", "ticker_sentiment_label": "Neutral"}, {"ticker": "LYV", "relevance_score": "0.099683", "ticker_sentiment_score": "0.083075", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.049939", "ticker_sentiment_score": "0.15101", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.149038", "ticker_sentiment_score": "-0.170392", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PLTR", "relevance_score": "0.099683", "ticker_sentiment_score": "0.350035", "ticker_sentiment_label": "Bullish"}]}, {"title": "Moderna's stock buoyed by positive data in trial of melanoma treatment", "url": "https://www.marketwatch.com/story/modernas-stock-rallies-7-9-after-announcing-positive-data-in-trial-of-melanoma-treatment-combined-with-mercks-keytruda-5319c3a1", "time_published": "20231214T152900", "authors": ["Ciara Linnane"], "summary": "Moderna's stock was on track for its biggest one-day gain in more than a year.", "banner_image": "https://images.mktw.net/im-611595/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": -0.038618, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.531326", "ticker_sentiment_score": "0.115454", "ticker_sentiment_label": "Neutral"}]}, {"title": "Jabil Posts Upbeat Earnings, Joins Moderna, Rivian Automotive And Other Big Stocks Moving Higher On Thursday - Alcoa  ( NYSE:AA ) , Alector  ( NASDAQ:ALEC ) ", "url": "https://www.benzinga.com/news/23/12/36239155/jabil-posts-upbeat-earnings-joins-moderna-rivian-automotive-and-other-big-stocks-moving-higher-on-th", "time_published": "20231214T151520", "authors": ["Avi Kapoor"], "summary": "U.S. stocks traded higher, with the Nasdaq Composite gaining around 75 points on Thursday. Shares of Jabil Inc. JBL rose during Thursday's session after the company reported first-quarter earnings. Jabil reported quarterly revenue of $8.39 billion, down by 13% year-on-year, beating the consensus ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/14/jabil_-_logo_0.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.744043"}, {"topic": "Real Estate & Construction", "relevance_score": "0.166667"}], "overall_sentiment_score": 0.210657, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AA", "relevance_score": "0.290033", "ticker_sentiment_score": "0.366527", "ticker_sentiment_label": "Bullish"}, {"ticker": "ENPH", "relevance_score": "0.195814", "ticker_sentiment_score": "0.501186", "ticker_sentiment_label": "Bullish"}, {"ticker": "CG", "relevance_score": "0.195814", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CFG", "relevance_score": "0.195814", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NOVA", "relevance_score": "0.195814", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIVN", "relevance_score": "0.195814", "ticker_sentiment_score": "0.303754", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GFI", "relevance_score": "0.195814", "ticker_sentiment_score": "0.129246", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALGN", "relevance_score": "0.290033", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "OPEN", "relevance_score": "0.195814", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LCID", "relevance_score": "0.290033", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "FSLR", "relevance_score": "0.195814", "ticker_sentiment_score": "0.501186", "ticker_sentiment_label": "Bullish"}, {"ticker": "RF", "relevance_score": "0.195814", "ticker_sentiment_score": "0.501186", "ticker_sentiment_label": "Bullish"}, {"ticker": "JBL", "relevance_score": "0.380012", "ticker_sentiment_score": "0.178746", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PACB", "relevance_score": "0.195814", "ticker_sentiment_score": "0.006443", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALEC", "relevance_score": "0.290033", "ticker_sentiment_score": "0.257527", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "POOL", "relevance_score": "0.195814", "ticker_sentiment_score": "0.501186", "ticker_sentiment_label": "Bullish"}, {"ticker": "MRNA", "relevance_score": "0.290033", "ticker_sentiment_score": "0.076997", "ticker_sentiment_label": "Neutral"}, {"ticker": "RDFN", "relevance_score": "0.195814", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biotech Stock Roundup: BLUE, CRSP & VRTX Get Gene Therapy Nod, ACAD Up on Patent News", "url": "https://www.zacks.com/stock/news/2198026/biotech-stock-roundup-blue-crsp-vrtx-get-gene-therapy-nod-acad-up-on-patent-news", "time_published": "20231214T145500", "authors": ["Zacks Equity Research"], "summary": "bluebird (BLUE) and Vertex (VRTX) are in the spotlight this week on approval of therapies and pipeline news.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7b/850.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.255199, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.142989", "ticker_sentiment_score": "0.144851", "ticker_sentiment_label": "Neutral"}, {"ticker": "EDIT", "relevance_score": "0.178196", "ticker_sentiment_score": "0.174354", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ACAD", "relevance_score": "0.107495", "ticker_sentiment_score": "0.067248", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.035929", "ticker_sentiment_score": "0.10456", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLUE", "relevance_score": "0.071784", "ticker_sentiment_score": "0.091535", "ticker_sentiment_label": "Neutral"}]}, {"title": "This Biotech Expects Europe To Reject Its Biggest Drug; Shares Crash", "url": "https://www.investors.com/news/technology/apls-stock-crashes-as-apellis-calls-for-european-rejection-of-eye-drug/", "time_published": "20231214T143100", "authors": ["Investor's Business Daily", "ALLISON GATLIN"], "summary": "APLS Stock Crashes As Apellis Calls For European Rejection Of Eye Drug Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2018/02/Stock-drugs-02-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.918141"}], "overall_sentiment_score": -0.130006, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "APLS", "relevance_score": "0.507107", "ticker_sentiment_score": "-0.5603", "ticker_sentiment_label": "Bearish"}, {"ticker": "MRNA", "relevance_score": "0.136113", "ticker_sentiment_score": "-0.750818", "ticker_sentiment_label": "Bearish"}]}, {"title": "2 Big Stocks Making Big Moves Thursday", "url": "https://www.fool.com/investing/2023/12/14/2-big-stocks-making-big-moves-thursday/", "time_published": "20231214T142848", "authors": ["Dan Caplinger"], "summary": "One is rising while the other's on the decline. Here's why.", "banner_image": "https://g.foolcdn.com/editorial/images/758277/programmer-gettyimages-691555348.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.955357"}, {"topic": "Earnings", "relevance_score": "0.650727"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.350591, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "ADBE", "relevance_score": "0.450354", "ticker_sentiment_score": "0.523066", "ticker_sentiment_label": "Bullish"}, {"ticker": "MRNA", "relevance_score": "0.391923", "ticker_sentiment_score": "0.353723", "ticker_sentiment_label": "Bullish"}]}, {"title": "Moderna Stock Is Soaring Today - Here's Why - Merck & Co  ( NYSE:MRK ) , Moderna  ( NASDAQ:MRNA ) ", "url": "https://www.benzinga.com/general/biotech/23/12/36234606/moderna-stock-is-soaring-today-heres-why", "time_published": "20231214T142222", "authors": ["Vandana Singh"], "summary": "Moderna Inc MRNA and Merck & Co Inc MRK announced follow-up data from the Phase 2b randomized KEYNOTE-942/mRNA-4157-P201 study of mRNA-4157 ( V940 ) , an investigational individualized neoantigen therapy ( INT ) , in combination with Keytruda in patients with resected high-risk melanoma ( stage ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/14/moderna_covid-19_vaccine_2021_g.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": -0.107885, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.499789", "ticker_sentiment_score": "0.111525", "ticker_sentiment_label": "Neutral"}]}, {"title": "Experimental cancer vaccine, combined with immunotherapy, continues to show benefits against melanoma, trial shows", "url": "https://www.cnn.com/2023/12/14/health/moderna-merck-melanoma-vaccine-immunotherapy/index.html", "time_published": "20231214T135100", "authors": ["Katherine Dillinger"], "summary": "An investigational mRNA vaccine used along with immunotherapy continues to show benefit for people with high-risk forms of the skin cancer melanoma, the drugmakers said Thursday. Experimental cancer vaccine combined with immunotherapy delayed return of melanoma, Moderna and Merck say", "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/230417105155-melanoma-experimental-cancer-vaccine.jpg?c=16x9&q=h_144,w_256,c_fill", "source": "CNN", "category_within_source": "Markets", "source_domain": "www.cnn.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.263532, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.349329", "ticker_sentiment_score": "-0.403501", "ticker_sentiment_label": "Bearish"}, {"ticker": "WBD", "relevance_score": "0.179121", "ticker_sentiment_score": "0.169676", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Moderna's Cancer Vaccine Cuts Risk Of Relapse, Death By 49%", "url": "https://www.investors.com/news/technology/moderna-stock-cancer-vaccine-cuts-risk-of-relapse-death/", "time_published": "20231214T134000", "authors": ["ALLISON GATLIN", "Investor's Business Daily"], "summary": "Moderna's ( MRK ) Merck ( MRK ) -partnered cancer vaccine reduced the risk of relapse or death by 49% in melanoma patients, the companies said Thursday. The update fueled big gains for Moderna stock, which has been hamstrung recently on Covid news.", "banner_image": "https://www.investors.com/wp-content/uploads/2020/12/Stock-moderna-vaccine-01-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.413559"}], "overall_sentiment_score": -0.316019, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.601191", "ticker_sentiment_score": "-0.466473", "ticker_sentiment_label": "Bearish"}, {"ticker": "PFE", "relevance_score": "0.148731", "ticker_sentiment_score": "-0.151083", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Pfizer  ( PFE )  Stock Sinks on Weak 2024 View as COVID Sales Fall", "url": "https://www.zacks.com/stock/news/2197825/pfizer-pfe-stock-sinks-on-weak-2024-view-as-covid-sales-fall", "time_published": "20231214T131300", "authors": ["Zacks Equity Research"], "summary": "Pfizer's (PFE) shares decline almost 7% in response to the muted guidance for 2024. Revenues are expected to be in the range of $58.5 to $61.5 billion, while adjusted EPS is expected in the range of $2.05 to $2.25.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ce/3721.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.998663"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.142657, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SGEN", "relevance_score": "0.526003", "ticker_sentiment_score": "0.131576", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.225425", "ticker_sentiment_score": "0.070517", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.748033", "ticker_sentiment_score": "0.175994", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BNTX", "relevance_score": "0.113866", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Nasdaq Welcomes 125 IPOs and 26 Exchange Transfers in 2023", "url": "https://www.globenewswire.com/news-release/2023/12/14/2796149/6948/en/Nasdaq-Welcomes-125-IPOs-and-26-Exchange-Transfers-in-2023.html", "time_published": "20231214T120500", "authors": ["Inc.", "Nasdaq"], "summary": "Leading U.S. exchange by number of IPOs and proceeds raised for the fifth consecutive year ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/a00d1214-f7e8-4665-89e0-dcfda84f5fc8", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "IPO", "relevance_score": "0.451494"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}, {"topic": "Real Estate & Construction", "relevance_score": "0.25"}], "overall_sentiment_score": 0.38899, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "COO", "relevance_score": "0.060848", "ticker_sentiment_score": "0.174053", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BATRA", "relevance_score": "0.060848", "ticker_sentiment_score": "0.174053", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "INTU", "relevance_score": "0.060848", "ticker_sentiment_score": "0.174053", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LVRO", "relevance_score": "0.060848", "ticker_sentiment_score": "0.174053", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AAL", "relevance_score": "0.060848", "ticker_sentiment_score": "0.174053", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DASH", "relevance_score": "0.060848", "ticker_sentiment_score": "0.174053", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GPAK", "relevance_score": "0.060848", "ticker_sentiment_score": "0.174053", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HSAI", "relevance_score": "0.060848", "ticker_sentiment_score": "0.174053", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PAYX", "relevance_score": "0.060848", "ticker_sentiment_score": "0.174053", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.060848", "ticker_sentiment_score": "0.174053", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABVX", "relevance_score": "0.060848", "ticker_sentiment_score": "0.174053", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MAR", "relevance_score": "0.060848", "ticker_sentiment_score": "0.174053", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NXT(EXP20091224)", "relevance_score": "0.121343", "ticker_sentiment_score": "0.198703", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "First In Vivo CAR-M Lead Candidate Nominated Under Carisma-Moderna Collaboration", "url": "https://www.prnewswire.com/news-releases/first-in-vivo-car-m-lead-candidate-nominated-under-carisma-moderna-collaboration-302014783.html", "time_published": "20231214T120000", "authors": ["Carisma Therapeutics Inc."], "summary": "First lead candidate to address a solid tumor indication with significant unmet medical need Supportive pre-clinical proof of concept data reported at SITC 2023 that demonstrated feasibility, tolerability and early efficacy of in vivo CAR-M therapy utilizing mRNA/LNPs in solid tumors", "banner_image": "https://mma.prnewswire.com/media/1219543/Carisma_Therapeutics_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.451494"}], "overall_sentiment_score": 0.229658, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.299478", "ticker_sentiment_score": "0.32131", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CARM", "relevance_score": "0.130926", "ticker_sentiment_score": "0.143677", "ticker_sentiment_label": "Neutral"}]}, {"title": "Bond king calls for 10-year yield to slide much further as Goldman forecasts three cuts in a row", "url": "https://www.marketwatch.com/story/gundlach-calls-for-10-year-yield-to-slide-much-further-as-goldman-forecasts-three-cuts-in-a-row-94f1087d", "time_published": "20231214T114700", "authors": ["Barbara Kollmeyer"], "summary": "DoubleLine Capital's Jeffrey Gundlach sees the 10-year yield at low 3%, and rate cuts next year, along with Goldman.", "banner_image": "https://images.mktw.net/im-31948797?width=700&height=348", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.142857"}, {"topic": "Energy & Transportation", "relevance_score": "0.142857"}, {"topic": "Technology", "relevance_score": "0.142857"}, {"topic": "Finance", "relevance_score": "0.142857"}, {"topic": "Economy - Monetary", "relevance_score": "0.576289"}, {"topic": "Retail & Wholesale", "relevance_score": "0.142857"}, {"topic": "Financial Markets", "relevance_score": "0.999993"}, {"topic": "Manufacturing", "relevance_score": "0.142857"}, {"topic": "Real Estate & Construction", "relevance_score": "0.142857"}], "overall_sentiment_score": 0.014488, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVDA", "relevance_score": "0.08197", "ticker_sentiment_score": "0.093187", "ticker_sentiment_label": "Neutral"}, {"ticker": "OXY", "relevance_score": "0.08197", "ticker_sentiment_score": "0.10322", "ticker_sentiment_label": "Neutral"}, {"ticker": "COST", "relevance_score": "0.08197", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LEN", "relevance_score": "0.08197", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.041039", "ticker_sentiment_score": "0.098663", "ticker_sentiment_label": "Neutral"}, {"ticker": "BRK-A", "relevance_score": "0.041039", "ticker_sentiment_score": "0.098663", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADBE", "relevance_score": "0.08197", "ticker_sentiment_score": "-0.054813", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMD", "relevance_score": "0.122685", "ticker_sentiment_score": "0.064108", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.041039", "ticker_sentiment_score": "0.150203", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.08197", "ticker_sentiment_score": "0.207822", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FOREX:GBP", "relevance_score": "0.041039", "ticker_sentiment_score": "0.101185", "ticker_sentiment_label": "Neutral"}]}, {"title": "Moderna, Merck vaccine with Keytruda delays return of deadly skin cancer after 3 years, data says", "url": "https://www.cnbc.com/2023/12/14/moderna-merck-cancer-vaccine-reduces-risk-of-skin-cancer-return.html", "time_published": "20231214T113001", "authors": ["Annika Kim Constantino"], "summary": "Those results build on midstage trial data Moderna and Merck released earlier this year, which examined the efficacy of the combination over a shorter period.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107261594-1687527949459-gettyimages-1258376361-ryanmoderna1biz.jpeg?v=1687528116&w=1920&h=1080", "source": "CNBC", "category_within_source": "Business", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": -0.320562, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.158", "ticker_sentiment_score": "-0.341563", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JPM", "relevance_score": "0.079392", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.079392", "ticker_sentiment_score": "-0.015767", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stock market today: After Dow hits unprecedented heights, Wall Street points still higher", "url": "https://apnews.com/article/stock-markets-china-ecb-powell-8097a9b2ae0cf759d20773d31c785b3a", "time_published": "20231214T103200", "authors": ["ELAINE KURTENBACH", "MATT OTT"], "summary": "Stock market today: World shares are mostly higher after the Dow hits a record high, US dollar falls The Associated Press ...", "banner_image": "https://dims.apnews.com/dims4/default/cbf3f5a/2147483647/strip/true/crop/5416x3608+0+2/resize/599x399!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2Fbd%2F95%2Fef5d9acba47120631394ea7971ba%2F456036ba8c754b07ad531785381f5aa2", "source": "Associated Press", "category_within_source": "Markets", "source_domain": "apnews.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.890401"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.990999"}], "overall_sentiment_score": 0.004859, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.065685", "ticker_sentiment_score": "-0.080475", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:JPY", "relevance_score": "0.130926", "ticker_sentiment_score": "0.156272", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FOREX:USD", "relevance_score": "0.130926", "ticker_sentiment_score": "0.156272", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.065685", "ticker_sentiment_score": "0.068987", "ticker_sentiment_label": "Neutral"}]}, {"title": "Company Rundown: Chewy, Lululemon, Smucker, and More", "url": "https://www.fool.com/investing/2023/12/13/company-rundown-chewy-lululemon-smucker/", "time_published": "20231213T215500", "authors": ["Motley Fool Staff"], "summary": "Author Bethany McLean also stops by to chat about her latest book, \"What the Pandemic Revealed About Who America Protects and Who It Leaves Behind.\" ...", "banner_image": "https://g.foolcdn.com/editorial/images/757752/mfm_08.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.838487"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "0.999992"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.081759, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.011959", "ticker_sentiment_score": "0.100449", "ticker_sentiment_label": "Neutral"}, {"ticker": "TGT", "relevance_score": "0.041838", "ticker_sentiment_score": "0.046731", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.035866", "ticker_sentiment_score": "0.108178", "ticker_sentiment_label": "Neutral"}, {"ticker": "CHWY", "relevance_score": "0.023915", "ticker_sentiment_score": "0.062112", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDB", "relevance_score": "0.023915", "ticker_sentiment_score": "0.008351", "ticker_sentiment_label": "Neutral"}, {"ticker": "BBBYQ", "relevance_score": "0.00598", "ticker_sentiment_score": "0.008189", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.017937", "ticker_sentiment_score": "0.021476", "ticker_sentiment_label": "Neutral"}, {"ticker": "DOCU", "relevance_score": "0.035866", "ticker_sentiment_score": "0.015646", "ticker_sentiment_label": "Neutral"}, {"ticker": "GME", "relevance_score": "0.035866", "ticker_sentiment_score": "0.013684", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.00598", "ticker_sentiment_score": "0.041441", "ticker_sentiment_label": "Neutral"}, {"ticker": "WMT", "relevance_score": "0.00598", "ticker_sentiment_score": "0.041644", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:NANO", "relevance_score": "0.00598", "ticker_sentiment_score": "0.095835", "ticker_sentiment_label": "Neutral"}]}, {"title": "What's Going On With Moderna  ( MRNA )  Stock? - Moderna  ( NASDAQ:MRNA ) ", "url": "https://www.benzinga.com/news/23/12/36221374/whats-going-on-with-moderna-mrna-stock", "time_published": "20231213T183049", "authors": ["Henry Khederian"], "summary": "Moderna Inc MRNA shares are trading lower by 4.5% to $74.50 during Wednesday's session. Shares of several COVID vaccine stocks are trading lower after Pfizer Inc. provided FY24 guidance. Investors might have been expecting higher performance across the board from COVID vaccine manufacturers.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/13/medic-563425.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.650727"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.088239, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.751437", "ticker_sentiment_score": "0.126769", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.613172", "ticker_sentiment_score": "0.28355", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SGEN", "relevance_score": "0.436009", "ticker_sentiment_score": "0.146311", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stocks Hold Steady, Yields Decline As Fed Meeting Looms: What's Driving Markets Wednesday? - SPDR Dow Jones Industrial Average ETF  ( ARCA:DIA ) ", "url": "https://www.benzinga.com/markets/equities/23/12/36221173/stocks-hold-steady-yields-decline-as-fed-meeting-looms-whats-driving-markets-wednesday", "time_published": "20231213T174507", "authors": ["Piero Cingari"], "summary": "Midway through the trading day on Wall Street, calm reigns supreme as investors eagerly await the Federal Reserve's decision on interest rates. The Federal Open Market Committee ( FOMC ) is scheduled to publish its policy statement at 2 p.m. ET, followed by Chair Jerome Powell's address at 2:30 ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/Wall-Street-subway-sign.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.769861"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.996718"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.176769, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "TSLA", "relevance_score": "0.163354", "ticker_sentiment_score": "-0.010032", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.163354", "ticker_sentiment_score": "0.230422", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.163354", "ticker_sentiment_score": "-0.468248", "ticker_sentiment_label": "Bearish"}, {"ticker": "PFE", "relevance_score": "0.163354", "ticker_sentiment_score": "-0.468248", "ticker_sentiment_label": "Bearish"}, {"ticker": "FOREX:USD", "relevance_score": "0.24289", "ticker_sentiment_score": "0.338327", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.163354", "ticker_sentiment_score": "0.349152", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Pfizer shares sink after it resets 2024 COVID expectations", "url": "https://www.foxbusiness.com/markets/pfizer-shares-sink-resets-2024-covid-expectations", "time_published": "20231213T173400", "authors": ["Reuters"], "summary": "Pfizer on Wednesday forecast 2024 sales that could be as much as $5 billion below Wall Street expectations, a move top executives said provided a more reliable view of its COVID-19 business than it had this year, driving shares down 9% to a 10-year low.", "banner_image": "https://cf-images.us-east-1.prod.boltdns.net/v1/static/854081161001/3c7fedc7-fdb7-46a4-9a44-63b3058afcae/d13fc6b9-8007-43eb-b3d1-0cf721325c0b/1280x720/match/image.jpg", "source": "Fox Business News", "category_within_source": "n/a", "source_domain": "www.foxbusiness.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}, {"topic": "Earnings", "relevance_score": "0.684621"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": -0.081581, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "C", "relevance_score": "0.082677", "ticker_sentiment_score": "-0.057406", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGEN", "relevance_score": "0.164468", "ticker_sentiment_score": "-0.22472", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MRNA", "relevance_score": "0.082677", "ticker_sentiment_score": "-0.048843", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.082677", "ticker_sentiment_score": "-0.315658", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PFE", "relevance_score": "0.532556", "ticker_sentiment_score": "0.026888", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.082677", "ticker_sentiment_score": "-0.048843", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pfizer Issues FY24 Forecast, Joins Target Hospitality, Southwest Airlines And Other Big Stocks Moving Lower On Wednesday - JetBlue Airways  ( NASDAQ:JBLU ) , BioNTech  ( NASDAQ:BNTX ) ", "url": "https://www.benzinga.com/news/23/12/36218848/pfizer-issues-fy24-forecast-joins-target-hospitality-southwest-airlines-and-other-big-stocks-moving", "time_published": "20231213T160310", "authors": ["Avi Kapoor"], "summary": "U.S. stocks traded mostly higher, with the Nasdaq Composite gaining around 40 points on Wednesday. Shares of Pfizer Inc. PFE shares fell sharply during Wednesday's session after the company provided FY24 guidance.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/13/pfizer_-_logo.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.108179"}, {"topic": "Real Estate & Construction", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}], "overall_sentiment_score": -0.072855, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BABA", "relevance_score": "0.147818", "ticker_sentiment_score": "-0.206767", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "XPEV", "relevance_score": "0.423843", "ticker_sentiment_score": "-0.432366", "ticker_sentiment_label": "Bearish"}, {"ticker": "LFMD", "relevance_score": "0.147818", "ticker_sentiment_score": "0.142262", "ticker_sentiment_label": "Neutral"}, {"ticker": "JBLU", "relevance_score": "0.290607", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TH", "relevance_score": "0.290607", "ticker_sentiment_score": "-0.038226", "ticker_sentiment_label": "Neutral"}, {"ticker": "PARA", "relevance_score": "0.147818", "ticker_sentiment_score": "-0.466869", "ticker_sentiment_label": "Bearish"}, {"ticker": "SGEN", "relevance_score": "0.290607", "ticker_sentiment_score": "0.162242", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LUV", "relevance_score": "0.423843", "ticker_sentiment_score": "-0.092968", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.423843", "ticker_sentiment_score": "-0.312202", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MED", "relevance_score": "0.423843", "ticker_sentiment_score": "0.307069", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.423843", "ticker_sentiment_score": "0.056296", "ticker_sentiment_label": "Neutral"}, {"ticker": "UIS", "relevance_score": "0.290607", "ticker_sentiment_score": "-0.676959", "ticker_sentiment_label": "Bearish"}]}, {"title": "Pfizer Crashes 9% As Seagen Guidance Update Disappoints", "url": "https://www.investors.com/news/technology/pfizer-stock-tumble-steepens-as-seagen-guidance-update-disappoints/", "time_published": "20231213T150400", "authors": ["ALLISON GATLIN", "Alan R. Elliott", "Investor's Business Daily"], "summary": "Pfizer Stock Crashes 9% On Disappointing Outlook As Seagen Takeover Looms Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2020/12/Stock-Pfizer-05-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.99793"}], "overall_sentiment_score": -0.145969, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVAX", "relevance_score": "0.264897", "ticker_sentiment_score": "-0.318316", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "SGEN", "relevance_score": "0.427184", "ticker_sentiment_score": "-0.305506", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MRNA", "relevance_score": "0.264897", "ticker_sentiment_score": "-0.318316", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PFE", "relevance_score": "0.740604", "ticker_sentiment_score": "-0.467006", "ticker_sentiment_label": "Bearish"}, {"ticker": "BNTX", "relevance_score": "0.264897", "ticker_sentiment_score": "-0.318316", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Pfizer shares fall as 2024 revenue and profit forecast disappoints", "url": "https://www.cnbc.com/2023/12/13/pfizer-forecasts-2024-revenue-below-wall-street-expectations.html", "time_published": "20231213T144018", "authors": ["Annika Kim Constantino"], "summary": "After raking in billions from Covid products, Pfizer has struggled to navigate a world beyond the pandemic and reassure investors about its growth potential.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107346955-17024720261702472023-32434665176-1080pnbcnews.jpg?v=1702472025&w=750&h=422&vtcrop=y", "source": "CNBC", "category_within_source": "Business", "source_domain": "www.cnbc.com", "topics": [{"topic": "Earnings", "relevance_score": "0.989041"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": -0.069876, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ABBV", "relevance_score": "0.088472", "ticker_sentiment_score": "-0.123286", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGEN", "relevance_score": "0.343279", "ticker_sentiment_score": "-0.108465", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.088472", "ticker_sentiment_score": "-0.022933", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.682689", "ticker_sentiment_score": "-0.120742", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.088472", "ticker_sentiment_score": "-0.123286", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.088472", "ticker_sentiment_score": "-0.022933", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pfizer Stock Sinks To 10-Year Low-Why Investors Have Soured On Covid-Era Giant", "url": "https://www.forbes.com/sites/dereksaul/2023/12/13/pfizer-stock-sinks-to-10-year-low-why-investors-have-soured-on-covid-era-giant/", "time_published": "20231213T143823", "authors": ["Derek Saul"], "summary": "Pfizer stock's struggles continued Wednesday, as shares of the healthcare titan dropped to their lowest level since before the Covid-19 pandemic, the latest dubious milestone for the battered stock that has failed to convert its vaccine boom into long-term sales growth.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/6579be819e8d6dd237334ba2/0x0.jpg?format=jpg&crop=1701,1134,x0,y0,safe&height=900&width=1600&fit=bounds", "source": "Forbes", "category_within_source": "n/a", "source_domain": "www.forbes.com", "topics": [{"topic": "Earnings", "relevance_score": "0.108179"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.002458, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SGEN", "relevance_score": "0.218817", "ticker_sentiment_score": "0.051337", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.110462", "ticker_sentiment_score": "0.033284", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.110462", "ticker_sentiment_score": "0.033284", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.66906", "ticker_sentiment_score": "0.003816", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.110462", "ticker_sentiment_score": "0.033284", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pfizer's Tumble Steepens As Seagen Guidance Update Disappoints", "url": "https://www.investors.com/news/pfizer-stock-tumble-steepens-as-seagen-guidance-update-disappoints/", "time_published": "20231213T130300", "authors": ["Investor's Business Daily", "ALAN R. ELLIOTT"], "summary": "Pfizer Stock Tumble Steepens As Seagen Guidance Update Disappoints Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2020/11/IT02_pfizer_112520_News.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Earnings", "relevance_score": "0.839681"}], "overall_sentiment_score": -0.118741, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SGEN", "relevance_score": "0.757528", "ticker_sentiment_score": "-0.303897", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MRNA", "relevance_score": "0.303175", "ticker_sentiment_score": "0.044358", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.757528", "ticker_sentiment_score": "-0.220962", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "BNTX", "relevance_score": "0.303175", "ticker_sentiment_score": "0.044358", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Dirt-Cheap Stocks to Buy Hand Over Fist Before the End of the Year", "url": "https://www.fool.com/investing/2023/12/13/3-dirt-cheap-stocks-to-buy-before-2024/", "time_published": "20231213T100000", "authors": ["Adria Cimino"], "summary": "These players could lift your portfolio when they rebound and over the long term.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F758030%2Finvestor-smiling-phone-at-home.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.99992"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.413559"}], "overall_sentiment_score": 0.278244, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.273399", "ticker_sentiment_score": "0.048774", "ticker_sentiment_label": "Neutral"}, {"ticker": "ETSY", "relevance_score": "0.424139", "ticker_sentiment_score": "0.361786", "ticker_sentiment_label": "Bullish"}, {"ticker": "DNA", "relevance_score": "0.11123", "ticker_sentiment_score": "0.213143", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.055751", "ticker_sentiment_score": "0.189947", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "What's Going On With Moderna Stock Today? - Moderna  ( NASDAQ:MRNA ) ", "url": "https://www.benzinga.com/general/biotech/23/12/36199743/whats-going-on-with-moderna-stock-today", "time_published": "20231212T183833", "authors": ["Vandana Singh"], "summary": "Moderna Inc MRNA announced changes to its operating model to bring focus to its short- and long-term business goals. The company is focused on driving continued sales of its COVID-19 vaccine and launching its Respiratory syncytial virus ( RSV ) vaccine in 2024, while also preparing to launch ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/12/moderna_covid-19_vaccine_2021_g.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.018945, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.754041", "ticker_sentiment_score": "0.035417", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.259727", "ticker_sentiment_score": "-0.138012", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.259727", "ticker_sentiment_score": "-0.138012", "ticker_sentiment_label": "Neutral"}]}, {"title": "Moderna  ( MRNA ) , Merck Start 2nd Late-Study on Cancer Therapy", "url": "https://www.zacks.com/stock/news/2196987/moderna-mrna-merck-start-2nd-late-study-on-cancer-therapy", "time_published": "20231212T181700", "authors": ["Zacks Equity Research"], "summary": "The second late-stage study will evaluate Moderna (MRNA)/Merck's investigational cancer combination therapy in certain lung cancer patients. A late-stage study in melanoma indication is ongoing.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/08/595.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.928139"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.102939, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.546745", "ticker_sentiment_score": "0.030291", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.178021", "ticker_sentiment_score": "0.126283", "ticker_sentiment_label": "Neutral"}, {"ticker": "CTMX", "relevance_score": "0.29234", "ticker_sentiment_score": "0.075936", "ticker_sentiment_label": "Neutral"}]}, {"title": "Moderna chief commercial officer steps down", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/moderna-chief-commercial-officer-steps-down-2023-12-12/", "time_published": "20231212T134000", "authors": ["Reuters"], "summary": "Moderna logo and stock graph are seen displayed in this illustration taken, May 3, 2022. REUTERS/Dado Ruvic/Illustration/File Photo Acquire Licensing Rights Dec 12 ( Reuters ) - U.S. drugmaker Moderna ( MRNA.O ) said on Tuesday Chief Commercial Officer ( CCO ) Arpa Garay has stepped down more ...", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/Q4CLEKHTANONJA2GIMMU7BMBTA.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.032939, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.76367", "ticker_sentiment_score": "0.023432", "ticker_sentiment_label": "Neutral"}]}, {"title": "Analysts Predict These Will Be Next Year's Top 10 Stocks", "url": "https://www.investors.com/etfs-and-funds/sectors/sp500-analysts-predict-these-will-be-next-years-top-10-stocks/", "time_published": "20231211T130000", "authors": ["MATT KRANTZ", "Investor's Business Daily"], "summary": "Want to own the very top S&P 500 stock of 2024? It's not going to be Nvidia ( NVDA ) again - and it won't even be in the top 5, analysts say.", "banner_image": "https://www.investors.com/wp-content/uploads/2022/03/Stock-moneytelescope-02-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Real Estate & Construction", "relevance_score": "0.2"}], "overall_sentiment_score": 0.365653, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "SLB", "relevance_score": "0.076602", "ticker_sentiment_score": "0.19369", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "META", "relevance_score": "0.152499", "ticker_sentiment_score": "0.095694", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.152499", "ticker_sentiment_score": "0.206725", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FSLR", "relevance_score": "0.369319", "ticker_sentiment_score": "0.511513", "ticker_sentiment_label": "Bullish"}, {"ticker": "WYNN", "relevance_score": "0.152499", "ticker_sentiment_score": "0.237535", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.152499", "ticker_sentiment_score": "0.237535", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Moderna, Merck begin late-stage study for mRNA cancer therapy", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/moderna-merck-begin-late-stage-study-mrna-cancer-therapy-2023-12-11/", "time_published": "20231211T120100", "authors": ["Reuters"], "summary": "[1/2] Moderna logo is seen displayed in this illustration taken, May 3, 2022. REUTERS/Dado Ruvic/Illustration Acquire Licensing Rights", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/EBPSIU4CJZPJDGFG46WZDQPWFI.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.103787, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.693563", "ticker_sentiment_score": "-0.420253", "ticker_sentiment_label": "Bearish"}]}, {"title": "These 2 Stocks Are All-Stars in the Making", "url": "https://www.fool.com/investing/2023/12/11/these-2-stocks-are-all-stars-in-the-making/", "time_published": "20231211T100000", "authors": ["Adria Cimino"], "summary": "These exciting players look cheap today considering their future prospects.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F757641%2Fgettyimages-915665172.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.961735"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}], "overall_sentiment_score": 0.329264, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.301686", "ticker_sentiment_score": "0.19679", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ETSY", "relevance_score": "0.514619", "ticker_sentiment_score": "0.486964", "ticker_sentiment_label": "Bullish"}]}, {"title": "Vertex Pharmaceuticals Just Proved Something Big to Investors. Time to Buy?", "url": "https://www.fool.com/investing/2023/12/10/vertex-pharmaceuticals-just-proved-something-big/", "time_published": "20231210T104500", "authors": ["Adria Cimino"], "summary": "The big biotech's shares have been on the rise this year.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F757762%2Fscientists-high-five-smile.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Earnings", "relevance_score": "0.992549"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.287526, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GS", "relevance_score": "0.049424", "ticker_sentiment_score": "0.056408", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.049424", "ticker_sentiment_score": "0.163801", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.098659", "ticker_sentiment_score": "0.181705", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Una gu\u00eda de regalos navide\u00f1os que presenta las \u00faltimas tendencias tecnol\u00f3gicas de estilo de vida con los productos ... - PR Newswire", "url": "https://www.prnewswire.com/news-releases/una-guia-de-regalos-navidenos-que-presenta-las-ultimas-tendencias-tecnologicas-de-estilo-de-vida-con-los-productos-mas-recientes-de-huawei-806453764.html", "time_published": "20231209T004600", "authors": [], "summary": "Una gu\u00eda de regalos navide\u00f1os que presenta las \u00faltimas tendencias tecnol\u00f3gicas de estilo de vida con los productos ... PR ...", "banner_image": null, "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.002345, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.016691", "ticker_sentiment_score": "-0.053449", "ticker_sentiment_label": "Neutral"}, {"ticker": "SZIHF", "relevance_score": "0.033375", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Soviet Mainframes To Silicon Mountains: Armenia As A Tech Powerhouse", "url": "https://www.forbes.com/sites/craigsmith/2023/12/08/soviet-mainframes-to-silicon-mountains-armenia-as-a-tech-powerhouse/", "time_published": "20231208T193624", "authors": ["Craig S. Smith"], "summary": "Armenia shot from relative obscurity to global prominence recently over tensions with neighboring Azerbaijan. But there is another reason to pay attention to this rugged, mountainous country: it's fast evolving tech sector.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/657243f2431c2a6916eaf41a/0x0.jpg?format=jpg&crop=2560,1200,x0,y34,safe&height=900&width=1600&fit=bounds", "source": "Forbes", "category_within_source": "n/a", "source_domain": "www.forbes.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.138319, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.054236", "ticker_sentiment_score": "0.102767", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.027134", "ticker_sentiment_score": "0.076524", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.027134", "ticker_sentiment_score": "0.076524", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:AMD", "relevance_score": "0.027134", "ticker_sentiment_score": "-0.107909", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:USD", "relevance_score": "0.027134", "ticker_sentiment_score": "-0.107909", "ticker_sentiment_label": "Neutral"}]}, {"title": "Moderna's Options Frenzy: What You Need to Know - Moderna  ( NASDAQ:MRNA ) ", "url": "https://www.benzinga.com/markets/options/23/12/36157929/modernas-options-frenzy-what-you-need-to-know", "time_published": "20231208T181740", "authors": ["Benzinga Insights"], "summary": "Investors with a lot of money to spend have taken a bearish stance on Moderna MRNA. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.413559"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.098769, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.714306", "ticker_sentiment_score": "0.169003", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JPM", "relevance_score": "0.085022", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Instant Soup Market is Anticipated to Reach USD 550 million, at a CAGR of 3.6% CAGR by 2031 - Transparency Market Research, Inc.", "url": "https://www.benzinga.com/pressreleases/23/12/g36149106/instant-soup-market-is-anticipated-to-reach-usd-550-million-at-a-cagr-of-3-6-cagr-by-2031-transpar", "time_published": "20231208T083645", "authors": ["Globe Newswire"], "summary": "Wilmington, Delaware, United States, Dec. 08, 2023 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. -Transparency Market Research shows Latin America's instant soup market was worth US$ 400 million in 2021. The industry is expected to reach US$ 550 million by 2031.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": 0.345749, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CPB", "relevance_score": "0.036587", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.036587", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AJINY", "relevance_score": "0.036587", "ticker_sentiment_score": "0.124168", "ticker_sentiment_label": "Neutral"}, {"ticker": "NSRGF", "relevance_score": "0.036587", "ticker_sentiment_score": "0.153642", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Adobe Earnings Are Coming. Where Do You Set Your Option Strikes?", "url": "https://www.investors.com/research/options/adobe-stock-setting-strikes-ahead-of-earnings/", "time_published": "20231207T205000", "authors": ["GAVIN McMASTER", "Investor's Business Daily"], "summary": "Adobe Stock: Setting Strikes Ahead Of Earnings Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2017/09/IT02-adbe-091517-shutter.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.846708"}, {"topic": "Earnings", "relevance_score": "0.857896"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": -0.00482, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ADBE", "relevance_score": "0.61135", "ticker_sentiment_score": "-0.124154", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.068698", "ticker_sentiment_score": "-0.093849", "ticker_sentiment_label": "Neutral"}, {"ticker": "DBX", "relevance_score": "0.068698", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "S&P 500's Hidden Gems: 27 Stocks With 30%+ Upside Potential According To Wall Street Analysts Targets - Albemarle  ( NYSE:ALB ) , Align Tech  ( NASDAQ:ALGN ) ", "url": "https://www.benzinga.com/news/23/12/36140178/s-p-500s-hidden-gems-27-stocks-with-30-upside-potential-according-to-wall-street-analysts-targets", "time_published": "20231207T180833", "authors": ["Piero Cingari"], "summary": "The S&P 500 Index has risen by 19% year-to-date, with three weeks remaining in the year and just a five percentage point gap from the all-time highs reached in January 2022.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/Businessman-Looking-MagnifyingGlass-Shut_0.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "0.972756"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Real Estate & Construction", "relevance_score": "0.166667"}], "overall_sentiment_score": 0.22392, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NVDA", "relevance_score": "0.262052", "ticker_sentiment_score": "0.350796", "ticker_sentiment_label": "Bullish"}, {"ticker": "FSLR", "relevance_score": "0.176502", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAL", "relevance_score": "0.176502", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALB", "relevance_score": "0.176502", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BKR", "relevance_score": "0.176502", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LVS", "relevance_score": "0.176502", "ticker_sentiment_score": "0.150981", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SLB", "relevance_score": "0.088799", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CZR", "relevance_score": "0.262052", "ticker_sentiment_score": "0.28235", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRO", "relevance_score": "0.176502", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.088799", "ticker_sentiment_score": "0.219104", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.262052", "ticker_sentiment_score": "0.095808", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Is Iovance Biotherapeutics  ( IOVA )  Up 53% Since Last Earnings Report?", "url": "https://www.zacks.com/stock/news/2194930/why-is-iovance-biotherapeutics-iova-up-53-since-last-earnings-report", "time_published": "20231207T163102", "authors": ["Zacks Equity Research"], "summary": "Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default31.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.503496"}, {"topic": "Earnings", "relevance_score": "0.904684"}], "overall_sentiment_score": 0.047382, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.298567", "ticker_sentiment_score": "0.040893", "ticker_sentiment_label": "Neutral"}, {"ticker": "IOVA", "relevance_score": "0.368227", "ticker_sentiment_score": "0.248279", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Biotech Stock Roundup: EXEL Partners RCUS for Study, PHVS & EYPT Gain on Study Data", "url": "https://www.zacks.com/stock/news/2194725/biotech-stock-roundup-exel-partners-rcus-for-study-phvs-eypt-gain-on-study-data", "time_published": "20231207T142500", "authors": ["Zacks Equity Research"], "summary": "Updates from Exelixis (EXEL) and Pharvaris (PHVS) are in the spotlight this week.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/07/905.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.148139, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "EYPT", "relevance_score": "0.124593", "ticker_sentiment_score": "0.092925", "ticker_sentiment_label": "Neutral"}, {"ticker": "PHVS", "relevance_score": "0.206157", "ticker_sentiment_score": "0.105515", "ticker_sentiment_label": "Neutral"}, {"ticker": "RCUS", "relevance_score": "0.083251", "ticker_sentiment_score": "0.086338", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXEL", "relevance_score": "0.246167", "ticker_sentiment_score": "0.130771", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.041682", "ticker_sentiment_score": "0.028791", "ticker_sentiment_label": "Neutral"}]}, {"title": "US sets policy to seize government-funded drug patents if price deemed too high", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/us-sets-policy-seize-government-funded-drug-patents-if-price-deemed-too-high-2023-12-07/", "time_published": "20231207T140300", "authors": ["Patrick Wingrove"], "summary": "Dec 7 ( Reuters ) - The Biden Administration on Thursday announced it is setting new policy that will allow it to seize patents for medicines developed with government funding if it believes their prices are too high.", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/BOJ62GDVXJKTXE3YUYPBPC7FOI.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.064779, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.100729", "ticker_sentiment_score": "-0.042185", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALPMF", "relevance_score": "0.100729", "ticker_sentiment_score": "-0.302498", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PFE", "relevance_score": "0.100729", "ticker_sentiment_score": "-0.302498", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Reverse Butterfly In Tesla Could Generate $1,315 Gain", "url": "https://www.investors.com/research/options/tsla-stock-today-this-reverse-butterfly-in-options-trading-could-generate-a-1315-dollar-net-gain/", "time_published": "20231206T193300", "authors": ["Investor's Business Daily", "GAVIN McMASTER"], "summary": "TSLA Stock Today: This Reverse Butterfly In Options Trading Could Generate A $1,315 Net Gain Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2019/11/stock-tesla-Cybertruck-05-company.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.779048"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": -0.048295, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.092569", "ticker_sentiment_score": "-0.100526", "ticker_sentiment_label": "Neutral"}, {"ticker": "DBX", "relevance_score": "0.092569", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.755086", "ticker_sentiment_score": "-0.133329", "ticker_sentiment_label": "Neutral"}]}, {"title": "CRISPR Therapeutics AG  ( CRSP )  Up 20.5% Since Last Earnings Report: Can It Continue?", "url": "https://www.zacks.com/stock/news/2194339/crispr-therapeutics-ag-crsp-up-205-since-last-earnings-report-can-it-continue", "time_published": "20231206T163032", "authors": ["Zacks Equity Research"], "summary": "CRISPR Therapeutics AG (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default321.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.938238"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.045242, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.290607", "ticker_sentiment_score": "0.037893", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRSP", "relevance_score": "0.358669", "ticker_sentiment_score": "0.296551", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "2024's Potential Stock Surprises: Goldman Sachs Unveils S&P 500 Laggards For Major Gains - Angi  ( NASDAQ:ANGI ) , Aptiv  ( NYSE:APTV ) ", "url": "https://www.benzinga.com/analyst-ratings/analyst-color/23/12/36113326/2024s-potential-stock-surprises-goldman-sachs-unveils-s-p-500-laggards-for-major-ga", "time_published": "20231206T142656", "authors": ["Piero Cingari"], "summary": "Investors are always on the lookout for untapped opportunities, especially in stocks that have been heavily discounted and now present promising opportunities for those prepared to wager on a recovery. As the new year looms, a seasoned strategy, known as the \"Laggards\" trade, is witnessing a ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/bull-chart-shutter2_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.202648, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ENPH", "relevance_score": "0.114409", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ST", "relevance_score": "0.114409", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARRY", "relevance_score": "0.114409", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.226477", "ticker_sentiment_score": "0.137918", "ticker_sentiment_label": "Neutral"}, {"ticker": "BBWI", "relevance_score": "0.114409", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.114409", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "APTV", "relevance_score": "0.114409", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.114409", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANGI", "relevance_score": "0.114409", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "FSLR", "relevance_score": "0.114409", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DAR", "relevance_score": "0.114409", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SHLS", "relevance_score": "0.114409", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.114409", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Don't Want The Unlimited Risk Of Shorting? Try This Option Strategy Instead", "url": "https://www.investors.com/research/options/coin-stock-moving-too-far-too-fast/", "time_published": "20231205T200800", "authors": ["GAVIN McMASTER", "Investor's Business Daily"], "summary": "COIN Stock Today: Is The Move Too Far Too Fast? Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2021/04/Stock-Coinbase-Stairs-company.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.922939"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}, {"topic": "Blockchain", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.029119, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.068112", "ticker_sentiment_score": "-0.09373", "ticker_sentiment_label": "Neutral"}, {"ticker": "COIN", "relevance_score": "0.65287", "ticker_sentiment_score": "0.088931", "ticker_sentiment_label": "Neutral"}, {"ticker": "DBX", "relevance_score": "0.068112", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.068112", "ticker_sentiment_score": "0.16767", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Here's How Much You Would Have Made Owning Moderna Stock In The Last 5 Years - Moderna  ( NASDAQ:MRNA ) ", "url": "https://www.benzinga.com/news/23/12/36090889/heres-how-much-you-would-have-made-owning-moderna-stock-in-the-last-5-years", "time_published": "20231205T140015", "authors": ["Benzinga Insights"], "summary": "Moderna MRNA has outperformed the market over the past 5 years by 21.8% on an annualized basis producing an average annual return of 33.32%. Currently, Moderna has a market capitalization of $30.19 billion.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.983605", "ticker_sentiment_score": "0.387251", "ticker_sentiment_label": "Bullish"}]}, {"title": "Absci  ( ABSI )  Up on AstraZeneca Deal to Design New Cancer Therapy", "url": "https://www.zacks.com/stock/news/2193427/absci-absi-up-on-astrazeneca-deal-to-design-new-cancer-therapy", "time_published": "20231205T131100", "authors": ["Zacks Equity Research"], "summary": "Absci (ABSI) announces a collaboration agreement with AstraZeneca to develop an AI-designed antibody for an undisclosed oncology target. The stock rises 13%.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f5/284.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.14095, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.255641", "ticker_sentiment_score": "0.130419", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABSI", "relevance_score": "0.615462", "ticker_sentiment_score": "0.34484", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.413199", "ticker_sentiment_score": "0.299485", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Standout examples of in-house lawyers' work", "url": "https://www.ft.com/content/e7abfd36-600a-481c-ab21-5e970a34670a", "time_published": "20231205T050059", "authors": [], "summary": "Case studies in best practice among general counsel and company legal teams in North America ...", "banner_image": "https://www.ft.com/__origami/service/image/v2/images/raw/https%3A%2F%2Fd1e00ek4ebabms.cloudfront.net%2Fproduction%2Fa04d4880-e9fb-4ff4-b353-fe2787e2cb41.jpg?source=next-article&fit=scale-down&quality=highest&width=700&dpr=1", "source": "Financial Times", "category_within_source": "Companies", "source_domain": "www.ft.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.142857"}, {"topic": "Energy & Transportation", "relevance_score": "0.142857"}, {"topic": "Technology", "relevance_score": "0.142857"}, {"topic": "Finance", "relevance_score": "0.142857"}, {"topic": "Retail & Wholesale", "relevance_score": "0.142857"}, {"topic": "Financial Markets", "relevance_score": "0.999822"}, {"topic": "Manufacturing", "relevance_score": "0.142857"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}, {"topic": "Real Estate & Construction", "relevance_score": "0.142857"}], "overall_sentiment_score": 0.387996, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "GM", "relevance_score": "0.085274", "ticker_sentiment_score": "0.17651", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HPQ", "relevance_score": "0.028473", "ticker_sentiment_score": "0.095055", "ticker_sentiment_label": "Neutral"}, {"ticker": "UPWK", "relevance_score": "0.042698", "ticker_sentiment_score": "0.068949", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAH", "relevance_score": "0.042698", "ticker_sentiment_score": "0.270853", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ACN", "relevance_score": "0.042698", "ticker_sentiment_score": "0.110953", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAM", "relevance_score": "0.014239", "ticker_sentiment_score": "0.197216", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CLX", "relevance_score": "0.05691", "ticker_sentiment_score": "0.164032", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXC", "relevance_score": "0.014239", "ticker_sentiment_score": "0.151582", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.014239", "ticker_sentiment_score": "0.104647", "ticker_sentiment_label": "Neutral"}, {"ticker": "LAC", "relevance_score": "0.042698", "ticker_sentiment_score": "0.061121", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.05691", "ticker_sentiment_score": "0.145029", "ticker_sentiment_label": "Neutral"}, {"ticker": "PRU", "relevance_score": "0.014239", "ticker_sentiment_score": "0.175602", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HPE", "relevance_score": "0.042698", "ticker_sentiment_score": "0.121435", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.028473", "ticker_sentiment_score": "0.226307", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RDFN", "relevance_score": "0.028473", "ticker_sentiment_score": "0.152776", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "UBER", "relevance_score": "0.05691", "ticker_sentiment_score": "0.246056", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Cramer on Monday's market action: Some investors are headed for a 'nasty hangover'", "url": "https://www.cnbc.com/2023/12/04/jim-cramer-says-some-investors-are-headed-for-a-nasty-hangover.html", "time_published": "20231205T000855", "authors": ["Julie Coleman"], "summary": "CNBC's Jim Cramer said many investors may not be buying with a clear head.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107342952-2ED3-MM-A-BLOCK-SHORT-120423.jpg?v=1701733424&w=750&h=422&vtcrop=y", "source": "CNBC", "category_within_source": "Top News", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.744043"}], "overall_sentiment_score": 0.0371, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.098255", "ticker_sentiment_score": "-0.108974", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.098255", "ticker_sentiment_score": "-0.096145", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.098255", "ticker_sentiment_score": "-0.108974", "ticker_sentiment_label": "Neutral"}]}, {"title": "This Cash-Secured Put Trade Could Seal A 5% Return", "url": "https://www.investors.com/research/options/dropbox-stock-today-why-this-cash-secured-put-trade-could-seal-a-5-return/", "time_published": "20231204T194700", "authors": ["Investor's Business Daily", "GAVIN McMASTER"], "summary": "Dropbox ( DBX ) closed at the high at the end of the day on Friday and is sitting nicely above the 50-day moving average. So, let's see how to potentially buy Dropbox stock for a discount via an option strategy called a cash secured put. A cash secured put is a slightly less bullish trade than ...", "banner_image": "https://www.investors.com/wp-content/uploads/2018/03/stock-dropbox-01-shutter.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}], "overall_sentiment_score": 0.078025, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.066784", "ticker_sentiment_score": "-0.093468", "ticker_sentiment_label": "Neutral"}, {"ticker": "DBX", "relevance_score": "0.497391", "ticker_sentiment_score": "0.02904", "ticker_sentiment_label": "Neutral"}]}, {"title": "Peering Into Moderna's Recent Short Interest - Moderna  ( NASDAQ:MRNA ) ", "url": "https://www.benzinga.com/short-sellers/23/12/36076375/peering-into-modernas-recent-short-interest", "time_published": "20231204T190014", "authors": ["Benzinga Insights"], "summary": "Moderna's MRNA short percent of float has risen 14.18% since its last report. The company recently reported that it has 22.38 million shares sold short, which is 7.81% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.96 days to cover their ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.26961, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.224903", "ticker_sentiment_score": "0.158881", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "3 Dirt Cheap Stocks You'll Regret Not Buying Before the New Year", "url": "https://www.fool.com/investing/2023/12/04/3-dirt-cheap-stocks-youll-regret-not-buying/", "time_published": "20231204T110000", "authors": ["Adria Cimino"], "summary": "Load up on these stocks while the price is right, and hold them for the long term.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F756891%2Fgettyimages-new-year-2024-fireworks.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Earnings", "relevance_score": "0.999612"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.218715, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.369456", "ticker_sentiment_score": "0.194408", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AAPL", "relevance_score": "0.452295", "ticker_sentiment_score": "0.429802", "ticker_sentiment_label": "Bullish"}]}, {"title": "Where Will Vertex Pharmaceuticals Be in 10 Years?", "url": "https://www.fool.com/investing/2023/12/04/where-will-vertex-pharmaceuticals-be-in-10-years/", "time_published": "20231204T103000", "authors": ["Adria Cimino"], "summary": "Vertex shares have soared 400% over the past decade.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F756785%2Fgettyimages-1197547531.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.961735"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.218885, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.050679", "ticker_sentiment_score": "0.104675", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.101154", "ticker_sentiment_score": "0.176507", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Largest 'Long Vax' Study To Date On Post-Covid-19 Vaccination Syndrome", "url": "https://www.forbes.com/sites/brucelee/2023/12/03/largest-long-vax-study-to-date-on-post-covid-19-vaccination-syndrome/", "time_published": "20231203T155946", "authors": ["Bruce Y. Lee"], "summary": "Since the Covid-19 vaccines first reached the market in late 2020, lots of unsubstantiated vaccination side effect claims have emerged such as assertions that Covid-19 vaccines can turn you into a gigantic magnet.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/656ca137b5b3d79b573122d0/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds", "source": "Forbes", "category_within_source": "n/a", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": -0.158975, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "CVS", "relevance_score": "0.036532", "ticker_sentiment_score": "0.030305", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.036532", "ticker_sentiment_score": "0.078383", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.036532", "ticker_sentiment_score": "-0.048632", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.036532", "ticker_sentiment_score": "-0.048632", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.036532", "ticker_sentiment_score": "-0.048632", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is Novavax Stock a Buy Now?", "url": "https://www.fool.com/investing/2023/12/01/is-novavax-stock-a-buy-now/", "time_published": "20231201T210000", "authors": ["Prosper Junior Bakiny"], "summary": "The company's shares may look cheap on the surface, but don't be too quick to jump in.", "banner_image": "https://media.ycharts.com/charts/178aa9a8b9018211a5db0ae6e8592179.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.538269"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}], "overall_sentiment_score": 0.007302, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVAX", "relevance_score": "0.626259", "ticker_sentiment_score": "-0.007342", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.128478", "ticker_sentiment_score": "0.059938", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.064449", "ticker_sentiment_score": "0.02208", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.064449", "ticker_sentiment_score": "0.02208", "ticker_sentiment_label": "Neutral"}]}, {"title": "Texas Attorney General Alleges Pfizer Misled Public on COVID-19 Vaccine Efficacy - Pfizer  ( NYSE:PFE ) ", "url": "https://www.benzinga.com/general/biotech/23/12/36041571/texas-attorney-general-alleges-pfizer-misled-public-on-covid-19-vaccine-efficacy", "time_published": "20231201T155903", "authors": ["Vandana Singh"], "summary": "Texas Attorney General Ken Paxton has filed a lawsuit against Pfizer Inc PFE, alleging the pharmaceutical giant misrepresented the efficacy of its widely-administered COVID-19 vaccine. Paxton argued that Pfizer's claim of 95% effectiveness was misleading, based on limited clinical trial data ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/01/pfe.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.064092, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.241684", "ticker_sentiment_score": "-0.148844", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.83383", "ticker_sentiment_score": "-0.25894", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JNJ", "relevance_score": "0.241684", "ticker_sentiment_score": "-0.148844", "ticker_sentiment_label": "Neutral"}]}, {"title": "Jim Cramer's top 10 things to watch in the stock market Friday", "url": "https://www.cnbc.com/2023/12/01/jim-cramers-top-10-things-to-watch-in-the-stock-market-friday.html", "time_published": "20231201T140404", "authors": ["Jim Cramer"], "summary": "Stocks edge lower in premarket trading, while the Fed could reportedly be done hiking interest rates.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107331870-1699573549860-gettyimages-1772924986-AA_10112023_1413921.jpeg?v=1701439409&w=1920&h=1080", "source": "CNBC", "category_within_source": "Top News", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.999999"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.77141"}], "overall_sentiment_score": 0.168013, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AVGO", "relevance_score": "0.062761", "ticker_sentiment_score": "0.145097", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCS", "relevance_score": "0.125134", "ticker_sentiment_score": "-0.0794", "ticker_sentiment_label": "Neutral"}, {"ticker": "C", "relevance_score": "0.125134", "ticker_sentiment_score": "0.077291", "ticker_sentiment_label": "Neutral"}, {"ticker": "ULTA", "relevance_score": "0.125134", "ticker_sentiment_score": "0.438834", "ticker_sentiment_label": "Bullish"}, {"ticker": "SPOT", "relevance_score": "0.125134", "ticker_sentiment_score": "-0.053785", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.062761", "ticker_sentiment_score": "-0.033074", "ticker_sentiment_label": "Neutral"}, {"ticker": "NOW", "relevance_score": "0.062761", "ticker_sentiment_score": "-0.067232", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.125134", "ticker_sentiment_score": "-0.038822", "ticker_sentiment_label": "Neutral"}, {"ticker": "DELL", "relevance_score": "0.125134", "ticker_sentiment_score": "-0.292719", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MRVL", "relevance_score": "0.125134", "ticker_sentiment_score": "0.253154", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "The Zacks Analyst Blog Highlights Avidity, Bristol Myers Squibb, Vertex, Arcturus and BioVie", "url": "https://www.zacks.com/stock/news/2191938/the-zacks-analyst-blog-highlights-avidity-bristol-myers-squibb-vertex-arcturus-and-biovie", "time_published": "20231201T100900", "authors": ["Zacks Investment Research"], "summary": "Avidity, Bristol Myers Squibb, Vertex, Arcturus and BioVie are included in this Analyst Blog.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/29/1920.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.929393"}], "overall_sentiment_score": 0.164184, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.160099", "ticker_sentiment_score": "0.102954", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARCT", "relevance_score": "0.238133", "ticker_sentiment_score": "0.220312", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.04028", "ticker_sentiment_score": "0.029739", "ticker_sentiment_label": "Neutral"}, {"ticker": "RNA", "relevance_score": "0.160099", "ticker_sentiment_score": "0.027595", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIVI", "relevance_score": "0.313817", "ticker_sentiment_score": "0.036968", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.238133", "ticker_sentiment_score": "0.102868", "ticker_sentiment_label": "Neutral"}]}, {"title": "Texas AG Sues Pfizer Over Covid Vaccine Effectiveness", "url": "https://www.forbes.com/sites/mollybohannon/2023/11/30/texas-ag-sues-pfizer-over-covid-vaccine-effectiveness/", "time_published": "20231130T223933", "authors": ["Molly Bohannon"], "summary": "Texas Attorney General Ken Paxton announced Thursday he sued pharmaceutical company Pfizer for misleading Texans about the efficacy of its Covid-19 vaccine and \"attempting to censor public discussion\"-despite the vaccine continuing to be effective and recommended by leading health agencies.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65690ead4f3849c2aa0fda5e/0x0.jpg?format=jpg&crop=4000,2252,x0,y206,safe&height=900&width=1600&fit=bounds", "source": "Forbes", "category_within_source": "n/a", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.070317, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.130217", "ticker_sentiment_score": "0.054082", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.488007", "ticker_sentiment_score": "-0.092263", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.130217", "ticker_sentiment_score": "0.054082", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biotech Stock Roundup: RNA Up on BMY Deal Expansion, BIVI Down on Setback & More", "url": "https://www.zacks.com/stock/news/2191567/biotech-stock-roundup-rna-up-on-bmy-deal-expansion-bivi-down-on-setback-more", "time_published": "20231130T153300", "authors": ["Zacks Equity Research"], "summary": "Regulatory and pipeline updates from Avidity Biosciences, Inc. (RNA) and BioVie (BIVI) are in the spotlight this week.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/57/40404.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}], "overall_sentiment_score": 0.173654, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.129284", "ticker_sentiment_score": "0.150144", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ARCT", "relevance_score": "0.2138", "ticker_sentiment_score": "0.296321", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.043264", "ticker_sentiment_score": "0.029874", "ticker_sentiment_label": "Neutral"}, {"ticker": "RNA", "relevance_score": "0.129284", "ticker_sentiment_score": "0.072436", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIVI", "relevance_score": "0.295867", "ticker_sentiment_score": "0.046906", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.2138", "ticker_sentiment_score": "0.123296", "ticker_sentiment_label": "Neutral"}]}, {"title": "Covid vaccine rates in the U.S. are slumping - and it will be a challenge to boost them", "url": "https://www.cnbc.com/2023/11/30/us-covid-shot-rates-are-low-and-it-will-be-a-challenge-to-boost-them.html", "time_published": "20231130T142333", "authors": ["Annika Kim Constantino"], "summary": "The one thing that experts, along with vaccine makers, can agree on is that low vaccination rates put people at risk of getting severe Covid infections.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107303643-1695217220166-gettyimages-1666316382-1348234-me-0914-new-covid-vaccine-004-ik.jpeg?v=1701301361&w=1920&h=1080", "source": "CNBC", "category_within_source": "Business", "source_domain": "www.cnbc.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": -0.055332, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "HESG", "relevance_score": "0.022794", "ticker_sentiment_score": "-0.039628", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVAX", "relevance_score": "0.090989", "ticker_sentiment_score": "0.050996", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.022794", "ticker_sentiment_score": "0.214218", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.136113", "ticker_sentiment_score": "0.102736", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.022794", "ticker_sentiment_score": "0.296306", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.113597", "ticker_sentiment_score": "0.072545", "ticker_sentiment_label": "Neutral"}]}, {"title": "Moderna Stock Looks Sick; Here's How To Take Advantage With Options", "url": "https://www.investors.com/research/options/moderna-stock-looks-sick-heres-how-to-take-advantage-with-options/", "time_published": "20231130T135000", "authors": ["Investor's Business Daily", "GAVIN McMASTER"], "summary": "Moderna Stock Looks Sick. Here's How To Take Advantage With ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2020/12/Stock-moderna-04-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.752319"}], "overall_sentiment_score": -0.029328, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.728189", "ticker_sentiment_score": "-0.245218", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "InnovationRx: The 30 Under 30 Healthcare List", "url": "https://www.forbes.com/sites/alexknapp/2023/11/29/innovationrx-the-30-under-30-healthcare-list/", "time_published": "20231129T212623", "authors": ["Katie Jennings"], "summary": "InnovationRx is your weekly digest of healthcare news. To get it in your inbox, subscribe here. Reid Waldman, 29, a Connecticut-based dermatologist believes there's a way to make wart removal less painful. His company Veradermics is testing a microneedle patch - basically a high-tech Band-Aid - ...", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/6567a50a605aee959d07cc86/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds", "source": "Forbes", "category_within_source": "n/a", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.191105, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MCO", "relevance_score": "0.047749", "ticker_sentiment_score": "0.038", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVAX", "relevance_score": "0.047749", "ticker_sentiment_score": "0.056645", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARCT", "relevance_score": "0.189298", "ticker_sentiment_score": "0.151318", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.047749", "ticker_sentiment_score": "0.056645", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.047749", "ticker_sentiment_score": "0.056645", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNH", "relevance_score": "0.047749", "ticker_sentiment_score": "0.070091", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.047749", "ticker_sentiment_score": "0.056645", "ticker_sentiment_label": "Neutral"}, {"ticker": "SWTX", "relevance_score": "0.047749", "ticker_sentiment_score": "0.092928", "ticker_sentiment_label": "Neutral"}]}, {"title": "Novavax's  ( NVAX )  Updated COVID Jab Gets WHO Nod for Emergency Use", "url": "https://www.zacks.com/stock/news/2191042/novavaxs-nvax-updated-covid-jab-gets-who-nod-for-emergency-use", "time_published": "20231129T165300", "authors": ["Zacks Equity Research"], "summary": "Following this authorization, Novavax's (NVAX) updated COVID-19 vaccine is available as an option to all 194 WHO member states.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/8a/2449.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.141365, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVAX", "relevance_score": "0.684305", "ticker_sentiment_score": "0.197296", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.236588", "ticker_sentiment_score": "0.085554", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.311829", "ticker_sentiment_score": "0.10663", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.236588", "ticker_sentiment_score": "0.085554", "ticker_sentiment_label": "Neutral"}]}, {"title": "Generation Bio Announces Strategic Reorganization to Extend Cash Runway for Development of ctLNP and iqDNA Platforms", "url": "https://www.globenewswire.com/news-release/2023/11/29/2787596/0/en/Generation-Bio-Announces-Strategic-Reorganization-to-Extend-Cash-Runway-for-Development-of-ctLNP-and-iqDNA-Platforms.html", "time_published": "20231129T115900", "authors": ["Generation Bio Co."], "summary": "CAMBRIDGE, Mass., Nov. 29, 2023 ( GLOBE NEWSWIRE ) -- Generation Bio Co. ( Nasdaq:GBIO ) , a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced a strategic reorganization to prioritize investment in the development of its ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/3a0c1452-8117-49fb-970e-4c1b31e67dc6", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.839681"}], "overall_sentiment_score": 0.152124, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GBIO", "relevance_score": "0.172713", "ticker_sentiment_score": "0.154757", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.043499", "ticker_sentiment_score": "0.049733", "ticker_sentiment_label": "Neutral"}]}, {"title": "What To Know About Rapidly Spreading 'Pirola' Covid Variant BA.2.86-And If Vaccines Offer Protection", "url": "https://www.forbes.com/sites/ariannajohnson/2023/11/28/what-to-know-about-rapidly-spreading-pirola-covid-variant-ba286-and-if-vaccines-offer-protection/", "time_published": "20231128T205759", "authors": ["Arianna Johnson"], "summary": "Pirola, or BA.2.86, is the third most prevalent Covid strain in the U.S., and although there may be concerns the new monovalent vaccines-which protect against the XBB lineage that Pirola isn't a part of-don't offer protection against Pirola and its subvariants, drugmakers and the CDC are sure ...", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/656653d74a876d37459056ff/0x0.jpg?format=jpg&crop=5000,2811,x0,y266,safe&height=900&width=1600&fit=bounds", "source": "Forbes", "category_within_source": "n/a", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.021393, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVAX", "relevance_score": "0.068502", "ticker_sentiment_score": "0.074419", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.068502", "ticker_sentiment_score": "0.074419", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.068502", "ticker_sentiment_score": "0.074419", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.068502", "ticker_sentiment_score": "0.074419", "ticker_sentiment_label": "Neutral"}]}, {"title": "GSK: 3 Pharma Stocks on the Rise - It's Time to Buy Now", "url": "https://stocknews.com/news/gsk-eton-ctmx-arwr-srra-3-pharma-stocks-on-the-rise-its-time-to/", "time_published": "20231128T164445", "authors": ["StockNews.com Staff"], "summary": "Given growing healthcare expenditure globally owing to the aging population and increasing prevalence of chronic and rare diseases, the sustained demand for innovative drugs and treatments positions the pharma industry for continued growth and expansion.", "banner_image": "https://stocknews.com/wp-content/uploads/2022/01/Mangeet-Kaur-Bouns_Image-4.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.999999"}, {"topic": "Earnings", "relevance_score": "0.999999"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.226194, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ARWR", "relevance_score": "0.04917", "ticker_sentiment_score": "0.157041", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CTMX", "relevance_score": "0.218598", "ticker_sentiment_score": "0.142313", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.024597", "ticker_sentiment_score": "0.082215", "ticker_sentiment_label": "Neutral"}, {"ticker": "ETON", "relevance_score": "0.146767", "ticker_sentiment_score": "0.072512", "ticker_sentiment_label": "Neutral"}, {"ticker": "GSK", "relevance_score": "0.311449", "ticker_sentiment_score": "0.33935", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Thermo Fisher Scientific & Flagship Pioneering Expand Ongoing Strategic Partnership to Jointly Create New Platform Companies with First-in-Class Enabling Technologies for Life Sciences", "url": "https://investingnews.com/thermo-fisher-scientific-flagship-pioneering-expand-ongoing-strategic-partnership-to-jointly-create-new-platform-companies-with-first-in-class-enabling-technologies-for-life-sciences/", "time_published": "20231128T140509", "authors": ["Investing News Network"], "summary": "Thermo Fisher Scientific Inc. ( NYSE: TMO ) , the world leader in serving science, and Flagship Pioneering, the bioplatform innovation company, today announced the formation of a strategic partnership to develop and commercially scale multiproduct platforms on an accelerated basis.", "banner_image": "https://investingnews.com/media-library/eyJhbGciOiJIUzI1NiIsInR5cCI6IkpXVCJ9.eyJpbWFnZSI6Imh0dHBzOi8vYXNzZXRzLnJibC5tcy8yNTg1ODg1NS9vcmlnaW4ucG5nIiwiZXhwaXJlc19hdCI6MTcwODY4MTIxOX0.Phin9ClvosnPNpkGRdBWHz_VFepTco5fqEYZcXCsZIQ/image.png?width=210", "source": "Investing News Network", "category_within_source": "n/a", "source_domain": "investingnews.com", "topics": [{"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.321795, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MCRB", "relevance_score": "0.140485", "ticker_sentiment_score": "0.136996", "ticker_sentiment_label": "Neutral"}, {"ticker": "FHTX", "relevance_score": "0.140485", "ticker_sentiment_score": "0.136996", "ticker_sentiment_label": "Neutral"}, {"ticker": "DNLI", "relevance_score": "0.140485", "ticker_sentiment_score": "0.136996", "ticker_sentiment_label": "Neutral"}, {"ticker": "SANA", "relevance_score": "0.140485", "ticker_sentiment_score": "0.136996", "ticker_sentiment_label": "Neutral"}, {"ticker": "TMO", "relevance_score": "0.276648", "ticker_sentiment_score": "0.319336", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.140485", "ticker_sentiment_score": "0.136996", "ticker_sentiment_label": "Neutral"}, {"ticker": "OMGA", "relevance_score": "0.140485", "ticker_sentiment_score": "0.136996", "ticker_sentiment_label": "Neutral"}]}, {"title": "Arcturus'  ( ARCT )  CF Drug Gets FDA's Orphan Status, Stock Up", "url": "https://www.zacks.com/stock/news/2190147/arcturus-arct-cf-drug-gets-fdas-orphan-status-stock-up", "time_published": "20231128T125600", "authors": ["Zacks Equity Research"], "summary": "Arcturus (ARCT) rises 8% as the FDA grants Orphan Drug Designation for its product candidate, ARCT-032, for the treatment of cystic fibrosis.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/57/40404.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.682689"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.135764, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.211191", "ticker_sentiment_score": "0.083487", "ticker_sentiment_label": "Neutral"}, {"ticker": "LGND", "relevance_score": "0.159218", "ticker_sentiment_score": "0.21889", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ARCT", "relevance_score": "0.496915", "ticker_sentiment_score": "0.322351", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.211191", "ticker_sentiment_score": "-0.146513", "ticker_sentiment_label": "Neutral"}]}, {"title": "WHO authorizes emergency use of Novavax's updated COVID vaccine", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/who-authorizes-emergency-use-novavaxs-updated-covid-vaccine-2023-11-28/", "time_published": "20231128T112800", "authors": ["Reuters"], "summary": "Vials labelled \"VACCINE Coronavirus COVID-19\" and a syringe are seen in front of a displayed Novavax logo in this illustration taken December 11, 2021. REUTERS/Dado Ruvic/Illustration Acquire Licensing Rights", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/HIWQMMD2UJKUBEH4CSY2A7U4P4.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.066781, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.24289", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.24289", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVAX", "relevance_score": "0.463792", "ticker_sentiment_score": "-0.049234", "ticker_sentiment_label": "Neutral"}]}, {"title": "Moderna begins work on China mRNA manufacturing site", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/moderna-begins-work-china-mrna-manufacturing-site-2023-11-28/", "time_published": "20231128T035628", "authors": ["Andrew Silver"], "summary": "A sign marks the headquarters of the coronavirus disease ( COVID-19 ) vaccine maker Moderna in Cambridge, Massachusetts, U.S., April 28, 2022. REUTERS/Brian Snyder/File Photo Acquire Licensing Rights", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/C6Q3QAL4JFO4JJUT7DXIWDYFKI.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.185767, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.591019", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "A Secretive $10 Billion Firm Backed By WhatsApp Billionaire Jan Koum Is Quietly Building A Startup Portfolio", "url": "https://www.forbes.com/sites/alexkonrad/2023/11/26/secretive-firm-backed-by-whatsapp-billionaire-jan-koum-has-10-billion/", "time_published": "20231127T113000", "authors": ["Alex Konrad"], "summary": "Led by former Sequoia partner Michael Abramson, two-year-old Newlands already holds billions in equities like Alphabet, Amazon and Meta alongside a smattering of early-stage startup bets - and then there's crypto flameout FTX. No one involved wants to talk.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/6555028413da26b745a7ab1a/0x0.jpg?format=jpg&crop=1920,1080,x0,y0,safe&height=900&width=1600&fit=bounds", "source": "Forbes", "category_within_source": "n/a", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}, {"topic": "Blockchain", "relevance_score": "0.310843"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.25"}], "overall_sentiment_score": 0.16879, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BABA", "relevance_score": "0.017756", "ticker_sentiment_score": "0.050383", "ticker_sentiment_label": "Neutral"}, {"ticker": "NFLX", "relevance_score": "0.017756", "ticker_sentiment_score": "0.050383", "ticker_sentiment_label": "Neutral"}, {"ticker": "PYPL", "relevance_score": "0.017756", "ticker_sentiment_score": "0.050383", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.017756", "ticker_sentiment_score": "0.092759", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.035502", "ticker_sentiment_score": "0.04779", "ticker_sentiment_label": "Neutral"}, {"ticker": "TRMNF", "relevance_score": "0.017756", "ticker_sentiment_score": "0.051158", "ticker_sentiment_label": "Neutral"}, {"ticker": "GTLB", "relevance_score": "0.017756", "ticker_sentiment_score": "0.050383", "ticker_sentiment_label": "Neutral"}, {"ticker": "DDOG", "relevance_score": "0.017756", "ticker_sentiment_score": "0.050383", "ticker_sentiment_label": "Neutral"}, {"ticker": "KHC", "relevance_score": "0.017756", "ticker_sentiment_score": "0.083126", "ticker_sentiment_label": "Neutral"}, {"ticker": "DASH", "relevance_score": "0.035502", "ticker_sentiment_score": "0.076133", "ticker_sentiment_label": "Neutral"}, {"ticker": "COIN", "relevance_score": "0.017756", "ticker_sentiment_score": "0.050383", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.017756", "ticker_sentiment_score": "0.050383", "ticker_sentiment_label": "Neutral"}, {"ticker": "SHOP", "relevance_score": "0.017756", "ticker_sentiment_score": "0.050383", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.017756", "ticker_sentiment_score": "0.050383", "ticker_sentiment_label": "Neutral"}, {"ticker": "SCHW", "relevance_score": "0.017756", "ticker_sentiment_score": "0.083126", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.017756", "ticker_sentiment_score": "0.050383", "ticker_sentiment_label": "Neutral"}, {"ticker": "DOCU", "relevance_score": "0.017756", "ticker_sentiment_score": "0.050383", "ticker_sentiment_label": "Neutral"}]}, {"title": "$100 Invested In Moderna 5 Years Ago Would Be Worth This Much Today - Moderna  ( NASDAQ:MRNA ) ", "url": "https://www.benzinga.com/news/23/11/35939382/100-invested-in-moderna-5-years-ago-would-be-worth-this-much-today", "time_published": "20231124T140038", "authors": ["Benzinga Insights"], "summary": "Moderna MRNA has outperformed the market over the past 5 years by 22.22% on an annualized basis producing an average annual return of 33.37%. Currently, Moderna has a market capitalization of $29.93 billion.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.983605", "ticker_sentiment_score": "0.387251", "ticker_sentiment_label": "Bullish"}]}, {"title": "Underdeveloped nations fighting drugmakers over access to TB, HIV drugs", "url": "https://www.business-standard.com/world-news/underdeveloped-nations-fighting-drugmakers-over-access-to-tb-hiv-drugs-123112400284_1.html", "time_published": "20231124T072501", "authors": ["AP"], "summary": "South Africa, Colombia and other countries that lost out in the global race for coronavirus vaccines are taking a more combative approach towards drugmakers and pushing back on policies that deny cheap treatment to millions of people with tuberculosis and HIV.", "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2023-05/03/full/1683122654-0391.jpg?im=FitAndFill=(826,465)", "source": "Business Standard", "category_within_source": "GoogleRSS", "source_domain": "www.business-standard.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.074593, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.035241", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.035241", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.035241", "ticker_sentiment_score": "0.008844", "ticker_sentiment_label": "Neutral"}]}, {"title": "South Africa, Colombia and others are fighting drugmakers over access to TB and HIV drugs", "url": "https://apnews.com/article/bedaquiline-dolutegravir-tuberculosis-hiv-south-africa-0f6de15ea57279b699c147c015b23c02", "time_published": "20231124T050700", "authors": ["MARIA CHENG", "GERALD IMRAY"], "summary": "CAPE TOWN, South Africa ( AP ) - South Africa, Colombia and other countries that lost out in the global race for coronavirus vaccines are taking a more combative approach towards drugmakers and pushing back on policies that deny cheap treatment to millions of people with tuberculosis and HIV.", "banner_image": "https://dims.apnews.com/dims4/default/5926877/2147483647/strip/true/crop/3176x2116+0+1/resize/599x399!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2F16%2F0f%2Fcb41a0d9801e064e795df24a6527%2Fa50210d3d5b048fc80c9e2df56d39a98", "source": "Associated Press", "category_within_source": "Business", "source_domain": "apnews.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.062535, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.035661", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.035661", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.035661", "ticker_sentiment_score": "0.008854", "ticker_sentiment_label": "Neutral"}]}, {"title": "Should You Invest In IPOs? It's Still A Risky Prospect", "url": "https://www.kiplinger.com/investing/ipos/should-you-invest-in-ipos", "time_published": "20231123T153057", "authors": ["Kim Clark"], "summary": "Do you let hope triumph over experience in your love life? Go for it. But in your investment portfolio? That's where you need to harden your heart. Nowhere is the conflict between hope and experience starker than the market for initial public offerings, or IPOs.", "banner_image": "https://cdn.mos.cms.futurecdn.net/FAmz8UGNptTAXimaZAaqyT-415-80.jpg", "source": "Kiplinger", "category_within_source": "n/a", "source_domain": "www.kiplinger.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "IPO", "relevance_score": "0.999989"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.2098, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "TSLA", "relevance_score": "0.065032", "ticker_sentiment_score": "-0.017084", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAVA", "relevance_score": "0.043381", "ticker_sentiment_score": "0.146512", "ticker_sentiment_label": "Neutral"}, {"ticker": "FHI", "relevance_score": "0.043381", "ticker_sentiment_score": "0.162436", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MS", "relevance_score": "0.021699", "ticker_sentiment_score": "0.077709", "ticker_sentiment_label": "Neutral"}, {"ticker": "MORN", "relevance_score": "0.021699", "ticker_sentiment_score": "0.158224", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABNB", "relevance_score": "0.043381", "ticker_sentiment_score": "0.029764", "ticker_sentiment_label": "Neutral"}, {"ticker": "WEWOW", "relevance_score": "0.021699", "ticker_sentiment_score": "-0.039417", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARM", "relevance_score": "0.108173", "ticker_sentiment_score": "0.114476", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.065032", "ticker_sentiment_score": "0.034089", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIRK", "relevance_score": "0.043381", "ticker_sentiment_score": "0.045598", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biotech Stock Roundup: BMY, TSVT Down on Setback, TRDA, MOR Offer Updates", "url": "https://www.zacks.com/stock/news/2188386/biotech-stock-roundup-bmy-tsvt-down-on-setback-trda-mor-offer-updates", "time_published": "20231123T143200", "authors": ["Zacks Equity Research"], "summary": "Regulatory setback for Bristol Myers (BMY) and other updates are in focus in the biotech sector.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/13/54831.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.099086, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MOR", "relevance_score": "0.108222", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSVT", "relevance_score": "0.266246", "ticker_sentiment_score": "0.090887", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.054236", "ticker_sentiment_score": "0.032028", "ticker_sentiment_label": "Neutral"}, {"ticker": "TRDA", "relevance_score": "0.108222", "ticker_sentiment_score": "-0.025725", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.316846", "ticker_sentiment_score": "0.112048", "ticker_sentiment_label": "Neutral"}]}, {"title": "Big Players' Recent Trades in MRNA Options - Moderna  ( NASDAQ:MRNA ) ", "url": "https://www.benzinga.com/markets/options/23/11/35920621/big-players-recent-trades-in-mrna-options", "time_published": "20231122T170037", "authors": ["Benzinga Insights"], "summary": "Financial giants have made a conspicuous bullish move on Moderna. Our analysis of options history for Moderna MRNA revealed 10 unusual trades. Delving into the details, we found 70% of traders were bullish, while 30% showed bearish tendencies.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Earnings", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.166719, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.831658", "ticker_sentiment_score": "0.224181", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "3 Biotech Stocks That Could Be Millionaire Makers", "url": "https://www.fool.com/investing/2023/11/22/3-biotech-stocks-that-could-be-millionaire-makers/", "time_published": "20231122T103000", "authors": ["Adria Cimino"], "summary": "Many biotech stocks offer exciting long-term growth prospects.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F755778%2Fgettyimages-667652037.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}, {"topic": "Earnings", "relevance_score": "0.87644"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.272056, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.054983", "ticker_sentiment_score": "0.060844", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.054983", "ticker_sentiment_score": "0.257973", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.269776", "ticker_sentiment_score": "0.070063", "ticker_sentiment_label": "Neutral"}, {"ticker": "JAZZ", "relevance_score": "0.054983", "ticker_sentiment_score": "0.039877", "ticker_sentiment_label": "Neutral"}, {"ticker": "AXSM", "relevance_score": "0.109705", "ticker_sentiment_score": "0.043593", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.054983", "ticker_sentiment_score": "0.257973", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "4 out of 5 Mexicans who got a flu shot this year turned down Cuban and Russian COVID-19 vaccines", "url": "https://apnews.com/article/mexico-vaccines-covid-influenza-sputnik-faeef82d7806cb2e5511beb5e1319221", "time_published": "20231121T212800", "authors": [], "summary": "MEXICO CITY ( AP ) - Four out of five people in Mexico who got influenza shots so far this year turned down the government's recommendation that they get Russian or at the same time, officials said Tuesday.", "banner_image": "https://dims.apnews.com/dims4/default/14b3e85/2147483647/strip/true/crop/3423x2280+317+0/resize/599x399!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2Fea%2F41%2F293aeb46641b01f1611308161e84%2Fb4152582807a46659439088f353273b7", "source": "Associated Press", "category_within_source": "Markets", "source_domain": "apnews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.059411, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.126784", "ticker_sentiment_score": "0.191954", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.126784", "ticker_sentiment_score": "0.191954", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Why Is COVID-19 Vaccine Maker Moderna  ( MRNA )  Stock Trading Lower Today? - Moderna  ( NASDAQ:MRNA ) ", "url": "https://www.benzinga.com/general/biotech/23/11/35900447/why-is-covid-19-vaccine-maker-moderna-stock-trading-lower-today", "time_published": "20231121T165907", "authors": ["Vandana Singh"], "summary": "Moderna Inc MRNA shares slipped on Tuesday trading after the European Patent Office said a contested mRNA patent owned by Moderna is invalid, marking a victory for Pfizer Inc PFE / BioNTech SE BNTX in a patent dispute between the biggest coronavirus vaccine makers.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/21/mrna_1.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": -0.034059, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.930026", "ticker_sentiment_score": "-0.124035", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.772973", "ticker_sentiment_score": "-0.408661", "ticker_sentiment_label": "Bearish"}, {"ticker": "BNTX", "relevance_score": "0.685927", "ticker_sentiment_score": "-0.099742", "ticker_sentiment_label": "Neutral"}]}, {"title": "Madrigal Pharmaceuticals Appoints Ronald Filippo as Chief Information Officer - Madrigal Pharmaceuticals  ( NASDAQ:MDGL ) ", "url": "https://www.benzinga.com/pressreleases/23/11/g35892268/madrigal-pharmaceuticals-appoints-ronald-filippo-as-chief-information-officer", "time_published": "20231121T130000", "authors": ["Globe Newswire"], "summary": "CONSHOHOCKEN, Pa., Nov. 21, 2023 ( GLOBE NEWSWIRE ) -- Madrigal Pharmaceuticals, Inc. MDGL, a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis ( NASH ) , today announced that Ronald Filippo has been appointed Chief Information Officer.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}], "overall_sentiment_score": 0.179117, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MDGL", "relevance_score": "0.256989", "ticker_sentiment_score": "0.124447", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.087027", "ticker_sentiment_score": "0.081309", "ticker_sentiment_label": "Neutral"}]}, {"title": "Flagship Pioneering Unveils Quotient Therapeutics to Create Transformative Medicines Informed by a New Frontier of ... - PR Newswire", "url": "https://www.prnewswire.com/news-releases/flagship-pioneering-unveils-quotient-therapeutics-to-create-transformative-medicines-informed-by-a-new-frontier-of-genetics-301994177.html", "time_published": "20231121T110000", "authors": [], "summary": "Flagship Pioneering Unveils Quotient Therapeutics to Create Transformative Medicines Informed by a New Frontier of ... PR ...", "banner_image": null, "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.198683, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MCRB", "relevance_score": "0.081552", "ticker_sentiment_score": "0.117296", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.081552", "ticker_sentiment_score": "0.117296", "ticker_sentiment_label": "Neutral"}, {"ticker": "OMGA", "relevance_score": "0.081552", "ticker_sentiment_score": "0.117296", "ticker_sentiment_label": "Neutral"}, {"ticker": "FHTX", "relevance_score": "0.081552", "ticker_sentiment_score": "0.117296", "ticker_sentiment_label": "Neutral"}, {"ticker": "DNLI", "relevance_score": "0.081552", "ticker_sentiment_score": "0.117296", "ticker_sentiment_label": "Neutral"}, {"ticker": "SANA", "relevance_score": "0.081552", "ticker_sentiment_score": "0.117296", "ticker_sentiment_label": "Neutral"}]}, {"title": "Vertex  ( VRTX )  Non-Cystic Fibrosis Pipeline Boosts Stock This Year", "url": "https://www.zacks.com/stock/news/2187003/vertex-vrtx-non-cystic-fibrosis-pipeline-boosts-stock-this-year", "time_published": "20231121T110000", "authors": ["Zacks Equity Research"], "summary": "Vertex Pharmaceuticals (VRTX) is likely to achieve multiple clinical milestones in late/2023 and 2024, both in its CF and non-CF portfolio.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/29/1920.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.576289"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.033553, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.155786", "ticker_sentiment_score": "-0.187907", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "VRTX", "relevance_score": "0.206685", "ticker_sentiment_score": "0.160053", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DVAX", "relevance_score": "0.206685", "ticker_sentiment_score": "0.15864", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "BioNTech says European Patent Office has declared Moderna patent invalid", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/biontech-says-european-patent-office-has-declared-moderna-patent-invalid-2023-11-21/", "time_published": "20231121T105200", "authors": ["Reuters"], "summary": "The logo of BioNTech is pictured at Biontech's research laboratory for individualised vaccines against cancer in Mainz, Germany, July 27, 2023. REUTERS/Wolfgang Rattay/ File photo Acquire Licensing Rights", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/56X4QQ6MY5IHFCPDVCREVKJT2M.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.144492, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.285526", "ticker_sentiment_score": "-0.341672", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PFE", "relevance_score": "0.285526", "ticker_sentiment_score": "-0.341672", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "BNTX", "relevance_score": "0.727604", "ticker_sentiment_score": "-0.541", "ticker_sentiment_label": "Bearish"}]}, {"title": "Big Players' Recent Trades in MRNA Options - Moderna  ( NASDAQ:MRNA ) ", "url": "https://www.benzinga.com/markets/options/23/11/35852593/big-players-recent-trades-in-mrna-options", "time_published": "20231117T170100", "authors": ["Benzinga Insights"], "summary": "Deep-pocketed investors have adopted a bearish approach towards Moderna MRNA, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Earnings", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.175915, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.716023", "ticker_sentiment_score": "0.244382", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "3 Key Trends to Consider in Ginkgo Bioworks' Q3 Earnings Report", "url": "https://www.fool.com/investing/2023/11/17/3-key-trends-to-consider-in-ginkgo-bioworks-q3-ear/", "time_published": "20231117T133500", "authors": ["Alex Carchidi"], "summary": "Favorable trends are continuing, but there are new headwinds too.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.818451"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.132082, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.05749", "ticker_sentiment_score": "0.185998", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DNA", "relevance_score": "0.114682", "ticker_sentiment_score": "0.022567", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.05749", "ticker_sentiment_score": "0.185998", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.171282", "ticker_sentiment_score": "0.203907", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "The Zacks Analyst Blog Highlights Arcellx, Bristol Myers Squibb, Solid Biosciences, Vertex Pharmaceuticals and CRISPR Therapeutics", "url": "https://www.zacks.com/stock/news/2185763/the-zacks-analyst-blog-highlights-arcellx-bristol-myers-squibb-solid-biosciences-vertex-pharmaceuticals-and-crispr-therapeutics", "time_published": "20231117T110000", "authors": ["Zacks Equity Research"], "summary": "Arcellx, Bristol Myers Squibb, Solid Biosciences, Vertex Pharmaceuticals and CRISPR Therapeutics are included in this Analyst Blog.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/29/1920.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.160843, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ACLX", "relevance_score": "0.29176", "ticker_sentiment_score": "0.105073", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.197011", "ticker_sentiment_score": "0.022826", "ticker_sentiment_label": "Neutral"}, {"ticker": "SHGI", "relevance_score": "0.099271", "ticker_sentiment_score": "0.037281", "ticker_sentiment_label": "Neutral"}, {"ticker": "SLDB", "relevance_score": "0.29176", "ticker_sentiment_score": "0.064817", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.049732", "ticker_sentiment_score": "-0.06097", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.148426", "ticker_sentiment_score": "0.02062", "ticker_sentiment_label": "Neutral"}]}, {"title": "Japan to buy 1.4 mln doses of Daiichi Sankyo COVID vaccine", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/japan-buy-14-mln-doses-daiichi-sankyo-covid-vaccine-2023-11-17/", "time_published": "20231117T020435", "authors": ["Reuters"], "summary": "Daiichi Sankyo's company logo is pictured at its headquarters in Tokyo, Japan, October 20, 2023. REUTERS/Kim Kyung-Hoon/ File Photo Acquire Licensing Rights TOKYO, Nov 17 ( Reuters ) - Japan's health ministry said on Friday it agreed to buy 1.4 million doses of Daiichi Sankyo's ( 4568.T ) updated ...", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/Z4PXTFPF6BN2PJGMDHKGJIHK6Q.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.102956, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.327366", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.327366", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biotech Stock Roundup: BMY's Drug Approval, VRTX & CRSP Gene Therapy Get MHRA Nod", "url": "https://www.zacks.com/stock/news/2185428/biotech-stock-roundup-bmys-drug-approval-vrtx-crsp-gene-therapy-get-mhra-nod", "time_published": "20231116T153000", "authors": ["Zacks Equity Research"], "summary": "Bristol Myers (BMY) and Vertex (VRTX) drug approvals are in focus in the biotech sector.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/37/2337.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.172496, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ACLX", "relevance_score": "0.263373", "ticker_sentiment_score": "0.143413", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.159922", "ticker_sentiment_score": "0.039427", "ticker_sentiment_label": "Neutral"}, {"ticker": "SHGI", "relevance_score": "0.107016", "ticker_sentiment_score": "0.038158", "ticker_sentiment_label": "Neutral"}, {"ticker": "SLDB", "relevance_score": "0.263373", "ticker_sentiment_score": "0.111584", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.053629", "ticker_sentiment_score": "-0.061006", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.107016", "ticker_sentiment_score": "0.043076", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is Vertex Pharmaceuticals Stock a Buy Now?", "url": "https://www.fool.com/investing/2023/11/16/is-vertex-pharmaceuticals-stock-a-buy-now/", "time_published": "20231116T124500", "authors": ["Prosper Junior Bakiny"], "summary": "The company is close to another breakthrough.", "banner_image": "https://media.ycharts.com/charts/ac9a79bb7b393cb01186fad3ff7a117e.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.243264, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.061631", "ticker_sentiment_score": "0.021018", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.357293", "ticker_sentiment_score": "0.27714", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABBV", "relevance_score": "0.061631", "ticker_sentiment_score": "0.086194", "ticker_sentiment_label": "Neutral"}]}, {"title": "Peering Into Moderna's Recent Short Interest - Moderna  ( NASDAQ:MRNA ) ", "url": "https://www.benzinga.com/short-sellers/23/11/35805728/peering-into-modernas-recent-short-interest", "time_published": "20231115T144518", "authors": ["Benzinga Insights"], "summary": "Moderna's MRNA short percent of float has risen 8.4% since its last report. The company recently reported that it has 19.61 million shares sold short, which is 6.84% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.78 days to cover their ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.26961, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.224903", "ticker_sentiment_score": "0.158881", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Could a Short Squeeze Be Coming for These 3 Heavily Shorted Stocks?", "url": "https://www.fool.com/investing/2023/11/15/could-short-squeeze-coming-heavily-shorted-stocks/", "time_published": "20231115T102000", "authors": ["David Jagielski"], "summary": "Should investors expect any of these stocks to turn their fortunes around next year?", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.54554"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": -0.080969, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BYND", "relevance_score": "0.250386", "ticker_sentiment_score": "-0.123224", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVAX", "relevance_score": "0.16849", "ticker_sentiment_score": "-0.027323", "ticker_sentiment_label": "Neutral"}, {"ticker": "UPST", "relevance_score": "0.367865", "ticker_sentiment_score": "0.06193", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.042421", "ticker_sentiment_score": "-0.106586", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.042421", "ticker_sentiment_score": "-0.106586", "ticker_sentiment_label": "Neutral"}]}, {"title": "China's foreign investment deficit should serve as a warning for Beijing", "url": "https://www.scmp.com/comment/opinion/article/3241369/chinas-first-deficit-foreign-investment-should-serve-warning-beijing-amid-efforts-attract-business", "time_published": "20231113T230022", "authors": ["Zhou Xin"], "summary": "Even after its first foreign investment deficit, China remains an attractive market for many firms, but bureaucrats need to do more to attract business.", "banner_image": "https://cdn.i-scmp.com/sites/default/files/styles/wide_landscape/public/d8/video/thumbnail/2023/09/28/Spotlight_overseasproperty_clean.jpg?itok=wY60mk7j", "source": "South China Morning Post", "category_within_source": "Business", "source_domain": "www.scmp.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Economy - Fiscal", "relevance_score": "0.310843"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": 0.009722, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.227538", "ticker_sentiment_score": "0.081461", "ticker_sentiment_label": "Neutral"}, {"ticker": "MU", "relevance_score": "0.057628", "ticker_sentiment_score": "-0.169996", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Pfizer Stock Hits 3-Year Low-Down 50% From 2021 Peak", "url": "https://www.forbes.com/sites/dereksaul/2023/11/13/pfizer-stock-hits-3-year-low-down-50-from-2021-peak/", "time_published": "20231113T210853", "authors": ["Derek Saul"], "summary": "Pfizer shares tumbled again Monday, continuing the pharmaceutical giant's struggles tied to declining demand for its Covid-19 products and essentially wiping out the entirety of the firm's peak pandemic gains. Pfizer stock slipped 1.6% to $28.96, closing at its lowest share price since March 26, ...", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65528ed147e90d7670350551/0x0.jpg?format=jpg&crop=4000,2250,x0,y186,safe&height=900&width=1600&fit=bounds", "source": "Forbes", "category_within_source": "n/a", "source_domain": "www.forbes.com", "topics": [{"topic": "Earnings", "relevance_score": "0.614606"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}], "overall_sentiment_score": -0.019531, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.110462", "ticker_sentiment_score": "-0.007782", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.218817", "ticker_sentiment_score": "0.193129", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.733479", "ticker_sentiment_score": "-0.031645", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.110462", "ticker_sentiment_score": "-0.007782", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.110462", "ticker_sentiment_score": "-0.007782", "ticker_sentiment_label": "Neutral"}]}, {"title": "Council Post: Why Intellectual Property-Based Financing Is Gaining Popularity", "url": "https://www.forbes.com/sites/forbesfinancecouncil/2023/11/13/why-intellectual-property-based-financing-is-gaining-popularity/", "time_published": "20231113T121500", "authors": ["Joseph K. Hopkins"], "summary": "Why Intellectual Property-Based Financing Is Gaining Popularity Forbes ...", "banner_image": "https://blogs-images.forbes.com/assets/images/avatars/blog-4409_400_7bca6d487f6cc72cdf2f893001e4a3c2.jpg", "source": "Forbes", "category_within_source": "n/a", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Blockchain", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.521298, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.047559", "ticker_sentiment_score": "0.293973", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "QCOM", "relevance_score": "0.047559", "ticker_sentiment_score": "0.104827", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Cathie Wood Bargain Buys That Should Be on Your List Too", "url": "https://www.fool.com/investing/2023/11/13/3-cathie-wood-buys-that-should-be-on-your-list/", "time_published": "20231113T100000", "authors": ["Adria Cimino"], "summary": "Wood just picked up shares of these companies recently.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F754792%2Fgettyimages-three-business-people-use-tablets.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.98396"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.989041"}], "overall_sentiment_score": 0.30049, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.384608", "ticker_sentiment_score": "0.294376", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ISRG", "relevance_score": "0.170475", "ticker_sentiment_score": "0.280953", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DNA", "relevance_score": "0.170475", "ticker_sentiment_score": "0.190203", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.057215", "ticker_sentiment_score": "0.079944", "ticker_sentiment_label": "Neutral"}]}, {"title": "Where Will Novavax Be in 3 Years?", "url": "https://www.fool.com/investing/2023/11/11/where-will-novavax-be-in-3-years/", "time_published": "20231111T103000", "authors": ["Adria Cimino"], "summary": "Novavax shares have plunged from early pandemic highs.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F754676%2Fgettyimages-1266812068.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.796627"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.136177, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.204503", "ticker_sentiment_score": "0.08364", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.154125", "ticker_sentiment_score": "0.07966", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVAX", "relevance_score": "0.781715", "ticker_sentiment_score": "0.232935", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "A popular maratona de Zhengzhou impulsiona o desenvolvimento do turismo cultural", "url": "https://www.prnewswire.com/news-releases/a-popular-maratona-de-zhengzhou-impulsiona-o-desenvolvimento-do-turismo-cultural-859492164.html", "time_published": "20231110T195700", "authors": ["The Organizing Committee of 2023 Zhengzhou Yellow-River Marathon"], "summary": "A maratona de Zhengzhou deste ano destacou as caracter\u00edsticas do Rio Amarelo, o segundo rio mais longo da China.", "banner_image": "https://mma.prnewswire.com/media/2273764/Zhengzhou_marathon.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.0, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.159569", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Top Biotech Stocks to Buy Right Now", "url": "https://www.fool.com/investing/2023/11/10/2-top-biotech-stocks-to-buy-right-now/", "time_published": "20231110T151500", "authors": ["Prosper Junior Bakiny"], "summary": "Don't give up on these stocks too fast.", "banner_image": "https://media.ycharts.com/charts/23bb3db224d5e90f0f2ad5eb3a2c68b0.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.891286"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.77141"}], "overall_sentiment_score": 0.186111, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.380426", "ticker_sentiment_score": "0.253569", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.521812", "ticker_sentiment_score": "0.388976", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.05654", "ticker_sentiment_score": "0.084917", "ticker_sentiment_label": "Neutral"}]}, {"title": "Novavax  ( NVAX )  Beats on Q3 Earnings & Sales, Cuts Sales View", "url": "https://www.zacks.com/stock/news/2182275/novavax-nvax-beats-on-q3-earnings-sales-cuts-sales-view", "time_published": "20231110T140600", "authors": ["Zacks Equity Research"], "summary": "Novavax (NVAX) reports better-than-expected third-quarter results, with earnings and revenues beating estimates. It lowers product sales guidance for 2023.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/8a/2449.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.993781"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.050301, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "APLS", "relevance_score": "0.221145", "ticker_sentiment_score": "-0.030018", "ticker_sentiment_label": "Neutral"}, {"ticker": "BHVN", "relevance_score": "0.148502", "ticker_sentiment_score": "-0.009213", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVAX", "relevance_score": "0.517338", "ticker_sentiment_score": "0.138383", "ticker_sentiment_label": "Neutral"}, {"ticker": "CDMO", "relevance_score": "0.185022", "ticker_sentiment_score": "0.088328", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.037329", "ticker_sentiment_score": "0.109888", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.037329", "ticker_sentiment_score": "0.109888", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Moderna Stock Was Cratering This Week", "url": "https://www.fool.com/investing/2023/11/10/why-moderna-stock-was-cratering-this-week/", "time_published": "20231110T112900", "authors": ["Eric Volkman"], "summary": "Perhaps the COVID-19 vaccine developer's best days are in the past.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Earnings", "relevance_score": "0.795202"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": -0.002443, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.672055", "ticker_sentiment_score": "0.161104", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SPGI", "relevance_score": "0.129516", "ticker_sentiment_score": "-0.003655", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.255641", "ticker_sentiment_score": "0.175606", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Brinc Hosts Successful Asia Health Innovation Summit 2023, Fostering Greater Ideations and Collaborations in the Healthcare Sector", "url": "https://www.prnewswire.com/apac/news-releases/brinc-hosts-successful-asia-health-innovation-summit-2023-fostering-greater-ideations-and-collaborations-in-the-healthcare-sector-301984610.html", "time_published": "20231110T104300", "authors": ["Brinc"], "summary": "Brinc Hosts Successful Asia Health Innovation Summit 2023, Fostering Greater Ideations and Collaborations in the ... PR ...", "banner_image": "https://mma.prnewswire.com/media/2273487/The_Honorable_Duncan_Chiu_speaking_Asia_Health_Innovation_Summit_2023.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Blockchain", "relevance_score": "0.451494"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.404531, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.04882", "ticker_sentiment_score": "0.210689", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SBGSF", "relevance_score": "0.04882", "ticker_sentiment_score": "0.17297", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Generation Bio Reports Business Highlights and Third Quarter 2023 Financial Results", "url": "https://www.globenewswire.com/news-release/2023/11/09/2777877/0/en/Generation-Bio-Reports-Business-Highlights-and-Third-Quarter-2023-Financial-Results.html", "time_published": "20231109T211500", "authors": ["Generation Bio Co."], "summary": "- Immune-quiet DNA evades innate immune sensors in both mice and non-human primates addressing a central challenge for non-viral DNA therapeutics ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/3a0c1452-8117-49fb-970e-4c1b31e67dc6", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.838487"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.451494"}], "overall_sentiment_score": 0.110636, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GBIO", "relevance_score": "0.198221", "ticker_sentiment_score": "0.098855", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.033375", "ticker_sentiment_score": "0.048809", "ticker_sentiment_label": "Neutral"}]}, {"title": "Novavax plans to slash costs by another $300 mn amid sagging demand", "url": "https://www.business-standard.com/companies/news/novavax-plans-to-slash-costs-by-another-300-mn-amid-sagging-demand-123111000010_1.html", "time_published": "20231109T184539", "authors": ["Bloomberg"], "summary": "Covid-19 vaccine maker Novavax Inc slashed its sales forecast and said it's ready to cut at least another $300 million in costs next year amid sagging demand for its shots.", "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2021-06/17/full/1623925459-1247.jpg?im=FitAndFill=(826,465)", "source": "Business Standard", "category_within_source": "GoogleRSS", "source_domain": "www.business-standard.com", "topics": [{"topic": "Earnings", "relevance_score": "0.918141"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.100849, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.091162", "ticker_sentiment_score": "0.178626", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.091162", "ticker_sentiment_score": "0.178626", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVAX", "relevance_score": "0.43303", "ticker_sentiment_score": "0.047095", "ticker_sentiment_label": "Neutral"}]}, {"title": "Revolution Medicines Completes Acquisition of EQRx - Revolution Medicines  ( NASDAQ:RVMD ) ", "url": "https://www.benzinga.com/pressreleases/23/11/g35700404/revolution-medicines-completes-acquisition-of-eqrx", "time_published": "20231109T141058", "authors": ["Globe Newswire"], "summary": "Acquisition Expected to Add Approximately $1.1 Billion in Net Cash to Revolution Medicines' Balance Sheet, Supporting Late-Stage Development of RAS ( ON ) Inhibitor Investigational Drugs Sandra Horning, M.D., Joins Revolution Medicines' Board of Directors", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Mergers", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.999606"}], "overall_sentiment_score": 0.158684, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "EQRX", "relevance_score": "0.460808", "ticker_sentiment_score": "0.24959", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GS", "relevance_score": "0.034984", "ticker_sentiment_score": "0.13518", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.034984", "ticker_sentiment_score": "0.022511", "ticker_sentiment_label": "Neutral"}, {"ticker": "OLMA", "relevance_score": "0.034984", "ticker_sentiment_score": "0.022511", "ticker_sentiment_label": "Neutral"}, {"ticker": "RVMD", "relevance_score": "0.595343", "ticker_sentiment_score": "0.235595", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Revolution Medicines Completes Acquisition of EQRx", "url": "https://www.globenewswire.com/news-release/2023/11/09/2777469/0/en/Revolution-Medicines-Completes-Acquisition-of-EQRx.html", "time_published": "20231109T141000", "authors": ["Inc.", "Revolution Medicines"], "summary": "Acquisition Expected to Add Approximately $1.1 Billion in Net Cash to Revolution Medicines' Balance Sheet, Supporting Late-Stage Development of RAS ( ON ) Inhibitor Investigational Drugs ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/09e35daa-517c-4cec-993c-245317935107", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.998947"}], "overall_sentiment_score": 0.168343, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "EQRX", "relevance_score": "0.470482", "ticker_sentiment_score": "0.258725", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GS", "relevance_score": "0.035821", "ticker_sentiment_score": "0.135581", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.035821", "ticker_sentiment_score": "0.022563", "ticker_sentiment_label": "Neutral"}, {"ticker": "OLMA", "relevance_score": "0.035821", "ticker_sentiment_score": "0.022563", "ticker_sentiment_label": "Neutral"}, {"ticker": "RVMD", "relevance_score": "0.58113", "ticker_sentiment_score": "0.242863", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Novavax shares rise as third-quarter results top expectations", "url": "https://www.marketwatch.com/story/novavax-shares-rise-as-third-quarter-results-top-expectations-a422bdca", "time_published": "20231109T135000", "authors": ["Eleanor Laise"], "summary": "Vaccine maker reins in full-year sales outlook, looks to expand cost-cutting program ...", "banner_image": "https://images.mktw.net/im-265132/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.107596, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.312158", "ticker_sentiment_score": "0.103064", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.312158", "ticker_sentiment_score": "0.103064", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVAX", "relevance_score": "0.716023", "ticker_sentiment_score": "0.188024", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Moderna's Stock Just Tumbled 12%. Here's Why It's Still a Buy.", "url": "https://www.fool.com/investing/2023/11/09/modernas-stock-just-tumbled-12-heres-why-its-still/", "time_published": "20231109T134500", "authors": ["Alex Carchidi"], "summary": "It's gearing up for its next growth spurt.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}, {"topic": "Earnings", "relevance_score": "0.858979"}], "overall_sentiment_score": 0.191602, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.335519", "ticker_sentiment_score": "0.293581", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.057628", "ticker_sentiment_score": "0.009028", "ticker_sentiment_label": "Neutral"}]}, {"title": "Novavax posts higher-than-expected revenue, says prepared to further cut costs", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/covid-vaccine-maker-novavax-reports-better-than-expected-revenue-2023-11-09/", "time_published": "20231109T130100", "authors": ["Reuters"], "summary": "A vial labelled \"Novavax V COVID-19 Vaccine\" is seen in this illustration taken January 16, 2022. REUTERS/Dado Ruvic/Illustration Acquire Licensing Rights", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/KQY6Q2HQGROSVPRNTFTB2D3LJU.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Earnings", "relevance_score": "0.538269"}], "overall_sentiment_score": 0.050196, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CVS", "relevance_score": "0.092569", "ticker_sentiment_score": "0.04888", "ticker_sentiment_label": "Neutral"}, {"ticker": "RADCQ", "relevance_score": "0.092569", "ticker_sentiment_score": "0.04888", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVAX", "relevance_score": "0.647749", "ticker_sentiment_score": "0.153915", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.092569", "ticker_sentiment_score": "0.04888", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.092569", "ticker_sentiment_score": "0.04888", "ticker_sentiment_label": "Neutral"}]}, {"title": "Carisma Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights", "url": "https://www.prnewswire.com/news-releases/carisma-therapeutics-reports-third-quarter-2023-financial-results-and-recent-business-highlights-301982660.html", "time_published": "20231109T123000", "authors": ["Carisma Therapeutics Inc."], "summary": "Presented updated data from Phase 1 clinical trial of CT-0508 at CAR-TCR Summit, further supporting CAR-M safety, feasibility and mechanism of action Selected clinical candidate for CT-1119, an anti-mesothelin CAR-Monocyte", "banner_image": "https://mma.prnewswire.com/media/1219543/Carisma_Therapeutics_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.998663"}], "overall_sentiment_score": 0.150928, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.068016", "ticker_sentiment_score": "0.107898", "ticker_sentiment_label": "Neutral"}, {"ticker": "CARM", "relevance_score": "0.202084", "ticker_sentiment_score": "0.172463", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Dr. Tom Frieden: Covid-19 is still around, and so are these misconceptions", "url": "https://www.cnn.com/2023/11/09/health/tom-frieden-covid-19-misconceptions/index.html", "time_published": "20231109T111400", "authors": [], "summary": "Editor's note: Dr. Tom Frieden was director of the US Centers for Disease Control and Prevention from 2009 to 2017, where he oversaw responses to the H1N1 influenza, Ebola and Zika epidemics. He is president and CEO of Resolve to Save Lives and Senior Fellow for Global Health at the Council on ...", "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/231101153604-vaccine-stock-110123.jpg?c=16x9&q=h_144,w_256,c_fill", "source": "CNN", "category_within_source": "Markets", "source_domain": "www.cnn.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.044615, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.054483", "ticker_sentiment_score": "0.128197", "ticker_sentiment_label": "Neutral"}, {"ticker": "WBD", "relevance_score": "0.054483", "ticker_sentiment_score": "0.076797", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.027257", "ticker_sentiment_score": "0.063364", "ticker_sentiment_label": "Neutral"}]}, {"title": "Moderna Unusual Options Activity For November 08 - Moderna  ( NASDAQ:MRNA ) ", "url": "https://www.benzinga.com/markets/options/23/11/35676642/moderna-unusual-options-activity-for-november-08", "time_published": "20231108T160230", "authors": ["Benzinga Insights"], "summary": "Someone with a lot of money to spend has taken a bullish stance on Moderna MRNA. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.159117, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.759278", "ticker_sentiment_score": "0.393608", "ticker_sentiment_label": "Bullish"}]}, {"title": "Upwork  ( UPWK )  Q3 2023 Earnings Call Transcript", "url": "https://www.fool.com/earnings/call-transcripts/2023/11/07/upwork-upwk-q3-2023-earnings-call-transcript/", "time_published": "20231108T043021", "authors": ["Motley Fool Transcribing"], "summary": "UPWK earnings call for the period ending September 30, 2023.", "banner_image": "https://g.foolcdn.com/misc-assets/fool-transcripts-logo.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.999998"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.375759, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "UPWK", "relevance_score": "0.186413", "ticker_sentiment_score": "0.321346", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DBX", "relevance_score": "0.006069", "ticker_sentiment_score": "0.146206", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.006069", "ticker_sentiment_score": "0.074028", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.006069", "ticker_sentiment_score": "0.146206", "ticker_sentiment_label": "Neutral"}, {"ticker": "UDMY", "relevance_score": "0.012138", "ticker_sentiment_score": "0.169212", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "COUR", "relevance_score": "0.012138", "ticker_sentiment_score": "0.169212", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Flagship Pioneering Expands into Asia-Pacific Region, with Regional Hub in Singapore - PR Newswire", "url": "https://www.prnewswire.com/apac/news-releases/flagship-pioneering-expands-into-asia-pacific-region-with-regional-hub-in-singapore-301980173.html", "time_published": "20231107T221911", "authors": [], "summary": "Flagship Pioneering Expands into Asia-Pacific Region, with Regional Hub in Singapore PR ...", "banner_image": null, "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": 0.350051, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "HESG", "relevance_score": "0.042876", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MCRB", "relevance_score": "0.085629", "ticker_sentiment_score": "0.118185", "ticker_sentiment_label": "Neutral"}, {"ticker": "FHTX", "relevance_score": "0.085629", "ticker_sentiment_score": "0.118185", "ticker_sentiment_label": "Neutral"}, {"ticker": "DNLI", "relevance_score": "0.085629", "ticker_sentiment_score": "0.118185", "ticker_sentiment_label": "Neutral"}, {"ticker": "SANA", "relevance_score": "0.085629", "ticker_sentiment_score": "0.118185", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.085629", "ticker_sentiment_score": "0.118185", "ticker_sentiment_label": "Neutral"}, {"ticker": "OMGA", "relevance_score": "0.085629", "ticker_sentiment_score": "0.118185", "ticker_sentiment_label": "Neutral"}, {"ticker": "MAS", "relevance_score": "0.042876", "ticker_sentiment_score": "0.11263", "ticker_sentiment_label": "Neutral"}]}, {"title": "CytomX Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update", "url": "https://www.globenewswire.com/news-release/2023/11/07/2775653/37704/en/CytomX-Therapeutics-Reports-Third-Quarter-2023-Financial-Results-and-Provides-Business-Update.html", "time_published": "20231107T211500", "authors": ["CytomX Therapeutics Inc."], "summary": "- CX-904 ( EGFRxCD3 T-cell engager ) initial Phase 1 dose escalation data anticipated in the first half of ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/c252869d-a4c1-4e56-88e8-d80b85d20c35", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.033385, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.089729", "ticker_sentiment_score": "0.013733", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.089729", "ticker_sentiment_score": "0.013733", "ticker_sentiment_label": "Neutral"}, {"ticker": "CTMX", "relevance_score": "0.107575", "ticker_sentiment_score": "0.029993", "ticker_sentiment_label": "Neutral"}]}, {"title": "CytomX Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update - CytomX Therapeutics  ( NASDAQ:CTMX ) ", "url": "https://www.benzinga.com/pressreleases/23/11/g35658764/cytomx-therapeutics-reports-third-quarter-2023-financial-results-and-provides-business-update", "time_published": "20231107T211500", "authors": ["Globe Newswire"], "summary": "- CX-904 ( EGFRxCD3 T-cell engager ) initial Phase 1 dose escalation data anticipated in the first half of 2024 - - CX-2051 ( EpCAM-directed ADC ) comprehensive preclinical profile presented at 14th Annual World ADC Conference; IND filing on track for year-end -", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.033338, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.087503", "ticker_sentiment_score": "0.040952", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.104911", "ticker_sentiment_score": "0.04202", "ticker_sentiment_label": "Neutral"}, {"ticker": "CTMX", "relevance_score": "0.104911", "ticker_sentiment_score": "0.014344", "ticker_sentiment_label": "Neutral"}]}, {"title": "Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update - Arbutus Biopharma  ( NASDAQ:ABUS ) ", "url": "https://www.benzinga.com/pressreleases/23/11/g35641107/arbutus-reports-third-quarter-2023-financial-results-and-provides-corporate-update", "time_published": "20231107T123000", "authors": ["Globe Newswire"], "summary": "WARMINSTER, Pa., Nov. 07, 2023 ( GLOBE NEWSWIRE ) -- Arbutus Biopharma Corporation ABUS ( \"Arbutus\" or the \"Company\" ) , a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a cure for people with chronic hepatitis B virus ( cHBV ) infection, today ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.955357"}, {"topic": "Earnings", "relevance_score": "0.818451"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.040916, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ABUS", "relevance_score": "0.078714", "ticker_sentiment_score": "0.024687", "ticker_sentiment_label": "Neutral"}, {"ticker": "FGROF", "relevance_score": "0.031529", "ticker_sentiment_score": "0.032037", "ticker_sentiment_label": "Neutral"}, {"ticker": "VACC", "relevance_score": "0.015767", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.047278", "ticker_sentiment_score": "0.059877", "ticker_sentiment_label": "Neutral"}, {"ticker": "ROIV", "relevance_score": "0.015767", "ticker_sentiment_score": "0.258722", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.063008", "ticker_sentiment_score": "0.060307", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.031529", "ticker_sentiment_score": "0.057819", "ticker_sentiment_label": "Neutral"}]}, {"title": "Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update", "url": "https://www.globenewswire.com/news-release/2023/11/07/2774965/14025/en/Arbutus-Reports-Third-Quarter-2023-Financial-Results-and-Provides-Corporate-Update.html", "time_published": "20231107T123000", "authors": ["Arbutus Biopharma Corporation"], "summary": "Multiple data presentations upcoming at AASLD - The Liver Meeting\u00ae, including preliminary data from Phase 2a clinical trial combining imdusiran, our RNAi therapeutic, with VTP-300, an HBV antigen-specific immunotherapy ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/be474abd-3f6d-4270-a58e-1e6ee5c80bb2", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.918141"}, {"topic": "Earnings", "relevance_score": "0.818451"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.04092, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ABUS", "relevance_score": "0.076896", "ticker_sentiment_score": "0.025643", "ticker_sentiment_label": "Neutral"}, {"ticker": "FGROF", "relevance_score": "0.030799", "ticker_sentiment_score": "0.051298", "ticker_sentiment_label": "Neutral"}, {"ticker": "VACC", "relevance_score": "0.015402", "ticker_sentiment_score": "0.050594", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.046184", "ticker_sentiment_score": "0.059816", "ticker_sentiment_label": "Neutral"}, {"ticker": "ROIV", "relevance_score": "0.015402", "ticker_sentiment_score": "0.258312", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.061552", "ticker_sentiment_score": "0.06023", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.030799", "ticker_sentiment_score": "0.057663", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is It Time to Buy the S&P 500's 4 Worst-Performing Stocks This Year?", "url": "https://www.fool.com/investing/2023/11/07/time-buy-sp-500-worst-performing-stocks/", "time_published": "20231107T100900", "authors": ["Jeremy Bowman"], "summary": "Should you buy the dip on these S&P 500 stocks?", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F753797%2Fstock-market-chart.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.990999"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.999996"}], "overall_sentiment_score": 0.109079, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.205807", "ticker_sentiment_score": "0.155516", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ENPH", "relevance_score": "0.103778", "ticker_sentiment_score": "-0.012108", "ticker_sentiment_label": "Neutral"}, {"ticker": "SEDG", "relevance_score": "0.351985", "ticker_sentiment_score": "0.147533", "ticker_sentiment_label": "Neutral"}]}, {"title": "Cathie Wood Just Bought This Struggling Stock After Its Billion-Dollar Quarterly Loss. Should You?", "url": "https://www.fool.com/investing/2023/11/07/cathie-wood-just-bought-this-struggling-stock/", "time_published": "20231107T100000", "authors": ["Adria Cimino"], "summary": "This particular stock has dropped more than 50% this year.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F753928%2Fgettyimages-1150572051.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.891286"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.989041"}], "overall_sentiment_score": 0.207075, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.597357", "ticker_sentiment_score": "0.215641", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.05133", "ticker_sentiment_score": "-0.041003", "ticker_sentiment_label": "Neutral"}]}, {"title": "Vertex Pharmaceuticals  ( VRTX )  Q3 2023 Earnings Call Transcript", "url": "https://www.fool.com/earnings/call-transcripts/2023/11/07/vertex-pharmaceuticals-vrtx-q3-2023-earnings-call/", "time_published": "20231107T061536", "authors": ["Motley Fool Transcribing"], "summary": "VRTX earnings call for the period ending September 30, 2023.", "banner_image": "https://g.foolcdn.com/misc-assets/fool-transcripts-logo.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.993856"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.161647"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.197676, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "EVR", "relevance_score": "0.004908", "ticker_sentiment_score": "0.120451", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.004908", "ticker_sentiment_score": "0.074064", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.004908", "ticker_sentiment_score": "0.130016", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.004908", "ticker_sentiment_score": "0.130016", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.004908", "ticker_sentiment_score": "0.20039", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GS", "relevance_score": "0.004908", "ticker_sentiment_score": "0.130016", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.009816", "ticker_sentiment_score": "0.071999", "ticker_sentiment_label": "Neutral"}]}, {"title": "BioNTech Se  ( BNTX )  Q3 2023 Earnings Call Transcript", "url": "https://www.fool.com/earnings/call-transcripts/2023/11/06/biontech-se-bntx-q3-2023-earnings-call-transcript/", "time_published": "20231106T213053", "authors": ["Motley Fool Transcribing"], "summary": "BNTX earnings call for the period ending September 30, 2023.", "banner_image": "https://g.foolcdn.com/misc-assets/fool-transcripts-logo.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.77141"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.744043"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.164859, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BAC", "relevance_score": "0.004571", "ticker_sentiment_score": "0.164238", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GS", "relevance_score": "0.004571", "ticker_sentiment_score": "0.166041", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.004571", "ticker_sentiment_score": "0.02576", "ticker_sentiment_label": "Neutral"}, {"ticker": "GMAB", "relevance_score": "0.009141", "ticker_sentiment_score": "-0.009426", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.127432", "ticker_sentiment_score": "0.092428", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.027419", "ticker_sentiment_score": "0.092558", "ticker_sentiment_label": "Neutral"}]}, {"title": "These Are The 5 Top S&P 500 Performers Today", "url": "https://www.investors.com/news/sp-500-eli-lilly-among-top-performers-monday/", "time_published": "20231106T212100", "authors": ["Investor's Business Daily", "ED CARSON"], "summary": "S&P 500: Eli Lilly, Power Generators Lead Top Performers Monday Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2018/04/stock-Eli-Lilly-01-company.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.316726"}], "overall_sentiment_score": -0.036685, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BAC", "relevance_score": "0.062434", "ticker_sentiment_score": "-0.1561", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "CEG", "relevance_score": "0.185781", "ticker_sentiment_score": "-0.027555", "ticker_sentiment_label": "Neutral"}, {"ticker": "D", "relevance_score": "0.124486", "ticker_sentiment_score": "0.029698", "ticker_sentiment_label": "Neutral"}, {"ticker": "PARA", "relevance_score": "0.245959", "ticker_sentiment_score": "-0.189767", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "BNTX", "relevance_score": "0.245959", "ticker_sentiment_score": "0.121294", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCS", "relevance_score": "0.062434", "ticker_sentiment_score": "0.07422", "ticker_sentiment_label": "Neutral"}, {"ticker": "SEDG", "relevance_score": "0.304679", "ticker_sentiment_score": "-0.347763", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "NCLH", "relevance_score": "0.245959", "ticker_sentiment_score": "-0.152669", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "WFC", "relevance_score": "0.062434", "ticker_sentiment_score": "-0.234378", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ALB", "relevance_score": "0.361626", "ticker_sentiment_score": "-0.432338", "ticker_sentiment_label": "Bearish"}, {"ticker": "LLY", "relevance_score": "0.245959", "ticker_sentiment_score": "0.098865", "ticker_sentiment_label": "Neutral"}, {"ticker": "CNC", "relevance_score": "0.185781", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.185781", "ticker_sentiment_score": "0.03801", "ticker_sentiment_label": "Neutral"}, {"ticker": "BKNG", "relevance_score": "0.361626", "ticker_sentiment_score": "0.138421", "ticker_sentiment_label": "Neutral"}]}, {"title": "Dow Jones Up As Yields Spike; Berkshire Slumps As Warren Buffett Snaps Up These Assets", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-up-as-yields-spike-berkshire-slumps-as-warren-buffett-snaps-up-these-assets/", "time_published": "20231106T203300", "authors": ["MICHAEL LARKIN", "Investor's Business Daily"], "summary": "Dow Jones Up As Yields Spike. Berkshire Slumps As Warren Buffett ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2023/11/SMT-warrenbuffett3-110623-news.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.576289"}], "overall_sentiment_score": 0.133333, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DKNG", "relevance_score": "0.114137", "ticker_sentiment_score": "0.288122", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GOOG", "relevance_score": "0.038162", "ticker_sentiment_score": "0.281024", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "META", "relevance_score": "0.076236", "ticker_sentiment_score": "0.290665", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVDA", "relevance_score": "0.076236", "ticker_sentiment_score": "0.290665", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AAPL", "relevance_score": "0.189076", "ticker_sentiment_score": "0.136807", "ticker_sentiment_label": "Neutral"}, {"ticker": "CEG", "relevance_score": "0.076236", "ticker_sentiment_score": "0.261004", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BRK-A", "relevance_score": "0.114137", "ticker_sentiment_score": "0.114174", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.076236", "ticker_sentiment_score": "0.076805", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.038162", "ticker_sentiment_score": "0.057527", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.189076", "ticker_sentiment_score": "0.058265", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAT", "relevance_score": "0.076236", "ticker_sentiment_score": "-0.347", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MRNA", "relevance_score": "0.076236", "ticker_sentiment_score": "-0.121419", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.076236", "ticker_sentiment_score": "0.210969", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DELL", "relevance_score": "0.151778", "ticker_sentiment_score": "0.31566", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CWCO", "relevance_score": "0.114137", "ticker_sentiment_score": "0.170672", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "What's Going On With BioNTech  ( BNTX )  Stock Today? - Pfizer  ( NYSE:PFE ) , BioNTech  ( NASDAQ:BNTX ) ", "url": "https://www.benzinga.com/general/biotech/23/11/35620073/like-moderna-biontech-cuts-annual-sales-forecast-by-20-as-pandemic-fades", "time_published": "20231106T150134", "authors": ["Vandana Singh"], "summary": "BioNTech SE BNTX has reported Q3 revenues of \u20ac895.3 million ( $974.49 million ) , sharply down from \u20ac3.461 billion a year ago. Analysts estimated $1.06 billion in sales. For the nine months, total revenues were \u20ac2.34 billion, compared to \u20ac13.03 billion for the comparative prior year period.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/06/pfizer-biontech_covid-19_vaccine_2020_g.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.538269"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.055272, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.194242", "ticker_sentiment_score": "-0.536123", "ticker_sentiment_label": "Bearish"}, {"ticker": "PFE", "relevance_score": "0.461283", "ticker_sentiment_score": "-0.024398", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.674691", "ticker_sentiment_score": "0.222518", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "BioNTech slashes Covid vaccine forecast as pandemic fades", "url": "https://www.financialexpress.com/healthcare/covid-19/biontech-slashes-covid-vaccine-forecast-as-pandemic-fades/3298817/", "time_published": "20231106T124243", "authors": ["Bloomberg"], "summary": "BioNTech SE cut its forecast for this year's COVID-19 vaccine sales by 20%, the latest among drugmakers forced to adjust as the world moves on from the pandemic. Vaccine sales will probably reach about \u20ac4 billion ( $4.3 billion ) , compared with an initial prediction of \u20ac5 billion, the German ...", "banner_image": "https://www.financialexpress.com/wp-content/uploads/2023/11/syring-1.jpg", "source": "The Financial Express", "category_within_source": "n/a", "source_domain": "www.financialexpress.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.02384, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.334008", "ticker_sentiment_score": "0.185077", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.48268", "ticker_sentiment_score": "0.189263", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BNTX", "relevance_score": "0.48268", "ticker_sentiment_score": "0.034686", "ticker_sentiment_label": "Neutral"}]}, {"title": "Down 84% From Its Peak. Is It Finally Time to Buy Moderna?", "url": "https://www.fool.com/investing/2023/11/05/down-84-from-its-peak-is-it-finally-time-to-buy-mo/", "time_published": "20231105T111800", "authors": ["Cory Renauer"], "summary": "The vaccine developer's huge profits have turned into heavy losses.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F753451%2Findividual-investor-with-devices-getty.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.108179"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.068356, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.392691", "ticker_sentiment_score": "-0.077564", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.051221", "ticker_sentiment_score": "0.04604", "ticker_sentiment_label": "Neutral"}]}, {"title": "Moderna May Be Facing Its Toughest Moment Ever. Time to Sell?", "url": "https://www.fool.com/investing/2023/11/04/moderna-facing-tough-moment-should-you-sell/", "time_published": "20231104T090000", "authors": ["Adria Cimino"], "summary": "Moderna still has big ambitions -- beyond the coronavirus vaccine -- that could pay off in a few years.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F753688%2Fgettyimages-1316264191.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.905476"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.072734, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.766922", "ticker_sentiment_score": "0.056307", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.09989", "ticker_sentiment_score": "0.08017", "ticker_sentiment_label": "Neutral"}]}, {"title": "These Analysts Cut Their Forecasts On Moderna After Q3 Results - Moderna  ( NASDAQ:MRNA ) ", "url": "https://www.benzinga.com/news/earnings/23/11/35596053/these-analysts-cut-their-forecasts-on-moderna-after-q3-results", "time_published": "20231103T162642", "authors": ["Lisa Levin"], "summary": "Moderna Inc MRNA posted a loss for the third quarter on Thursday. Moderna reported a quarterly loss of $ ( 9.53 ) , down from EPS income of $2.53. The analysts' estimate stood at $ ( 1.93 ) .", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/03/moderna_-_logo.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.0, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GS", "relevance_score": "0.535653", "ticker_sentiment_score": "-0.326861", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MRNA", "relevance_score": "0.989562", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Cyberark Software To Rally Around 21%? Here Are 10 Top Analyst Forecasts For Friday - Cohu  ( NASDAQ:COHU ) , CyberArk Software  ( NASDAQ:CYBR ) ", "url": "https://www.benzinga.com/news/23/11/35588852/cyberark-software-to-rally-around-21-here-are-10-top-analyst-forecasts-for-friday", "time_published": "20231103T121109", "authors": ["Lisa Levin"], "summary": "Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Keybanc cut Skyworks Solutions Inc SWKS price target from $130 to $120.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/03/cyberark_software_-_logo.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.897321"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}], "overall_sentiment_score": 0.0, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "OTLK", "relevance_score": "0.246999", "ticker_sentiment_score": "0.096782", "ticker_sentiment_label": "Neutral"}, {"ticker": "PZZA", "relevance_score": "0.246999", "ticker_sentiment_score": "-0.130426", "ticker_sentiment_label": "Neutral"}, {"ticker": "FTNT", "relevance_score": "0.246999", "ticker_sentiment_score": "0.011686", "ticker_sentiment_label": "Neutral"}, {"ticker": "COHU", "relevance_score": "0.246999", "ticker_sentiment_score": "-0.109914", "ticker_sentiment_label": "Neutral"}, {"ticker": "CYBR", "relevance_score": "0.166169", "ticker_sentiment_score": "0.153968", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SWKS", "relevance_score": "0.166169", "ticker_sentiment_score": "-0.191243", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MRNA", "relevance_score": "0.246999", "ticker_sentiment_score": "0.00394", "ticker_sentiment_label": "Neutral"}, {"ticker": "INMD", "relevance_score": "0.246999", "ticker_sentiment_score": "-0.126559", "ticker_sentiment_label": "Neutral"}, {"ticker": "SQ", "relevance_score": "0.246999", "ticker_sentiment_score": "0.122724", "ticker_sentiment_label": "Neutral"}]}, {"title": "The daily business briefing: November 3, 2023", "url": "https://theweek.com/business/the-daily-business-briefing-november-3-2023", "time_published": "20231103T121038", "authors": ["Harold Maass", "The Week US"], "summary": "1. Sam Bankman-Fried convicted in FTX fraud trial 2. Eric Trump denies working on father's financial documents 3. Moderna shares fall as falling Covid shot demand hurts earnings 4. Ukraine slams Nestl\u00e9 for Russia operations 5. Stock futures struggle ahead of jobs report", "banner_image": "https://cdn.mos.cms.futurecdn.net/eD6XSqfZaA5idpZxS5xqp8-415-80.jpg", "source": "The Week News", "category_within_source": "n/a", "source_domain": "theweek.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Blockchain", "relevance_score": "0.158519"}, {"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.744043"}], "overall_sentiment_score": 0.012253, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "FRNWF", "relevance_score": "0.034039", "ticker_sentiment_score": "0.05559", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDLZ", "relevance_score": "0.034039", "ticker_sentiment_score": "-0.040804", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.034039", "ticker_sentiment_score": "-0.00482", "ticker_sentiment_label": "Neutral"}, {"ticker": "UL", "relevance_score": "0.034039", "ticker_sentiment_score": "-0.040804", "ticker_sentiment_label": "Neutral"}, {"ticker": "PEP", "relevance_score": "0.034039", "ticker_sentiment_score": "-0.040804", "ticker_sentiment_label": "Neutral"}, {"ticker": "WEWOW", "relevance_score": "0.034039", "ticker_sentiment_score": "-0.158758", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MRNA", "relevance_score": "0.101869", "ticker_sentiment_score": "-0.170123", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "FOX", "relevance_score": "0.034039", "ticker_sentiment_score": "0.052734", "ticker_sentiment_label": "Neutral"}, {"ticker": "NSRGF", "relevance_score": "0.101869", "ticker_sentiment_score": "-0.043817", "ticker_sentiment_label": "Neutral"}]}, {"title": "Moderna reports $3.6 billion loss on covid supply writedowns", "url": "https://www.financialexpress.com/healthcare/pharma-healthcare/moderna-reports-3-6-billion-loss-on-covid-supply-writedowns/3295412/", "time_published": "20231103T033000", "authors": ["Bloomberg"], "summary": "Moderna Inc. reported a larger-than-expected loss in the third quarter after registering a $3.1 billion charge to write down excess Covid shots and reduce its manufacturing footprint as the vaccine maker prepares for a post-pandemic era.", "banner_image": "https://www.financialexpress.com/wp-content/uploads/2023/11/pills-g5a602a81d_1920.jpg", "source": "The Financial Express", "category_within_source": "n/a", "source_domain": "www.financialexpress.com", "topics": [{"topic": "Earnings", "relevance_score": "0.650727"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.128357, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.564813", "ticker_sentiment_score": "-0.179999", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PFE", "relevance_score": "0.205225", "ticker_sentiment_score": "-0.173867", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Cathie Wood's Ark Invest Goes Shopping For Moderna Stock - Sells DraftKings Shares Amid Quarterly Rise In Revenue, EPS Beat - DraftKings  ( NASDAQ:DKNG ) , NVIDIA  ( NASDAQ:NVDA ) , ARK Genomic Revolution ETF  ( BATS:ARKG ) , General Motors  ( NYSE:GM ) ", "url": "https://www.benzinga.com/markets/equities/23/11/35583205/cathie-woods-ark-invest-goes-shopping-for-moderna-stock-sells-draftkings-shares-amid-quarterly-r", "time_published": "20231103T022707", "authors": ["Benzinga Neuro"], "summary": "On Thursday, Cathie Wood-led Ark Invest made notable adjustments to its holdings, with a significant sale of DraftKings Inc DKNG shares and the addition of Moderna Inc MRNA stock. This move comes amidst DraftKings' positive earnings report and Moderna's challenges with vaccine demand.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/cathie_wood_bz_ark_3.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.875462"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.818451"}], "overall_sentiment_score": 0.253662, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DKNG", "relevance_score": "0.61135", "ticker_sentiment_score": "0.228901", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IONS", "relevance_score": "0.269776", "ticker_sentiment_score": "0.02314", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.269776", "ticker_sentiment_score": "0.299878", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.395012", "ticker_sentiment_score": "0.295005", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GM", "relevance_score": "0.269776", "ticker_sentiment_score": "0.347565", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Why Moderna Stock Plummeted by Almost 7% Today", "url": "https://www.fool.com/investing/2023/11/02/why-moderna-stock-plummeted-by-almost-7-today/", "time_published": "20231102T232647", "authors": ["Eric Volkman"], "summary": "Many investors felt queasy after reviewing the company's latest earnings report.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.77141"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.002419, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.696319", "ticker_sentiment_score": "-0.199605", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Moderna Takes $1.3 Billion Hit From Sluggish Covid Vaccine Uptake", "url": "https://www.thedailyupside.com/industries/healthcare/moderna-takes-1-3-billion-hit-from-sluggish-covid-vaccine-uptake/", "time_published": "20231102T213553", "authors": ["Isobel Asher Hamilton"], "summary": "When vaccines go bad, so does your bottom line. Moderna posted a quarterly loss of $3.63 billion on Thursday, half of which was accounted for by...", "banner_image": "https://www.thedailyupside.com/wp-content/uploads/2023/11/2_moderna-covid-vaccine_11-03-23_unsplash-ian-hutchinson-1280x853.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.thedailyupside.com", "topics": [{"topic": "Earnings", "relevance_score": "0.87644"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.077088, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.556298", "ticker_sentiment_score": "0.109379", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.101582", "ticker_sentiment_score": "0.082331", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.298264", "ticker_sentiment_score": "0.033557", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.101582", "ticker_sentiment_score": "0.153004", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Dow Jones Rallies As Apple Earnings Loom; Warren Buffett Stock Offers 'Attractive Entry Point'", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-rallies-as-apple-earnings-loom-warren-buffett-stock-offers-attractive-entry-point-treasury-yields-jerome-powell/", "time_published": "20231102T191915", "authors": ["Investor's Business Daily", "MICHAEL LARKIN"], "summary": "Dow Jones Rallies As Apple Earnings Loom. Warren Buffett Stock ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2017/11/Stock-WarrenBuffett-01-shutt.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.142857"}, {"topic": "Energy & Transportation", "relevance_score": "0.142857"}, {"topic": "Technology", "relevance_score": "0.142857"}, {"topic": "Finance", "relevance_score": "0.142857"}, {"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "Retail & Wholesale", "relevance_score": "0.142857"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.142857"}, {"topic": "Earnings", "relevance_score": "0.998311"}, {"topic": "Real Estate & Construction", "relevance_score": "0.142857"}], "overall_sentiment_score": 0.055614, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AAPL", "relevance_score": "0.159305", "ticker_sentiment_score": "0.019052", "ticker_sentiment_label": "Neutral"}, {"ticker": "BRK-A", "relevance_score": "0.11983", "ticker_sentiment_score": "0.012829", "ticker_sentiment_label": "Neutral"}, {"ticker": "TFX", "relevance_score": "0.080055", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NKE", "relevance_score": "0.080055", "ticker_sentiment_score": "0.170196", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LCID", "relevance_score": "0.080055", "ticker_sentiment_score": "0.010748", "ticker_sentiment_label": "Neutral"}, {"ticker": "OXY", "relevance_score": "0.080055", "ticker_sentiment_score": "0.096591", "ticker_sentiment_label": "Neutral"}, {"ticker": "AFYA", "relevance_score": "0.11983", "ticker_sentiment_score": "-0.015629", "ticker_sentiment_label": "Neutral"}, {"ticker": "SEDG", "relevance_score": "0.080055", "ticker_sentiment_score": "-0.198862", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "SBUX", "relevance_score": "0.159305", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "QCOM", "relevance_score": "0.080055", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VST", "relevance_score": "0.080055", "ticker_sentiment_score": "-0.019294", "ticker_sentiment_label": "Neutral"}, {"ticker": "WBA", "relevance_score": "0.080055", "ticker_sentiment_score": "0.170196", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.080055", "ticker_sentiment_score": "0.010748", "ticker_sentiment_label": "Neutral"}, {"ticker": "TS", "relevance_score": "0.11983", "ticker_sentiment_score": "0.010927", "ticker_sentiment_label": "Neutral"}]}, {"title": "Moderna  ( MRNA )  Q3 2023 Earnings Call Transcript", "url": "https://www.fool.com/earnings/call-transcripts/2023/11/02/moderna-mrna-q3-2023-earnings-call-transcript/", "time_published": "20231102T170022", "authors": ["Motley Fool Transcribing"], "summary": "MRNA earnings call for the period ending September 30, 2023.", "banner_image": "https://g.foolcdn.com/misc-assets/fool-transcripts-logo.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "0.972476"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.179845, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BCS", "relevance_score": "0.004718", "ticker_sentiment_score": "0.107384", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.004718", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.023589", "ticker_sentiment_score": "0.059706", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.004718", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.033019", "ticker_sentiment_score": "0.095575", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.009437", "ticker_sentiment_score": "0.01224", "ticker_sentiment_label": "Neutral"}]}, {"title": "Moderna  ( MRNA )  Beats on Q3 Earnings & Sales, Expects Lower COVID Demand", "url": "https://www.zacks.com/stock/news/2177609/moderna-mrna-beats-on-q3-earnings-sales-expects-lower-covid-demand", "time_published": "20231102T161900", "authors": ["Zacks Equity Research"], "summary": "Moderna (MRNA) beats expectations for earnings and sales. However, the company projects lower-than-expected 2024 guidance, which likely led to a decline in share price after the earnings announcement.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/6f/3484.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.995869"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.02383, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.038223", "ticker_sentiment_score": "0.112084", "ticker_sentiment_label": "Neutral"}, {"ticker": "DVAX", "relevance_score": "0.114318", "ticker_sentiment_score": "0.072729", "ticker_sentiment_label": "Neutral"}, {"ticker": "LGND", "relevance_score": "0.114318", "ticker_sentiment_score": "0.076205", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.434763", "ticker_sentiment_score": "-0.014556", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.038223", "ticker_sentiment_score": "0.012818", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stock market today: Wall Street rallies toward its best week of 2023 on hopes for halt to rate hikes", "url": "https://apnews.com/article/stock-market-treasury-japan-powell-a864a592f5abfcf7c081b538be1265b1", "time_published": "20231102T151000", "authors": ["STAN CHOE"], "summary": "Stock market today: Wall Street rallies toward best week in almost a year on hopes for halt to hikes The Associated Press ...", "banner_image": "https://dims.apnews.com/dims4/default/37f9eab/2147483647/strip/true/crop/5438x3622+33+0/resize/599x399!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2F7b%2F0c%2F5507282fd8acfccfc5aec17ce0c3%2F7cfab3d512cb45a792d2988c14e7cbe5", "source": "Associated Press", "category_within_source": "Markets", "source_domain": "apnews.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.9545"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.413559"}], "overall_sentiment_score": 0.090112, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.043738", "ticker_sentiment_score": "-0.264617", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "SBUX", "relevance_score": "0.043738", "ticker_sentiment_score": "0.085186", "ticker_sentiment_label": "Neutral"}, {"ticker": "FUN", "relevance_score": "0.043738", "ticker_sentiment_score": "0.079337", "ticker_sentiment_label": "Neutral"}]}, {"title": "Wall St touches two-week high on bets of end to Fed's rate hikes", "url": "https://www.reuters.com/markets/us/futures-climb-bets-end-feds-rate-hikes-2023-11-02/", "time_published": "20231102T140000", "authors": ["Shashwat Chauhan", "Amruta Khandekar"], "summary": "Traders work on the floor at the New York Stock Exchange ( NYSE ) in New York City, U.S., October 27, 2023. REUTERS/Brendan McDermid Acquire Licensing Rights Nov 2 ( Reuters ) - Wall Street's main stock indexes rallied on Thursday on hopes that the U.S.", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/6FNAFVDOJNM65EKIL5LZ6FSYPA.jpg", "source": "Reuters", "category_within_source": "Markets", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.962106"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.495866"}], "overall_sentiment_score": 0.088565, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.068502", "ticker_sentiment_score": "0.157654", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PYPL", "relevance_score": "0.068502", "ticker_sentiment_score": "0.310113", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVDA", "relevance_score": "0.068502", "ticker_sentiment_score": "0.157654", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TSLA", "relevance_score": "0.068502", "ticker_sentiment_score": "0.157654", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SBUX", "relevance_score": "0.068502", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.068502", "ticker_sentiment_score": "-0.209051", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PLTR", "relevance_score": "0.068502", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Down 75% From Its High, Has Novavax Stock Become Too Cheap to Pass Up?", "url": "https://www.fool.com/investing/2023/11/02/down-75-from-its-high-has-novavax-stock-become-too/", "time_published": "20231102T140000", "authors": ["David Jagielski"], "summary": "It won't be easy for this company to win back investors, as the business faces some big challenges.", "banner_image": "https://media.ycharts.com/charts/6111596d4f588e37522f5a29a271f7b7.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.538269"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.503496"}], "overall_sentiment_score": -0.173832, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.163354", "ticker_sentiment_score": "0.021199", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.24289", "ticker_sentiment_score": "-0.098512", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVAX", "relevance_score": "0.743214", "ticker_sentiment_score": "-0.255406", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "China's mRNA Pioneer Stemirna Faces Post-Covid Reinvention Test - Moderna  ( NASDAQ:MRNA ) , BioNTech  ( NASDAQ:BNTX ) ", "url": "https://www.benzinga.com/markets/asia/23/11/35564074/chinas-mrna-pioneer-stemirna-faces-post-covid-reinvention-test", "time_published": "20231102T134030", "authors": ["The Bamboo Works"], "summary": "Flush with funds from its backers, Stemirna built manufacturing plants that were able to produce up to 400 million vaccine doses a year and put together a sales force for an anticipated surge in Covid demand", "banner_image": "https://cdn.benzinga.com/files/stemirna.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.016895, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GLP", "relevance_score": "0.039614", "ticker_sentiment_score": "0.054922", "ticker_sentiment_label": "Neutral"}, {"ticker": "WUXAY", "relevance_score": "0.039614", "ticker_sentiment_score": "0.063669", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.07913", "ticker_sentiment_score": "0.066947", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.039614", "ticker_sentiment_score": "0.067562", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.07913", "ticker_sentiment_score": "0.066947", "ticker_sentiment_label": "Neutral"}, {"ticker": "CASBF", "relevance_score": "0.039614", "ticker_sentiment_score": "0.067562", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Is Moderna Stock Trading Lower Today? - Moderna  ( NASDAQ:MRNA ) ", "url": "https://www.benzinga.com/general/biotech/23/11/35562778/moderna-struggles-with-weaker-covid-19-vaccine-demand-expects-to-return-to-growth-in-2025-stock-p", "time_published": "20231102T133326", "authors": ["Vandana Singh"], "summary": "Moderna Inc MRNA shares are trading lower after the company reported a deeper Q3 loss of $ ( 9.53 ) , down from EPS income of $2.53. The analysts' estimate stood at $ ( 1.93 ) . The company's Q3 sales reached $1.8 billion ( all from COVID-19 vaccine ) , beating the consensus of $1.4 ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/02/moderna_covid-19_vaccine_2021_g.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.070988, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.664235", "ticker_sentiment_score": "0.184245", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Lion TCR clinched the prestigious T-Up Excellence Awards in Singapore - PR Newswire", "url": "https://www.prnewswire.com/apac/news-releases/lion-tcr-clinched-the-prestigious-t-up-excellence-awards-in-singapore-301975866.html", "time_published": "20231102T125214", "authors": [], "summary": "Lion TCR clinched the prestigious T-Up Excellence Awards in Singapore PR ...", "banner_image": null, "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.481595, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.038345", "ticker_sentiment_score": "0.200141", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.038345", "ticker_sentiment_score": "0.200141", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BNTX", "relevance_score": "0.038345", "ticker_sentiment_score": "0.200141", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Moderna tempers 2023 Covid vaccine sales forecast on weaker demand", "url": "https://www.business-standard.com/companies/news/moderna-tempers-2023-covid-vaccine-sales-forecast-on-weaker-demand-123110200941_1.html", "time_published": "20231102T121023", "authors": ["Reuters"], "summary": "Moderna on Thursday said it expected 2023 revenue of at least $6 billion, tempering its forecast to reflect weaker demand for COVID-19 vaccines, but added it would return to sales growth in 2025 and break even the following year.", "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2023-08/18/full/1692323521-0371.jpg?im=FitAndFill=(826,465)", "source": "Business Standard", "category_within_source": "GoogleRSS", "source_domain": "www.business-standard.com", "topics": [{"topic": "Earnings", "relevance_score": "0.94762"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.004791, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.332883", "ticker_sentiment_score": "0.069668", "ticker_sentiment_label": "Neutral"}]}, {"title": "Moderna tempers 2023 COVID vaccine sales forecast", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/moderna-revenue-tops-expectations-expects-return-sales-growth-2025-2023-11-02/", "time_published": "20231102T112300", "authors": ["Patrick Wingrove"], "summary": "Nov 2 ( Reuters ) - Moderna ( MRNA.O ) on Thursday said it expected 2023 revenue of at least $6 billion, tempering its forecast to reflect weaker demand for COVID-19 vaccines, but added it would return to sales growth in 2025 and break even the following year.", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/RDFYN6EYINO4RCCKNCXMM7LMX4.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Earnings", "relevance_score": "0.94762"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": -0.031134, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.282234", "ticker_sentiment_score": "0.039973", "ticker_sentiment_label": "Neutral"}]}, {"title": "Nasdaq, S&P 500 Futures Rise Ahead Of Apple Earnings - Roku  ( NASDAQ:ROKU ) , Wendy's  ( NASDAQ:WEN ) , Paramount Global  ( NASDAQ:PARA ) , Peloton Interactive  ( NASDAQ:PTON ) ", "url": "https://www.benzinga.com/news/earnings/23/11/35559421/us-stocks-on-track-for-solid-start-amid-lingering-fed-optimism-traders-eye-earnings-from-market-bel", "time_published": "20231102T111924", "authors": ["Shanthi Rexaline"], "summary": "After the Federal Reserve's decision, the stock market rally is poised to gain momentum on Thursday, with stock futures indicating an uptick. Positive earnings reports may bolster this rally, and the decline in bond yields, driven by rising rate-cut expectations, could be viewed favorably by ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/nyse_shutter_2.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.142857"}, {"topic": "Energy & Transportation", "relevance_score": "0.142857"}, {"topic": "Technology", "relevance_score": "0.142857"}, {"topic": "Finance", "relevance_score": "0.142857"}, {"topic": "Blockchain", "relevance_score": "0.158519"}, {"topic": "Economy - Monetary", "relevance_score": "0.682689"}, {"topic": "Retail & Wholesale", "relevance_score": "0.142857"}, {"topic": "Financial Markets", "relevance_score": "0.999975"}, {"topic": "Manufacturing", "relevance_score": "0.142857"}, {"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Real Estate & Construction", "relevance_score": "0.142857"}], "overall_sentiment_score": 0.162501, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ROKU", "relevance_score": "0.088635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "WEN", "relevance_score": "0.088635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.132611", "ticker_sentiment_score": "0.091357", "ticker_sentiment_label": "Neutral"}, {"ticker": "PARA", "relevance_score": "0.088635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PTON", "relevance_score": "0.088635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CROX", "relevance_score": "0.088635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXPE", "relevance_score": "0.088635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "H", "relevance_score": "0.088635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.044386", "ticker_sentiment_score": "0.152804", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CLX", "relevance_score": "0.088635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LMND", "relevance_score": "0.088635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SBUX", "relevance_score": "0.088635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "QCOM", "relevance_score": "0.088635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.088635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DBX", "relevance_score": "0.088635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SQ", "relevance_score": "0.088635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PLTR", "relevance_score": "0.088635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DKNG", "relevance_score": "0.088635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PYPL", "relevance_score": "0.088635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TNDM", "relevance_score": "0.088635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "COP", "relevance_score": "0.088635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CI", "relevance_score": "0.088635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LYV", "relevance_score": "0.088635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SWKS", "relevance_score": "0.088635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOX", "relevance_score": "0.044386", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ETSY", "relevance_score": "0.088635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "FTNT", "relevance_score": "0.088635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "FSLY", "relevance_score": "0.088635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BHC", "relevance_score": "0.088635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.088635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.088635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MAR", "relevance_score": "0.088635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.088635", "ticker_sentiment_score": "0.184545", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Moderna posts quarterly loss as company takes $1.3 billion write-down on unused Covid shots", "url": "https://www.cnbc.com/2023/11/02/moderna-mrna-q3-earnings-report-2023.html", "time_published": "20231102T103326", "authors": ["Annika Kim Constantino"], "summary": "Moderna's total revenue for the third quarter still topped Wall Street's expectations despite plummeting demand for its Covid-19 shot.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107261604-1687528288611-gettyimages-1239618774-npekiaridis_vaccines-4.jpeg?v=1698866136&w=1920&h=1080", "source": "CNBC", "category_within_source": "Earnings", "source_domain": "www.cnbc.com", "topics": [{"topic": "Earnings", "relevance_score": "0.976913"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.074158, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.684999", "ticker_sentiment_score": "0.186836", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.057215", "ticker_sentiment_score": "0.049946", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVAX", "relevance_score": "0.057215", "ticker_sentiment_score": "0.049946", "ticker_sentiment_label": "Neutral"}]}, {"title": "Moderna Beats Sales Views, But Light Outlook Could Rattle Shares", "url": "https://www.investors.com/news/technology/moderna-stock-will-light-guidance-rattle-shares-despite-a-massive-sales-beat/", "time_published": "20231102T103025", "authors": ["ALLISON GATLIN", "Investor's Business Daily"], "summary": "Moderna Stock: Will Light Guidance Rattle Shares Despite A ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2020/11/Stock-moderna-02-shutt.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.962106"}], "overall_sentiment_score": -0.040915, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVAX", "relevance_score": "0.119235", "ticker_sentiment_score": "-0.186073", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MRNA", "relevance_score": "0.797691", "ticker_sentiment_score": "-0.160283", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PFE", "relevance_score": "0.178021", "ticker_sentiment_score": "-0.129621", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.119235", "ticker_sentiment_score": "-0.186073", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Rule Breaker Investing: 9 Foolish Truths", "url": "https://www.fool.com/investing/2023/11/01/rule-breaker-investing-9-foolish-truths/", "time_published": "20231102T024700", "authors": ["Motley Fool Staff"], "summary": "What are the eternal verities in the world of money?", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.213781, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NFLX", "relevance_score": "0.019158", "ticker_sentiment_score": "0.037637", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.031924", "ticker_sentiment_score": "0.080803", "ticker_sentiment_label": "Neutral"}, {"ticker": "MELI", "relevance_score": "0.006386", "ticker_sentiment_score": "0.075526", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.006386", "ticker_sentiment_score": "0.037099", "ticker_sentiment_label": "Neutral"}, {"ticker": "HUBS", "relevance_score": "0.012772", "ticker_sentiment_score": "0.02492", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.019158", "ticker_sentiment_score": "0.018462", "ticker_sentiment_label": "Neutral"}, {"ticker": "ISRG", "relevance_score": "0.006386", "ticker_sentiment_score": "0.219614", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.019158", "ticker_sentiment_score": "0.018462", "ticker_sentiment_label": "Neutral"}]}, {"title": "Exploring Analyst Estimates for Moderna  ( MRNA )  Q3 Earnings, Beyond Revenue and EPS", "url": "https://www.zacks.com/stock/news/2176516/exploring-analyst-estimates-for-moderna-mrna-q3-earnings-beyond-revenue-and-eps", "time_published": "20231101T141300", "authors": ["Zacks Equity Research"], "summary": "Beyond analysts' top -and-bottom-line estimates for Moderna (MRNA), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2023.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default232.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.997902"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.134634, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.551295", "ticker_sentiment_score": "0.096974", "ticker_sentiment_label": "Neutral"}]}, {"title": "Unlike Pfizer, Moderna can meet 2023 COVID forecast, analysts say", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/unlike-pfizer-moderna-can-meet-2023-covid-forecast-analysts-say-2023-11-01/", "time_published": "20231101T102000", "authors": ["Khushi Mandowara"], "summary": "Syringes with needles are seen in front of a displayed Moderna logo in this illustration taken, November 27, 2021. REUTERS/Dado Ruvic/Illustration/File Photo Acquire Licensing Rights", "banner_image": "https://graphics.reuters.com/MODERNA-RESULTS/PREVIEW/jnpwwzyaxpw/chart_eikon.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.120832, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.395012", "ticker_sentiment_score": "-0.156879", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PFE", "relevance_score": "0.320974", "ticker_sentiment_score": "-0.075093", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pfizer Layoffs Confirmed As Vaccine Manufacturer Drives For Cost Savings", "url": "https://www.forbes.com/sites/qai/2023/11/01/pfizer-layoffs-confirmed-as-vaccine-manufacturer-drives-for-cost-savings/", "time_published": "20231101T092604", "authors": ["Q.ai - Powering a Personal Wealth Movement"], "summary": "\u2022 Pfizer is laying off an undisclosed amount of employees after confirming it's shutting down its New Jersey facility \u2022 Two other facilities are closing in North Carolina, with other layoffs in Illinois and Colorado \u2022 Pfizer's share price was flat as the company reported a narrower-than-expected ...", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65421997d4718e624351ab50/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds", "source": "Forbes", "category_within_source": "n/a", "source_domain": "www.forbes.com", "topics": [{"topic": "Earnings", "relevance_score": "0.998663"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}], "overall_sentiment_score": -0.03368, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SGEN", "relevance_score": "0.044141", "ticker_sentiment_score": "-0.134818", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.044141", "ticker_sentiment_score": "-0.283851", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "AZN", "relevance_score": "0.044141", "ticker_sentiment_score": "-0.283851", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PFE", "relevance_score": "0.624172", "ticker_sentiment_score": "-0.047063", "ticker_sentiment_label": "Neutral"}]}, {"title": "Never Mind Covid, Investors Want a Pfizer Obesity Pill", "url": "https://www.wsj.com/health/pharma/nevermind-covid-investors-want-a-pfizer-obesity-pill-18f6a9e5", "time_published": "20231031T163500", "authors": ["David Wainer"], "summary": "The pharmaceutical company's silence on its oral obesity drug worries investors.", "banner_image": "https://images.wsj.net/im-877521?width=700&height=466", "source": "Wall Street Journal", "category_within_source": "Markets", "source_domain": "www.wsj.com", "topics": [{"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.294959, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.178459", "ticker_sentiment_score": "0.244118", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVO", "relevance_score": "0.178459", "ticker_sentiment_score": "0.244118", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.633079", "ticker_sentiment_score": "0.390329", "ticker_sentiment_label": "Bullish"}]}, {"title": "Gilead Sciences  ( GILD )  Earnings Expected to Grow: Should You Buy?", "url": "https://www.zacks.com/stock/news/2175549/gilead-sciences-gild-earnings-expected-to-grow-should-you-buy", "time_published": "20231031T140130", "authors": ["Zacks Equity Research"], "summary": "Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default169.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.126412, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.174272", "ticker_sentiment_score": "-0.025617", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.087663", "ticker_sentiment_score": "0.088507", "ticker_sentiment_label": "Neutral"}]}, {"title": "Repligen  ( RGEN )  Tops Q3 Earnings and Revenue Estimates", "url": "https://www.zacks.com/stock/news/2175244/repligen-rgen-tops-q3-earnings-and-revenue-estimates", "time_published": "20231031T125005", "authors": ["Zacks Equity Research"], "summary": "Repligen (RGEN) delivered earnings and revenue surprises of 64.29% and 2.01%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default111.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999992"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.126045, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.139669", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "RGEN", "relevance_score": "0.402403", "ticker_sentiment_score": "0.074298", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pfizer swings to quarterly loss due to Paxlovid, Covid vaccine write-offs", "url": "https://www.cnbc.com/2023/10/31/pfizer-pfe-q3-earnings-report-2023.html", "time_published": "20231031T110302", "authors": ["Annika Kim Constantino"], "summary": "The results come two weeks after Pfizer slashed its full-year adjusted earnings and revenue guidance and launched a sweeping $3.5 billion cost-cutting plan.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107261572-1687527104868-gettyimages-1246630418-Illustration_Pfizer_Inc.jpeg?v=1687527515&w=1920&h=1080", "source": "CNBC", "category_within_source": "Earnings", "source_domain": "www.cnbc.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999162"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.009586, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SGEN", "relevance_score": "0.063258", "ticker_sentiment_score": "-0.12108", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.063258", "ticker_sentiment_score": "-0.075254", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.063258", "ticker_sentiment_score": "0.065188", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.697809", "ticker_sentiment_score": "0.01151", "ticker_sentiment_label": "Neutral"}]}, {"title": "How to get the lying out of hiring", "url": "https://www.economist.com/business/2023/10/30/how-to-get-the-lying-out-of-hiring", "time_published": "20231030T175740", "authors": ["The Economist"], "summary": "H be thought of as a battle between candour and dishonesty. You might imagine this is a simple fight between truth-seeking firms and self-promoting candidates, and to a certain extent it is. But companies themselves are prone to bend reality out of shape in ways that are self-defeating.", "banner_image": "https://www.economist.com/img/b/1280/720/90/media-assets/image/20231104_WBD001.jpg", "source": "The Economist", "category_within_source": "BusinessGoogleRSS", "source_domain": "www.economist.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.229156, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.054983", "ticker_sentiment_score": "0.210925", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MSFT", "relevance_score": "0.054983", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Check Out What Whales Are Doing With MRNA - Moderna  ( NASDAQ:MRNA ) ", "url": "https://www.benzinga.com/markets/options/23/10/35492457/check-out-what-whales-are-doing-with-mrna", "time_published": "20231030T144649", "authors": ["Benzinga Insights"], "summary": "A whale with a lot of money to spend has taken a noticeably bearish stance on Moderna. Looking at options history for Moderna MRNA we detected 10 strange trades. If we consider the specifics of each trade, it is accurate to state that 30% of the investors opened trades with bullish expectations ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.149187, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.736438", "ticker_sentiment_score": "0.058229", "ticker_sentiment_label": "Neutral"}]}, {"title": "McCormick, CME Group And 2 Other Stocks Insiders Are Selling - CME Gr  ( NASDAQ:CME ) , Airbnb  ( NASDAQ:ABNB ) ", "url": "https://www.benzinga.com/news/23/10/35487776/mccormick-cme-group-and-2-other-stocks-insiders-are-selling", "time_published": "20231030T120024", "authors": ["Lisa Levin"], "summary": "The Nasdaq 100 closed higher by 0.5% on Friday. Investors, meanwhile, focused on some notable insider trades. When insiders sell shares, it could be a preplanned sale, or could indicate their concern in the company's prospects or that they view the stock as being overpriced.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/30/mccormick_-_logo.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}, {"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.116379, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.422897", "ticker_sentiment_score": "-0.002859", "ticker_sentiment_label": "Neutral"}, {"ticker": "CME", "relevance_score": "0.422897", "ticker_sentiment_score": "0.477339", "ticker_sentiment_label": "Bullish"}, {"ticker": "ABNB", "relevance_score": "0.422897", "ticker_sentiment_score": "0.101279", "ticker_sentiment_label": "Neutral"}]}, {"title": "CytomX Therapeutics to Present Preclinical Data for Conditionally Activated Interferon Alpha-2b at the SITC 2023 Annual Meeting - CytomX Therapeutics  ( NASDAQ:CTMX ) ", "url": "https://www.benzinga.com/pressreleases/23/10/g35487786/cytomx-therapeutics-to-present-preclinical-data-for-conditionally-activated-interferon-alpha-2b-at", "time_published": "20231030T120000", "authors": ["Globe Newswire"], "summary": "- IND filing for CX-801 anticipated by the end of 2023 - SOUTH SAN FRANCISCO, Calif., Oct. 30, 2023 ( GLOBE NEWSWIRE ) -- CytomX Therapeutics, Inc.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.007243, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.043579", "ticker_sentiment_score": "-0.008973", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.087027", "ticker_sentiment_score": "-0.009532", "ticker_sentiment_label": "Neutral"}, {"ticker": "CTMX", "relevance_score": "0.215319", "ticker_sentiment_score": "0.005188", "ticker_sentiment_label": "Neutral"}]}, {"title": "Morning Bid: Markets hold their nerve amid Mid East trouble", "url": "https://www.reuters.com/markets/europe/global-markets-view-europe-2023-10-30/", "time_published": "20231030T050019", "authors": ["Wayne Cole"], "summary": "Smoke rises during Israeli strikes, amid the ongoing conflict between Israel and Palestinian Islamist group Hamas, in Gaza City, October 29, 2023. REUTERS/Yasser Qudih Acquire Licensing Rights Oct 30 ( Reuters ) - A look at the day ahead in European and global markets from Wayne Cole.", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/EKFMQKCURJNIHIXZFMEBFKQSD4.jpg", "source": "Reuters", "category_within_source": "Markets", "source_domain": "www.reuters.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.94762"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.055092, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ABNB", "relevance_score": "0.067919", "ticker_sentiment_score": "0.048101", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDNDF", "relevance_score": "0.067919", "ticker_sentiment_score": "0.048101", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.067919", "ticker_sentiment_score": "0.048101", "ticker_sentiment_label": "Neutral"}, {"ticker": "DCNSF", "relevance_score": "0.067919", "ticker_sentiment_score": "-0.068423", "ticker_sentiment_label": "Neutral"}, {"ticker": "NWG", "relevance_score": "0.067919", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Asia stocks dip on Middle East, central bank meetings", "url": "https://www.moneycontrol.com/news/business/markets/asia-stocks-dip-on-middle-east-central-bank-meetings-11621671.html", "time_published": "20231030T005015", "authors": [], "summary": "The earnings season also continues with Apple, Airbnb, McDonald's, Moderna and Eli Lilly Co among the many reporting this week. Results so far have been underwhelming, contributing to the SP 500's retreat into correction territory at 4,117.", "banner_image": "https://images.moneycontrol.com/static-mcnews/2017/03/asian-markets.jpg?impolicy=website&width=168&height=118", "source": "Money Control", "category_within_source": "Markets", "source_domain": "www.moneycontrol.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.682689"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.980716"}, {"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": -0.082263, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ABNB", "relevance_score": "0.051663", "ticker_sentiment_score": "0.045672", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCS", "relevance_score": "0.051663", "ticker_sentiment_score": "-0.118965", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.051663", "ticker_sentiment_score": "0.037988", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDNDF", "relevance_score": "0.051663", "ticker_sentiment_score": "0.045672", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.051663", "ticker_sentiment_score": "0.045672", "ticker_sentiment_label": "Neutral"}, {"ticker": "NWG", "relevance_score": "0.051663", "ticker_sentiment_score": "0.100498", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:JPY", "relevance_score": "0.051663", "ticker_sentiment_score": "0.109487", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:EUR", "relevance_score": "0.051663", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:USD", "relevance_score": "0.204503", "ticker_sentiment_score": "-0.039464", "ticker_sentiment_label": "Neutral"}]}, {"title": "Asia stocks dip on Middle East, central bank meetings", "url": "https://www.reuters.com/markets/global-markets-wrapup-1-pix-2023-10-30/", "time_published": "20231030T000030", "authors": ["Wayne Cole"], "summary": "Passersby are reflected on an electric stock quotation board outside a brokerage in Tokyo, Japan April 18, 2023. REUTERS/Issei Kato Acquire Licensing Rights", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/RZMV5XSY2BN6BNXMCATQDOJV7Y.jpg", "source": "Reuters", "category_within_source": "Markets", "source_domain": "www.reuters.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.682689"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.990893"}, {"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": -0.077302, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ABNB", "relevance_score": "0.049629", "ticker_sentiment_score": "0.04452", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCS", "relevance_score": "0.049629", "ticker_sentiment_score": "-0.118856", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.049629", "ticker_sentiment_score": "0.037948", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDNDF", "relevance_score": "0.049629", "ticker_sentiment_score": "0.04452", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.049629", "ticker_sentiment_score": "0.04452", "ticker_sentiment_label": "Neutral"}, {"ticker": "NWG", "relevance_score": "0.049629", "ticker_sentiment_score": "0.100211", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:JPY", "relevance_score": "0.049629", "ticker_sentiment_score": "0.103202", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:EUR", "relevance_score": "0.049629", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:USD", "relevance_score": "0.19661", "ticker_sentiment_score": "-0.038259", "ticker_sentiment_label": "Neutral"}]}, {"title": "How the Fed is using its multi-trillion-dollar balance sheet to fight inflation | Business", "url": "https://www.cnn.com/2023/10/29/economy/stocks-week-ahead-fed-balance-sheet/index.html", "time_published": "20231029T113000", "authors": ["Bryan Mena"], "summary": "How the Fed is using its multi-trillion-dollar balance sheet to fight inflation ...", "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/230323082125-01-federal-reserve-0321.jpg?c=16x9&q=w_800,c_fill", "source": "CNN", "category_within_source": "Economy", "source_domain": "www.cnn.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.142857"}, {"topic": "Energy & Transportation", "relevance_score": "0.142857"}, {"topic": "Technology", "relevance_score": "0.142857"}, {"topic": "Finance", "relevance_score": "0.142857"}, {"topic": "Economy - Monetary", "relevance_score": "1.0"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.142857"}, {"topic": "Financial Markets", "relevance_score": "0.929393"}, {"topic": "Manufacturing", "relevance_score": "0.142857"}, {"topic": "Earnings", "relevance_score": "0.682689"}, {"topic": "Real Estate & Construction", "relevance_score": "0.142857"}], "overall_sentiment_score": 0.129213, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CVS", "relevance_score": "0.027195", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDLZ", "relevance_score": "0.027195", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MPC", "relevance_score": "0.027195", "ticker_sentiment_score": "-0.009436", "ticker_sentiment_label": "Neutral"}, {"ticker": "ROKU", "relevance_score": "0.027195", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "D", "relevance_score": "0.027195", "ticker_sentiment_score": "0.036559", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDNDF", "relevance_score": "0.027195", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.108466", "ticker_sentiment_score": "0.107245", "ticker_sentiment_label": "Neutral"}, {"ticker": "AFL", "relevance_score": "0.027195", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "KHC", "relevance_score": "0.027195", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXPE", "relevance_score": "0.027195", "ticker_sentiment_score": "0.013893", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABNB", "relevance_score": "0.027195", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRO", "relevance_score": "0.027195", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "APOS", "relevance_score": "0.027195", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DASH", "relevance_score": "0.027195", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.027195", "ticker_sentiment_score": "-0.009436", "ticker_sentiment_label": "Neutral"}, {"ticker": "SHOP", "relevance_score": "0.027195", "ticker_sentiment_score": "0.013893", "ticker_sentiment_label": "Neutral"}, {"ticker": "GDDY", "relevance_score": "0.027195", "ticker_sentiment_score": "0.013893", "ticker_sentiment_label": "Neutral"}, {"ticker": "SBUX", "relevance_score": "0.027195", "ticker_sentiment_score": "0.013893", "ticker_sentiment_label": "Neutral"}, {"ticker": "NCLH", "relevance_score": "0.027195", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "QCOM", "relevance_score": "0.027195", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.054359", "ticker_sentiment_score": "-0.027999", "ticker_sentiment_label": "Neutral"}, {"ticker": "W", "relevance_score": "0.027195", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "WBD", "relevance_score": "0.054359", "ticker_sentiment_score": "0.141796", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPGI", "relevance_score": "0.108466", "ticker_sentiment_score": "0.009954", "ticker_sentiment_label": "Neutral"}, {"ticker": "Z", "relevance_score": "0.027195", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DBX", "relevance_score": "0.027195", "ticker_sentiment_score": "0.013893", "ticker_sentiment_label": "Neutral"}, {"ticker": "DUK", "relevance_score": "0.027195", "ticker_sentiment_score": "0.013893", "ticker_sentiment_label": "Neutral"}, {"ticker": "PINS", "relevance_score": "0.027195", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PSA", "relevance_score": "0.027195", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DKNG", "relevance_score": "0.027195", "ticker_sentiment_score": "0.013893", "ticker_sentiment_label": "Neutral"}, {"ticker": "PYPL", "relevance_score": "0.027195", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "HUM", "relevance_score": "0.027195", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "WING", "relevance_score": "0.027195", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "COP", "relevance_score": "0.027195", "ticker_sentiment_score": "0.013893", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLCO", "relevance_score": "0.027195", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SIRI", "relevance_score": "0.027195", "ticker_sentiment_score": "-0.009436", "ticker_sentiment_label": "Neutral"}, {"ticker": "GRMN", "relevance_score": "0.027195", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SUN", "relevance_score": "0.027195", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "YUM", "relevance_score": "0.027195", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "QSR", "relevance_score": "0.027195", "ticker_sentiment_score": "0.036559", "ticker_sentiment_label": "Neutral"}, {"ticker": "SYY", "relevance_score": "0.027195", "ticker_sentiment_score": "-0.009436", "ticker_sentiment_label": "Neutral"}, {"ticker": "ETSY", "relevance_score": "0.027195", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.027195", "ticker_sentiment_score": "0.013893", "ticker_sentiment_label": "Neutral"}, {"ticker": "MET", "relevance_score": "0.027195", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MAR", "relevance_score": "0.027195", "ticker_sentiment_score": "0.013893", "ticker_sentiment_label": "Neutral"}]}, {"title": "Got $1,000? 3 Growth Stocks to Buy That Could Double Your Money", "url": "https://www.fool.com/investing/2023/10/27/got-1000-3-growth-stocks-to-buy-that-could-double/", "time_published": "20231027T141500", "authors": ["Rachel Warren"], "summary": "These companies come from very different industries, but each has businesses that investors may find compelling.", "banner_image": "https://g.foolcdn.com/editorial/images/752142/getty-smiling-person-with-phone.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.990999"}, {"topic": "Earnings", "relevance_score": "0.988915"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.201372, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.116161", "ticker_sentiment_score": "0.135385", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABNB", "relevance_score": "0.266828", "ticker_sentiment_score": "0.190245", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "UPST", "relevance_score": "0.33884", "ticker_sentiment_score": "0.053564", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.038843", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "The Dreaded Market Crash Is Already Here For 14 Stocks", "url": "https://www.investors.com/etfs-and-funds/sectors/sp500-dreaded-market-crash-is-already-here-for-14-stocks/", "time_published": "20231027T120000", "authors": ["Investor's Business Daily", "MATT KRANTZ"], "summary": "Investors fearing a brutal stock market crash are still waiting with dread. But it's already arrived for a group of battered S&P 500 stocks.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/10/stock-money-7-adobe.jpeg.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.905476"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": -0.111898, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ENPH", "relevance_score": "0.152499", "ticker_sentiment_score": "-0.029493", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPGI", "relevance_score": "0.076602", "ticker_sentiment_score": "-0.022583", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.152499", "ticker_sentiment_score": "0.121741", "ticker_sentiment_label": "Neutral"}, {"ticker": "SEDG", "relevance_score": "0.299478", "ticker_sentiment_score": "0.093517", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.227007", "ticker_sentiment_score": "0.02972", "ticker_sentiment_label": "Neutral"}]}, {"title": "The Zacks Analyst Blog Highlights Bristol Myers, PTC Therapeutics, Beam Therapeutics and BioMarin Pharmaceutical", "url": "https://www.zacks.com/stock/news/2173493/the-zacks-analyst-blog-highlights-bristol-myers-ptc-therapeutics-beam-therapeutics-and-biomarin-pharmaceutical", "time_published": "20231027T111500", "authors": ["Zacks Investment Research"], "summary": "Bristol Myers, PTC Therapeutics, Beam Therapeutics and BioMarin Pharmaceutical are included in this Analyst Blog.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/37/2337.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Earnings", "relevance_score": "0.972193"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.21373, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BEAM", "relevance_score": "0.410505", "ticker_sentiment_score": "0.134111", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMRN", "relevance_score": "0.128592", "ticker_sentiment_score": "0.140342", "ticker_sentiment_label": "Neutral"}, {"ticker": "PTCT", "relevance_score": "0.294345", "ticker_sentiment_score": "0.201423", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RPRX", "relevance_score": "0.212674", "ticker_sentiment_score": "0.223843", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.085936", "ticker_sentiment_score": "-0.127835", "ticker_sentiment_label": "Neutral"}, {"ticker": "BX", "relevance_score": "0.04303", "ticker_sentiment_score": "0.135567", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Healthcare Stocks That Could Make You Richer", "url": "https://www.fool.com/investing/2023/10/27/2-healthcare-stocks-that-could-make-you-richer/", "time_published": "20231027T092000", "authors": ["Rachel Warren"], "summary": "The need for healthcare is consistent and ongoing, a reality that makes this industry resilient to economic downturns.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.976913"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}], "overall_sentiment_score": 0.247522, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.129052", "ticker_sentiment_score": "0.25619", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TDOC", "relevance_score": "0.086245", "ticker_sentiment_score": "-0.102833", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.043186", "ticker_sentiment_score": "0.049687", "ticker_sentiment_label": "Neutral"}, {"ticker": "HCSG", "relevance_score": "0.043186", "ticker_sentiment_score": "0.007984", "ticker_sentiment_label": "Neutral"}]}, {"title": "Got $2,000? Here Are 2 Beaten-Down Growth Stocks to Buy Right Now", "url": "https://www.fool.com/investing/2023/10/27/got-2000-2-beaten-down-growth-stocks-to-buy/", "time_published": "20231027T090000", "authors": ["Adria Cimino"], "summary": "Now, you can scoop up these future growth winners for a bargain.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.980716"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.311198, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.414559", "ticker_sentiment_score": "0.201616", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AXSM", "relevance_score": "0.108466", "ticker_sentiment_score": "0.182621", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Millennials seem to dig bond ETFs despite volatile fixed-income market, Charles Schwab finds", "url": "https://www.marketwatch.com/story/millennials-seem-to-dig-bond-etfs-despite-volatile-fixed-income-market-charles-schwab-finds-f7451a0f", "time_published": "20231026T203300", "authors": ["Christine Idzelis"], "summary": "This week's ETF Wrap takes a look at the findings in Schwab's latest annual ETF survey as well as how Thursday's economic data rippled through the bond market.", "banner_image": "https://images.mktw.net/im-341402/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.769861"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.064794, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GS", "relevance_score": "0.142777", "ticker_sentiment_score": "0.102974", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.107335", "ticker_sentiment_score": "0.130026", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.071677", "ticker_sentiment_score": "0.119289", "ticker_sentiment_label": "Neutral"}]}, {"title": "Neoantigen Cancer Vaccine Market Size is Projected to Reach $1.38 billion by 2030: Straits Research", "url": "https://www.benzinga.com/pressreleases/23/10/g35449061/neoantigen-cancer-vaccine-market-size-is-projected-to-reach-1-38-billion-by-2030-straits-research", "time_published": "20231026T190000", "authors": ["Globe Newswire"], "summary": "New York, United States, Oct. 26, 2023 ( GLOBE NEWSWIRE ) -- Neoantigens that arise from cancer-specific mutations are an additional class of antigens that are desirable for therapeutic cancer vaccines.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}], "overall_sentiment_score": -0.004881, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AGEN", "relevance_score": "0.04823", "ticker_sentiment_score": "-0.002986", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.04823", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CVAC", "relevance_score": "0.04823", "ticker_sentiment_score": "-0.029003", "ticker_sentiment_label": "Neutral"}, {"ticker": "GRTS", "relevance_score": "0.04823", "ticker_sentiment_score": "-0.002986", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDGEF", "relevance_score": "0.04823", "ticker_sentiment_score": "-0.002986", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.04823", "ticker_sentiment_score": "-0.002986", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.04823", "ticker_sentiment_score": "-0.002986", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.096283", "ticker_sentiment_score": "0.055359", "ticker_sentiment_label": "Neutral"}]}, {"title": "Moderna Named a Top Employer by Science for Ninth Consecutive Year", "url": "https://www.wsj.com/articles/moderna-named-a-top-employer-by-science-for-ninth-consecutive-year-b5865175", "time_published": "20231026T185000", "authors": [], "summary": "CAMBRIDGE, MA / ACCESSWIRE / October 26, 2023 / Moderna, Inc. ( NASDAQ:MRNA ) today announced it was ranked as one of the top employers in the global biopharmaceutical industry in Science and Science Careers' 2023 Top Employers Survey for the ninth consecutive year.", "banner_image": "https://www.barrons.com/asset/barrons/images/Barrons-Logo-AMP.png", "source": "Barrons", "category_within_source": "n/a", "source_domain": "www.wsj.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.417157, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.913524", "ticker_sentiment_score": "0.658934", "ticker_sentiment_label": "Bullish"}]}, {"title": "Merck  ( MRK )  Q3 2023 Earnings Call Transcript", "url": "https://www.fool.com/earnings/call-transcripts/2023/10/26/merck-mrk-q3-2023-earnings-call-transcript/", "time_published": "20231026T180027", "authors": ["Motley Fool Transcribing"], "summary": "MRK earnings call for the period ending September 30, 2023.", "banner_image": "https://g.foolcdn.com/misc-assets/fool-transcripts-logo.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.250111, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BCS", "relevance_score": "0.0045", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "C", "relevance_score": "0.0045", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.0045", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PTAIF", "relevance_score": "0.0045", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.0045", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.0045", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SKXJF", "relevance_score": "0.044978", "ticker_sentiment_score": "0.158713", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DSKYF", "relevance_score": "0.044978", "ticker_sentiment_score": "0.158713", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GS", "relevance_score": "0.0045", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.0045", "ticker_sentiment_score": "0.066163", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biotech Stock Roundup: BMY's Q3 Results, PTCT Up on Deal, BEAM's Restructuring News", "url": "https://www.zacks.com/stock/news/2173070/biotech-stock-roundup-bmys-q3-results-ptct-up-on-deal-beams-restructuring-news", "time_published": "20231026T152800", "authors": ["Zacks Equity Research"], "summary": "Earnings and other updates from Bristol Myers (BMY) and PTC Therapeutic (PTCT) are in focus in the biotech sector.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/67/1932.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Earnings", "relevance_score": "0.983605"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.220737, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BEAM", "relevance_score": "0.394322", "ticker_sentiment_score": "0.167634", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BMRN", "relevance_score": "0.091335", "ticker_sentiment_score": "0.251988", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PTCT", "relevance_score": "0.26928", "ticker_sentiment_score": "0.260487", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RPRX", "relevance_score": "0.22574", "ticker_sentiment_score": "0.227335", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.091335", "ticker_sentiment_score": "-0.129555", "ticker_sentiment_label": "Neutral"}, {"ticker": "BX", "relevance_score": "0.045743", "ticker_sentiment_score": "0.136148", "ticker_sentiment_label": "Neutral"}]}, {"title": "Merck  ( MRK )  Q3 Earnings Top Estimates, COVID Drug Boosts Sales", "url": "https://www.zacks.com/stock/news/2172963/merck-mrk-q3-earnings-top-estimates-covid-drug-boosts-sales", "time_published": "20231026T151300", "authors": ["Zacks Equity Research"], "summary": "Merck (MRK) beats Q3 estimates for earnings and sales. It raises its 2023 guidance. Stock rises in pre-market.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/20/2483.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.997874"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.658903"}], "overall_sentiment_score": 0.106966, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SKXJF", "relevance_score": "0.132806", "ticker_sentiment_score": "0.034841", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.106423", "ticker_sentiment_score": "0.165144", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DSKYF", "relevance_score": "0.132806", "ticker_sentiment_score": "0.034841", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.106423", "ticker_sentiment_score": "-0.025234", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.079921", "ticker_sentiment_score": "0.050166", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.02668", "ticker_sentiment_score": "-0.001852", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Pharma Giant Merck's  ( MRK )  Shares Are Shooting Higher Today - Merck & Co  ( NYSE:MRK ) ", "url": "https://www.benzinga.com/markets/equities/23/10/35440988/why-pharma-giant-mercks-shares-are-shooting-higher-today", "time_published": "20231026T145531", "authors": ["Nabaparna Bhattacharya"], "summary": "Merck & Company, Inc. MRK Q3 sales reached $15.962 billion, up 7% Y/Y, beating the consensus of $15.320 billion, reflecting sustained growth in Oncology and Vaccines. Lagevrio Q3 sales jumped 51% Y/Y to $640 million, and GARDASIL / GARDASIL 9 sales grew 16% to $2.585 billion.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/26/mrk.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.214378"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}], "overall_sentiment_score": 0.199802, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SKXJF", "relevance_score": "0.249106", "ticker_sentiment_score": "0.065584", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSKYF", "relevance_score": "0.249106", "ticker_sentiment_score": "0.065584", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.249106", "ticker_sentiment_score": "0.259101", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ORINY", "relevance_score": "0.126119", "ticker_sentiment_score": "0.164012", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Earnings Preview: Moderna  ( MRNA )  Q3 Earnings Expected to Decline", "url": "https://www.zacks.com/stock/news/2172833/earnings-preview-moderna-mrna-q3-earnings-expected-to-decline", "time_published": "20231026T140216", "authors": ["Zacks Equity Research"], "summary": "Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default143.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.107687, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALNY", "relevance_score": "0.088147", "ticker_sentiment_score": "0.038091", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.260189", "ticker_sentiment_score": "-0.067891", "ticker_sentiment_label": "Neutral"}]}, {"title": "How to be a better boss", "url": "https://www.economist.com/leaders/2023/10/26/how-to-be-a-better-boss", "time_published": "20231026T123533", "authors": ["The Economist"], "summary": "W changed dramatically over the past four years, let alone the past 40. Teams have become more dispersed, thanks to remote work, as well as more diverse. Technology has brought with it great benefits but also constant interruptions, from endless Zoom calls to the ping of another message on Slack.", "banner_image": "https://www.economist.com/img/b/1424/1873/90/media-assets/image/20231028_DE_US.jpg", "source": "The Economist", "category_within_source": "BusinessGoogleRSS", "source_domain": "www.economist.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.128284, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.050572", "ticker_sentiment_score": "0.081409", "ticker_sentiment_label": "Neutral"}, {"ticker": "SHOP", "relevance_score": "0.100941", "ticker_sentiment_score": "0.05708", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.050572", "ticker_sentiment_score": "0.030886", "ticker_sentiment_label": "Neutral"}]}, {"title": "Covid shots may slightly increase risk of stroke in older adults, particularly when administered with certain flu vaccines", "url": "https://www.cnn.com/2023/10/25/health/covid-flu-vaccine-stroke-risk-study/index.html", "time_published": "20231026T122400", "authors": ["Brenda Goodman"], "summary": "Vaccines for Covid-19 and influenza may slightly increase the risk of strokes caused by blood clots in the brains of seniors, particularly when the two vaccines are given at the same time and when they are given to adults who are age 85 and older, according to a new study.", "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/231020200714-vaccine-clinic-la-101223-restricted.jpg?c=16x9&q=h_144,w_256,c_fill", "source": "CNN", "category_within_source": "Markets", "source_domain": "www.cnn.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.088344, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.068404", "ticker_sentiment_score": "-0.018071", "ticker_sentiment_label": "Neutral"}, {"ticker": "WBD", "relevance_score": "0.034233", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.068404", "ticker_sentiment_score": "-0.018071", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pfizer's combination Covid, flu vaccine will move to final-stage trial after positive data", "url": "https://www.cnbc.com/2023/10/26/pfizer-combination-covid-flu-vaccine-shows-positive-trial-data.html", "time_published": "20231026T121045", "authors": ["Annika Kim Constantino"], "summary": "Pfizer, Moderna and Novavax believe combination shots will simplify the process for people to protect themselves against Covid and the flu.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107261571-1687527102801-gettyimages-1246630116-Illustration_Pfizer_Inc.jpeg?v=1698322245&w=1920&h=1080", "source": "CNBC", "category_within_source": "Business", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.172239, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NVAX", "relevance_score": "0.236972", "ticker_sentiment_score": "0.132424", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.236972", "ticker_sentiment_score": "0.132424", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.634282", "ticker_sentiment_score": "0.36164", "ticker_sentiment_label": "Bullish"}, {"ticker": "BNTX", "relevance_score": "0.236972", "ticker_sentiment_score": "0.149716", "ticker_sentiment_label": "Neutral"}]}, {"title": "Generation Bio Announces Demonstration of Highly Selective T Cell Transduction In Vivo with Cell-Targeted LNP Platform", "url": "https://www.globenewswire.com/news-release/2023/10/26/2767332/0/en/Generation-Bio-Announces-Demonstration-of-Highly-Selective-T-Cell-Transduction-In-Vivo-with-Cell-Targeted-LNP-Platform.html", "time_published": "20231026T105900", "authors": ["Generation Bio Co."], "summary": "CAMBRIDGE, Mass., Oct. 26, 2023 ( GLOBE NEWSWIRE ) -- Generation Bio Co. ( Nasdaq:GBIO ) , a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that it has reached two significant achievements through in vivo studies, including ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/9dedd290-1c0c-4c1a-9ef3-6bba7dabf2e4", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.451494"}], "overall_sentiment_score": 0.142645, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GBIO", "relevance_score": "0.244723", "ticker_sentiment_score": "0.12724", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.184834", "ticker_sentiment_score": "0.062604", "ticker_sentiment_label": "Neutral"}]}, {"title": "Generation Bio Announces Demonstration of Highly Selective T Cell Transduction In Vivo with Cell-Targeted LNP Platform - Generation Bio  ( NASDAQ:GBIO ) ", "url": "https://www.benzinga.com/pressreleases/23/10/g35435076/generation-bio-announces-demonstration-of-highly-selective-t-cell-transduction-in-vivo-with-cell-t", "time_published": "20231026T105900", "authors": ["Globe Newswire"], "summary": "70% of circulating and splenic T cells positive for mRNA expression in humanized mice with less than 8% delivery to off-target immune cells Stealth properties of cell-targeted lipid nanoparticle ( ctLNP ) platform confirmed in non-human primates, demonstrating prolonged circulation and less than ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.614606"}], "overall_sentiment_score": 0.135652, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GBIO", "relevance_score": "0.287537", "ticker_sentiment_score": "0.142621", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.175009", "ticker_sentiment_score": "0.058734", "ticker_sentiment_label": "Neutral"}]}, {"title": "Merck results beat expectations on strong Keytruda sales, surprise Covid drug growth", "url": "https://www.cnbc.com/2023/10/26/merck-mrk-q3-earnings-report-2023.html", "time_published": "20231026T103736", "authors": ["Annika Kim Constantino"], "summary": "Merck's revenue and earnings beat expectations, and it hiked its sales forecast while lowering its profit outlook.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107227287-1681843820437-gettyimages-1251953331-MERCK_PROMETHEUS.jpeg?v=1698316656&w=1920&h=1080", "source": "CNBC", "category_within_source": "Business", "source_domain": "www.cnbc.com", "topics": [{"topic": "Earnings", "relevance_score": "0.996718"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.106894, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SKXJF", "relevance_score": "0.067727", "ticker_sentiment_score": "0.236985", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DSKYF", "relevance_score": "0.067727", "ticker_sentiment_score": "0.236985", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.067727", "ticker_sentiment_score": "0.074172", "ticker_sentiment_label": "Neutral"}, {"ticker": "RXDX", "relevance_score": "0.134968", "ticker_sentiment_score": "-0.003702", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.067727", "ticker_sentiment_score": "0.074172", "ticker_sentiment_label": "Neutral"}]}, {"title": "Vertex Pharmaceuticals: Buy at the High?", "url": "https://www.fool.com/investing/2023/10/26/vertex-pharmaceuticals-buy-at-the-high/", "time_published": "20231026T101500", "authors": ["Adria Cimino"], "summary": "Vertex shares have been flying high in recent times.", "banner_image": "https://media.ycharts.com/charts/e991abaec0e078763739e30524d58c14.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.95493"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}], "overall_sentiment_score": 0.181345, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.057907", "ticker_sentiment_score": "-0.046965", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.115509", "ticker_sentiment_score": "0.033291", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 No-Brainer Growth Stocks to Buy Right Now", "url": "https://www.fool.com/investing/2023/10/26/2-no-brainer-growth-stocks-to-buy-right-now/", "time_published": "20231026T090500", "authors": ["Rachel Warren"], "summary": "These businesses are thriving and raking in profits.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.796627"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.972756"}], "overall_sentiment_score": 0.213973, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.056407", "ticker_sentiment_score": "0.098002", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.112532", "ticker_sentiment_score": "0.087797", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABNB", "relevance_score": "0.520773", "ticker_sentiment_score": "0.22583", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "A new study flags a link between Covid-19 and influenza vaccines and stroke in older adults, but experts say vaccination is still your best bet", "url": "https://www.cnn.com/2023/10/25/health/a-new-study-flags-a-link-between-covid-19-and-influenza-vaccines-and-stroke-in-older-adults-but-experts-say-vaccination-is-still-your-best-bet/index.html", "time_published": "20231025T235435", "authors": ["Brenda Goodman"], "summary": "Covid shots may slightly increase risk of stroke in older adults, particularly when administered with certain flu vaccines ...", "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/231012132127-updated-covid-vaccine-091523.jpg?c=16x9&q=w_800,c_fill", "source": "CNN", "category_within_source": "Markets", "source_domain": "www.cnn.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.07647, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.069495", "ticker_sentiment_score": "-0.018088", "ticker_sentiment_label": "Neutral"}, {"ticker": "WBD", "relevance_score": "0.03478", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.069495", "ticker_sentiment_score": "-0.018088", "ticker_sentiment_label": "Neutral"}]}, {"title": "Thermo Fisher Scientific  ( TMO )  Q3 2023 Earnings Call Transcript", "url": "https://www.fool.com/earnings/call-transcripts/2023/10/25/thermo-fisher-scientific-tmo-q3-2023-earnings-call/", "time_published": "20231025T180023", "authors": ["Motley Fool Transcribing"], "summary": "TMO earnings call for the period ending September 30, 2023.", "banner_image": "https://g.foolcdn.com/misc-assets/fool-transcripts-logo.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.576289"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.890401"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.304489, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AWON", "relevance_score": "0.004951", "ticker_sentiment_score": "-0.097892", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.004951", "ticker_sentiment_score": "0.159311", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.004951", "ticker_sentiment_score": "0.029349", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.004951", "ticker_sentiment_score": "0.029349", "ticker_sentiment_label": "Neutral"}, {"ticker": "TMO", "relevance_score": "0.019801", "ticker_sentiment_score": "0.11635", "ticker_sentiment_label": "Neutral"}]}, {"title": "Among the S&P 500, these 20 companies have made the best use of investors' money", "url": "https://www.marketwatch.com/story/among-the-s-p-500-these-20-companies-have-made-the-best-use-of-investors-money-dc4637b9", "time_published": "20231025T161100", "authors": ["Philip van Doorn"], "summary": "High returns on invested capital can be useful for narrowing down a list of stocks for investment.", "banner_image": "https://images.mktw.net/im-874932/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.99676"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.129889, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVDA", "relevance_score": "0.040829", "ticker_sentiment_score": "0.080558", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.081552", "ticker_sentiment_score": "0.111552", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.081552", "ticker_sentiment_score": "0.111552", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRSN", "relevance_score": "0.202028", "ticker_sentiment_score": "0.053425", "ticker_sentiment_label": "Neutral"}]}, {"title": "Looking At Moderna's Recent Unusual Options Activity - Moderna  ( NASDAQ:MRNA ) ", "url": "https://www.benzinga.com/markets/options/23/10/35418085/looking-at-modernas-recent-unusual-options-activity", "time_published": "20231025T150155", "authors": ["Benzinga Insights"], "summary": "Someone with a lot of money to spend has taken a bearish stance on Moderna MRNA. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.120252, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.798255", "ticker_sentiment_score": "0.286859", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Moderna  ( MRNA )  to Report Q3 Earnings: What's in the Cards?", "url": "https://www.zacks.com/stock/news/2171770/moderna-mrna-to-report-q3-earnings-whats-in-the-cards", "time_published": "20231025T131000", "authors": ["Zacks Equity Research"], "summary": "Investors' focus will likely be on updates on Moderna's (MRNA) pipeline, especially its late-stage pipeline candidates, when it reports third-quarter earnings.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/db/3160.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.99998"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.03106, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.593341", "ticker_sentiment_score": "0.07016", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.201523", "ticker_sentiment_score": "0.055846", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.201523", "ticker_sentiment_score": "-0.006354", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.050894", "ticker_sentiment_score": "0.04899", "ticker_sentiment_label": "Neutral"}]}, {"title": "Jim Cramer Says 'I'd Rather Just Own Bitcoin,' Over Investing In BTC Miner Stock", "url": "https://www.benzinga.com/trading-ideas/long-ideas/23/10/35409469/jim-cramer-says-id-rather-just-own-bitcoin-over-investing-in-btc-miner-stock", "time_published": "20231025T121325", "authors": ["Lisa Levin"], "summary": "On CNBC's \"Mad Money Lightning Round,\" Jim Cramer said AT&T Inc. T is not his favorite. \"I remain a stalwart for T-Mobile US, Inc. TMUS, and I continue to believe that T-Mobile represents the best buy in that group,\" he added. When asked about Moderna, Inc.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/25/jim_cramer_bitcoin_shutter.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Real Estate & Construction", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}], "overall_sentiment_score": 0.083377, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MARA", "relevance_score": "0.468029", "ticker_sentiment_score": "0.432215", "ticker_sentiment_label": "Bullish"}, {"ticker": "TMUS", "relevance_score": "0.323078", "ticker_sentiment_score": "-0.185245", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MGM", "relevance_score": "0.468029", "ticker_sentiment_score": "0.476405", "ticker_sentiment_label": "Bullish"}, {"ticker": "T", "relevance_score": "0.323078", "ticker_sentiment_score": "0.279645", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PLNT", "relevance_score": "0.468029", "ticker_sentiment_score": "0.460301", "ticker_sentiment_label": "Bullish"}, {"ticker": "BBY", "relevance_score": "0.165031", "ticker_sentiment_score": "-0.110427", "ticker_sentiment_label": "Neutral"}, {"ticker": "WYNN", "relevance_score": "0.323078", "ticker_sentiment_score": "-0.266546", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MRNA", "relevance_score": "0.595343", "ticker_sentiment_score": "0.392525", "ticker_sentiment_label": "Bullish"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.323078", "ticker_sentiment_score": "-0.385773", "ticker_sentiment_label": "Bearish"}]}, {"title": "Moderna  ( MRNA )  Outpaces Stock Market Gains: What You Should Know", "url": "https://www.zacks.com/stock/news/2171079/moderna-mrna-outpaces-stock-market-gains-what-you-should-know", "time_published": "20231024T215018", "authors": ["Zacks Equity Research"], "summary": "Moderna (MRNA) closed the most recent trading day at $79.76, moving +1.42% from the previous trading session.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default184.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.938793"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.108695, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.462953", "ticker_sentiment_score": "0.208064", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Moderna's stock snaps record losing streak as Cathie Wood's ETF boosts stake by more than $4 million", "url": "https://www.marketwatch.com/story/modernas-stock-snaps-record-losing-streak-as-cathie-woods-etf-boosts-stake-by-more-than-4-million-d24e3dc6", "time_published": "20231024T155200", "authors": ["Tomi Kilgore"], "summary": "Moderna Inc. investors enjoyed a rare rally Tuesday as the shares of the biotechnology company headed for their first gain in two weeks.", "banner_image": "https://images.mktw.net/im-874258/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.988915"}], "overall_sentiment_score": 0.216336, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.514619", "ticker_sentiment_score": "0.325861", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities - Geovax Labs  ( NASDAQ:GOVXW ) , Geovax Labs  ( NASDAQ:GOVX ) ", "url": "https://www.benzinga.com/pressreleases/23/10/g35392979/geovax-update-clinical-and-operational-progress-toward-transformative-opportunities", "time_published": "20231024T130000", "authors": ["Globe Newswire"], "summary": "ATLANTA, GA, Oct. 24, 2023 ( GLOBE NEWSWIRE ) -- via NewMediaWire - GeoVax Labs, Inc. GOVX, a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced an update on key strategic initiatives.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.162398, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GOVX", "relevance_score": "0.102303", "ticker_sentiment_score": "0.080314", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.034185", "ticker_sentiment_score": "0.047062", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.034185", "ticker_sentiment_score": "0.047062", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.034185", "ticker_sentiment_score": "0.047062", "ticker_sentiment_label": "Neutral"}]}, {"title": "Moderna Stock Hasn't Been This Cheap Since 2020: Is Now the Time to Buy?", "url": "https://www.fool.com/investing/2023/10/24/moderna-stock-hasnt-been-this-cheap-since-2020-is/", "time_published": "20231024T124800", "authors": ["David Jagielski"], "summary": "Pfizer recently slashed its guidance and that could be a big warning for Moderna investors as well.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.998682"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.980922"}], "overall_sentiment_score": -0.058922, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.593341", "ticker_sentiment_score": "-0.057757", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.151858", "ticker_sentiment_score": "-0.070184", "ticker_sentiment_label": "Neutral"}]}, {"title": "The Best Stocks to Invest $5,000 In Right Now", "url": "https://www.fool.com/investing/2023/10/24/the-best-stocks-to-invest-5000-in-right-now/", "time_published": "20231024T093000", "authors": ["Adria Cimino"], "summary": "Today, the following three healthcare players look like fantastic bargains.", "banner_image": "https://media.ycharts.com/charts/9580ab8fffe7217f39b1987355fdd495.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972476"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.323116, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "KVUE", "relevance_score": "0.102668", "ticker_sentiment_score": "0.183773", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.102668", "ticker_sentiment_score": "0.214111", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.203643", "ticker_sentiment_score": "0.121416", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.102668", "ticker_sentiment_score": "0.175114", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Amid A Crypto Rally, Cathie Wood's Ark Invest Sells Coinbase, Grayscale Bitcoin Trust, Buys Robinhood Shares", "url": "https://markets.businessinsider.com/news/etf/amid-a-crypto-rally-cathie-wood-s-ark-invest-sells-coinbase-grayscale-bitcoin-trust-buys-robinhood-shares-1032730413", "time_published": "20231024T035613", "authors": ["Benzinga Neuro"], "summary": "On Monday, Cathie Wood-led Ark Invest made a notable move by selling shares of Coinbase Global Inc ( NASDAQ:COIN ) amid a surge in Bitcoin ( CRYPTO: BTC ) prices. At the time of writing, the apex cryptocurrency was seen trading at $34,878.65, it had spiked 15.2% over 24 hours.", "banner_image": "https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2023/cathie_wood_bitcoin_0.jpeg", "source": "Business Insider", "category_within_source": "GoogleRSS", "source_domain": "markets.businessinsider.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.744043"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}, {"topic": "Blockchain", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.355642, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "NVDA", "relevance_score": "0.127456", "ticker_sentiment_score": "0.112818", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.127456", "ticker_sentiment_score": "0.200379", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HOOD", "relevance_score": "0.127456", "ticker_sentiment_score": "0.200379", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "COIN", "relevance_score": "0.369685", "ticker_sentiment_score": "0.227261", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.577527", "ticker_sentiment_score": "0.495036", "ticker_sentiment_label": "Bullish"}]}, {"title": "Amid A Crypto Rally, Cathie Wood's Ark Invest Sells Coinbase, Grayscale Bitcoin Trust, Buys Robinhood Shares - NVIDIA  ( NASDAQ:NVDA ) , ARK Fintech Innovation ETF  ( ARCA:ARKF ) , ARK Genomic Revolution ETF  ( BATS:ARKG ) , ARK Next Generation Internet ETF  ( ARCA:ARKW ) ", "url": "https://www.benzinga.com/23/10/35386552/amid-a-crypto-rally-cathie-woods-ark-invest-sells-coinbase-grayscale-bitcoin-trust-buys-robinhood-sh", "time_published": "20231024T024255", "authors": ["Benzinga Neuro"], "summary": "On Monday, Cathie Wood-led Ark Invest made a notable move by selling shares of Coinbase Global Inc COIN amid a surge in Bitcoin BTC/USD prices. At the time of writing, the apex cryptocurrency was seen trading at $34,878.65, it had spiked 15.2% over 24 hours.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/cathie_wood_bitcoin_0.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.839681"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}, {"topic": "Blockchain", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.354277, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "NVDA", "relevance_score": "0.213048", "ticker_sentiment_score": "0.314903", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.213048", "ticker_sentiment_score": "0.234564", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HOOD", "relevance_score": "0.213048", "ticker_sentiment_score": "0.314903", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "COIN", "relevance_score": "0.411176", "ticker_sentiment_score": "0.242068", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.500753", "ticker_sentiment_score": "0.477456", "ticker_sentiment_label": "Bullish"}]}, {"title": "Moderna's stock suffering record losing streak as 'investor caution remains high' over COVID vaccine sales", "url": "https://www.marketwatch.com/story/modernas-stock-suffering-record-losing-streak-as-investor-caution-remains-high-over-covid-vaccine-sales-2663eafa", "time_published": "20231023T165800", "authors": ["Tomi Kilgore"], "summary": "Moderna's stock was in danger of breaking its record for consecutive losses as investors expressed increasing caution over slowing sales of COVID vaccines.", "banner_image": "https://images.mktw.net/im-873698/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Earnings", "relevance_score": "0.161647"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.977154"}], "overall_sentiment_score": -0.108377, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.47672", "ticker_sentiment_score": "-0.046979", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.201523", "ticker_sentiment_score": "0.0066", "ticker_sentiment_label": "Neutral"}]}, {"title": "Moderna Unusual Options Activity - Moderna  ( NASDAQ:MRNA ) ", "url": "https://www.benzinga.com/markets/options/23/10/35377616/moderna-unusual-options-activity", "time_published": "20231023T154554", "authors": ["Benzinga Insights"], "summary": "Someone with a lot of money to spend has taken a bearish stance on Moderna MRNA. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.108587, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.812724", "ticker_sentiment_score": "0.292432", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "3 No-Brainer Stocks to Buy Right Now for Less than $100", "url": "https://www.fool.com/investing/2023/10/23/3-no-brainer-stocks-to-buy-right-now-for-less-than/", "time_published": "20231023T093000", "authors": ["Adria Cimino"], "summary": "You can start with a small investment and win big over time.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.986714"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.858979"}], "overall_sentiment_score": 0.106611, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.418863", "ticker_sentiment_score": "0.068587", "ticker_sentiment_label": "Neutral"}, {"ticker": "JAZZ", "relevance_score": "0.054983", "ticker_sentiment_score": "0.126837", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.054983", "ticker_sentiment_score": "-0.179134", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "AXSM", "relevance_score": "0.163909", "ticker_sentiment_score": "0.216246", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Is It Time to Buy the S&P 500's 3 Worst-Performing Stocks This Year?", "url": "https://www.fool.com/investing/2023/10/22/is-it-time-to-buy-the-sp-500s-3-worst-performing-s/", "time_published": "20231022T141300", "authors": ["Anders Bylund"], "summary": "Venture beyond the headlines on a journey among 2023's least celebrated S&P 500 stocks. A roadmap to informed investment decisions awaits.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.99393"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": -0.019673, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.218423", "ticker_sentiment_score": "-0.029677", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.088309", "ticker_sentiment_score": "-0.112646", "ticker_sentiment_label": "Neutral"}, {"ticker": "SEDG", "relevance_score": "0.30211", "ticker_sentiment_score": "-0.121974", "ticker_sentiment_label": "Neutral"}]}, {"title": "Hidden Gems: 3 Stealthy AI Stocks Quietly Conquering the 2023 Market", "url": "https://www.fool.com/investing/2023/10/22/hidden-gems-3-stealthy-ai-stocks/", "time_published": "20231022T111900", "authors": ["Adam Spatacco"], "summary": "Twilio, UiPath, and Ginkgo Bioworks are all massively underrated opportunities in artificial intelligence.", "banner_image": "https://media.ycharts.com/charts/90cfe1abccd1b8a1ff0bde19890a81ca.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.999612"}, {"topic": "Real Estate & Construction", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.15061, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.066691", "ticker_sentiment_score": "0.101642", "ticker_sentiment_label": "Neutral"}, {"ticker": "PATH", "relevance_score": "0.26217", "ticker_sentiment_score": "0.145241", "ticker_sentiment_label": "Neutral"}, {"ticker": "DNA", "relevance_score": "0.09989", "ticker_sentiment_score": "0.072452", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.033375", "ticker_sentiment_score": "0.137295", "ticker_sentiment_label": "Neutral"}, {"ticker": "APG", "relevance_score": "0.033375", "ticker_sentiment_score": "0.035546", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.033375", "ticker_sentiment_score": "0.137295", "ticker_sentiment_label": "Neutral"}, {"ticker": "DASH", "relevance_score": "0.033375", "ticker_sentiment_score": "0.035546", "ticker_sentiment_label": "Neutral"}, {"ticker": "UBER", "relevance_score": "0.033375", "ticker_sentiment_score": "0.035546", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.033375", "ticker_sentiment_score": "0.137295", "ticker_sentiment_label": "Neutral"}]}, {"title": "65 Million People Suffer From Long Covid. Our Experts Say New Vaccines Are The Best Defense", "url": "https://www.forbes.com/sites/melissadelaney/2023/10/20/covid-19-vaccines/", "time_published": "20231022T100000", "authors": ["Melissa Delaney"], "summary": "New Covid vaccines based on Nobel prize-winning mRNA technology provide updated protection - especially important heading into the winter, when Covid-19, flu and RSV infections spike. eart palpitations. Anxiety. Fatigue. Dizziness. Difficulty breathing.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/6532d8f953557b5eff4c2331/0x0.jpg?format=jpg&crop=1920,1080,x0,y0,safe&height=900&width=1600&fit=bounds", "source": "Forbes", "category_within_source": "n/a", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.031382, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVAX", "relevance_score": "0.068698", "ticker_sentiment_score": "0.084985", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.068698", "ticker_sentiment_score": "0.036169", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.068698", "ticker_sentiment_score": "0.036169", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.068698", "ticker_sentiment_score": "0.036169", "ticker_sentiment_label": "Neutral"}]}, {"title": "Cathie Wood Just Doubled Down on This Biotech Stock. Should You Follow Her Lead?", "url": "https://www.fool.com/investing/2023/10/21/cathie-wood-just-doubled-down-on-this-biotech-stoc/", "time_published": "20231021T104500", "authors": ["Adam Spatacco"], "summary": "Cathie Wood has bought over 5 million shares in Ginkgo Bioworks so far this month.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F750320%2Fgettyimages-1441663123.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.997405"}, {"topic": "Earnings", "relevance_score": "0.214378"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.15817, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.040078", "ticker_sentiment_score": "0.125551", "ticker_sentiment_label": "Neutral"}, {"ticker": "DNA", "relevance_score": "0.419575", "ticker_sentiment_score": "0.200977", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVO", "relevance_score": "0.080055", "ticker_sentiment_score": "0.110537", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.080055", "ticker_sentiment_score": "0.131308", "ticker_sentiment_label": "Neutral"}, {"ticker": "SSUMF", "relevance_score": "0.040078", "ticker_sentiment_score": "0.125551", "ticker_sentiment_label": "Neutral"}, {"ticker": "PLTR", "relevance_score": "0.040078", "ticker_sentiment_score": "0.125203", "ticker_sentiment_label": "Neutral"}]}, {"title": "Experimente un nuevo mausoleo de capilla y arte de categor\u00eda mundial: jornada de puertas abiertas exclusiva con 0% de inter\u00e9s durante 48 meses", "url": "https://www.prnewswire.com/news-releases/experimente-un-nuevo-mausoleo-de-capilla-y-arte-de-categoria-mundial-jornada-de-puertas-abiertas-exclusiva-con-0-de-interes-durante-48-meses-830997490.html", "time_published": "20231021T000300", "authors": ["Catholic Cemeteries of the Archdiocese of Newark"], "summary": "Experimente un nuevo mausoleo de capilla y arte de categor\u00eda mundial: jornada de puertas abiertas exclusiva con 0 ... PR ...", "banner_image": "https://i.ytimg.com/vi/vi54xh1cchE/hqdefault.jpg", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.046971, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.063933", "ticker_sentiment_score": "-0.068035", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biotech stocks are in a post-pandemic slump and recovery in 2024 is questionable", "url": "https://www.marketwatch.com/story/biotech-stocks-are-in-a-post-pandemic-slump-and-recovery-in-2024-is-questionable-344e8e9f", "time_published": "20231020T111000", "authors": ["Jurica Dujmovic"], "summary": "Once buoyed by demand for COVID-19 vaccines and treatments, the biotech industry is experiencing a sobering leveling out ...", "banner_image": "https://images.mktw.net/im-871885/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Earnings", "relevance_score": "0.538269"}], "overall_sentiment_score": -0.017235, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVAX", "relevance_score": "0.229149", "ticker_sentiment_score": "0.016599", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.115787", "ticker_sentiment_score": "0.10847", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.172919", "ticker_sentiment_score": "0.153656", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BNTX", "relevance_score": "0.115787", "ticker_sentiment_score": "0.10847", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Moderna Stock Is Sinking This Week", "url": "https://www.fool.com/investing/2023/10/19/why-moderna-stock-is-sinking-this-week/", "time_published": "20231019T211459", "authors": ["Keith Speights"], "summary": "Investors appear to believe that bad news for Pfizer could mean bad news for Moderna.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": -0.026692, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SPGI", "relevance_score": "0.128135", "ticker_sentiment_score": "-0.068001", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.803061", "ticker_sentiment_score": "0.012244", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.371523", "ticker_sentiment_score": "-0.133229", "ticker_sentiment_label": "Neutral"}, {"ticker": "BRK-A", "relevance_score": "0.128135", "ticker_sentiment_score": "-0.064018", "ticker_sentiment_label": "Neutral"}]}, {"title": "Exclusive: Lilly hires CordenPharma to make diabetes drug Mounjaro's active ingredient -source", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-hires-cordenpharma-make-diabetes-drug-mounjaros-active-ingredient-source-2023-10-19/", "time_published": "20231019T175800", "authors": ["Maggie Fick"], "summary": "Exclusive: Lilly hires CordenPharma to make diabetes drug Mounjaro's active ingredient ...", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/RZUU2AEA3ROCVG6D6KFWGWZ5AY.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.073652, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.084423", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.084423", "ticker_sentiment_score": "-0.039689", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pfizer Reportedly Doubles Paxlovid Price To $1,390 In The U.S.", "url": "https://www.investors.com/news/technology/pfizer-stock-slips-as-covid-drugmaker-hikes-paxlovid-price/", "time_published": "20231019T150600", "authors": ["ALLISON GATLIN", "Investor's Business Daily"], "summary": "Pfizer Stock Slips As Covid Drugmaker Hikes Paxlovid Price To $1,390 Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2020/12/Stock-Pfizer-05-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.977154"}], "overall_sentiment_score": 0.028427, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVAX", "relevance_score": "0.183198", "ticker_sentiment_score": "-0.019006", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.183198", "ticker_sentiment_score": "-0.019006", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.835459", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.271777", "ticker_sentiment_score": "-0.025786", "ticker_sentiment_label": "Neutral"}]}, {"title": "Flagship Pioneering Announces the Merger of Two Leading Programmable Medicine Platforms to Form Sail Biomedicines", "url": "https://www.prnewswire.com/news-releases/flagship-pioneering-announces-the-merger-of-two-leading-programmable-medicine-platforms-to-form-sail-biomedicines-301961581.html", "time_published": "20231019T143000", "authors": ["Flagship Pioneering"], "summary": "Flagship Pioneering Announces the Merger of Two Leading Programmable Medicine Platforms to Form Sail ... PR ...", "banner_image": "https://mma.prnewswire.com/media/2156098/Flagship_Pioneering_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.325439, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MCRB", "relevance_score": "0.104002", "ticker_sentiment_score": "0.130235", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.104002", "ticker_sentiment_score": "0.130235", "ticker_sentiment_label": "Neutral"}, {"ticker": "OMGA", "relevance_score": "0.104002", "ticker_sentiment_score": "0.130235", "ticker_sentiment_label": "Neutral"}, {"ticker": "FHTX", "relevance_score": "0.104002", "ticker_sentiment_score": "0.130235", "ticker_sentiment_label": "Neutral"}, {"ticker": "DNLI", "relevance_score": "0.104002", "ticker_sentiment_score": "0.130235", "ticker_sentiment_label": "Neutral"}, {"ticker": "SANA", "relevance_score": "0.104002", "ticker_sentiment_score": "0.130235", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pfizer and Moderna Don't See Eye to Eye on This 1 Particular Point", "url": "https://www.fool.com/investing/2023/10/19/pfizer-moderna-dont-agree-on-1-point/", "time_published": "20231019T090000", "authors": ["Adria Cimino"], "summary": "The coronavirus vaccine leaders recently made different decisions.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.87644"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.079801, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.657331", "ticker_sentiment_score": "0.117018", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.577979", "ticker_sentiment_score": "0.072286", "ticker_sentiment_label": "Neutral"}]}, {"title": "With education funding cut and trouble tracking doses, experts see scattered Covid-19 vaccine rollout ahead of winter season", "url": "https://www.cnn.com/2023/10/18/health/covid-vaccine-awareness-campaigns/index.html", "time_published": "20231018T223000", "authors": ["Brenda Goodman", "Jacqueline Howard"], "summary": "With education funding cut and trouble tracking doses, experts see scattered Covid-19 vaccine rollout ahead of winter ... ...", "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/230913092631-01-covid-19-vaccine-file.jpg?c=16x9&q=h_144,w_256,c_fill", "source": "CNN", "category_within_source": "Markets", "source_domain": "www.cnn.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}], "overall_sentiment_score": -0.116251, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "WBD", "relevance_score": "0.046452", "ticker_sentiment_score": "0.075833", "ticker_sentiment_label": "Neutral"}, {"ticker": "CVS", "relevance_score": "0.023236", "ticker_sentiment_score": "0.049667", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVAX", "relevance_score": "0.023236", "ticker_sentiment_score": "0.135707", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.046452", "ticker_sentiment_score": "0.082141", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.046452", "ticker_sentiment_score": "0.082141", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.046452", "ticker_sentiment_score": "0.082141", "ticker_sentiment_label": "Neutral"}]}, {"title": "Moderna  ( MRNA )  Stock Moves -0.37%: What You Should Know", "url": "https://www.zacks.com/stock/news/2168381/moderna-mrna-stock-moves--037-what-you-should-know", "time_published": "20231018T215019", "authors": ["Zacks Equity Research"], "summary": "In the latest trading session, Moderna (MRNA) closed at $86.01, marking a -0.37% move from the previous day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default274.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.858979"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.108534, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.473208", "ticker_sentiment_score": "0.137652", "ticker_sentiment_label": "Neutral"}]}, {"title": "CytomX Therapeutics Presents Preclinical Profile of EpCAM-directed Antibody Drug Conjugate CX-2051 at 2023 World ADC Conference", "url": "https://www.globenewswire.com/news-release/2023/10/18/2762767/37704/en/CytomX-Therapeutics-Presents-Preclinical-Profile-of-EpCAM-directed-Antibody-Drug-Conjugate-CX-2051-at-2023-World-ADC-Conference.html", "time_published": "20231018T203000", "authors": ["CytomX Therapeutics Inc."], "summary": "- CX-2051 is tailored for treatment of EpCAM-expressing cancers by matching target expression and tumor sensitivity with a topoisomerase-1 inhibitor payload ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/c252869d-a4c1-4e56-88e8-d80b85d20c35", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.028895, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.036926", "ticker_sentiment_score": "-0.00888", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.073773", "ticker_sentiment_score": "-0.00924", "ticker_sentiment_label": "Neutral"}, {"ticker": "CTMX", "relevance_score": "0.183059", "ticker_sentiment_score": "-0.059197", "ticker_sentiment_label": "Neutral"}]}, {"title": "HTR Recognizes RXNT as a \"True Trailblazer\" Among Top 100 Health Tech Companies of 2023", "url": "https://www.prnewswire.com/news-releases/htr-recognizes-rxnt-as-a-true-trailblazer-among-top-100-health-tech-companies-of-2023-301961225.html", "time_published": "20231018T201800", "authors": ["RXNT"], "summary": "ANNAPOLIS, Md., Oct. 18, 2023 /PRNewswire/ -- , an enduring pioneer in the ambulatory healthcare technology space, today announced that it has been recognized as one of the \"Top 100 Healthcare Technology Companies of 2023\" by the .", "banner_image": "https://mma.prnewswire.com/media/1596362/RXNT_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.326552, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MDT", "relevance_score": "0.090816", "ticker_sentiment_score": "0.142504", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.090816", "ticker_sentiment_score": "0.142504", "ticker_sentiment_label": "Neutral"}, {"ticker": "BSX", "relevance_score": "0.090816", "ticker_sentiment_score": "0.142504", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.090816", "ticker_sentiment_score": "0.142504", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.090816", "ticker_sentiment_score": "0.142504", "ticker_sentiment_label": "Neutral"}]}, {"title": "Mainz Biomed's Groundbreaking Study Results Mark A Big Advancement In The Battle Against Colorectal Cancer - Pfizer  ( NYSE:PFE ) ", "url": "https://www.benzinga.com/markets/penny-stocks/23/10/35311158/mainz-biomeds-groundbreaking-study-results-mark-a-big-advancement-in-the-battle-against-colo", "time_published": "20231018T150308", "authors": ["Upwallstreet"], "summary": "Mainz Biomed N.V. MYNZ, a molecular genetics diagnostic company specializing in the early detection of cancer, was scheduled to present the groundbreaking results from its CRC study at the 4th International Conference on Gastroenterology in Paris, but the event was postponed from October to ...", "banner_image": "https://cdn.benzinga.com/files/close-up-people-wearing-lab-coats.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": -0.090808, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.230017", "ticker_sentiment_score": "-0.147987", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.230017", "ticker_sentiment_score": "-0.147987", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biotech Stock Roundup: ALDX, EVLO Down on Setback, SRRK Offers Updates & More", "url": "https://www.zacks.com/stock/news/2167932/biotech-stock-roundup-aldx-evlo-down-on-setback-srrk-offers-updates-more", "time_published": "20231018T123000", "authors": ["Ekta Bagri"], "summary": "Regulatory and pipeline updates from Aldeyra Therapeutics (ALDX) and Scholar Rock (SRRK) are in focus in the biotech sector.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ba/1149.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "IPO", "relevance_score": "0.576289"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.045389, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALDX", "relevance_score": "0.070517", "ticker_sentiment_score": "0.019285", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANVS", "relevance_score": "0.070517", "ticker_sentiment_score": "0.029251", "ticker_sentiment_label": "Neutral"}, {"ticker": "EVLO", "relevance_score": "0.070517", "ticker_sentiment_score": "-0.057611", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.035293", "ticker_sentiment_score": "-0.044954", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMLX", "relevance_score": "0.070517", "ticker_sentiment_score": "-0.068604", "ticker_sentiment_label": "Neutral"}, {"ticker": "SRRK", "relevance_score": "0.175094", "ticker_sentiment_score": "0.080572", "ticker_sentiment_label": "Neutral"}]}, {"title": "Generation Bio Announces Breakthrough in its Non-Viral Genetic Medicine Platform with Novel \"Immune-Quiet\" DNA - Generation Bio  ( NASDAQ:GBIO ) ", "url": "https://www.benzinga.com/pressreleases/23/10/g35304632/generation-bio-announces-breakthrough-in-its-non-viral-genetic-medicine-platform-with-novel-immune", "time_published": "20231018T105916", "authors": ["Globe Newswire"], "summary": "- Immune-quiet DNA ( iqDNA ) is a novel variant of closed-ended DNA ( ceDNA ) that evades host innate immune detection in both mice and non-human primates ( NHPs ) with a systemic cytokine profile and tolerability comparable to mRNA", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.94762"}], "overall_sentiment_score": 0.201698, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GBIO", "relevance_score": "0.235315", "ticker_sentiment_score": "0.230817", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.053035", "ticker_sentiment_score": "0.19194", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Nvidia, United Airlines, Moderna, Lucid, Bank Of America: Why These Five Stocks Are On Investors' Horizons Today - Lucid Gr  ( NASDAQ:LCID ) , NVIDIA  ( NASDAQ:NVDA ) , United Airlines Holdings  ( NASDAQ:UAL ) , Bank of America  ( NYSE:BAC ) ", "url": "https://www.benzinga.com/markets/23/10/35300620/nvidia-united-airlines-moderna-lucid-bank-of-america-why-these-five-stocks-are-on-investors-horizons", "time_published": "20231018T014426", "authors": ["Benzinga Neuro"], "summary": "U.S. stocks exhibited a mixed performance as the trading day drew to a close, with the Nasdaq Composite taking a dip of around 30 points. The Dow Jones Industrial Average marginally rose by 0.04% to settle at 33,997.65, while the NASDAQ saw a 0.25% reduction, ending the day at 13,533.75.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/Stocks_Photo_by_Phongphan_on_Shutterstock_14.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Real Estate & Construction", "relevance_score": "0.2"}], "overall_sentiment_score": -0.031574, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LCID", "relevance_score": "0.181137", "ticker_sentiment_score": "-0.128344", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.353059", "ticker_sentiment_score": "-0.148172", "ticker_sentiment_label": "Neutral"}, {"ticker": "UAL", "relevance_score": "0.181137", "ticker_sentiment_score": "-0.053033", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.181137", "ticker_sentiment_score": "0.257582", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.181137", "ticker_sentiment_score": "-0.264386", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "How One Stock's 18% Dive Dragged Down An Entire Industry", "url": "https://www.investors.com/news/technology/ntct-stock-plummets-and-drags-down-an-entire-industry-on-its-preannouncement/", "time_published": "20231017T161500", "authors": ["ALLISON GATLIN", "Investor's Business Daily"], "summary": "NTCT Stock Plummets On Disappointing Preannouncement Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2023/10/Stock-netscout-01-company.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.955357"}, {"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.063251, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NTCT", "relevance_score": "0.704675", "ticker_sentiment_score": "-0.058658", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.138464", "ticker_sentiment_score": "0.016936", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.138464", "ticker_sentiment_score": "0.016936", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.138464", "ticker_sentiment_score": "0.016936", "ticker_sentiment_label": "Neutral"}]}, {"title": "Moderna  ( MRNA )  Down Despite Maintaining COVID Jab Sales View", "url": "https://www.zacks.com/stock/news/2167338/moderna-mrna-down-despite-maintaining-covid-jab-sales-view", "time_published": "20231017T141700", "authors": ["Zacks Equity Research"], "summary": "Though Moderna (MRNA) reiterated its sales guidance for COVID vaccine, it warned investors that it could not predict exact demand yet.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/6f/3484.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.796627"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.048185, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVAX", "relevance_score": "0.384102", "ticker_sentiment_score": "0.172005", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.633479", "ticker_sentiment_score": "0.051915", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.577838", "ticker_sentiment_score": "0.007022", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.311829", "ticker_sentiment_score": "0.079145", "ticker_sentiment_label": "Neutral"}]}, {"title": "What's Going On With Moderna Stock? - Moderna  ( NASDAQ:MRNA ) ", "url": "https://www.benzinga.com/news/23/10/35288500/whats-going-on-with-moderna-stock", "time_published": "20231017T135219", "authors": ["Adam Eckert"], "summary": "Moderna Inc MRNA shares are continuing to trade lower Tuesday following Pfizer Inc's PFE warning about reduced Covid-19 product demand. What Happened: Moderna shares closed Monday down 6.47% at $91.94 after Pfizer slashed its full-year 2023 sales outlook from a range of $67 billion to $70 billion ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/17/vaccine-6557409_1920.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.045248, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.946216", "ticker_sentiment_score": "0.085324", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.716023", "ticker_sentiment_score": "-0.08523", "ticker_sentiment_label": "Neutral"}]}, {"title": "J&J Raises Outlook As Health Bellwether Tries To Reinvent Itself", "url": "https://www.investors.com/news/technology/jnj-stock-johnson-johnson-earnings-q3-2023/", "time_published": "20231017T130500", "authors": ["Investor's Business Daily", "ALLISON GATLIN"], "summary": "JNJ Stock: Health Care Bellwether Boosts Outlook As It Refocuses ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2021/01/Stock-JohnsonAndJohnson-syringe-shut.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.682689"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.918141"}], "overall_sentiment_score": 0.327439, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "KVUE", "relevance_score": "0.303175", "ticker_sentiment_score": "0.368734", "ticker_sentiment_label": "Bullish"}, {"ticker": "MRNA", "relevance_score": "0.154455", "ticker_sentiment_score": "0.018124", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.154455", "ticker_sentiment_score": "0.018124", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.154455", "ticker_sentiment_score": "0.018124", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.880871", "ticker_sentiment_score": "0.573042", "ticker_sentiment_label": "Bullish"}]}, {"title": "Pfizer Looks for a Covid Bottom", "url": "https://www.wsj.com/health/pharma/pfizer-looks-for-a-covid-bottom-f9b551fa", "time_published": "20231017T100000", "authors": ["David Wainer"], "summary": "The pharma giant has had to slash projections, but investors welcome its plans to cut costs.", "banner_image": "https://images.wsj.net/im-869213?width=700&height=466", "source": "Wall Street Journal", "category_within_source": "Markets", "source_domain": "www.wsj.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.110381, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.7887", "ticker_sentiment_score": "-0.183703", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PFE", "relevance_score": "0.7887", "ticker_sentiment_score": "-0.183703", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Do These 5 Words From Pfizer Mean Trouble for Novavax?", "url": "https://www.fool.com/investing/2023/10/17/does-this-pfizer-comment-mean-trouble-for-novavax/", "time_published": "20231017T100000", "authors": ["Adria Cimino"], "summary": "Coronavirus vaccine sales could represent recurrent annual revenue for Novavax and rivals.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999365"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.009779, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.051551", "ticker_sentiment_score": "0.004008", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.439364", "ticker_sentiment_score": "0.089844", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVAX", "relevance_score": "0.599382", "ticker_sentiment_score": "-0.068746", "ticker_sentiment_label": "Neutral"}]}, {"title": "European Shares Flat To Slightly Higher On Positive German Data", "url": "https://markets.businessinsider.com/news/stocks/european-shares-flat-to-slightly-higher-on-positive-german-data-1032711678", "time_published": "20231017T094438", "authors": ["markets.businessinsider.com"], "summary": "( RTTNews ) - European stocks were little changed in cautious trade on Tuesday, with prospects of escalation in the Middle East conflict and downbeat quarterly results from the likes of Ericsson and Lonza keeping weighing on sentiment.", "banner_image": "https://markets.businessinsider.com/Images/FacebookIcon.jpg", "source": "Business Insider", "category_within_source": "RSS", "source_domain": "markets.businessinsider.com", "topics": [{"topic": "Earnings", "relevance_score": "0.714479"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.05545, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "RYCEF", "relevance_score": "0.112532", "ticker_sentiment_score": "-0.095978", "ticker_sentiment_label": "Neutral"}, {"ticker": "DPSTF", "relevance_score": "0.112532", "ticker_sentiment_score": "0.097683", "ticker_sentiment_label": "Neutral"}, {"ticker": "HESAF", "relevance_score": "0.112532", "ticker_sentiment_score": "0.060548", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.112532", "ticker_sentiment_score": "-0.041603", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLWYF", "relevance_score": "0.112532", "ticker_sentiment_score": "-0.122631", "ticker_sentiment_label": "Neutral"}, {"ticker": "PPRUF", "relevance_score": "0.112532", "ticker_sentiment_score": "0.060548", "ticker_sentiment_label": "Neutral"}]}, {"title": "Markets Pop on Bargain Hunting, Stronger Economy", "url": "https://www.zacks.com/stock/news/2166817/markets-pop-on-bargain-hunting-stronger-economy", "time_published": "20231016T224200", "authors": ["Zacks Investment Research"], "summary": "The small-cap Russell 2000, still under water over the past month, led the way higher today.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/81/48849.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.977154"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.148243, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "UAL", "relevance_score": "0.174587", "ticker_sentiment_score": "0.036241", "ticker_sentiment_label": "Neutral"}, {"ticker": "LMT", "relevance_score": "0.174587", "ticker_sentiment_score": "0.036241", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.174587", "ticker_sentiment_score": "0.036241", "ticker_sentiment_label": "Neutral"}, {"ticker": "ETSY", "relevance_score": "0.174587", "ticker_sentiment_score": "0.101763", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.174587", "ticker_sentiment_score": "0.036241", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.174587", "ticker_sentiment_score": "0.036241", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.174587", "ticker_sentiment_score": "0.101763", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.174587", "ticker_sentiment_score": "0.101763", "ticker_sentiment_label": "Neutral"}]}, {"title": "Price of lifesaving Covid-19 antiviral Paxlovid expected to rise next year, raising concerns about access", "url": "https://www.cnn.com/2023/10/16/health/paxlovid-price-expected-to-rise/index.html", "time_published": "20231016T213400", "authors": ["Meg Tirrell"], "summary": "The price of the lifesaving Covid-19 medication Paxlovid is likely to rise next year for most patients as the United States continues to transition out of the emergency phase of the pandemic, sparking concerns among doctors that it will become less accessible.", "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/230322183130-covid-19-vaccine-112122-restricted.jpg?c=16x9&q=h_144,w_256,c_fill", "source": "CNN", "category_within_source": "Markets", "source_domain": "www.cnn.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": -0.031439, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "EVR", "relevance_score": "0.03804", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "WBD", "relevance_score": "0.03804", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVAX", "relevance_score": "0.03804", "ticker_sentiment_score": "0.059151", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.03804", "ticker_sentiment_score": "0.059151", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.188486", "ticker_sentiment_score": "0.09113", "ticker_sentiment_label": "Neutral"}]}, {"title": "Check Out What Whales Are Doing With MRNA - Moderna  ( NASDAQ:MRNA ) ", "url": "https://www.benzinga.com/markets/options/23/10/35276224/check-out-what-whales-are-doing-with-mrna", "time_published": "20231016T203046", "authors": ["Benzinga Insights"], "summary": "A whale with a lot of money to spend has taken a noticeably bearish stance on Moderna. Looking at options history for Moderna MRNA we detected 28 strange trades. If we consider the specifics of each trade, it is accurate to state that 42% of the investors opened trades with bullish expectations ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.106556, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.821747", "ticker_sentiment_score": "0.23099", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Novavax positive on updated COVID vaccine availability in US", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/novavax-positive-updated-covid-vaccine-availability-us-2023-10-16/", "time_published": "20231016T200500", "authors": ["Reuters"], "summary": "A vial labelled \"Novavax V COVID-19 Vaccine\" is seen in this illustration taken January 16, 2022. REUTERS/Dado Ruvic/Illustration/File Photo Acquire Licensing Rights", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/KQY6Q2HQGROSVPRNTFTB2D3LJU.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.040475, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.245339", "ticker_sentiment_score": "-0.223231", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PFE", "relevance_score": "0.468029", "ticker_sentiment_score": "-0.255789", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "NVAX", "relevance_score": "0.88183", "ticker_sentiment_score": "-0.07519", "ticker_sentiment_label": "Neutral"}]}, {"title": "Moderna's stock slides to three-year low as co-founder sells more shares", "url": "https://www.marketwatch.com/story/modernas-stock-slides-to-three-year-low-as-co-founder-sells-more-shares-ab48a02a", "time_published": "20231016T185500", "authors": ["Tomi Kilgore"], "summary": "Moderna's stock slid toward a fourth straight loss Monday. The company's co-founder and chair, Noubar Afeyan, has sold $3 million worth of shares in October.", "banner_image": "https://images.mktw.net/im-869413/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.918141"}], "overall_sentiment_score": 0.051106, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.436009", "ticker_sentiment_score": "0.062413", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.436009", "ticker_sentiment_score": "0.056316", "ticker_sentiment_label": "Neutral"}]}, {"title": "Moderna Becomes Oversold", "url": "https://www.forbes.com/sites/dividendchannel/2023/10/16/moderna-becomes-oversold/", "time_published": "20231016T155851", "authors": ["Dividend Channel"], "summary": "In trading on Monday, shares of Moderna entered into oversold territory, hitting an RSI reading of 29.6, after changing hands as low as $90.18 per share.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/652d5cf548db3eb6b130206c/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds", "source": "Forbes", "category_within_source": "Markets", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}], "overall_sentiment_score": -0.014606, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.388879", "ticker_sentiment_score": "0.177756", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Pfizer confronts 'peak of anti-vaccination rhetoric' as shares rebound", "url": "https://www.marketwatch.com/story/pfizer-confronts-peak-of-anti-vaccination-rhetoric-as-shares-rebound-54c5ef89", "time_published": "20231016T150500", "authors": ["Eleanor Laise"], "summary": "Cost-saving program \"will touch all parts of the business\" but won't affect Seagen acquisition, Pfizer says.", "banner_image": "https://images.mktw.net/im-504042/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Earnings", "relevance_score": "0.614606"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.115007, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.145145", "ticker_sentiment_score": "0.149177", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.727604", "ticker_sentiment_score": "0.162829", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SGEN", "relevance_score": "0.216215", "ticker_sentiment_score": "0.076262", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stock Market Starts The Week With A Bang; Lululemon Stock Rallies", "url": "https://www.investors.com/market-trend/stock-market-today/stock-market-starts-week-with-a-bang-lululemon-rallies-on-sp-addition/", "time_published": "20231016T145200", "authors": ["Investor's Business Daily", "KIMBERLEY KOENIG"], "summary": "Stock Market Starts The Week With A Bang. Lululemon Stock Rallies Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2019/09/stock-Lululemon-11-shutter.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.650727"}], "overall_sentiment_score": 0.086637, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CVS", "relevance_score": "0.141726", "ticker_sentiment_score": "-0.169803", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "BAC", "relevance_score": "0.141726", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TTD", "relevance_score": "0.141726", "ticker_sentiment_score": "-0.120072", "ticker_sentiment_label": "Neutral"}, {"ticker": "SLB", "relevance_score": "0.141726", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.071145", "ticker_sentiment_score": "0.257219", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.344712", "ticker_sentiment_score": "0.035346", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.211191", "ticker_sentiment_score": "-0.253576", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "VSTO", "relevance_score": "0.141726", "ticker_sentiment_score": "-0.140376", "ticker_sentiment_label": "Neutral"}, {"ticker": "LULU", "relevance_score": "0.141726", "ticker_sentiment_score": "0.121487", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.141726", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "RAD", "relevance_score": "0.211191", "ticker_sentiment_score": "0.04014", "ticker_sentiment_label": "Neutral"}, {"ticker": "SCHW", "relevance_score": "0.141726", "ticker_sentiment_score": "-0.16733", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "NVAX", "relevance_score": "0.141726", "ticker_sentiment_score": "-0.10663", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.211191", "ticker_sentiment_score": "-0.140532", "ticker_sentiment_label": "Neutral"}]}, {"title": "Moderna, BioNTech Leads Covid Sell-Off After Pfizer Slashes Outlook", "url": "https://www.investors.com/news/technology/moderna-stock-biontech-stock-lead-covid-sell-off-after-pfizer-slashes-guidance/", "time_published": "20231016T141800", "authors": ["Investor's Business Daily", "ALLISON GATLIN"], "summary": "Moderna ( MRNA ) stock and BioNTech ( BNTX ) led a sell-off Monday among Covid vaccine makers after Pfizer ( PFE ) slashed about $9 billion from its full-year guidance. Pfizer said it wrote off about $5.5 billion in inventory during the third quarter due to lower-than-expected demand for ...", "banner_image": "https://www.investors.com/wp-content/uploads/2018/08/stock-Pfizer-03-shutter.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.576289"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.999967"}], "overall_sentiment_score": 0.091058, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.067919", "ticker_sentiment_score": "0.309934", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVAX", "relevance_score": "0.135347", "ticker_sentiment_score": "-0.201507", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MRNA", "relevance_score": "0.329992", "ticker_sentiment_score": "-0.014699", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.651499", "ticker_sentiment_score": "0.118694", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.449219", "ticker_sentiment_score": "-0.045032", "ticker_sentiment_label": "Neutral"}]}, {"title": "Moderna confirms COVID sales guidance as shares sink on Pfizer news", "url": "https://www.marketwatch.com/story/moderna-confirms-covid-sales-guidance-as-shares-sink-on-pfizer-news-fdde463b", "time_published": "20231016T133700", "authors": ["Eleanor Laise"], "summary": "Company sees full-year COVID sales of $6 billion to $8 billion but says size of U.S. market is still uncertain ...", "banner_image": "https://images.mktw.net/im-852408/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.070636, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.815635", "ticker_sentiment_score": "0.119021", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.574235", "ticker_sentiment_score": "0.077691", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVAX", "relevance_score": "0.404563", "ticker_sentiment_score": "-0.068035", "ticker_sentiment_label": "Neutral"}]}, {"title": "Moderna reaffirms annual COVID vaccine sales forecast", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/moderna-reaffirms-annual-covid-vaccine-sales-forecast-2023-10-16/", "time_published": "20231016T131700", "authors": ["Reuters"], "summary": "Syringes with needles are seen in front of a displayed Moderna logo in this illustration taken, November 27, 2021. REUTERS/Dado Ruvic/Illustration/File Photo Acquire Licensing Rights", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/WGZ74XM54ZM23LH6JTU2TW2Y64.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.035407, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.973732", "ticker_sentiment_score": "0.064187", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.421485", "ticker_sentiment_score": "-0.303389", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Novavax Faces Setback, European Authority Delays Decision On Variant-Tailored COVID-19 Vaccine", "url": "https://markets.businessinsider.com/news/stocks/novavax-faces-setback-european-authority-delays-decision-on-variant-tailored-covid-19-vaccine-1032708167", "time_published": "20231016T123124", "authors": ["Vandana Singh"], "summary": "Novavax Inc ( NASDAQ:NVAX ) faces a setback as the European Medicines Agency ( EMA ) delays a decision on its variant-tailored COVID-19 vaccine. This delay comes at a challenging time for the US-listed biotech, grappling with declining demand for COVID-19 vaccines.", "banner_image": "https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2023/10/16/novavax-photo_by_jernej_furman_via_flickr.jpg", "source": "Business Insider", "category_within_source": "GoogleRSS", "source_domain": "markets.businessinsider.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.109072, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVAX", "relevance_score": "0.459624", "ticker_sentiment_score": "0.012131", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.16171", "ticker_sentiment_score": "0.123483", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.16171", "ticker_sentiment_score": "0.123483", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.16171", "ticker_sentiment_score": "0.123483", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pfizer cuts full-year outlook due to declining sales of Covid-19-related products", "url": "https://apnews.com/article/pfizer-vaccine-covid-comirnaty-paxlovid-3f3d5291232c08c21fe3a11f143f76ff", "time_published": "20231016T122100", "authors": ["MICHELLE CHAPMAN"], "summary": "Shares of Pfizer are in retreat on the first day of trading after the drug company said sales of its COVID-19 vaccine and its coronavirus treatment are in less than expected and cut revenue expectations for the year by $9 billion.", "banner_image": "https://dims.apnews.com/dims4/default/699cbd4/2147483647/strip/true/crop/5184x3453+0+1/resize/599x399!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2F4c%2F91%2F67c20e7e8664a588c726993677c2%2F0f78893939a340c790b47af124d0025e", "source": "Associated Press", "category_within_source": "Markets", "source_domain": "apnews.com", "topics": [{"topic": "Earnings", "relevance_score": "0.995973"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.0377, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.122269", "ticker_sentiment_score": "0.212035", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JPM", "relevance_score": "0.122269", "ticker_sentiment_score": "0.078778", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.644033", "ticker_sentiment_score": "0.04743", "ticker_sentiment_label": "Neutral"}]}, {"title": "Futures Rise As Netflix, Tesla Earnings Loom", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-netflix-tesla-earnings-loom-lululemon-surges-on-sp-news/", "time_published": "20231016T121700", "authors": ["SCOTT LEHTONEN", "Investor's Business Daily"], "summary": "Dow Jones futures rose Monday ahead of a big week of earning reports, headlined by Netflix ( NFLX ) and Tesla ( TSLA ) . Meanwhile, Lululemon Athletica ( LULU ) jumped on news that the company will join the S&P 500 index this week.", "banner_image": "https://www.investors.com/wp-content/uploads/2021/09/Stock-wallstreetflag-01-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.614606"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.127382, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NFLX", "relevance_score": "0.070207", "ticker_sentiment_score": "0.062244", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.174335", "ticker_sentiment_score": "0.075356", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.070207", "ticker_sentiment_score": "-0.054204", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.174335", "ticker_sentiment_score": "0.026112", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANET", "relevance_score": "0.105141", "ticker_sentiment_score": "0.157877", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IVZ", "relevance_score": "0.035138", "ticker_sentiment_score": "0.107945", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.070207", "ticker_sentiment_score": "-0.312709", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "UNH", "relevance_score": "0.139872", "ticker_sentiment_score": "0.097439", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.174335", "ticker_sentiment_score": "0.033145", "ticker_sentiment_label": "Neutral"}, {"ticker": "LULU", "relevance_score": "0.070207", "ticker_sentiment_score": "0.062244", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.208464", "ticker_sentiment_score": "0.039608", "ticker_sentiment_label": "Neutral"}, {"ticker": "ATVI", "relevance_score": "0.035138", "ticker_sentiment_score": "0.043454", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.070207", "ticker_sentiment_score": "0.217439", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.070207", "ticker_sentiment_score": "0.175048", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "PacBio Announces Appointment of David Meline to Board of Directors", "url": "https://www.prnewswire.com/news-releases/pacbio-announces-appointment-of-david-meline-to-board-of-directors-301957110.html", "time_published": "20231016T120500", "authors": ["Inc.", "Pacific Biosciences of California"], "summary": "Former CFO of Moderna, Amgen, and 3M Brings Decades of Relevant Experience to the PacBio Board MENLO PARK, Calif., Oct. 16, 2023 /PRNewswire/ -- PacBio ( NASDAQ: PACB ) , a leading developer of high-quality, highly accurate sequencing solutions, today announced the appointment of David Meline to ...", "banner_image": "https://mma.prnewswire.com/media/1861430/PacBio_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.313974, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HPQ", "relevance_score": "0.081552", "ticker_sentiment_score": "0.058019", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABLZF", "relevance_score": "0.081552", "ticker_sentiment_score": "0.058019", "ticker_sentiment_label": "Neutral"}, {"ticker": "MMM", "relevance_score": "0.081552", "ticker_sentiment_score": "0.058019", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.317869", "ticker_sentiment_score": "0.28883", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.081552", "ticker_sentiment_score": "0.058019", "ticker_sentiment_label": "Neutral"}, {"ticker": "GM", "relevance_score": "0.081552", "ticker_sentiment_score": "0.058019", "ticker_sentiment_label": "Neutral"}]}, {"title": "Novavax  ( NVAX )  Stock Is Falling Today - Here's Why - Novavax  ( NASDAQ:NVAX ) ", "url": "https://www.benzinga.com/general/biotech/23/10/35262408/novavax-faces-setback-european-authority-delays-decision-on-variant-tailored-covid-19-vaccine", "time_published": "20231016T120444", "authors": ["Vandana Singh"], "summary": "Novavax Inc NVAX faces a setback as the European Medicines Agency ( EMA ) delays a decision on its variant-tailored COVID-19 vaccine. This delay comes at a challenging time for the US-listed biotech, grappling with declining demand for COVID-19 vaccines.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/16/novavax-photo_by_jernej_furman_via_flickr.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.101494, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVAX", "relevance_score": "0.558244", "ticker_sentiment_score": "0.01022", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.299478", "ticker_sentiment_score": "0.188578", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.299478", "ticker_sentiment_score": "0.188578", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BNTX", "relevance_score": "0.299478", "ticker_sentiment_score": "0.188578", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Ten Most Shorted Stocks Include 3 Tesla Rivals, But Not TSLA", "url": "https://www.investors.com/news/tesla-stock-10-most-shorted-stocks-include-3-ev-rivals-but-not-tsla/", "time_published": "20231016T120100", "authors": ["Investor's Business Daily", "ED CARSON"], "summary": "Tesla ( TSLA ) has a large number of shares sold short, but it's relatively low as share of the float. But three EV makers are among the most-shorted stocks: VinFast Auto ( VFS ) , Fisker ( FSR ) and Faraday Future Intelligent Electric ( FFIE ) .", "banner_image": "https://www.investors.com/wp-content/uploads/2023/08/Stock-Vinfast-cars-01-company.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "IPO", "relevance_score": "0.310843"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.998682"}, {"topic": "Real Estate & Construction", "relevance_score": "0.166667"}], "overall_sentiment_score": -0.036212, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BYND", "relevance_score": "0.2317", "ticker_sentiment_score": "0.027966", "ticker_sentiment_label": "Neutral"}, {"ticker": "VFS", "relevance_score": "0.155702", "ticker_sentiment_score": "0.02472", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.268927", "ticker_sentiment_score": "0.008204", "ticker_sentiment_label": "Neutral"}, {"ticker": "FSR", "relevance_score": "0.155702", "ticker_sentiment_score": "0.113917", "ticker_sentiment_label": "Neutral"}, {"ticker": "CVNA", "relevance_score": "0.305532", "ticker_sentiment_score": "-0.137637", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVAX", "relevance_score": "0.155702", "ticker_sentiment_score": "-0.054127", "ticker_sentiment_label": "Neutral"}, {"ticker": "UPST", "relevance_score": "0.2317", "ticker_sentiment_score": "-0.061297", "ticker_sentiment_label": "Neutral"}, {"ticker": "FFIE", "relevance_score": "0.117104", "ticker_sentiment_score": "-0.071499", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.078226", "ticker_sentiment_score": "-0.142144", "ticker_sentiment_label": "Neutral"}, {"ticker": "SLNO", "relevance_score": "0.2317", "ticker_sentiment_score": "-0.066918", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.078226", "ticker_sentiment_score": "-0.142144", "ticker_sentiment_label": "Neutral"}, {"ticker": "WHLR", "relevance_score": "0.155702", "ticker_sentiment_score": "0.095595", "ticker_sentiment_label": "Neutral"}]}, {"title": "BioNTech, Moderna And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Elbit Systems  ( NASDAQ:ESLT ) , BioNTech  ( NASDAQ:BNTX ) ", "url": "https://www.benzinga.com/news/23/10/35263882/biontech-moderna-and-other-big-stocks-moving-lower-in-mondays-pre-market-session", "time_published": "20231016T113335", "authors": ["Lisa Levin"], "summary": "U.S. stock futures traded higher this morning on Monday. Here are some big stocks recording losses in today's pre-market trading session. Manchester United plc MANU fell 11.8% to $17.62 in pre-market trading .", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/16/biontech-_logo.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.503496"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": -0.309187, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "TTD", "relevance_score": "0.443626", "ticker_sentiment_score": "-0.645291", "ticker_sentiment_label": "Bearish"}, {"ticker": "ESLT", "relevance_score": "0.443626", "ticker_sentiment_score": "-0.665972", "ticker_sentiment_label": "Bearish"}, {"ticker": "MANU", "relevance_score": "0.443626", "ticker_sentiment_score": "-0.665972", "ticker_sentiment_label": "Bearish"}, {"ticker": "MAXN", "relevance_score": "0.443626", "ticker_sentiment_score": "-0.665972", "ticker_sentiment_label": "Bearish"}, {"ticker": "NVAX", "relevance_score": "0.443626", "ticker_sentiment_score": "-0.308494", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MRNA", "relevance_score": "0.443626", "ticker_sentiment_score": "-0.672661", "ticker_sentiment_label": "Bearish"}, {"ticker": "PFE", "relevance_score": "0.443626", "ticker_sentiment_score": "-0.160671", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "BNTX", "relevance_score": "0.443626", "ticker_sentiment_score": "0.011961", "ticker_sentiment_label": "Neutral"}]}, {"title": "Vaccine Stocks-Including Pfizer, Moderna, BioNTech And Novavax-Slide Amid Plummeting Demand", "url": "https://www.forbes.com/sites/roberthart/2023/10/16/vaccine-stocks-including-pfizer-moderna-biontech-and-novavax-slide-amid-plummeting-demand/", "time_published": "20231016T111814", "authors": ["Robert Hart"], "summary": "Pfizer slashed its revenue forecasts on Friday amid falling demand for its Covid vaccine and antiviral drug Paxlovid.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/618bb4fd4b6dcbb9db1a3887/0x0.jpg?format=jpg&crop=1729,972,x0,y90,safe&height=900&width=1600&fit=bounds", "source": "Forbes", "category_within_source": "Business", "source_domain": "www.forbes.com", "topics": [{"topic": "Earnings", "relevance_score": "0.744043"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.016934, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.399204", "ticker_sentiment_score": "-0.072284", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.616842", "ticker_sentiment_score": "0.065191", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.399204", "ticker_sentiment_score": "0.050062", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is Novavax Stock a Buy Now?", "url": "https://www.fool.com/investing/2023/10/16/is-novavax-stock-a-buy-now/", "time_published": "20231016T103400", "authors": ["Prosper Junior Bakiny"], "summary": "Is this company just a pandemic stock?", "banner_image": "https://media.ycharts.com/charts/26a4b10e17462e704e299406addf654c.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.928769"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.119227, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVAX", "relevance_score": "0.67522", "ticker_sentiment_score": "0.221861", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.05234", "ticker_sentiment_score": "-0.026996", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.05234", "ticker_sentiment_score": "-0.026996", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.05234", "ticker_sentiment_score": "-0.026996", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pfizer shares fall on guidance cut, weighing on BioNTech and Moderna stocks, and other shares on the move", "url": "https://www.marketwatch.com/story/pfizer-shares-fall-on-guidance-cut-weighing-on-biontech-and-moderna-stocks-and-other-shares-on-the-move-8f868658", "time_published": "20231016T100900", "authors": ["MarketWatch"], "summary": "Shares in Pfizer, BioNTech, Moderna, Manchester United, and Lululemon Atheltica were all active in premarket trading ...", "banner_image": "https://images.mktw.net/im-783192/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": 0.053595, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LULU", "relevance_score": "0.350564", "ticker_sentiment_score": "0.352331", "ticker_sentiment_label": "Bullish"}, {"ticker": "MANU", "relevance_score": "0.350564", "ticker_sentiment_score": "-0.047334", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVAX", "relevance_score": "0.350564", "ticker_sentiment_score": "-0.206285", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MRNA", "relevance_score": "0.350564", "ticker_sentiment_score": "0.276843", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.504646", "ticker_sentiment_score": "-0.349854", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "BNTX", "relevance_score": "0.350564", "ticker_sentiment_score": "0.276843", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HUBB", "relevance_score": "0.350564", "ticker_sentiment_score": "0.260137", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Breast Cancer Awareness Month: Tennis great Martina Navratilova shares journey of her dual cancer battle", "url": "https://www.foxbusiness.com/sports/breast-cancer-awareness-month-tennis-great-martina-navratilova-shares-journey-her-dual-cancer-battle", "time_published": "20231015T194714", "authors": ["Sumner Park", "Gerri Willis"], "summary": "Breast Cancer Awareness Month: Tennis great Martina Navratilova ... Fox Business ...", "banner_image": "https://cf-images.us-east-1.prod.boltdns.net/v1/static/854081161001/a702f5ce-7b09-4add-a03d-5f20574ac729/3cb5d478-df97-4f6a-9ee9-2fb6a0cae406/1280x720/match/image.jpg", "source": "Fox Business News", "category_within_source": "n/a", "source_domain": "www.foxbusiness.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.109524, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.067347", "ticker_sentiment_score": "-0.324933", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "HOLX", "relevance_score": "0.067347", "ticker_sentiment_score": "0.063164", "ticker_sentiment_label": "Neutral"}]}, {"title": "Shanghai mayor vows to attract more foreign firms like Tesla, Boston Scientific", "url": "https://www.scmp.com/business/china-business/article/3238024/shanghai-mayor-vows-attract-even-more-foreign-business-after-tesla-and-boston-scientific-factories", "time_published": "20231015T133021", "authors": ["Daniel Ren"], "summary": "Mayor Gong Zheng said more landmark deals are in the works as Shanghai tries to burnish its image as an international investment magnet.", "banner_image": "https://cdn.i-scmp.com/sites/default/files/d8/images/canvas/2023/10/15/ac19e27b-6835-489a-8e02-d5d25695f4ca_c61c0c38.jpg", "source": "South China Morning Post", "category_within_source": "Economy", "source_domain": "www.scmp.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.151537, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "TSLA", "relevance_score": "0.254973", "ticker_sentiment_score": "0.076406", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.064797", "ticker_sentiment_score": "0.086082", "ticker_sentiment_label": "Neutral"}, {"ticker": "BSX", "relevance_score": "0.129168", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.064797", "ticker_sentiment_score": "-0.00605", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pfizer's stock sinks after company slashes $9 billion from outlook, foreshadows layoffs", "url": "https://www.marketwatch.com/story/pfizers-stock-sinks-after-company-cuts-outlook-on-lower-demand-for-covid-products-c84f7c93", "time_published": "20231013T215300", "authors": ["Wallace Witkowski"], "summary": "Pfizer and biotech drug maker shares fell after Pfizer slashed its full-year earnings outlook due to a drop in demand for COVID pills and more.", "banner_image": "https://images.mktw.net/im-821225/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Earnings", "relevance_score": "0.980716"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.009621, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVAX", "relevance_score": "0.235062", "ticker_sentiment_score": "-0.001852", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.235062", "ticker_sentiment_score": "-0.001852", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.86509", "ticker_sentiment_score": "0.016694", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.235062", "ticker_sentiment_score": "0.007348", "ticker_sentiment_label": "Neutral"}]}, {"title": "J&J  ( JNJ )  to Report Q3 Earnings, Its First After Unit Spin-Off", "url": "https://www.zacks.com/stock/news/2165582/jj-jnj-to-report-q3-earnings-its-first-after-unit-spin-off", "time_published": "20231013T134900", "authors": ["Zacks Equity Research"], "summary": "J&J's (JNJ) third-quarter results are the first quarterly update for the new company after the Consumer Health spin-off.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ff/1612.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.99393"}, {"topic": "Earnings", "relevance_score": "0.999992"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.149943, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "KVUE", "relevance_score": "0.130453", "ticker_sentiment_score": "0.063321", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.173333", "ticker_sentiment_score": "-0.063835", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.257442", "ticker_sentiment_score": "0.135924", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.215702", "ticker_sentiment_score": "0.094996", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.173333", "ticker_sentiment_score": "0.080645", "ticker_sentiment_label": "Neutral"}]}, {"title": "Novavax says new COVID shot now available in many U.S. pharmacies", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/novavaxs-updated-covid-19-vaccines-available-us-pharmacies-2023-10-13/", "time_published": "20231013T134800", "authors": ["Reuters"], "summary": "Syringes with needles are seen in front of a displayed Novavax logo in this illustration taken, November 27, 2021. REUTERS/Dado Ruvic/Illustration/File Photo Acquire Licensing Rights", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/GHTDDZVPHVNBDFXQD27Y5KPIAY.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}], "overall_sentiment_score": 0.002422, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CVS", "relevance_score": "0.229149", "ticker_sentiment_score": "0.229473", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "COST", "relevance_score": "0.229149", "ticker_sentiment_score": "0.229473", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RAD", "relevance_score": "0.229149", "ticker_sentiment_score": "0.229473", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVAX", "relevance_score": "0.756001", "ticker_sentiment_score": "0.039932", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.229149", "ticker_sentiment_score": "-0.056397", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.229149", "ticker_sentiment_score": "-0.056397", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.229149", "ticker_sentiment_score": "-0.056397", "ticker_sentiment_label": "Neutral"}]}, {"title": "First on : HHS awards more than $500 million to study Covid-19 vaccine nasal sprays and more", "url": "https://www.cnn.com/2023/10/13/health/hhs-project-nextgen-covid/index.html", "time_published": "20231013T120000", "authors": ["Jacqueline Howard"], "summary": "First on CNN: HHS awards more than $500 million to study Covid-19 vaccine nasal sprays and more ...", "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/230817230825-covid-vaccine-arm-wellness.jpg?c=16x9&q=h_144,w_256,c_fill", "source": "CNN", "category_within_source": "Markets", "source_domain": "www.cnn.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.220741, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "WBD", "relevance_score": "0.042876", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GRTS", "relevance_score": "0.042876", "ticker_sentiment_score": "0.094847", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVAX", "relevance_score": "0.042876", "ticker_sentiment_score": "-0.02284", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.128135", "ticker_sentiment_score": "0.152232", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.042876", "ticker_sentiment_score": "-0.02284", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.042876", "ticker_sentiment_score": "-0.02284", "ticker_sentiment_label": "Neutral"}]}, {"title": "5 things to know for Oct. 13: Israel, House speaker, Covid-19, Medicare, TikTok", "url": "https://www.cnn.com/2023/10/13/us/5-things-to-know-for-oct-13-israel-house-speaker-covid-19-medicare-tiktok/index.html", "time_published": "20231013T104100", "authors": ["Alexandra Meeks"], "summary": "5 things to know for Oct. 13: Israel, House speaker, Covid-19, Medicare, ...", "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/231012200220-02-steve-scalise-1012.jpg?c=16x9&q=w_850,c_fill", "source": "CNN", "category_within_source": "Economy", "source_domain": "www.cnn.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.040996, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVAX", "relevance_score": "0.033144", "ticker_sentiment_score": "0.08015", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.033144", "ticker_sentiment_score": "0.08015", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.033144", "ticker_sentiment_score": "0.08015", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.033144", "ticker_sentiment_score": "0.08015", "ticker_sentiment_label": "Neutral"}]}, {"title": "1 Artificial Intelligence Stock to Buy Hand Over Fist in October and 1 to Avoid", "url": "https://www.fool.com/investing/2023/10/13/1-artificial-intelligence-stock-to-buy-1-to-avoid/", "time_published": "20231013T100000", "authors": ["Adria Cimino"], "summary": "One of these players could win in AI -- and in the healthcare market, in general.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.955357"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.714479"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.284536, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NVDA", "relevance_score": "0.101582", "ticker_sentiment_score": "0.147528", "ticker_sentiment_label": "Neutral"}, {"ticker": "RXRX", "relevance_score": "0.101582", "ticker_sentiment_score": "0.123946", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.47672", "ticker_sentiment_score": "0.445383", "ticker_sentiment_label": "Bullish"}, {"ticker": "IBM", "relevance_score": "0.050894", "ticker_sentiment_score": "0.125363", "ticker_sentiment_label": "Neutral"}]}, {"title": "Despite rocky rollout, more than 7 million Americans have received updated Covid-19 vaccines, HHS says", "url": "https://www.cnn.com/2023/10/12/health/hhs-covid-vaccine/index.html", "time_published": "20231012T185800", "authors": ["Jacqueline Howard"], "summary": "This year's uptake of the updated Covid-19 vaccine appears to be somewhat slower than last year's, according to data from the US Department of Health and Human Services and the US Centers for Disease Control and Prevention. More than 7 million Americans have received a dose of the latest ...", "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/210831142109-01-covid-vaccine-card-file.jpg?c=16x9&q=h_144,w_256,c_fill", "source": "CNN", "category_within_source": "Markets", "source_domain": "www.cnn.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.04055, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "WBD", "relevance_score": "0.056943", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVAX", "relevance_score": "0.056943", "ticker_sentiment_score": "0.105942", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.056943", "ticker_sentiment_score": "0.105942", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.056943", "ticker_sentiment_score": "0.105942", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.056943", "ticker_sentiment_score": "0.105942", "ticker_sentiment_label": "Neutral"}]}, {"title": "Moderna Unusual Options Activity For October 12 - Moderna  ( NASDAQ:MRNA ) ", "url": "https://www.benzinga.com/markets/options/23/10/35227151/moderna-unusual-options-activity-for-october-12", "time_published": "20231012T182228", "authors": ["Benzinga Insights"], "summary": "Someone with a lot of money to spend has taken a bearish stance on Moderna MRNA. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.157685, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.753715", "ticker_sentiment_score": "0.146738", "ticker_sentiment_label": "Neutral"}]}, {"title": "Cardiol Therapeutics Fights Heart Inflammation With Novel Formulations - Cardiol Therapeutics  ( NASDAQ:CRDL ) ", "url": "https://www.benzinga.com/general/biotech/23/10/35220787/cardiol-therapeutics-fights-heart-inflammation-with-novel-formulations", "time_published": "20231012T135319", "authors": ["Beau Sharpe"], "summary": "697,000 people die from heart disease every year in the United States - that is one in every five deaths. In fact, cardiovascular disease is the number one killer for most Americans per the CDC. Everyday life choices play an essential role in heart health, and sometimes unfortunate accidents can ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/12/shutterstock_1381636952.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.096094, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CRDL", "relevance_score": "0.323927", "ticker_sentiment_score": "0.140733", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.066598", "ticker_sentiment_score": "-0.014349", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.033328", "ticker_sentiment_score": "-0.01534", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.033328", "ticker_sentiment_score": "-0.056748", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Top Biotech Stocks to Buy Right Now", "url": "https://www.fool.com/investing/2023/10/12/2-top-biotech-stocks-to-buy-right-now/", "time_published": "20231012T133700", "authors": ["Prosper Junior Bakiny"], "summary": "Both companies are known innovators.", "banner_image": "https://media.ycharts.com/charts/dbfc587c384e5d4e4783a3f4889228b7.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.99737"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}], "overall_sentiment_score": 0.159876, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.367606", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.215415", "ticker_sentiment_score": "0.362586", "ticker_sentiment_label": "Bullish"}]}, {"title": "Biotech Stock Roundup: BMY Grabs MRTX, AKRO Down on Study Data, ALNY Faces Setback", "url": "https://www.zacks.com/stock/news/2164807/biotech-stock-roundup-bmy-grabs-mrtx-akro-down-on-study-data-alny-faces-setback", "time_published": "20231012T122400", "authors": ["Ekta Bagri"], "summary": "Acquisition and pipeline updates from Bristol Myers (BMY) and Akero Therapeutics (AKRO) are in focus in the biotech sector.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/86/1981.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.104407, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALNY", "relevance_score": "0.134402", "ticker_sentiment_score": "0.063039", "ticker_sentiment_label": "Neutral"}, {"ticker": "AKRO", "relevance_score": "0.101012", "ticker_sentiment_score": "0.039293", "ticker_sentiment_label": "Neutral"}, {"ticker": "QURE", "relevance_score": "0.067441", "ticker_sentiment_score": "-0.02003", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.033751", "ticker_sentiment_score": "0.092178", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRTX", "relevance_score": "0.101012", "ticker_sentiment_score": "0.064655", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.033751", "ticker_sentiment_score": "0.032519", "ticker_sentiment_label": "Neutral"}]}, {"title": "Moderna to Report Third Quarter 2023 Financial Results on Thursday, November 2, 2023", "url": "https://www.barrons.com/articles/moderna-to-report-third-quarter-2023-financial-results-on-thursday-november-2-2023-84787405", "time_published": "20231012T110100", "authors": [], "summary": "Moderna to Report Third Quarter 2023 Financial Results on ... ...", "banner_image": "https://www.barrons.com/asset/barrons/images/Barrons-Logo-AMP.png", "source": "Barrons", "category_within_source": "n/a", "source_domain": "www.barrons.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.0, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.751437", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "The Fall Vaccination Season Is Here. Is Novavax a Buy?", "url": "https://www.fool.com/investing/2023/10/12/fall-vaccine-season-is-here-is-novavax-a-buy/", "time_published": "20231012T100000", "authors": ["Adria Cimino"], "summary": "Novavax shares have declined 28% this year.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.87644"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.117591, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.154785", "ticker_sentiment_score": "0.079753", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.20537", "ticker_sentiment_score": "0.088114", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVAX", "relevance_score": "0.702224", "ticker_sentiment_score": "0.219879", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Moderna  ( MRNA )  Stock Drops Despite Market Gains: Important Facts to Note", "url": "https://www.zacks.com/stock/news/2164563/moderna-mrna-stock-drops-despite-market-gains-important-facts-to-note", "time_published": "20231011T215020", "authors": ["Zacks Equity Research"], "summary": "In the closing of the recent trading day, Moderna (MRNA) stood at $102.76, denoting a -1.6% change from the preceding trading day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default19.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.858979"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.078659, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.48028", "ticker_sentiment_score": "0.172153", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "The COVID Vaccine Market Is Changing Dramatically. Do Vaccine Stocks Still Make Good Investments?", "url": "https://www.fool.com/investing/2023/10/11/vaccine-market-is-changing-shoud-you-invest/", "time_published": "20231011T093000", "authors": ["Adria Cimino"], "summary": "Vaccine revenue may have slipped but could still represent billions of dollars for these companies.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.986714"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.123172, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVAX", "relevance_score": "0.106778", "ticker_sentiment_score": "0.006656", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.361501", "ticker_sentiment_score": "0.131419", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.211652", "ticker_sentiment_score": "0.008524", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.211652", "ticker_sentiment_score": "0.033365", "ticker_sentiment_label": "Neutral"}]}, {"title": "Get to know the 2023 Nobel Prize winners", "url": "https://theweek.com/science/get-to-know-the-2023-nobel-prize-winners", "time_published": "20231011T084538", "authors": ["Devika Rao"], "summary": "Meet this year's Nobel Prize winners The Week ...", "banner_image": "https://cdn.mos.cms.futurecdn.net/JZR9b8FQ6XFPHXpjeyKDeJ-415-80.jpg", "source": "The Week News", "category_within_source": "n/a", "source_domain": "theweek.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": 0.198404, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NYT", "relevance_score": "0.047749", "ticker_sentiment_score": "0.021887", "ticker_sentiment_label": "Neutral"}, {"ticker": "WBD", "relevance_score": "0.023885", "ticker_sentiment_score": "0.021572", "ticker_sentiment_label": "Neutral"}, {"ticker": "FRNWF", "relevance_score": "0.023885", "ticker_sentiment_score": "0.05258", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.023885", "ticker_sentiment_score": "0.07818", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.023885", "ticker_sentiment_score": "0.07818", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.023885", "ticker_sentiment_score": "0.07818", "ticker_sentiment_label": "Neutral"}]}, {"title": "Big Pharma Could Transform Into BioTech Pharma - Pfizer  ( NYSE:PFE ) ", "url": "https://www.benzinga.com/markets/penny-stocks/23/10/35168562/big-pharma-could-transform-into-biotech-pharma", "time_published": "20231010T175342", "authors": ["Upwallstreet"], "summary": "As the word itself says, biotechnology is simply technology based on biology. It uses the knowledge of cellular and biomolecular processes to develop technologies that improve our lives and overall health of the planet that is only our home.", "banner_image": "https://cdn.benzinga.com/files/medical-researcher-dripping-blood-into-test-tube-from-micropipette-doctor-working-with-various-bacteria-tissue-pharmaceutical-research-antibiotics-against-covid19.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.104663, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AKRO", "relevance_score": "0.119532", "ticker_sentiment_score": "-0.001163", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.401331", "ticker_sentiment_score": "0.306098", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CRBU", "relevance_score": "0.178459", "ticker_sentiment_score": "-0.001478", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.293038", "ticker_sentiment_score": "-0.002182", "ticker_sentiment_label": "Neutral"}]}, {"title": "Mana.bio Advances AI-Based Lipid Nanoparticle  ( LNP )  Platform to Accelerate \"Programmable Drug Delivery\" for RNA and Gene Therapies", "url": "https://www.prnewswire.com/news-releases/manabio-advances-ai-based-lipid-nanoparticle-lnp-platform-to-accelerate-programmable-drug-delivery-for-rna-and-gene-therapies-301952340.html", "time_published": "20231010T163000", "authors": ["Mana.bio"], "summary": "Mana.bio Advances AI-Based Lipid Nanoparticle ( LNP ) Platform to Accelerate \"Programmable Drug Delivery\" for RNA ... PR ...", "banner_image": "https://mma.prnewswire.com/media/2242153/MANA_BIO_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Mergers & Acquisitions", "relevance_score": "0.214378"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.275223, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BEAM", "relevance_score": "0.03443", "ticker_sentiment_score": "0.083694", "ticker_sentiment_label": "Neutral"}, {"ticker": "TWST", "relevance_score": "0.068797", "ticker_sentiment_score": "0.08833", "ticker_sentiment_label": "Neutral"}, {"ticker": "EBAY", "relevance_score": "0.03443", "ticker_sentiment_score": "0.083694", "ticker_sentiment_label": "Neutral"}, {"ticker": "STOK", "relevance_score": "0.03443", "ticker_sentiment_score": "0.083694", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.03443", "ticker_sentiment_score": "0.083694", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.03443", "ticker_sentiment_score": "0.083694", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.03443", "ticker_sentiment_score": "0.083694", "ticker_sentiment_label": "Neutral"}]}, {"title": "Novavax  ( NVAX )  Focuses on Diversifying Vaccines Portfolio", "url": "https://www.zacks.com/stock/news/2163659/novavax-nvax-focuses-on-diversifying-vaccines-portfolio", "time_published": "20231010T160400", "authors": ["Zacks Equity Research"], "summary": "Owing to the slow uptake of Novavax's (NVAX) COVID-19 vaccine, the company is trying to develop other vaccine candidates targeting different indications.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/8a/2449.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.052599, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVAX", "relevance_score": "0.659096", "ticker_sentiment_score": "0.154698", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.366061", "ticker_sentiment_score": "-0.012901", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.366061", "ticker_sentiment_score": "-0.012901", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.366061", "ticker_sentiment_score": "-0.012901", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gates Foundation donates $40M to enhance accessibility to mRNA vaccines - .com", "url": "https://www.upi.com/Top_News/World-News/2023/10/09/bill-melinda-gates-mrna-research/7601696879247/", "time_published": "20231009T195943", "authors": [], "summary": "Gates Foundation donates $40M to enhance accessibility to mRNA vaccines UPI News ...", "banner_image": "https://cdnph.upi.com/sv/ph/og/upi/7601696879247/2023/1/9d4afcc44a1349bc4b0e434020c833f2/v1.5/Gates-Foundation-donates-40M-to-enhance-accessibility-to-mRNA-vaccines.jpg", "source": "UPI Business", "category_within_source": "n/a", "source_domain": "www.upi.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.413816, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.112008", "ticker_sentiment_score": "0.070819", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.112008", "ticker_sentiment_score": "0.070819", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.112008", "ticker_sentiment_score": "0.070819", "ticker_sentiment_label": "Neutral"}]}, {"title": "Timing Favors Novavax's Delayed Approval, Arrival Ahead of Peak COVID Vaccine Demand - Novavax  ( NASDAQ:NVAX ) ", "url": "https://www.benzinga.com/general/biotech/23/10/35149072/timing-favors-novavaxs-delayed-approval-arrival-ahead-of-peak-covid-vaccine-demand", "time_published": "20231009T182327", "authors": ["Vandana Singh"], "summary": "Last week, Novavax Inc NVAX received FDA authorization for its updated COVID-19 vaccine, targeting the omicron subvariant XBB.1.5 in individuals aged 12 and older. Wall Street analysts are optimistic about Novavax's prospects despite its vaccine's release delay compared to Pfizer Inc PFE and ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/09/novavax-photo_by_jernej_furman_via_flickr.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.069578, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.44622", "ticker_sentiment_score": "0.20334", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.570165", "ticker_sentiment_score": "0.253677", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVAX", "relevance_score": "0.76367", "ticker_sentiment_score": "0.039875", "ticker_sentiment_label": "Neutral"}]}, {"title": "Timing Favors Novavax's Delayed Approval, Arrival Ahead of Peak COVID Vaccine Demand", "url": "https://markets.businessinsider.com/news/stocks/timing-favors-novavax-s-delayed-approval-arrival-ahead-of-peak-covid-vaccine-demand-1032689900", "time_published": "20231009T182327", "authors": ["Vandana Singh"], "summary": "Last week, Novavax Inc ( NASDAQ:NVAX ) received FDA authorization for its updated COVID-19 vaccine, targeting the omicron subvariant XBB.1.5 in individuals aged 12 and older.", "banner_image": "https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2023/10/09/novavax-photo_by_jernej_furman_via_flickr.jpg", "source": "Business Insider", "category_within_source": "RSS", "source_domain": "markets.businessinsider.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.072143, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.325208", "ticker_sentiment_score": "0.166396", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.470894", "ticker_sentiment_score": "0.230886", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVAX", "relevance_score": "0.705799", "ticker_sentiment_score": "0.038578", "ticker_sentiment_label": "Neutral"}]}, {"title": "Privatized Vaccine Distribution Sparks Confusion, Payment Challenges - Pfizer  ( NYSE:PFE ) ", "url": "https://www.benzinga.com/general/biotech/23/10/35147852/privatized-vaccine-distribution-sparks-confusion-payment-challenges", "time_published": "20231009T164019", "authors": ["Vandana Singh"], "summary": "As the rollout of the updated COVID-19 vaccine progresses, some individuals have been surprised by requests for upfront payments ranging from $150 to $200.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/09/pfizer-biontech_covid-19_vaccine_2020_g.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}], "overall_sentiment_score": 0.0, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CVS", "relevance_score": "0.219809", "ticker_sentiment_score": "0.052567", "ticker_sentiment_label": "Neutral"}, {"ticker": "MCK", "relevance_score": "0.219809", "ticker_sentiment_score": "0.052567", "ticker_sentiment_label": "Neutral"}, {"ticker": "WBA", "relevance_score": "0.219809", "ticker_sentiment_score": "0.052567", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAH", "relevance_score": "0.219809", "ticker_sentiment_score": "0.052567", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.324495", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.423251", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.219809", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "WMT", "relevance_score": "0.219809", "ticker_sentiment_score": "0.052567", "ticker_sentiment_label": "Neutral"}]}, {"title": "Alexandria Real Estate Equities, Inc. Awarded GRESB 4 Star Ratings and Seventh Consecutive Green Star Designation in the 2023 GRESB Real Estate Assessment, Reinforcing Its Sustained ESG Leadership and Performance", "url": "https://www.prnewswire.com/news-releases/alexandria-real-estate-equities-inc-awarded-gresb-4-star-ratings-and-seventh-consecutive-green-star-designation-in-the-2023-gresb-real-estate-assessment-reinforcing-its-sustained-esg-leadership-and-performance-301950270.html", "time_published": "20231009T123000", "authors": ["Inc.", "Alexandria Real Estate Equities"], "summary": "Alexandria Real Estate Equities, Inc. Awarded GRESB 4 Star Ratings and Seventh Consecutive Green Star ... PR ...", "banner_image": "https://mma.prnewswire.com/media/2060728/Alexandria_Real_Estate_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Real Estate & Construction", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.98396"}], "overall_sentiment_score": 0.355661, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "AGTEF", "relevance_score": "0.093653", "ticker_sentiment_score": "0.215292", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ARE", "relevance_score": "0.093653", "ticker_sentiment_score": "0.214233", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.031282", "ticker_sentiment_score": "0.13679", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.031282", "ticker_sentiment_score": "0.13679", "ticker_sentiment_label": "Neutral"}]}, {"title": "Intuit, Nordstrom And 2 Other Stocks Insiders Are Selling - Nordstrom  ( NYSE:JWN ) , Intuit  ( NASDAQ:INTU ) ", "url": "https://www.benzinga.com/news/23/10/35143997/intuit-nordstrom-and-2-other-stocks-insiders-are-selling", "time_published": "20231009T122433", "authors": ["Lisa Levin"], "summary": "The Nasdaq 100 closed higher by around 250 points on Friday. Investors, meanwhile, focused on some notable insider trades. When insiders sell shares, it could be a preplanned sale, or could indicate their concern in the company's prospects or that they view the stock as being overpriced.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/09/intuit_-_logo.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Earnings", "relevance_score": "0.614606"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.129413, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JWN", "relevance_score": "0.561606", "ticker_sentiment_score": "0.32296", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "INTU", "relevance_score": "0.420083", "ticker_sentiment_score": "0.131075", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.342093", "ticker_sentiment_score": "-0.002484", "ticker_sentiment_label": "Neutral"}, {"ticker": "PDCO", "relevance_score": "0.420083", "ticker_sentiment_score": "0.156095", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Gates Foundation funding $40 mn to help develop mRNA vaccines in Africa", "url": "https://www.business-standard.com/world-news/gates-foundation-funding-40-mn-to-help-develop-mrna-vaccines-in-africa-123100900749_1.html", "time_published": "20231009T115140", "authors": ["AP"], "summary": "A $ 40 million investment will help several African manufacturers produce new messenger RNA vaccines on the continent where people were last in line to receive jabs during the COVID-19 pandemic, the Bill and Melinda Gates Foundation announced Monday.", "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2021-06/28/full/1624885768-0949.jpg?im=FeatureCrop,size=(826,465)", "source": "Business Standard", "category_within_source": "GoogleRSS", "source_domain": "www.business-standard.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.073316, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.064623", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.064623", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "A Gallup Faz Parceria com a Radiant Foundation no Novo Relat\u00f3rio Global sobre a Espiritualidade como uma Ferramenta de Apoio \u00e0 Sa\u00fade Mental", "url": "https://www.prnewswire.com/news-releases/a-gallup-faz-parceria-com-a-radiant-foundation-no-novo-relatorio-global-sobre-a-espiritualidade-como-uma-ferramenta-de-apoio-a-saude-mental-812768334.html", "time_published": "20231009T110000", "authors": ["Faith & Media Initiative"], "summary": "A Gallup Faz Parceria com a Radiant Foundation no Novo Relat\u00f3rio Global sobre a Espiritualidade como uma ... PR ...", "banner_image": "https://www.prnewswire.com/content/dam/prnewswire/common/newsletter-signup.png", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.009336, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.049835", "ticker_sentiment_score": "0.011935", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gates Foundation funding $40 million effort to help develop mRNA vaccines in Africa in coming years", "url": "https://apnews.com/article/bill-gates-foundation-africa-vaccines-mrna-institut-pasteur-biovac-fa28c0502925a4152df1709cc8f228fe", "time_published": "20231009T104600", "authors": ["KRISTA LARSON"], "summary": "DAKAR, Senegal ( AP ) - A $40 million investment will help several African manufacturers produce new messenger RNA vaccines on the continent where people were last in line to receive jabs during the COVID-19 pandemic, the Bill & Melinda Gates Foundation announced Monday.", "banner_image": "https://dims.apnews.com/dims4/default/13114a5/2147483647/strip/true/crop/6908x4601+0+2/resize/599x399!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2Fbd%2F36%2F7f8d661e992d3aed5c9ebe63456c%2F7ee9b928a8a4419896e88c65af621d04", "source": "Associated Press", "category_within_source": "Markets", "source_domain": "apnews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.061523, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.066047", "ticker_sentiment_score": "-0.021093", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.066047", "ticker_sentiment_score": "-0.021093", "ticker_sentiment_label": "Neutral"}]}, {"title": "Nobel Prize winner Katalin Karik\u00f3 raised a two-time Olympic gold medalist: Here's her No. 1 piece of parenting advice", "url": "https://www.cnbc.com/2023/10/08/nobel-prize-winner-raised-a-two-time-olympic-gold-medalist-.html", "time_published": "20231008T150002", "authors": [], "summary": "Karik\u00f3's persistence and confidence didn't just make her a good scientist, she says. Those qualities also made her a good parent.", "banner_image": null, "source": "CNBC", "category_within_source": "Top News", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.362907, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.069495", "ticker_sentiment_score": "0.289155", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.069495", "ticker_sentiment_score": "0.289155", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BNTX", "relevance_score": "0.069495", "ticker_sentiment_score": "0.289155", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "New COVID shots still hard to find for some Americans", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/new-covid-shots-still-hard-find-some-americans-2023-10-08/", "time_published": "20231008T120500", "authors": ["Michael Erman", "Ahmed Aboulenein"], "summary": "The word \"COVID-19\" is reflected in a drop on a syringe needle in this illustration taken November 9, 2020. REUTERS/Dado Ruvic/Illustration/File Photo Acquire Licensing Rights", "banner_image": "https://s3.amazonaws.com/arc-authors/reuters/0b82a826-fb3f-4043-b864-a941ebaf669d.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}], "overall_sentiment_score": -0.051626, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CVS", "relevance_score": "0.042122", "ticker_sentiment_score": "-0.102536", "ticker_sentiment_label": "Neutral"}, {"ticker": "WBA", "relevance_score": "0.042122", "ticker_sentiment_score": "0.013755", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAH", "relevance_score": "0.042122", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.125898", "ticker_sentiment_score": "0.020693", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.125898", "ticker_sentiment_score": "0.020693", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.042122", "ticker_sentiment_score": "0.036845", "ticker_sentiment_label": "Neutral"}, {"ticker": "WMT", "relevance_score": "0.042122", "ticker_sentiment_score": "0.013755", "ticker_sentiment_label": "Neutral"}]}, {"title": "Rule Breaker Investing's \"Market Cap Game Show\" Rolls On", "url": "https://www.fool.com/investing/2023/10/07/rule-breaker-investings-market-cap-game-show-rolls/", "time_published": "20231007T131500", "authors": ["Motley Fool Staff"], "summary": "This episode required a tiebreaker.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.142857"}, {"topic": "Energy & Transportation", "relevance_score": "0.142857"}, {"topic": "Technology", "relevance_score": "0.142857"}, {"topic": "Finance", "relevance_score": "0.142857"}, {"topic": "Blockchain", "relevance_score": "0.451494"}, {"topic": "IPO", "relevance_score": "0.576289"}, {"topic": "Retail & Wholesale", "relevance_score": "0.142857"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.142857"}, {"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Real Estate & Construction", "relevance_score": "0.142857"}], "overall_sentiment_score": 0.204223, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ASR", "relevance_score": "0.010223", "ticker_sentiment_score": "0.039928", "ticker_sentiment_label": "Neutral"}, {"ticker": "NFLX", "relevance_score": "0.027257", "ticker_sentiment_score": "0.032326", "ticker_sentiment_label": "Neutral"}, {"ticker": "PATH", "relevance_score": "0.020445", "ticker_sentiment_score": "0.064633", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.010223", "ticker_sentiment_score": "0.03969", "ticker_sentiment_label": "Neutral"}, {"ticker": "ROKU", "relevance_score": "0.003408", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GLP", "relevance_score": "0.003408", "ticker_sentiment_score": "0.04828", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABNB", "relevance_score": "0.010223", "ticker_sentiment_score": "0.010095", "ticker_sentiment_label": "Neutral"}, {"ticker": "NOK", "relevance_score": "0.006816", "ticker_sentiment_score": "0.082049", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSCO", "relevance_score": "0.030663", "ticker_sentiment_score": "0.097363", "ticker_sentiment_label": "Neutral"}, {"ticker": "SMAR", "relevance_score": "0.030663", "ticker_sentiment_score": "0.127179", "ticker_sentiment_label": "Neutral"}, {"ticker": "COIN", "relevance_score": "0.013631", "ticker_sentiment_score": "0.03912", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.006816", "ticker_sentiment_score": "0.097131", "ticker_sentiment_label": "Neutral"}, {"ticker": "ATVI", "relevance_score": "0.030663", "ticker_sentiment_score": "-0.000957", "ticker_sentiment_label": "Neutral"}, {"ticker": "MIDD", "relevance_score": "0.003408", "ticker_sentiment_score": "0.106837", "ticker_sentiment_label": "Neutral"}, {"ticker": "FDX", "relevance_score": "0.037472", "ticker_sentiment_score": "0.061004", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.017038", "ticker_sentiment_score": "0.088733", "ticker_sentiment_label": "Neutral"}, {"ticker": "FUN", "relevance_score": "0.034068", "ticker_sentiment_score": "0.122378", "ticker_sentiment_label": "Neutral"}, {"ticker": "MAR", "relevance_score": "0.071468", "ticker_sentiment_score": "0.094938", "ticker_sentiment_label": "Neutral"}, {"ticker": "WMT", "relevance_score": "0.003408", "ticker_sentiment_score": "0.137643", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.020445", "ticker_sentiment_score": "-0.002675", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:ETH", "relevance_score": "0.003408", "ticker_sentiment_score": "0.047333", "ticker_sentiment_label": "Neutral"}]}, {"title": "Novavax's updated Covid vaccine can still catch up to Pfizer, Moderna shots this fall", "url": "https://www.cnbc.com/2023/10/07/novavax-covid-vaccine-can-still-catch-up-to-pfizer-moderna-shots.html", "time_published": "20231007T120002", "authors": ["Annika Kim Constantino"], "summary": "Novavax's Covid shot is arriving nearly three weeks after new jabs from Pfizer and Moderna reached Americans - but analysts aren't worried about that delay.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107034325-1647902082944-gettyimages-1239402283-prvk0657.jpeg?v=1696680001&w=1920&h=1080", "source": "CNBC", "category_within_source": "Business", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": -0.019117, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.199584", "ticker_sentiment_score": "0.008055", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.199584", "ticker_sentiment_score": "0.008055", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVAX", "relevance_score": "0.231963", "ticker_sentiment_score": "0.077371", "ticker_sentiment_label": "Neutral"}]}, {"title": "These 2 Top Stocks Are Screaming Buys Right Now", "url": "https://www.fool.com/investing/2023/10/07/these-2-top-stocks-are-screaming-buys-right-now/", "time_published": "20231007T100000", "authors": ["Adria Cimino"], "summary": "These stocks are dirt cheap today.", "banner_image": "https://media.ycharts.com/charts/2478566d1a0a9c11c930613d29d9d77d.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.858979"}, {"topic": "Earnings", "relevance_score": "0.99737"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.156458, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.60415", "ticker_sentiment_score": "0.290381", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "QEBR", "relevance_score": "0.056407", "ticker_sentiment_score": "0.024075", "ticker_sentiment_label": "Neutral"}, {"ticker": "DOCS", "relevance_score": "0.563609", "ticker_sentiment_score": "0.169044", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "This Could be Novavax's Big Opportunity", "url": "https://www.fool.com/investing/2023/10/07/this-could-be-novavaxs-big-opportunity/", "time_published": "20231007T093000", "authors": ["Adria Cimino"], "summary": "Novavax has lagged behind bigger rivals in the vaccine market.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.796627"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.263049, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.361626", "ticker_sentiment_score": "0.224074", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.361626", "ticker_sentiment_score": "0.224074", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVAX", "relevance_score": "0.652756", "ticker_sentiment_score": "0.459863", "ticker_sentiment_label": "Bullish"}]}, {"title": "Alexandria  ( ARE )  Receives Rating Affirmation From Moody's", "url": "https://www.zacks.com/stock/news/2161407/alexandria-are-receives-rating-affirmation-from-moodys", "time_published": "20231006T115000", "authors": ["Zacks Equity Research"], "summary": "Underpinning Alexandria's (ARE) solid operating and financial performance, Moody's Investors Service reaffirms the company's credit ratings of Baa1 and maintains its outlook rating at stable.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/24/28006.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Real Estate & Construction", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.334992, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MCO", "relevance_score": "0.053749", "ticker_sentiment_score": "0.111107", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPGI", "relevance_score": "0.053749", "ticker_sentiment_score": "0.44203", "ticker_sentiment_label": "Bullish"}, {"ticker": "COLD", "relevance_score": "0.107255", "ticker_sentiment_score": "0.040034", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARE", "relevance_score": "0.053749", "ticker_sentiment_score": "0.111107", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.107255", "ticker_sentiment_score": "0.055202", "ticker_sentiment_label": "Neutral"}, {"ticker": "WELL", "relevance_score": "0.107255", "ticker_sentiment_score": "0.040034", "ticker_sentiment_label": "Neutral"}]}, {"title": "Who are the 2023 Nobel Prize winners so far?", "url": "https://www.aljazeera.com/news/2023/10/6/who-are-the-2023-nobel-prize-winners-so-far", "time_published": "20231006T114105", "authors": ["Al Jazeera"], "summary": "This year's laureates have opened doors for disease control, technological advancements and subversive literature. This week marks the announcement of Nobel Prizes for 2023. The six prizes recognise individuals and groups for their contributions to particular fields.", "banner_image": "https://www.aljazeera.com/wp-content/uploads/2023/10/33XC9TA-highres-1696328111.jpg?w=770&resize=770%2C492", "source": "Al Jareeza", "category_within_source": "n/a", "source_domain": "www.aljazeera.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.382283, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.09402", "ticker_sentiment_score": "0.056373", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.09402", "ticker_sentiment_score": "0.056373", "ticker_sentiment_label": "Neutral"}]}, {"title": "Did Moderna Just Jump Ahead of Rivals in a Potential Billion-Dollar Market?", "url": "https://www.fool.com/investing/2023/10/06/did-moderna-just-jump-ahead-of-rivals/", "time_published": "20231006T100000", "authors": ["Adria Cimino"], "summary": "Moderna, Pfizer, and Novavax all are working on combined vaccine candidates.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.161647"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.161434, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.644603", "ticker_sentiment_score": "0.229062", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.381255", "ticker_sentiment_score": "0.183085", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVAX", "relevance_score": "0.277748", "ticker_sentiment_score": "0.154353", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "2 Nasdaq 100 Stocks That Are Surefire Buys in October, and 1 to Avoid Like the Plague", "url": "https://www.fool.com/investing/2023/10/06/2-nasdaq-100-stocks-buy-and-1-to-avoid-like-plague/", "time_published": "20231006T092100", "authors": ["Sean Williams"], "summary": "Two Nasdaq 100 components stand out as plain-as-day values, while another widely owned Nasdaq 100 stock may find it impossible to meet investors' lofty growth expectations.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F749471%2Fstock-chart-crash-correction-plunge-bounce-bear-market-bar-trend-invest-crypto-getty.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.503496"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.614606"}], "overall_sentiment_score": 0.138799, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVDA", "relevance_score": "0.286528", "ticker_sentiment_score": "0.015214", "ticker_sentiment_label": "Neutral"}, {"ticker": "SBUX", "relevance_score": "0.313726", "ticker_sentiment_score": "0.233114", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.116772", "ticker_sentiment_score": "0.064897", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMD", "relevance_score": "0.029292", "ticker_sentiment_score": "-0.035711", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.029292", "ticker_sentiment_score": "0.133784", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.029292", "ticker_sentiment_score": "0.133784", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.029292", "ticker_sentiment_score": "0.133784", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSM", "relevance_score": "0.029292", "ticker_sentiment_score": "0.007708", "ticker_sentiment_label": "Neutral"}]}, {"title": "The Zacks Analyst Blog Highlights Novavax, ALX Oncology, Regeneron Pharmaceuticals, Intellia and Moderna", "url": "https://www.zacks.com/stock/news/2161291/the-zacks-analyst-blog-highlights-novavax-alx-oncology-regeneron-pharmaceuticals-intellia-and-moderna", "time_published": "20231006T085900", "authors": ["Zacks Investment Research"], "summary": "Novavax, ALX Oncology, Regeneron Pharmaceuticals, Intellia and Moderna are included in this Analyst Blog.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/6f/3484.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.155556, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NVAX", "relevance_score": "0.195182", "ticker_sentiment_score": "0.058056", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALXO", "relevance_score": "0.233183", "ticker_sentiment_score": "0.104583", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.27063", "ticker_sentiment_score": "0.091829", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.11787", "ticker_sentiment_score": "0.004529", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTLA", "relevance_score": "0.11787", "ticker_sentiment_score": "0.004529", "ticker_sentiment_label": "Neutral"}]}, {"title": "Small Biotech Promosome Drops Lawsuit Against Pfizer, BioNTech in COVID-19 Vaccine Patent Dispute - Moderna  ( NASDAQ:MRNA ) , Pfizer  ( NYSE:PFE ) ", "url": "https://www.benzinga.com/general/biotech/23/10/35114073/small-biotech-promosome-drops-lawsuit-against-pfizer-biontech-in-covid-19-vaccine-patent-dispute", "time_published": "20231005T190432", "authors": ["Vandana Singh"], "summary": "Biotech firm Promosome has agreed to end the lawsuit, which accused the COVID-19 vaccine manufacturers, Pfizer Inc PFE and BioNTech SE BNTX, of patent infringement related to messenger RNA technology. However, the financial terms of the agreement were not disclosed.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/05/pfizer-biontech_covid-19_vaccine_2020_g.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.061357, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ABUS", "relevance_score": "0.31282", "ticker_sentiment_score": "-0.491947", "ticker_sentiment_label": "Bearish"}, {"ticker": "MRNA", "relevance_score": "0.685927", "ticker_sentiment_score": "0.305051", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.841282", "ticker_sentiment_score": "-0.210998", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "BNTX", "relevance_score": "0.892763", "ticker_sentiment_score": "-0.165473", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Bioprocess Validation Market Size Set to Grow at 6.5% CAGR, With Focus on Filter Elements Segment, Says Straits Research", "url": "https://www.benzinga.com/pressreleases/23/10/g35110924/bioprocess-validation-market-size-set-to-grow-at-6-5-cagr-with-focus-on-filter-elements-segment-sa", "time_published": "20231005T150000", "authors": ["Globe Newswire"], "summary": "New York, United States, Oct. 05, 2023 ( GLOBE NEWSWIRE ) -- Bioprocess validation comprises several activities that occur throughout the bioproduct manufacturing cycle. An essential component of bioprocess validation is the evaluation of active medicinal components and other possible ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.236844, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PVARF", "relevance_score": "0.042346", "ticker_sentiment_score": "0.132043", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.042346", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.042346", "ticker_sentiment_score": "0.150135", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DHR", "relevance_score": "0.042346", "ticker_sentiment_score": "0.147571", "ticker_sentiment_label": "Neutral"}, {"ticker": "TMO", "relevance_score": "0.126561", "ticker_sentiment_score": "0.17159", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Biotech Stock Roundup: NVAX Up on Updates, ALXO Gains on Study Data & More", "url": "https://www.zacks.com/stock/news/2160940/biotech-stock-roundup-nvax-up-on-updates-alxo-gains-on-study-data-more", "time_published": "20231005T145800", "authors": ["Zacks Equity Research"], "summary": "Regulatory and pipeline updates from Novavax (NVAX) and ALX Oncology Holdings (ALXO) are in focus in the biotech sector.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default313.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.162562, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NVAX", "relevance_score": "0.167904", "ticker_sentiment_score": "0.079946", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALXO", "relevance_score": "0.209004", "ticker_sentiment_score": "0.132684", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.249531", "ticker_sentiment_score": "0.120357", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.084423", "ticker_sentiment_score": "0.008282", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTLA", "relevance_score": "0.084423", "ticker_sentiment_score": "0.008282", "ticker_sentiment_label": "Neutral"}]}, {"title": "Moderna  ( MRNA )  to Advance COVID/Flu Combo Jab to Late-Stage Study", "url": "https://www.zacks.com/stock/news/2160900/moderna-mrna-to-advance-covidflu-combo-jab-to-late-stage-study", "time_published": "20231005T142100", "authors": ["Zacks Equity Research"], "summary": "Moderna's (MRNA) intends to start the late-stage study on its COVID-19-influenza combination vaccine candidate before year-end. A commercial launch is expected in 2025.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/8a/2449.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.075305, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.676525", "ticker_sentiment_score": "0.041235", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVAX", "relevance_score": "0.295867", "ticker_sentiment_score": "0.080362", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.180236", "ticker_sentiment_score": "0.101225", "ticker_sentiment_label": "Neutral"}]}, {"title": "The 2023 Nobel prizes honour work that touched millions of lives", "url": "https://www.economist.com/science-and-technology/2023/10/05/the-2023-nobel-prizes-honour-work-that-touched-millions-of-lives", "time_published": "20231005T124755", "authors": ["The Economist"], "summary": "T which award the Nobel prizes are hard to second-guess. Last year, for instance, the prize in physiology or medicine went to Svante Paabo, a pioneer of the study of fossil , which has shed much light on human evolution. A worthy winner.", "banner_image": "https://www.economist.com/cdn-cgi/image/width=1424,quality=80,format=auto/content-assets/images/20231007_STD002.jpg", "source": "The Economist", "category_within_source": "BusinessGoogleRSS", "source_domain": "www.economist.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.130079, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.024372", "ticker_sentiment_score": "0.053705", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.024372", "ticker_sentiment_score": "0.053705", "ticker_sentiment_label": "Neutral"}]}, {"title": "Can Moderna Achieve Its Most Ambitious Goal Yet?", "url": "https://www.fool.com/investing/2023/10/05/can-moderna-achieve-its-most-ambitious-goal-yet/", "time_published": "20231005T093000", "authors": ["Adria Cimino"], "summary": "Even the best of news has failed to boost Moderna shares in recent times.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.214378"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.156879, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.694664", "ticker_sentiment_score": "0.163116", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.054483", "ticker_sentiment_score": "0.044999", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Novavax Stock Fell Today - Novavax  ( NASDAQ:NVAX ) ", "url": "https://www.benzinga.com/news/23/10/35095052/why-novavax-stock-fell-today", "time_published": "20231004T232224", "authors": ["Ryan Gustafson"], "summary": "Novavax, Inc. NVAX shares are trading lower Wednesday amid a pullback in the stock, which gained Tuesday after the FDA granted Emergency Use Authorization for the company's updated protein-based COVID-19 vaccine for people 12 and older.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/04/medical-5835701_12803.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.116073, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVAX", "relevance_score": "0.854693", "ticker_sentiment_score": "0.340811", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.439786", "ticker_sentiment_score": "-0.152461", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PFE", "relevance_score": "0.439786", "ticker_sentiment_score": "-0.152461", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "BNTX", "relevance_score": "0.439786", "ticker_sentiment_score": "-0.152461", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Moderna  ( MRNA )  Surpasses Market Returns: Some Facts Worth Knowing", "url": "https://www.zacks.com/stock/news/2160346/moderna-mrna-surpasses-market-returns-some-facts-worth-knowing", "time_published": "20231004T215018", "authors": ["Zacks Equity Research"], "summary": "In the latest trading session, Moderna (MRNA) closed at $104.26, marking a +1.14% move from the previous day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default77.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.905476"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.115346, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.473208", "ticker_sentiment_score": "0.199639", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Moderna's flu-Covid combo vaccine elicits 'strong' immune response in Phase 1/2 study, company says", "url": "https://www.cnn.com/2023/10/04/health/moderna-flu-covid-vaccine-trial-results/index.html", "time_published": "20231004T165342", "authors": ["Jacqueline Howard"], "summary": "In a Phase 1/2 clinical trial, Moderna's combination vaccine appeared to elicit \"strong\" immune responses against both influenza and Covid-19 and was found to be safe, the company announced Wednesday.", "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/230918182825-covid-19-vaccination-vs-flu-rates.jpg?c=16x9&q=h_144,w_256,c_fill", "source": "CNN", "category_within_source": "Markets", "source_domain": "www.cnn.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.099118, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "WBD", "relevance_score": "0.132368", "ticker_sentiment_score": "0.008478", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVAX", "relevance_score": "0.066414", "ticker_sentiment_score": "-0.019143", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.261117", "ticker_sentiment_score": "-0.038715", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.066414", "ticker_sentiment_score": "-0.019143", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.066414", "ticker_sentiment_score": "-0.019143", "ticker_sentiment_label": "Neutral"}]}, {"title": "Mainz Biomed Continues To Transform Early Cancer Detection Across The Globe - Pfizer, Inc. Common Stock  ( NYSE:PFE ) ", "url": "https://www.benzinga.com/markets/penny-stocks/23/10/35093169/mainz-biomed-continues-to-transform-early-cancer-detection-across-the-globe", "time_published": "20231004T161021", "authors": ["Upwallstreet"], "summary": "While Pfizer Inc PFE and Moderna Inc MRNA are making great progress in cancer treatments, the importance of early detection in combating this disease cannot be overstated.", "banner_image": "https://cdn.benzinga.com/files/3d-medical-background-with-male-figure-with-brain-dna-strands.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": -0.090152, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SGEN", "relevance_score": "0.095138", "ticker_sentiment_score": "-0.153524", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MRNA", "relevance_score": "0.188928", "ticker_sentiment_score": "0.0369", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.526707", "ticker_sentiment_score": "-0.251526", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ERAS", "relevance_score": "0.095138", "ticker_sentiment_score": "-0.153524", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Novavax  ( NVAX )  Up 8% on FDA Nod for Updated COVID Booster Jab", "url": "https://www.zacks.com/stock/news/2160224/novavax-nvax-up-8-on-fda-nod-for-updated-covid-booster-jab", "time_published": "20231004T151900", "authors": ["Zacks Equity Research"], "summary": "Novavax's (NVAX) updated COVID vaccine is authorized under emergency use for individuals aged 12 years and older. It is currently the only non-mRNA COVID vaccine available in the country.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/8a/2449.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.132301, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVAX", "relevance_score": "0.682689", "ticker_sentiment_score": "0.212091", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.28387", "ticker_sentiment_score": "0.070099", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.350564", "ticker_sentiment_score": "0.114288", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.28387", "ticker_sentiment_score": "0.070099", "ticker_sentiment_label": "Neutral"}]}, {"title": "Teva Hooks Immunology Powerhouse Sanofi In $1.5 Billion Deal", "url": "https://www.investors.com/news/technology/teva-stock-dives-after-inking-deal-for-inflammation-drug/", "time_published": "20231004T144700", "authors": ["Investor's Business Daily", "ALLISON GATLIN"], "summary": "Teva Stock Dives After Inking $1.5 Billion Deal For Inflammation Drug Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2022/07/Stock-tevapharmaceuticals-01-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.996023"}], "overall_sentiment_score": 0.190416, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NVAX", "relevance_score": "0.049732", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.049732", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.099271", "ticker_sentiment_score": "0.11034", "ticker_sentiment_label": "Neutral"}, {"ticker": "ROIV", "relevance_score": "0.099271", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.148426", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.382193", "ticker_sentiment_score": "0.176752", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Moderna reports positive results for combination flu and COVID vaccine", "url": "https://www.marketwatch.com/story/moderna-reports-positive-results-for-combination-flu-and-covid-vaccine-de6cb204", "time_published": "20231004T143100", "authors": ["Ciara Linnane"], "summary": "Moderna Inc. announced positive interim results from a Phase 1/2 trial of its combination vaccine against COVID-19 and flu on Wednesday.", "banner_image": "https://images.mktw.net/im-862510/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.031409, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVAX", "relevance_score": "0.348103", "ticker_sentiment_score": "0.283887", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.501398", "ticker_sentiment_score": "0.133756", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.264897", "ticker_sentiment_score": "0.215505", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BNTX", "relevance_score": "0.178459", "ticker_sentiment_score": "0.129354", "ticker_sentiment_label": "Neutral"}]}, {"title": "Cancer Drug Maker 3D Medicines Inc. Trading Higher After Company Announces It Will Repurchase Up To 10% Of Outstanding Shares - Novartis  ( NYSE:NVS ) ", "url": "https://www.benzinga.com/markets/penny-stocks/23/10/35089590/cancer-drug-maker-3d-medicines-inc-trading-higher-after-company-announces-it-will-repurchase", "time_published": "20231004T134903", "authors": ["Daniel Harrison"], "summary": "3D Medicines Inc. was trading 7.2% higher in the Hong Kong Wednesday morning session at HK$5.53 after the company announced that it is buying back up to 10% of its own stock. 3D Pharma said in a statement that it would buy back up to 25,605,700 shares over the next 12 months.", "banner_image": "https://cdn.benzinga.com/files/logo-3.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.977154"}], "overall_sentiment_score": 0.156683, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NVS", "relevance_score": "0.220809", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.220809", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.220809", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.220809", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "What's Going On With Moderna Stock Wednesday? - Moderna  ( NASDAQ:MRNA ) ", "url": "https://www.benzinga.com/news/23/10/35088350/whats-going-on-with-moderna-stock-wednesday", "time_published": "20231004T132710", "authors": ["Adam Eckert"], "summary": "Moderna, Inc MRNA shares are trading higher Wednesday. The company announced positive data from its combination vaccine against influenza and Covid-19. What To Know: Moderna highlighted positive interim results from its Phase 1/2 trial of mRNA-1083, the company's investigational vaccine for the ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/04/vaccine-6557409_1920.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.266935, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.866386", "ticker_sentiment_score": "0.527698", "ticker_sentiment_label": "Bullish"}, {"ticker": "NVAX", "relevance_score": "0.29234", "ticker_sentiment_score": "0.240058", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Alexandria  ( ARE )  Expedites Delivery of Moderna's New HQ", "url": "https://www.zacks.com/stock/news/2160086/alexandria-are-expedites-delivery-of-modernas-new-hq", "time_published": "20231004T131400", "authors": ["Zacks Equity Research"], "summary": "Alexandria (ARE) to hand over the new global headquarters and core R&D operations center to Moderna in November 2023. ARE will benefit from the project's incremental annual net operating income.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/d6/2257.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Real Estate & Construction", "relevance_score": "0.5"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.327975, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "COLD", "relevance_score": "0.109705", "ticker_sentiment_score": "0.040376", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARE", "relevance_score": "0.109705", "ticker_sentiment_score": "0.122342", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.217346", "ticker_sentiment_score": "0.354088", "ticker_sentiment_label": "Bullish"}, {"ticker": "WELL", "relevance_score": "0.109705", "ticker_sentiment_score": "0.040376", "ticker_sentiment_label": "Neutral"}]}, {"title": "Wall Street Says Ginkgo Bioworks Stock Will Soar 132%, and Cathie Wood's Buying It. Should You?", "url": "https://www.fool.com/investing/2023/10/04/wall-street-says-ginkgo-bioworks-stock-will-soar/", "time_published": "20231004T130000", "authors": ["Alex Carchidi"], "summary": "It's not a stock for the faint of heart, but its ambitious vision might pay off.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.108179"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}], "overall_sentiment_score": 0.217901, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.057628", "ticker_sentiment_score": "0.157051", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DNA", "relevance_score": "0.171688", "ticker_sentiment_score": "0.158552", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVO", "relevance_score": "0.057628", "ticker_sentiment_score": "0.157051", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.057628", "ticker_sentiment_score": "0.157051", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Stocks making the biggest moves premarket: Cal-Maine Foods, Intel, Apple & more", "url": "https://www.cnbc.com/2023/10/04/stocks-making-the-biggest-moves-premarket-calm-intc-aapl.html", "time_published": "20231004T120045", "authors": ["Pia Singh"], "summary": "These are the stocks posting the largest moves in premarket trading.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107186187-1675118446665-gettyimages-1246677564-INTEL_EARNS.jpeg?v=1696420845&w=1920&h=1080", "source": "CNBC", "category_within_source": "Market Insider", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Real Estate & Construction", "relevance_score": "0.2"}], "overall_sentiment_score": 0.278228, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CALM", "relevance_score": "0.109956", "ticker_sentiment_score": "-0.128727", "ticker_sentiment_label": "Neutral"}, {"ticker": "NOVA", "relevance_score": "0.109956", "ticker_sentiment_score": "0.298692", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RUN", "relevance_score": "0.217834", "ticker_sentiment_score": "0.434455", "ticker_sentiment_label": "Bullish"}, {"ticker": "BAC", "relevance_score": "0.109956", "ticker_sentiment_score": "0.257612", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.321673", "ticker_sentiment_score": "0.400554", "ticker_sentiment_label": "Bullish"}, {"ticker": "FLR", "relevance_score": "0.217834", "ticker_sentiment_score": "0.434455", "ticker_sentiment_label": "Bullish"}]}, {"title": "PM360 Announces 2023 Trailblazer Award Winners", "url": "https://www.prnewswire.com/news-releases/pm360-announces-2023-trailblazer-award-winners-301943290.html", "time_published": "20231004T120000", "authors": ["PM360"], "summary": "Top Companies, Marketers, CEOs, Products, and Initiatives Were Honored During Gala on October 3rd NEW YORK, Oct. 4, 2023 /PRNewswire/ -- Last night at a gala event held at Gotham Hall in New York City, PM360 announced the winners of its 15th annual Trailblazer Awards.", "banner_image": "https://mma.prnewswire.com/media/545940/PM360_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.316548, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "TVTX", "relevance_score": "0.020615", "ticker_sentiment_score": "0.337018", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "OPRX", "relevance_score": "0.020615", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MAYNF", "relevance_score": "0.020615", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.082322", "ticker_sentiment_score": "0.061158", "ticker_sentiment_label": "Neutral"}, {"ticker": "NBIX", "relevance_score": "0.020615", "ticker_sentiment_score": "0.257102", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SYNH", "relevance_score": "0.020615", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DVAX", "relevance_score": "0.020615", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TARS", "relevance_score": "0.020615", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CDNA", "relevance_score": "0.020615", "ticker_sentiment_score": "-0.068139", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRTX", "relevance_score": "0.020615", "ticker_sentiment_score": "-0.253155", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PFE", "relevance_score": "0.020615", "ticker_sentiment_score": "0.305846", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BMY", "relevance_score": "0.020615", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.041216", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.020615", "ticker_sentiment_score": "-0.292847", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "SSUMF", "relevance_score": "0.020615", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CHRS", "relevance_score": "0.041216", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARGX", "relevance_score": "0.06179", "ticker_sentiment_score": "0.097016", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.020615", "ticker_sentiment_score": "0.20635", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNY", "relevance_score": "0.020615", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Moderna combo COVID-19/flu vaccine succeeds in early-stage trial", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/moderna-combo-covid-19flu-vaccine-succeeds-early-stage-trial-2023-10-04/", "time_published": "20231004T110200", "authors": ["Patrick Wingrove"], "summary": "Syringes with needles are seen in front of a displayed Moderna logo in this illustration taken, November 27, 2021. REUTERS/Dado Ruvic/Illustration/File Photo Acquire Licensing Rights", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/VXGDVMVOKVKCTH5ETBRFOUZTZI.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.007286, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.660192", "ticker_sentiment_score": "0.030237", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.108466", "ticker_sentiment_score": "-0.175241", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Moderna combination Covid, flu vaccine moves to final stage trial after positive data", "url": "https://www.cnbc.com/2023/10/04/moderna-combination-covid-flu-vaccine-shows-positive-data.html", "time_published": "20231004T110001", "authors": ["Annika Kim Constantino"], "summary": "Moderna and other vaccine makers like Pfizer believe combination shots will simplify what people can do to protect themselves against Covid, RSV and the flu.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107261603-1687528289059-gettyimages-1237672961-widak-covid19s220112_npv5n.jpeg?v=1696417201&w=1920&h=1080", "source": "CNBC", "category_within_source": "Top News", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.153616, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.546745", "ticker_sentiment_score": "0.20843", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.235823", "ticker_sentiment_score": "0.046774", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.119235", "ticker_sentiment_score": "-0.072112", "ticker_sentiment_label": "Neutral"}]}, {"title": "Trump's SPAC Partner Digital World, Novavax, Palantir, And Tesla: Why These Stocks Are Trending Today? - Tesla  ( NASDAQ:TSLA ) , Digital World Acq  ( NASDAQ:DWAC ) , Novavax  ( NASDAQ:NVAX ) , Palantir Technologies  ( NYSE:PLTR ) ", "url": "https://www.benzinga.com/markets/equities/23/10/35077102/trumps-spac-partner-digital-world-novavax-palantir-and-tesla-why-these-stocks-are-trending-today", "time_published": "20231004T014750", "authors": ["Benzinga Neuro"], "summary": "U.S. stocks experienced a downturn, with significant losses noted toward the end of trading. The S&P 500 fell approximately 1.4%, echoing the performance of the Dow and the NASDAQ, which declined by 1.3% and 1.9% respectively.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/Stocks_Photo_by_Phongphan_on_Shutterstock_12.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": -0.048564, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "TSLA", "relevance_score": "0.235823", "ticker_sentiment_score": "-0.159706", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "DWAC", "relevance_score": "0.235823", "ticker_sentiment_score": "0.016566", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVAX", "relevance_score": "0.235823", "ticker_sentiment_score": "-0.057469", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.119235", "ticker_sentiment_score": "-0.036585", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.119235", "ticker_sentiment_score": "-0.036585", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.119235", "ticker_sentiment_score": "-0.036585", "ticker_sentiment_label": "Neutral"}, {"ticker": "PLTR", "relevance_score": "0.235823", "ticker_sentiment_score": "-0.118734", "ticker_sentiment_label": "Neutral"}]}, {"title": "Researcher Demoted By University Of Pennsylvania Wins Nobel Prize For mRNA Discoveries-And Some Academics Urge Penn To Apologize", "url": "https://www.forbes.com/sites/conormurray/2023/10/03/researcher-demoted-by-university-of-pennsylvania-wins-nobel-prize-for-mrna-discoveries-and-some-academics-urge-penn-to-apologize/", "time_published": "20231003T204621", "authors": ["Conor Murray"], "summary": "Katalin Karik\u00f3's research laid the foundation for both the Pfizer/BioNTech and Moderna Covid-19 vaccines.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/651c7d49c173582924f04fec/0x0.jpg?format=jpg&crop=2805,1578,x157,y33,safe&width=1200", "source": "Forbes", "category_within_source": "Business", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.019616, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "WBD", "relevance_score": "0.082535", "ticker_sentiment_score": "0.177743", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.041323", "ticker_sentiment_score": "0.107063", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.082535", "ticker_sentiment_score": "0.036569", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.244109", "ticker_sentiment_score": "0.005811", "ticker_sentiment_label": "Neutral"}]}, {"title": "Novavax Surges After FDA Signs Off On Its Updated Covid Shot", "url": "https://www.investors.com/news/technology/nvax-stock-surges-after-fda-signs-off-on-its-updated-covid-shot/", "time_published": "20231003T203600", "authors": ["ALLISON GATLIN", "Investor's Business Daily"], "summary": "The Food and Drug Administration signed off on Novavax's ( NVAX ) updated Covid booster late Tuesday, and NVAX stock surged just before the close. Novavax expects doses to be available \"at thousands of locations\" in the coming days. Specifically, the agency signed off on Novavax's shot for ...", "banner_image": "https://www.investors.com/wp-content/uploads/2022/06/Stock-novavaxbottles-01-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}], "overall_sentiment_score": 0.189994, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NVAX", "relevance_score": "0.645516", "ticker_sentiment_score": "0.186202", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.541149", "ticker_sentiment_score": "0.291898", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.421485", "ticker_sentiment_score": "0.256592", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BNTX", "relevance_score": "0.421485", "ticker_sentiment_score": "0.256592", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "US adds another option for fall COVID vaccination with updated Novavax shots", "url": "https://apnews.com/article/covid19-vaccine-novavax-ffba40058fe64d6a6a32cfdb760e2043", "time_published": "20231003T200100", "authors": ["LAURAN NEERGAARD"], "summary": "WASHINGTON ( AP ) - U.S. regulators on Tuesday authorized another option for fall COVID-19 vaccination, updated shots made by Novavax. began rolling out last month, intended for adults and children as young as age 6 months.", "banner_image": "https://dims.apnews.com/dims4/default/ab9dfdb/2147483647/strip/true/crop/4357x2902+423+0/resize/599x399!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2F35%2F0c%2Fab3896a0bd3016f9f9e2881ce1f8%2Fb9189293e05647478feb7a1c94d9568b", "source": "Associated Press", "category_within_source": "Markets", "source_domain": "apnews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": -0.009711, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "HHH", "relevance_score": "0.140896", "ticker_sentiment_score": "0.204993", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVAX", "relevance_score": "0.522333", "ticker_sentiment_score": "-0.019488", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.140896", "ticker_sentiment_score": "-0.287248", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PFE", "relevance_score": "0.140896", "ticker_sentiment_score": "-0.287248", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Novavax updated COVID vaccine gets FDA approval", "url": "https://www.marketwatch.com/story/novavax-updated-covid-vaccine-gets-fda-approval-68b4c1b5", "time_published": "20231003T193200", "authors": ["Eleanor Laise"], "summary": "Stock jumps 12% on regulatory approval of new shot ...", "banner_image": "https://images.mktw.net/im-852408/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.246204, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NVAX", "relevance_score": "0.882924", "ticker_sentiment_score": "0.393272", "ticker_sentiment_label": "Bullish"}, {"ticker": "MRNA", "relevance_score": "0.498188", "ticker_sentiment_score": "0.352971", "ticker_sentiment_label": "Bullish"}, {"ticker": "PFE", "relevance_score": "0.498188", "ticker_sentiment_score": "0.352971", "ticker_sentiment_label": "Bullish"}, {"ticker": "BNTX", "relevance_score": "0.345674", "ticker_sentiment_score": "0.26659", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Novavax Stock Soars On FDA Clearance For Updated Covid-19 Shot: What's Going On? - Novavax  ( NASDAQ:NVAX ) ", "url": "https://www.benzinga.com/news/23/10/35071468/novavax-stock-soars-on-fda-clearance-for-updated-covid-19-shot-whats-going-on", "time_published": "20231003T191737", "authors": ["Adam Eckert"], "summary": "Novavax Inc NVAX shares are surging Tuesday afternoon after the U.S. Food and Drug Administration ( FDA ) granted Emergency Use Authorization for the company's Covid-19 vaccine, Adjuvanted ( 2023-2024 Formula ) to prevent Covid in individuals aged 12 and older.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/03/50769671858_714d78d113_k.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.075622, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVAX", "relevance_score": "0.762438", "ticker_sentiment_score": "0.329894", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.363388", "ticker_sentiment_score": "0.140284", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.363388", "ticker_sentiment_score": "0.140284", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.363388", "ticker_sentiment_score": "0.140284", "ticker_sentiment_label": "Neutral"}]}, {"title": "US FDA authorizes Novavax's updated COVID shot", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-authorizes-novavaxs-updated-covid-shot-2023-10-03/", "time_published": "20231003T184700", "authors": ["Reuters"], "summary": "A vial labelled \"Novavax COVID-19 Vaccine\" is seen in this illustration taken January 16, 2022. REUTERS/Dado Ruvic/Illustration/File Photo Acquire Licensing Rights Oct 3 ( Reuters ) - The U.S.", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/BSYGKPNE5ZPRXH2OTG23T4DSYI.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.052987, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVAX", "relevance_score": "0.279015", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.279015", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.279015", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.279015", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "FDA authorizes updated Novavax Covid vaccine as Pfizer, Moderna shots roll out in U.S.", "url": "https://www.cnbc.com/2023/10/03/fda-approves-novavax-updated-covid-vaccine.html", "time_published": "20231003T184449", "authors": ["Annika Kim Constantino"], "summary": "Health officials see Novavax's protein-based vaccine as a valuable alternative for people who don't want to take messenger RNA shots from Pfizer and Moderna.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107290093-16927148072022-01-16t000000z_1335663153_rc2i0s9llhii_rtrmadp_0_health-coronavirus-vaccine.jpeg?v=1696358689&w=1920&h=1080", "source": "CNBC", "category_within_source": "Business", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.04055, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.268589", "ticker_sentiment_score": "0.004059", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.216376", "ticker_sentiment_score": "-0.025415", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVAX", "relevance_score": "0.369163", "ticker_sentiment_score": "0.051811", "ticker_sentiment_label": "Neutral"}]}, {"title": "Walgreens resolves COVID-19 vaccine supply after appointment challenges", "url": "https://www.foxbusiness.com/lifestyle/walgreens-covid-19-vaccine-supply-appointment-availability-challenges", "time_published": "20231003T155044", "authors": ["Angelica Stabile"], "summary": "Walgreens is adjusting its COVID-19 vaccine availability in response to ongoing appointment disruptions, a company spokesperson told Fox News Digital. Customers on social media have reported numerous vaccine appointment cancellations at Walgreens locations.", "banner_image": "https://cf-images.us-east-1.prod.boltdns.net/v1/static/854081161001/10f4d13b-24e7-46b4-b62b-630ef1971c26/7f54aa13-e402-4157-88a1-576180d5806f/1280x720/match/image.jpg", "source": "Fox Business News", "category_within_source": "n/a", "source_domain": "www.foxbusiness.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.036129, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.157483", "ticker_sentiment_score": "0.079654", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOX", "relevance_score": "0.380591", "ticker_sentiment_score": "0.082783", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.157483", "ticker_sentiment_score": "0.079654", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is Pfizer Stock a Buy Now?", "url": "https://www.fool.com/investing/2023/10/03/is-pfizer-stock-a-buy-now/", "time_published": "20231003T100000", "authors": ["Adria Cimino"], "summary": "Pfizer shares have dropped 35% this year.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999956"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.062417, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BHVN", "relevance_score": "0.04794", "ticker_sentiment_score": "0.09495", "ticker_sentiment_label": "Neutral"}, {"ticker": "TRMNF", "relevance_score": "0.04794", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGEN", "relevance_score": "0.04794", "ticker_sentiment_score": "0.09495", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.04794", "ticker_sentiment_score": "-0.040764", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.770793", "ticker_sentiment_score": "0.115427", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Top Biotech Stocks to Buy in October", "url": "https://www.fool.com/investing/2023/10/03/2-top-biotech-stocks-to-buy-in-october/", "time_published": "20231003T093000", "authors": ["Adria Cimino"], "summary": "Growth catalysts lie ahead for both of these players.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.684621"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}], "overall_sentiment_score": 0.314084, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.173333", "ticker_sentiment_score": "0.17143", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.058188", "ticker_sentiment_score": "0.174", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JAZZ", "relevance_score": "0.058188", "ticker_sentiment_score": "0.014064", "ticker_sentiment_label": "Neutral"}, {"ticker": "AXSM", "relevance_score": "0.173333", "ticker_sentiment_score": "0.118718", "ticker_sentiment_label": "Neutral"}]}, {"title": "The Zacks Analyst Blog Highlights Intel, Anheuser-Busch InBev, HCA Healthcare, Moderna and DuPont de Nemours", "url": "https://www.zacks.com/stock/news/2158986/the-zacks-analyst-blog-highlights-intel-anheuser-busch-inbev-hca-healthcare-moderna-and-dupont-de-nemours", "time_published": "20231003T085800", "authors": ["Zacks Investment Research"], "summary": "Intel, Anheuser-Busch InBev, HCA Healthcare, Moderna and DuPont de Nemours are included in this Analyst Blog.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e5/419.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.495866"}], "overall_sentiment_score": 0.168495, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BUD", "relevance_score": "0.214937", "ticker_sentiment_score": "0.053829", "ticker_sentiment_label": "Neutral"}, {"ticker": "DD", "relevance_score": "0.144275", "ticker_sentiment_score": "0.040745", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSEM", "relevance_score": "0.072435", "ticker_sentiment_score": "0.180525", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.144275", "ticker_sentiment_score": "0.040745", "ticker_sentiment_label": "Neutral"}, {"ticker": "INTC", "relevance_score": "0.28387", "ticker_sentiment_score": "0.147064", "ticker_sentiment_label": "Neutral"}, {"ticker": "HCA", "relevance_score": "0.350564", "ticker_sentiment_score": "0.248583", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Bill Gates Applauds Nobel Laureates Katalin Kariko And Drew Weissman Behind Revolutionary mRNA COVID-19 Vaccines", "url": "https://www.benzinga.com/general/biotech/23/10/35044448/bill-gates-applauds-nobel-laureates-katalin-kariko-and-drew-weissman-behind-revolutionary-mrna-co", "time_published": "20231003T031743", "authors": ["Benzinga Neuro"], "summary": "Tech visionary Bill Gates commended the groundbreaking work of Nobel Prize laureates Katalin Kariko and Drew Weissman, whose research on mRNA has revolutionized vaccine development against COVID-19. What Happened: Gates took to X, formerly Twitter, to acknowledge the work of scientists Kariko and ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/Bill_Gates_Photo_by_Frederic_Legrand_-_COMEO_on_Shutterstock_16.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.498862, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "SSTK", "relevance_score": "0.132368", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.132368", "ticker_sentiment_score": "0.141415", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.132368", "ticker_sentiment_score": "0.141415", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.132368", "ticker_sentiment_score": "0.141415", "ticker_sentiment_label": "Neutral"}]}, {"title": "A Nobel prize in physiology for mRNA vaccines", "url": "https://www.economist.com/science-and-technology/2023/10/02/a-nobel-prize-in-physiology-for-mrna-vaccines", "time_published": "20231002T160950", "authors": ["The Economist"], "summary": "T which award the Nobel science prizes ( chemistry, physics and physiology or medicine ) are hard to second-guess. Last year, for instance, the physiology prize went to Svante Paabo, who helped invent the field of fossil , and then used that invention to shed copious light on human evolution.", "banner_image": "https://www.economist.com/img/b/1280/720/90/media-assets/image/20231007_STP501.jpg", "source": "The Economist", "category_within_source": "BusinessGoogleRSS", "source_domain": "www.economist.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.088564, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.066414", "ticker_sentiment_score": "0.009059", "ticker_sentiment_label": "Neutral"}]}, {"title": "What is the Nobel Prize and what to expect this year?", "url": "https://www.aljazeera.com/news/2023/10/2/what-is-the-nobel-prize-and-what-to-expect-this-year", "time_published": "20231002T140050", "authors": ["Al Jazeera"], "summary": "There are 351 nominees for the Nobel Peace Prize this year. The Nobel Prizes are slated to be announced this week with the first award in medicine or physiology won by Hungary's Katalin Kariko and Drew Weissman of the United States on Monday.", "banner_image": "https://www.aljazeera.com/wp-content/uploads/2021/10/INTERACTIVE-Nobel-Prize-Categories.png?w=770&resize=770%2C770", "source": "Al Jareeza", "category_within_source": "n/a", "source_domain": "www.aljazeera.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.498024, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.065685", "ticker_sentiment_score": "0.091406", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.065685", "ticker_sentiment_score": "0.091406", "ticker_sentiment_label": "Neutral"}]}, {"title": "Have The Bulls Returned? Get Prepared For October And Q4 With Markets With Mando! - Apple  ( NASDAQ:AAPL ) ", "url": "https://www.benzinga.com/23/10/35031884/have-the-bulls-returned-get-prepared-for-october-and-q4-with-markets-with-mando", "time_published": "20231002T134024", "authors": ["Mando Trading"], "summary": "Take a screen shot of wherever you are reading this article, whether it is on Benzinga, Webull or TOS, and tag @Mandotrading and @Benzinga in a tweet with the screenshot for a FREE membership to my daily newsletter, Markets with Mando! Low set last week?", "banner_image": "https://cdn.benzinga.com/files/hans-eiskonen-wn57csq7vzi-unsplash_6.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.614606"}], "overall_sentiment_score": 0.205432, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.215894", "ticker_sentiment_score": "0.308557", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GOOG", "relevance_score": "0.108958", "ticker_sentiment_score": "0.004653", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:USD", "relevance_score": "0.108958", "ticker_sentiment_score": "0.156583", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Nobel Prize Honors Scientists Behind mRNA Vaccines Against Covid-19 - Moderna  ( NASDAQ:MRNA ) , Pfizer  ( NYSE:PFE ) , BioNTech  ( NASDAQ:BNTX ) ", "url": "https://www.benzinga.com/general/biotech/23/10/35030546/nobel-prize-honors-scientists-behind-mrna-vaccines-against-covid-19", "time_published": "20231002T125551", "authors": ["Piero Cingari"], "summary": "The Nobel Assembly has awarded two scientists with the Nobel Prize in medicine for their pioneering work in the development of messenger-RNA ( mRNA ) vaccines against Covid-19. The research of Katalin Kariko and Drew Weissman paved the way for companies like Moderna Inc. MRNA and the Pfizer ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/covid_vaccine_shutter.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.09973, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.381463", "ticker_sentiment_score": "0.118337", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.291182", "ticker_sentiment_score": "0.167754", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BNTX", "relevance_score": "0.19661", "ticker_sentiment_score": "-0.004695", "ticker_sentiment_label": "Neutral"}]}, {"title": "Flagship Pioneering Appoints John Lepore as CEO-Partner and CEO of ProFound Therapeutics - PR Newswire", "url": "https://www.prnewswire.com/news-releases/flagship-pioneering-appoints-john-lepore-as-ceo-partner-and-ceo-of-profound-therapeutics-301943851.html", "time_published": "20231002T110000", "authors": [], "summary": "Flagship Pioneering Appoints John Lepore as CEO-Partner and CEO of ProFound Therapeutics PR ...", "banner_image": null, "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.385477, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "MCRB", "relevance_score": "0.079524", "ticker_sentiment_score": "0.137324", "ticker_sentiment_label": "Neutral"}, {"ticker": "FHTX", "relevance_score": "0.079524", "ticker_sentiment_score": "0.137324", "ticker_sentiment_label": "Neutral"}, {"ticker": "DNLI", "relevance_score": "0.079524", "ticker_sentiment_score": "0.137324", "ticker_sentiment_label": "Neutral"}, {"ticker": "SANA", "relevance_score": "0.079524", "ticker_sentiment_score": "0.137324", "ticker_sentiment_label": "Neutral"}, {"ticker": "HHH", "relevance_score": "0.039811", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.079524", "ticker_sentiment_score": "0.137324", "ticker_sentiment_label": "Neutral"}, {"ticker": "OMGA", "relevance_score": "0.079524", "ticker_sentiment_score": "0.137324", "ticker_sentiment_label": "Neutral"}]}, {"title": "Katalin Kariko, Scientific Maverick Who Paved Way For MRNA Vaccines", "url": "https://www.barrons.com/news/katalin-kariko-scientific-maverick-who-paved-way-for-mrna-vaccines-bfd9daaa", "time_published": "20231002T104600", "authors": ["Issam AHMED"], "summary": "Hungarian-born scientist Katalin Kariko's obsession with researching a substance called mRNA to fight disease once cost her a faculty position at a prestigious US university, which dismissed the idea as a dead end.", "banner_image": "https://www.barrons.com/asset/external-media/afp/AFP1019411260184049259926265123363646674092---2.jpg", "source": "Barrons", "category_within_source": "n/a", "source_domain": "www.barrons.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.134942, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LRLCF", "relevance_score": "0.064276", "ticker_sentiment_score": "0.494761", "ticker_sentiment_label": "Bullish"}, {"ticker": "MRNA", "relevance_score": "0.128135", "ticker_sentiment_score": "0.143825", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.128135", "ticker_sentiment_score": "0.143825", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.128135", "ticker_sentiment_score": "0.143825", "ticker_sentiment_label": "Neutral"}]}, {"title": "Nobel Prize Given To Researchers Behind mRNA Tech In Covid Vaccines", "url": "https://www.forbes.com/sites/siladityaray/2023/10/02/nobel-prize-given-to-researchers-behind-mrna-tech-in-covid-vaccines/", "time_published": "20231002T101828", "authors": ["Siladitya Ray"], "summary": "The mRNA technology was used to rapidly develop and deploy two effective vaccines that offered protection against the Covid-19 pandemic.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/651a98c624fd0435e9e8f2e1/0x0.jpg?format=jpg&crop=2849,1602,x0,y79,safe&width=1200", "source": "Forbes", "category_within_source": "Business", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.365197, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.345674", "ticker_sentiment_score": "0.416413", "ticker_sentiment_label": "Bullish"}, {"ticker": "PFE", "relevance_score": "0.345674", "ticker_sentiment_score": "0.416413", "ticker_sentiment_label": "Bullish"}, {"ticker": "BNTX", "relevance_score": "0.345674", "ticker_sentiment_score": "0.416413", "ticker_sentiment_label": "Bullish"}]}, {"title": "Nobel Prize Goes To MRNA Covid Vaccine Researchers", "url": "https://www.barrons.com/news/nobel-prize-goes-to-mrna-covid-vaccine-researchers-c65535aa", "time_published": "20231002T101300", "authors": ["Pia OHLIN"], "summary": "Katalin Kariko and Drew Weissman won the Nobel Medicine Prize on Monday for work on messenger RNA ( mRNA ) technology that paved the way for groundbreaking Covid-19 vaccines.", "banner_image": "https://asset.barrons.com/barrons/images/afp-metadata-default.jpg", "source": "Barrons", "category_within_source": "n/a", "source_domain": "www.barrons.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.129753, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.12645", "ticker_sentiment_score": "0.11007", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.12645", "ticker_sentiment_score": "0.11007", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.12645", "ticker_sentiment_score": "0.11007", "ticker_sentiment_label": "Neutral"}]}, {"title": "Katalin Kariko, Drew Weissman win Nobel Prize in medicine", "url": "https://www.aljazeera.com/news/2023/10/2/katalin-kariko-drew-weissman-win-nobel-prize-in-medicine", "time_published": "20231002T095214", "authors": ["Al Jazeera"], "summary": "The duo win the prestigious prize for the research that led directly to the first mRNA vaccines to fight COVID-19.", "banner_image": "https://www.aljazeera.com/wp-content/uploads/2020/09/breaking-news@2x.png?resize=770%2C513&quality=80", "source": "Al Jareeza", "category_within_source": "n/a", "source_domain": "www.aljazeera.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.514631, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.570165", "ticker_sentiment_score": "0.55758", "ticker_sentiment_label": "Bullish"}, {"ticker": "PFE", "relevance_score": "0.570165", "ticker_sentiment_score": "0.55758", "ticker_sentiment_label": "Bullish"}]}, {"title": "Nobel Prize in medicine goes to Katalin Karik\u00f3 and Drew Weissman for work on mRNA Covid-19 vaccines", "url": "https://www.cnn.com/2023/10/02/europe/nobel-prize-medicine-mrna-covid-vaccines-2023-intl-scn/index.html", "time_published": "20231002T094823", "authors": ["Christian Edwards"], "summary": "This year's Nobel Prize in physiology or medicine has been awarded to Katalin Karik\u00f3 and Drew Weissman for their work on mRNA vaccines, which were crucial in curtailing the spread of Covid-19.", "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/231002105813-01-nobel-prize-100223-medicine.jpg?c=16x9&q=h_720,w_1280,c_fill", "source": "CNN", "category_within_source": "Markets", "source_domain": "www.cnn.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.203084, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.096671", "ticker_sentiment_score": "0.088414", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.096671", "ticker_sentiment_score": "0.088414", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.096671", "ticker_sentiment_score": "0.088414", "ticker_sentiment_label": "Neutral"}]}, {"title": "Narcolepsy, Cancer Tipped As Medicine Prize Opens Nobel Week", "url": "https://www.barrons.com/news/narcolepsy-cancer-tipped-as-medicine-prize-opens-nobel-week-f8055e7", "time_published": "20231002T030300", "authors": ["Pia OHLIN"], "summary": "Narcolepsy, cancer or mRNA vaccine research could win the Nobel Medicine Prize on Monday when a week of announcements kick off, but experts see no clear frontrunner for the Peace Prize.", "banner_image": "https://www.barrons.com/asset/external-media/afp/AFP8963777796403504504795877984148914798790---1.jpg", "source": "Barrons", "category_within_source": "n/a", "source_domain": "www.barrons.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.248539, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CLVT", "relevance_score": "0.051221", "ticker_sentiment_score": "-0.073993", "ticker_sentiment_label": "Neutral"}, {"ticker": "DTST", "relevance_score": "0.051221", "ticker_sentiment_score": "0.143038", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.051221", "ticker_sentiment_score": "0.057999", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSSMY", "relevance_score": "0.051221", "ticker_sentiment_score": "0.283673", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.051221", "ticker_sentiment_score": "0.057999", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Revolutionary Stocks I'd Buy Right Now Without Hesitation", "url": "https://www.fool.com/investing/2023/10/01/3-revolutionary-stocks-id-buy-right-now-without-he/", "time_published": "20231002T020700", "authors": ["Prosper Junior Bakiny"], "summary": "These companies are helping change medicine. they could make boatloads of money along the way.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.325233, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.09239", "ticker_sentiment_score": "0.086438", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABT", "relevance_score": "0.228287", "ticker_sentiment_score": "0.373606", "ticker_sentiment_label": "Bullish"}, {"ticker": "MRNA", "relevance_score": "0.272282", "ticker_sentiment_score": "0.123322", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.046273", "ticker_sentiment_score": "0.292442", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Billie Jean King intends to 'live better' as she heads into her 80s. Her plan includes weightlifting and plenty of tennis.", "url": "https://africa.businessinsider.com/health/billie-jean-king-intends-to-live-better-as-she-heads-into-her-80s-her-plan-includes/798bcn8.amp", "time_published": "20230930T125302", "authors": ["Meredith Cash"], "summary": "The gloomy day we connect on Zoom from 65 blocks apart in New York City is the same day King and her wife - fellow former tennis pro Ilana Kloss - are moving. Amidst the chaos of packing boxes and transporting furniture, she's trying to squeeze in a trip to get the latest COVID-19 booster.", "banner_image": "https://ocdn.eu/pulscms-transforms/1/acUktkuTURBXy83NDI2NjVhMC04Y2QwLTQ5NjYtYjIwZS0zY2JlNmE1N2FiZGQuanBlZ5GTBc0EsM0Cdg", "source": "Business Insider", "category_within_source": "GoogleRSS", "source_domain": "africa.businessinsider.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.282769, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.087503", "ticker_sentiment_score": "0.143264", "ticker_sentiment_label": "Neutral"}]}, {"title": "Moderna's Shares Could Take Off if These 2 Things Happen", "url": "https://www.fool.com/investing/2023/09/30/moderna-could-rise-if-these-2-things-happen/", "time_published": "20230930T100000", "authors": ["Adria Cimino"], "summary": "Moderna stock soared early in the pandemic.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.918141"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.990999"}], "overall_sentiment_score": 0.231424, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.655824", "ticker_sentiment_score": "0.349618", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.160633", "ticker_sentiment_score": "0.173537", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Here's Why You Should Consider Moderna Stock, and No, It's Not the COVID Vaccine", "url": "https://www.fool.com/investing/2023/09/30/heres-why-you-should-consider-moderna-stock-and-no/", "time_published": "20230930T093000", "authors": ["Jeff Santoro"], "summary": "The COVID-19 vaccine put Moderna on the map, but its pipeline is going to be what keeps it there.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999612"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.064365, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.673371", "ticker_sentiment_score": "0.060061", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.06515", "ticker_sentiment_score": "0.114691", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.06515", "ticker_sentiment_score": "0.114691", "ticker_sentiment_label": "Neutral"}]}, {"title": "One family of flu viruses hasn't been seen since 2020. WHO says it can be left out of future flu vaccines", "url": "https://www.cnn.com/2023/09/29/health/who-flu-vaccine-recommendation-2024/index.html", "time_published": "20230929T225500", "authors": ["Jamie Gumbrecht"], "summary": "When the World Health Organization recommended on Friday which influenza viruses to target in vaccines for next year, it removed a family of viruses that hasn't been seen since the early days of the Covid-19 pandemic. Is it a cold, flu or Covid-19? A doctor helps sort it out", "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/230927134712-cold-symptoms-stock.jpg?c=16x9&q=h_144,w_256,c_fill", "source": "CNN", "category_within_source": "Markets", "source_domain": "www.cnn.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.127092, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.066414", "ticker_sentiment_score": "0.222888", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WBD", "relevance_score": "0.066414", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Around 1.8 mln Americans received COVID shots last week -IQVIA", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/around-18-mln-americans-received-covid-shots-last-week-iqvia-2023-09-29/", "time_published": "20230929T195821", "authors": ["Michael Erman"], "summary": "Around 1.8 mln Americans received COVID shots last ...", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/GPVLY7LBLBMADHGN6YAABQ6O7Q.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.049562, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.137671", "ticker_sentiment_score": "-0.056619", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.137671", "ticker_sentiment_score": "-0.056619", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.137671", "ticker_sentiment_score": "-0.056619", "ticker_sentiment_label": "Neutral"}, {"ticker": "IQV", "relevance_score": "0.137671", "ticker_sentiment_score": "0.109971", "ticker_sentiment_label": "Neutral"}]}, {"title": "If I Could Only Buy 3 Stocks in 2023, I'd Pick These", "url": "https://www.fool.com/investing/2023/09/29/if-i-could-only-buy-3-stocks-in-2023-id-pick-these/", "time_published": "20230929T093000", "authors": ["Adria Cimino"], "summary": "These stocks have what it takes to grow in leaps and bounds.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Earnings", "relevance_score": "0.614606"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.274502, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DTST", "relevance_score": "0.055236", "ticker_sentiment_score": "0.166315", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TRMNF", "relevance_score": "0.055236", "ticker_sentiment_score": "0.345008", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.372315", "ticker_sentiment_score": "0.092944", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.420608", "ticker_sentiment_score": "0.412865", "ticker_sentiment_label": "Bullish"}]}, {"title": "From Mexico, a Caped Crusader Who Wrestled Like No Woman Before Her", "url": "https://www.nytimes.com/2023/09/29/movies/the-batwoman-maura-monti.html", "time_published": "20230929T090152", "authors": ["Nicolas Rapold"], "summary": "Maura Monti Remembers 'The Batwoman' The New York Times ...", "banner_image": "https://static01.nyt.com/images/2023/10/01/multimedia/01BATWOMAN-cfzt/01BATWOMAN-cfzt-articleLarge.jpg?quality=75&auto=webp&disable=upscale", "source": "New York Times", "category_within_source": "GoogleRSS", "source_domain": "www.nytimes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.222568, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.03448", "ticker_sentiment_score": "0.129073", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is it Time to Buy Pfizer, Moderna, or AstraZeneca's Stock?", "url": "https://www.zacks.com/stock/news/2157418/is-it-time-to-buy-pfizer-moderna-or-astrazenecas-stock", "time_published": "20230929T021300", "authors": ["Shaun Pruitt"], "summary": "Despite slowing COVID-19 vaccine sales these healthcare titans are trading at more reasonable valuations with a lot of the risk-to-reward being priced into their stocks considering their earnings potential.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default8.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.995921"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.990999"}], "overall_sentiment_score": 0.150959, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.369163", "ticker_sentiment_score": "0.149301", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.268589", "ticker_sentiment_score": "0.205987", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.268589", "ticker_sentiment_score": "0.024587", "ticker_sentiment_label": "Neutral"}]}, {"title": "Moderna  ( MRNA )  Outpaces Stock Market Gains: What You Should Know", "url": "https://www.zacks.com/stock/news/2157344/moderna-mrna-outpaces-stock-market-gains-what-you-should-know", "time_published": "20230928T215019", "authors": ["Zacks Equity Research"], "summary": "In the latest trading session, Moderna (MRNA) closed at $100.27, marking a +0.83% move from the previous day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default16.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.905476"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.150351, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.502693", "ticker_sentiment_score": "0.283729", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "What to know as fall vaccinations against COVID, flu and RSV get underway", "url": "https://apnews.com/article/vaccines-flu-covid19-rsv-viruses-fall-8ffa6bf0c2c0da1a8842db524aad5006", "time_published": "20230928T210200", "authors": ["LAURAN NEERGAARD"], "summary": "WASHINGTON ( AP ) - Updated may be getting a little easier for adults to find but they're still frustratingly scarce for young children. Health officials said Thursday the kid shots have started shipping - and reminded most everyone to get a fall flu shot too.", "banner_image": "https://dims.apnews.com/dims4/default/5e15441/2147483647/strip/true/crop/4171x2778+0+1/resize/599x399!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2F93%2F1f%2F012c38962005406e5ddb72505b60%2F96701a07a16d4b69bc8f9db397fbde09", "source": "Associated Press", "category_within_source": "Markets", "source_domain": "apnews.com", "topics": [{"topic": "Real Estate & Construction", "relevance_score": "0.333333"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}], "overall_sentiment_score": -0.070067, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CVS", "relevance_score": "0.036365", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "HHC", "relevance_score": "0.036365", "ticker_sentiment_score": "0.161419", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.036365", "ticker_sentiment_score": "-0.05016", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.036365", "ticker_sentiment_score": "0.047182", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.072655", "ticker_sentiment_score": "-0.002031", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.036365", "ticker_sentiment_score": "0.047182", "ticker_sentiment_label": "Neutral"}]}, {"title": "Check Out What Whales Are Doing With MRNA - Moderna  ( NASDAQ:MRNA ) ", "url": "https://www.benzinga.com/markets/options/23/09/34982282/check-out-what-whales-are-doing-with-mrna", "time_published": "20230928T163256", "authors": ["Benzinga Insights"], "summary": "A whale with a lot of money to spend has taken a noticeably bullish stance on Moderna. Looking at options history for Moderna MRNA we detected 10 strange trades. If we consider the specifics of each trade, it is accurate to state that 50% of the investors opened trades with bullish expectations ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.147874, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.846873", "ticker_sentiment_score": "0.375716", "ticker_sentiment_label": "Bullish"}]}, {"title": "Covid-19 Vaccine Uptake Could Beat Expectations, Poll Indicates", "url": "https://www.barrons.com/articles/covid-19-vaccine-uptake-moderna-pfizer-ffc99e30", "time_published": "20230928T152300", "authors": ["Josh Nathan-Kazis"], "summary": "Nearly half of U.S. adults say they plan to get a Covid-19 shot this year, according to a poll from the healthcare policy research group KFF, suggesting more demand than expected.", "banner_image": "https://images.barrons.com/im-07497264?width=639&height=426", "source": "Barrons", "category_within_source": "n/a", "source_domain": "www.barrons.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.023883, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.293214", "ticker_sentiment_score": "0.052112", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.293214", "ticker_sentiment_score": "0.052112", "ticker_sentiment_label": "Neutral"}]}, {"title": "The Anti-obesity Drug Market Is About to Get More Crowded", "url": "https://www.thedailyupside.com/industries/the-anti-obesity-drug-market-is-about-to-get-more-crowded/", "time_published": "20230928T143133", "authors": ["Griffin Kelly"], "summary": "Obesity is an epidemic that affects more than 40% of all American adults, and it's creating a feeding frenzy for investors. With the rise of...", "banner_image": null, "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.thedailyupside.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.004809, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.091162", "ticker_sentiment_score": "-0.078458", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.091162", "ticker_sentiment_score": "-0.02647", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.181137", "ticker_sentiment_score": "-0.109422", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.091162", "ticker_sentiment_score": "-0.078458", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biotech Stock Roundup: ICPT Up on Buyout Deal, IMVT & PLRX Gain on Study Data", "url": "https://www.zacks.com/stock/news/2157170/biotech-stock-roundup-icpt-up-on-buyout-deal-imvt-plrx-gain-on-study-data", "time_published": "20230928T135800", "authors": ["Zacks Equity Research"], "summary": "Acquisition news from Intercept (ICPT) and study updates from Immunovant (IMVT) are in focus in the biotech sector.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default180.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.121319, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "IMVT", "relevance_score": "0.30658", "ticker_sentiment_score": "-0.036433", "ticker_sentiment_label": "Neutral"}, {"ticker": "IONS", "relevance_score": "0.062843", "ticker_sentiment_score": "-0.008022", "ticker_sentiment_label": "Neutral"}, {"ticker": "ICPT", "relevance_score": "0.062843", "ticker_sentiment_score": "0.039005", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.062843", "ticker_sentiment_score": "-0.043289", "ticker_sentiment_label": "Neutral"}, {"ticker": "SLNO", "relevance_score": "0.062843", "ticker_sentiment_score": "0.055146", "ticker_sentiment_label": "Neutral"}, {"ticker": "PLRX", "relevance_score": "0.062843", "ticker_sentiment_score": "0.136086", "ticker_sentiment_label": "Neutral"}]}, {"title": "A weekend in Stockholm: travel guide, things to do, food and drink", "url": "https://theweek.com/83310/style-with-a-smile-a-guide-to-stockholm-sweden", "time_published": "20230928T061618", "authors": ["The Week Staff"], "summary": "Sweden's \"capital of cool\" is a vibrant city, sprinkled across 14 islands which feature many historical and cultural sites, and an endless selection of bustling restaurants and bars. Distinctive neighbourhoods include the old town, Gamla Stan, with its lamp-lit cobbles.", "banner_image": "https://cdn.mos.cms.futurecdn.net/vLcPULyi3ETe9kcoWdrc5h-415-80.jpg", "source": "The Week News", "category_within_source": "n/a", "source_domain": "theweek.com", "topics": [{"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.305394, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NYT", "relevance_score": "0.032646", "ticker_sentiment_score": "0.057746", "ticker_sentiment_label": "Neutral"}, {"ticker": "FRNWF", "relevance_score": "0.032646", "ticker_sentiment_score": "0.055228", "ticker_sentiment_label": "Neutral"}, {"ticker": "UAL", "relevance_score": "0.032646", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "RCL", "relevance_score": "0.032646", "ticker_sentiment_score": "0.112657", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.032646", "ticker_sentiment_score": "0.142028", "ticker_sentiment_label": "Neutral"}]}, {"title": "Mainz Biomed To Present The Power Of mRNA That Promises To Revolutionize Medicine - Pfizer  ( NYSE:PFE ) ", "url": "https://www.benzinga.com/markets/penny-stocks/23/09/34953715/mainz-biomed-to-present-the-power-of-mrna-that-promises-to-revolutionize-medicine", "time_published": "20230927T154300", "authors": ["Upwallstreet"], "summary": "Pharma companies across the globe, including Pfizer Inc PFE and Moderna Inc MRNA, are harnessing the potential of mRNA which is creating plenty of space for scientific improvement in the fight against pathogens. The world learned about messenger RNA molecules and their flexibility, speed and ...", "banner_image": "https://cdn.benzinga.com/files/3d-male-figure-sprinting-pose-abstract-low-poly-background.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": -0.039343, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.394125", "ticker_sentiment_score": "-0.111795", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.231884", "ticker_sentiment_score": "-0.074778", "ticker_sentiment_label": "Neutral"}]}, {"title": "As Covid Infections Rise, Nursing Homes Are Still Waiting for Vaccines", "url": "https://www.nytimes.com/2023/09/27/health/nursing-homes-covid-vaccines.html", "time_published": "20230927T143010", "authors": ["Tony Leys", "Jordan Rau"], "summary": "Now that the U.S. government has stepped back from issuing vaccines, long-term care operators have yet to start administering shots to protect one of the most vulnerable populations.", "banner_image": "https://static01.nyt.com/images/2023/09/26/multimedia/00NH-VACCINES-01-tgmq/00NH-VACCINES-01-tgmq-articleLarge.jpg?quality=75&auto=webp&disable=upscale", "source": "New York Times", "category_within_source": "Business", "source_domain": "www.nytimes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.038362, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.023304", "ticker_sentiment_score": "-0.060542", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.023304", "ticker_sentiment_score": "-0.060542", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVAX", "relevance_score": "0.046588", "ticker_sentiment_score": "-0.077837", "ticker_sentiment_label": "Neutral"}]}, {"title": "Top Stories Wednesday, Sep 27: Apple Defends Its $19B Google Search Deal, Hollywood's Writers Secure Credit For AI Training, China's Ambitious Chip Fund Faces Headwinds - Alibaba Gr Holding  ( NYSE:BABA ) ", "url": "https://www.benzinga.com/news/23/09/34949379/apple-defends-its-19b-google-search-deal-hollywoods-writers-secure-credit-for-ai-training-chinas-amb", "time_published": "20230927T134747", "authors": ["Vandana Singh"], "summary": "Alibaba Group Holding Limited BABA stock is trading higher Wednesday as the company's logistics arm Cainiao Smart Logistics Network Ltd filed for its Hong Kong initial public offering on Tuesday. The first-time share sale could fetch a minimum of $1 billion.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/27/google_search_iphone.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.148277, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BABA", "relevance_score": "0.111144", "ticker_sentiment_score": "0.095986", "ticker_sentiment_label": "Neutral"}, {"ticker": "NFLX", "relevance_score": "0.07423", "ticker_sentiment_score": "0.159668", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TGT", "relevance_score": "0.07423", "ticker_sentiment_score": "0.077628", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.184176", "ticker_sentiment_score": "0.084378", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.111144", "ticker_sentiment_score": "0.025411", "ticker_sentiment_label": "Neutral"}, {"ticker": "PARA", "relevance_score": "0.07423", "ticker_sentiment_score": "0.159668", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JPM", "relevance_score": "0.07423", "ticker_sentiment_score": "0.07364", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.07423", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TRI", "relevance_score": "0.111144", "ticker_sentiment_score": "0.053298", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.07423", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSM", "relevance_score": "0.07423", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SSNLF", "relevance_score": "0.07423", "ticker_sentiment_score": "-0.051384", "ticker_sentiment_label": "Neutral"}, {"ticker": "WMG", "relevance_score": "0.07423", "ticker_sentiment_score": "0.273503", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.07423", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PAYX", "relevance_score": "0.111144", "ticker_sentiment_score": "0.070338", "ticker_sentiment_label": "Neutral"}, {"ticker": "QCOM", "relevance_score": "0.147818", "ticker_sentiment_score": "-0.038811", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.147818", "ticker_sentiment_score": "0.067619", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.07423", "ticker_sentiment_score": "0.083661", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.07423", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Moderna Talks Offer Hope for Enhanced COVID-19 Vaccine Availability In Europe - Moderna  ( NASDAQ:MRNA ) ", "url": "https://www.benzinga.com/general/biotech/23/09/34909329/moderna-talks-offer-hope-for-enhanced-covid-19-vaccine-availability-in-europe", "time_published": "20230926T163143", "authors": ["Vandana Singh"], "summary": "European countries are actively negotiating a fresh COVID-19 vaccine procurement agreement with Moderna Inc MRNA as concerns mount within EU health authorities regarding a surge in coronavirus infections.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/26/moderna_covid-19_vaccine_2021_g.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.203445, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.582526", "ticker_sentiment_score": "0.374832", "ticker_sentiment_label": "Bullish"}, {"ticker": "PFE", "relevance_score": "0.31482", "ticker_sentiment_score": "0.029786", "ticker_sentiment_label": "Neutral"}]}, {"title": "Wall St poised for weak open as rate worries keep Treasury yields elevated", "url": "https://www.reuters.com/markets/us/futures-drop-rate-concerns-keep-treasury-yields-elevated-2023-09-26/", "time_published": "20230926T124500", "authors": ["Ankika Biswas", "Shashwat Chauhan"], "summary": "Traders work on the floor of the New York Stock Exchange ( NYSE ) in New York City, U.S., July 26, 2023. REUTERS/Brendan McDermid/File Photo Acquire Licensing Rights", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/53MM6GUWAZKTPOGQBAMIOEKYL4.jpg", "source": "Reuters", "category_within_source": "Markets", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.838487"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.918141"}, {"topic": "Manufacturing", "relevance_score": "0.25"}], "overall_sentiment_score": -0.045539, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.070517", "ticker_sentiment_score": "0.014291", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.070517", "ticker_sentiment_score": "0.014291", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.070517", "ticker_sentiment_score": "0.014291", "ticker_sentiment_label": "Neutral"}, {"ticker": "MCO", "relevance_score": "0.070517", "ticker_sentiment_score": "-0.081373", "ticker_sentiment_label": "Neutral"}, {"ticker": "SIRI", "relevance_score": "0.070517", "ticker_sentiment_score": "0.186212", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GS", "relevance_score": "0.070517", "ticker_sentiment_score": "-0.069813", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.070517", "ticker_sentiment_score": "0.094447", "ticker_sentiment_label": "Neutral"}, {"ticker": "ROIV", "relevance_score": "0.070517", "ticker_sentiment_score": "0.091428", "ticker_sentiment_label": "Neutral"}]}, {"title": "EU in talks with Moderna over new deal for COVID vaccines - FT", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/eu-talks-with-moderna-over-new-covid-vaccine-deal-ft-2023-09-26/", "time_published": "20230926T123300", "authors": ["Reuters"], "summary": "EU in talks with Moderna over new COVID vaccine deal - FT ...", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/G45V5XDC7ZL6LPFYPPXB6XZLSM.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.130113, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.366061", "ticker_sentiment_score": "0.100672", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.249106", "ticker_sentiment_score": "-0.058677", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.126119", "ticker_sentiment_score": "-0.055113", "ticker_sentiment_label": "Neutral"}]}, {"title": "Conspiracy theories about FEMA's Oct. 4 emergency alert test spread online", "url": "https://apnews.com/article/fact-check-fema-test-graphene-oxide-covid-vaccine-517946413392", "time_published": "20230925T184700", "authors": ["Philip Marcelo"], "summary": "CLAIM: An emergency broadcast system test on Oct. 4 will send a signal to cell phones nationwide in order to activate nanoparticles such as graphene oxide that have been introduced into people's bodies. AP'S ASSESSMENT: False.", "banner_image": "https://dims.apnews.com/dims4/default/21a6cc0/2147483647/strip/true/crop/3457x2303+6+0/resize/599x399!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2F4f%2Ff8%2F353a5712c9a1f0de4e92a12a4281%2F1d066b7954ea4bf6b1beacedd27de5d5", "source": "Associated Press", "category_within_source": "Markets", "source_domain": "apnews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.104404, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.042876", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.042876", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.042876", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Buying These 2 Remarkable Growth Stocks in Any Market Could Be a Genius Move", "url": "https://www.fool.com/investing/2023/09/25/buying-2-remarkable-growth-stocks-in-market/", "time_published": "20230925T162241", "authors": ["Rachel Warren"], "summary": "Great companies haven't gone anywhere.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.918141"}, {"topic": "Earnings", "relevance_score": "0.929393"}], "overall_sentiment_score": 0.228135, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CHWY", "relevance_score": "0.403088", "ticker_sentiment_score": "0.280723", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.038345", "ticker_sentiment_score": "0.056599", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.227007", "ticker_sentiment_score": "0.15098", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "How to Find Strong Medical Stocks Slated for Positive Earnings Surprises", "url": "https://www.zacks.com/stock/news/2154737/how-to-find-strong-medical-stocks-slated-for-positive-earnings-surprises", "time_published": "20230925T125006", "authors": ["Zacks Equity Research"], "summary": "Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default2.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}, {"topic": "Earnings", "relevance_score": "0.999756"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.364983, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.269776", "ticker_sentiment_score": "0.309143", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CNC", "relevance_score": "0.395012", "ticker_sentiment_score": "0.460432", "ticker_sentiment_label": "Bullish"}]}, {"title": "Cidade Wenling, no leste da China: um \"le\u00e3o brilhante\" galopando no caminho da moderniza\u00e7\u00e3o chinesa", "url": "https://www.prnewswire.com/news-releases/cidade-wenling-no-leste-da-china-um-leao-brilhante-galopando-no-caminho-da-modernizacao-chinesa-849830262.html", "time_published": "20230923T010500", "authors": ["The People's Government of Wenling Municipality"], "summary": "Em 2022, o PIB de Wenling ultrapassou os 130 mil milh\u00f5es de yuans, tornando-a uma das mais de 50 cidades chinesas que fazem parte do seleto grupo cujo PIB ultrapassou 100 bilh\u00f5es de yuans, de acordo com o Governo Popular do Munic\u00edpio de Wenling.", "banner_image": "https://mma.prnewswire.com/media/2218909/Wenling.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.044114, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.084127", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Moderna  ( MRNA )  Dips More Than Broader Markets: What You Should Know", "url": "https://www.zacks.com/stock/news/2154470/moderna-mrna-dips-more-than-broader-markets-what-you-should-know", "time_published": "20230922T215017", "authors": ["Zacks Equity Research"], "summary": "Moderna (MRNA) closed the most recent trading day at $99.99, moving -0.24% from the previous trading session.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default328.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.905476"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.127963, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.516656", "ticker_sentiment_score": "0.206843", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "As Covid-19 hospitalizations climb, rates among seniors and children raise concern", "url": "https://edition.cnn.com/2023/09/22/health/covid-hospitalizations-seniors-kids-vaccines/index.html", "time_published": "20230922T213400", "authors": ["Betsy Klein", "Deidre McPhillips", "Jamie Gumbrecht"], "summary": "Covid-19 hospitalizations have been on the rise in the United States for months, with weekly admissions now more than triple what they were two months ago. Seniors have the highest rates of Covid hospitalizations by far, but hospitalizations among children - especially among those younger than 5 ...", "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/230913133529-home-tests-false-negative.jpg?c=16x9&q=h_144,w_256,c_fill", "source": "CNN", "category_within_source": "Markets", "source_domain": "edition.cnn.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.062046, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.030759", "ticker_sentiment_score": "0.065068", "ticker_sentiment_label": "Neutral"}, {"ticker": "WBD", "relevance_score": "0.122581", "ticker_sentiment_score": "0.057868", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.030759", "ticker_sentiment_score": "0.065068", "ticker_sentiment_label": "Neutral"}]}, {"title": "As Covid-19 hospitalizations climb, rates among seniors and children raise concern", "url": "https://www.cnn.com/2023/09/22/health/covid-hospitalizations-seniors-kids-vaccines/index.html", "time_published": "20230922T213400", "authors": ["Jamie Gumbrecht", "Betsy Klein", "Deidre McPhillips"], "summary": "Covid-19 hospitalizations have been on the rise in the United States for months, with weekly admissions now more than triple what they were two months ago. Seniors have the highest rates of Covid hospitalizations by far, but hospitalizations among children - especially among those younger than 5 ...", "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/230913133529-home-tests-false-negative.jpg?c=16x9&q=h_144,w_256,c_fill", "source": "CNN", "category_within_source": "Markets", "source_domain": "www.cnn.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.062046, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.030759", "ticker_sentiment_score": "0.065068", "ticker_sentiment_label": "Neutral"}, {"ticker": "WBD", "relevance_score": "0.122581", "ticker_sentiment_score": "0.057868", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.030759", "ticker_sentiment_score": "0.065068", "ticker_sentiment_label": "Neutral"}]}, {"title": "WW International Shares Jump On BCBS Michigan's Revised Authorization For Wegovy, Other Weight Loss Drugs - WW International  ( NASDAQ:WW ) , Novo Nordisk  ( NYSE:NVO ) ", "url": "https://www.benzinga.com/general/biotech/23/09/34832242/ww-international-shares-jump-on-bcbs-michigans-revised-authorization-for-wegovy-other-weight-loss", "time_published": "20230922T202554", "authors": ["AJ Fabino"], "summary": "Shares of WW International Inc WW spiked as much as 15% on Friday after Blue Cross Blue Shield of Michigan and Blue Care Network announced changes to the prior authorization coverage criteria for certain brand-name weight loss medications.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/ww_international_shutter2.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": 0.185912, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "WW", "relevance_score": "0.233556", "ticker_sentiment_score": "0.156135", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVAX", "relevance_score": "0.07887", "ticker_sentiment_score": "0.065377", "ticker_sentiment_label": "Neutral"}, {"ticker": "KO", "relevance_score": "0.07887", "ticker_sentiment_score": "0.039876", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.07887", "ticker_sentiment_score": "0.065377", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.233556", "ticker_sentiment_score": "0.029235", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.07887", "ticker_sentiment_score": "0.065377", "ticker_sentiment_label": "Neutral"}]}, {"title": "New Covid Vaccine Rollout Is Slowed by Insurance and Supply Snags", "url": "https://www.nytimes.com/2023/09/22/well/covid-vaccine-booster-insurance.html", "time_published": "20230922T174931", "authors": ["Dani Blum"], "summary": "New Covid Vaccines Hit Insurance Snags: What to Do if Yours Gets Denied The New York Times ...", "banner_image": "https://static01.nyt.com/images/2023/09/21/multimedia/WELL-BOOSTER-INSURANCE1-mgbq/WELL-BOOSTER-INSURANCE1-mgbq-articleLarge.jpg?quality=75&auto=webp&disable=upscale", "source": "New York Times", "category_within_source": "GoogleRSS", "source_domain": "www.nytimes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}], "overall_sentiment_score": -0.023818, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CVS", "relevance_score": "0.187827", "ticker_sentiment_score": "-0.044179", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.047371", "ticker_sentiment_score": "0.147645", "ticker_sentiment_label": "Neutral"}, {"ticker": "RAD", "relevance_score": "0.047371", "ticker_sentiment_score": "-0.031858", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.047371", "ticker_sentiment_score": "0.147645", "ticker_sentiment_label": "Neutral"}]}, {"title": "We Can Finally Do Something About the Third 'Tripledemic' Virus", "url": "https://www.theatlantic.com/health/archive/2023/09/tripledemic-virus-rsv-vaccine/675417/", "time_published": "20230922T161108", "authors": ["Sarah Zhang"], "summary": "Every fall, when the air turns chilly and the leaves red, pediatric ICUs begin preparing for the onslaught of the virus known as RSV. Not flu, not COVID, but RSV, or respiratory syncytial virus, is the No. 1 reason babies are hospitalized, year after year.", "banner_image": "https://cdn.theatlantic.com/thumbor/lCKp76bDRrGXOlASeHqK9j7F2nc=/0x0:4800x2700/960x540/media/img/mt/2023/09/vax_copy2/original.jpg", "source": "The Atlantic", "category_within_source": "n/a", "source_domain": "www.theatlantic.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.0, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.056474", "ticker_sentiment_score": "-0.031015", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.028254", "ticker_sentiment_score": "0.11233", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.084622", "ticker_sentiment_score": "0.027121", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.028254", "ticker_sentiment_score": "0.11233", "ticker_sentiment_label": "Neutral"}]}, {"title": "Moderna Is Expecting Massive Growth Over the Next Decade. Is the Stock a No-Brainer Buy?", "url": "https://www.fool.com/investing/2023/09/22/moderna-is-expecting-massive-growth-over-the-next/", "time_published": "20230922T124500", "authors": ["David Jagielski"], "summary": "The stock has been struggling this year, but could things soon be getting brighter for Moderna?", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.929393"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.002444, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.601928", "ticker_sentiment_score": "0.003625", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.056143", "ticker_sentiment_score": "0.020025", "ticker_sentiment_label": "Neutral"}]}, {"title": "Merck and Eisai say two lung-cancer trials failed to meet their main goals", "url": "https://www.marketwatch.com/story/merck-and-eisai-say-two-lung-cancer-trials-failed-to-meet-their-main-goals-c5bc1935", "time_published": "20230922T113100", "authors": ["Ciara Linnane"], "summary": "Two late-stage trials of a treatment for a certain type of non-small lung cancer failed to meet their primary goals, the companies said Friday.", "banner_image": "https://images.mktw.net/im-766178/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.166492, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.126119", "ticker_sentiment_score": "-0.068827", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.126119", "ticker_sentiment_score": "-0.133386", "ticker_sentiment_label": "Neutral"}]}, {"title": "Providers struggle to get latest Covid shots into arms amid early supply issues", "url": "https://www.cnbc.com/2023/09/21/covid-vaccine-boosters-some-appointments-canceled-amid-supply-issues.html", "time_published": "20230921T213911", "authors": ["Angelica Peebles"], "summary": "Some Americans are having Covid vaccine appointments canceled or finding a pharmacy doesn't have a shot for them, as the U.S. tries an unprecedented rollout.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107303642-1695217220302-gettyimages-1666316328-1348234-me-0914-new-covid-vaccine-016-ik.jpeg?v=1695333162&w=1920&h=1080", "source": "CNBC", "category_within_source": "Top News", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}], "overall_sentiment_score": 0.089705, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CVS", "relevance_score": "0.246167", "ticker_sentiment_score": "0.066635", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAH", "relevance_score": "0.083251", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.165598", "ticker_sentiment_score": "0.237827", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.083251", "ticker_sentiment_score": "0.180448", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WMT", "relevance_score": "0.083251", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Booking a COVID-19 vaccine? Some are reporting canceled appointments or insurance issues", "url": "https://apnews.com/article/covid-vaccine-delays-cdc-moderna-pfizer-ba66d06cbcc31ba4b22d60e93d3d5024", "time_published": "20230921T200700", "authors": ["DEVI SHASTRI"], "summary": "MILWAUKEE ( AP ) - Some people seeking the newest COVID-19 vaccine are running into high demand, insurance headaches and supply delays coast to coast. Millions of the have shipped out since the Centers for Disease Control and Prevention signed off on them last week for ages 6 months and up.", "banner_image": "https://dims.apnews.com/dims4/default/792e131/2147483647/strip/true/crop/5221x3478+0+1/resize/599x399!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2F3c%2Ffc%2F7206b6f5ade23415704173e5c7b6%2F8c745f6c03f94d2bbb5fbd75110c3633", "source": "Associated Press", "category_within_source": "Business", "source_domain": "apnews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}], "overall_sentiment_score": 0.02391, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.169676", "ticker_sentiment_score": "0.029201", "ticker_sentiment_label": "Neutral"}, {"ticker": "CVS", "relevance_score": "0.224903", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.224903", "ticker_sentiment_score": "0.03613", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biotech Stock Roundup: GSK's Drug Approval, MRNA's Vaccine News, PTCT & SPRY Down", "url": "https://www.zacks.com/stock/news/2153765/biotech-stock-roundup-gsks-drug-approval-mrnas-vaccine-news-ptct-spry-down", "time_published": "20230921T144300", "authors": ["Zacks Equity Research"], "summary": "Regulatory updates from GSK and Moderna (MRNA) are in focus in the biotech sector.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default25.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.085314, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PTCT", "relevance_score": "0.193465", "ticker_sentiment_score": "-0.03937", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPRY", "relevance_score": "0.097457", "ticker_sentiment_score": "0.067661", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.28664", "ticker_sentiment_score": "0.115369", "ticker_sentiment_label": "Neutral"}, {"ticker": "GSK", "relevance_score": "0.375722", "ticker_sentiment_score": "0.005291", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.04882", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGIOF", "relevance_score": "0.04882", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Looking Into Moderna's Recent Short Interest - Moderna  ( NASDAQ:MRNA ) ", "url": "https://www.benzinga.com/short-sellers/23/09/34793889/looking-into-modernas-recent-short-interest", "time_published": "20230921T141529", "authors": ["Benzinga Insights"], "summary": "Moderna's MRNA short percent of float has risen 4.82% since its last report. The company recently reported that it has 18.05 million shares sold short, which is 6.31% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.04 days to cover their ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.26961, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.224903", "ticker_sentiment_score": "0.158881", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "LLYC's first-half net profit rises 13.4% to 4.5 million euros - PR Newswire", "url": "https://www.prnewswire.com/news-releases/llycs-first-half-net-profit-rises-13-4-to-4-5-million-euros-301934631.html", "time_published": "20230921T123600", "authors": [], "summary": "LLYC's first-half net profit rises 13.4% to 4.5 million euros PR ...", "banner_image": null, "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.955357"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.385779, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.055236", "ticker_sentiment_score": "0.308", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GOOG", "relevance_score": "0.055236", "ticker_sentiment_score": "0.145001", "ticker_sentiment_label": "Neutral"}]}, {"title": "HP Inc. Names David Meline to Board of Directors", "url": "https://www.globenewswire.com/news-release/2023/09/21/2747292/0/en/HP-Inc-Names-David-Meline-to-Board-of-Directors.html", "time_published": "20230921T123500", "authors": ["HP Inc."], "summary": "PALO ALTO, Calif., Sept. 21, 2023 ( GLOBE NEWSWIRE ) -- HP Inc. ( NYSE: HPQ ) today announced the appointment of David Meline to its Board of Directors. Meline is the former Chief Financial Officer for Moderna Inc., a global biotechnology and pharmaceutical leader. His appointment is effective ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/37c4d49c-63cd-4ba2-9a1a-c89d07424eb9", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.303015, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HPQ", "relevance_score": "0.493128", "ticker_sentiment_score": "0.574569", "ticker_sentiment_label": "Bullish"}, {"ticker": "ABLZF", "relevance_score": "0.105604", "ticker_sentiment_score": "0.071151", "ticker_sentiment_label": "Neutral"}, {"ticker": "MMM", "relevance_score": "0.105604", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.209365", "ticker_sentiment_score": "0.065542", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.105604", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GM", "relevance_score": "0.105604", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Merck  ( MRK )  Keytruda Cervical Cancer sBLA Gets FDA Priority Tag", "url": "https://www.zacks.com/stock/news/2153513/merck-mrk-keytruda-cervical-cancer-sbla-gets-fda-priority-tag", "time_published": "20230921T122600", "authors": ["Zacks Equity Research"], "summary": "The FDA grants priority review to Merck's (MRK) sBLA seeking expanded use of Keytruda for an earlier stage of cervical cancer disease.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f9/384.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.928139"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.183643, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.176287", "ticker_sentiment_score": "-0.079892", "ticker_sentiment_label": "Neutral"}, {"ticker": "CORT", "relevance_score": "0.118064", "ticker_sentiment_score": "0.058303", "ticker_sentiment_label": "Neutral"}, {"ticker": "AUPH", "relevance_score": "0.289576", "ticker_sentiment_score": "0.223364", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "You can get more free Covid-19 tests mailed to your door, starting Monday-here's how", "url": "https://www.cnbc.com/2023/09/21/how-to-get-more-free-covid-19-tests-mailed-to-your-door.html", "time_published": "20230921T120001", "authors": ["Kamaron McNair"], "summary": "With Covid-19 cases rising again, the federal government is brining back one tool to help mitigate the spread of illness.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107229363-Unlocked_Thumb_Net_Zero_Home_clean.png?v=1682176409&w=750&h=422&vtcrop=y", "source": "CNBC", "category_within_source": "Top News", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.129449, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.100729", "ticker_sentiment_score": "0.021698", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.100729", "ticker_sentiment_score": "0.021698", "ticker_sentiment_label": "Neutral"}]}, {"title": "Does This Message From Moderna Mean Bad News for Novavax?", "url": "https://www.fool.com/investing/2023/09/21/does-moderna-message-mean-bad-news-novavax/", "time_published": "20230921T113000", "authors": ["Adria Cimino"], "summary": "So far, Novavax has lagged behind Moderna when it comes to bringing a vaccine to market.", "banner_image": "https://media.ycharts.com/charts/b125517b34888b69de9a5a39f3cd23bc.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.108179"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.115401, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.486627", "ticker_sentiment_score": "0.128172", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVAX", "relevance_score": "0.733479", "ticker_sentiment_score": "0.216265", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "$10,000 Invested in These Growth Stocks Could Make You a Fortune Over the Next 10 Years", "url": "https://www.fool.com/investing/2023/09/21/10000-invested-in-these-growth-stocks-could-make-y/", "time_published": "20230921T093000", "authors": ["Adria Cimino"], "summary": "I favor holding onto these players for the long term to truly benefit from their earnings potential.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Earnings", "relevance_score": "0.995973"}], "overall_sentiment_score": 0.356946, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "CHWY", "relevance_score": "0.303175", "ticker_sentiment_score": "0.231406", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.204936", "ticker_sentiment_score": "0.241792", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMZN", "relevance_score": "0.254573", "ticker_sentiment_score": "0.33668", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "DeSantis says he won't support Covid vaccine funding if elected president | Politics", "url": "https://www.cnn.com/2023/09/20/politics/desantis-covid-vaccine-funding/index.html", "time_published": "20230921T030400", "authors": ["Steve Contorno", "Kit Maher"], "summary": "DeSantis says he won't support Covid vaccine funding if elected president ...", "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/230920220119-ron-desantis-09132023.jpg?c=16x9&q=w_800,c_fill", "source": "CNN", "category_within_source": "Markets", "source_domain": "www.cnn.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.105086, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.053992", "ticker_sentiment_score": "-0.003", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.053992", "ticker_sentiment_score": "-0.003", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.053992", "ticker_sentiment_score": "-0.003", "ticker_sentiment_label": "Neutral"}]}, {"title": "Updated Covid Vaccine US Rollout Hit by Insurance Coverage Delays - What It Means? - Moderna  ( NASDAQ:MRNA ) , Pfizer  ( NYSE:PFE ) ", "url": "https://www.benzinga.com/general/biotech/23/09/34769704/updated-covid-vaccine-us-rollout-hit-by-insurance-coverage-delays-what-it-means", "time_published": "20230920T181525", "authors": ["Vandana Singh"], "summary": "As the U.S. launches a fresh round of updated COVID-19 vaccines, some patients encounter hurdles in obtaining prompt health insurance coverage for their shots. Under the recommendation of U.S. regulators, Pfizer Inc PFE/ BioNTech SE BNTX and Moderna Inc's MRNA new vaccine doses have become ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/20/pfizer-biontech_covid-19_vaccine_2020_g.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}], "overall_sentiment_score": 0.123829, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CVS", "relevance_score": "0.419153", "ticker_sentiment_score": "-0.231356", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MRNA", "relevance_score": "0.2872", "ticker_sentiment_score": "0.271426", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ELV", "relevance_score": "0.2872", "ticker_sentiment_score": "0.582609", "ticker_sentiment_label": "Bullish"}, {"ticker": "PFE", "relevance_score": "0.2872", "ticker_sentiment_score": "0.271426", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BNTX", "relevance_score": "0.2872", "ticker_sentiment_score": "0.271426", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Fall Covid shot rollout gets off to a bumpy start as some patients see insurance delays", "url": "https://www.cnbc.com/2023/09/20/covid-vaccine-rollout-some-patients-see-insurance-coverage-delays.html", "time_published": "20230920T145626", "authors": ["Annika Kim Constantino"], "summary": "The reports are fueling confusion among insured patients about whether they can still access Covid shots for free - just as cases tick up across the country.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107300123-1694617440486-gettyimages-1660859768-1347136-me-flu-shots-1-brv.jpeg?v=1695221786&w=1920&h=1080", "source": "CNBC", "category_within_source": "Business", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}], "overall_sentiment_score": 0.023839, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CVS", "relevance_score": "0.13347", "ticker_sentiment_score": "0.004958", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.06697", "ticker_sentiment_score": "0.085171", "ticker_sentiment_label": "Neutral"}, {"ticker": "ELV", "relevance_score": "0.06697", "ticker_sentiment_score": "0.122305", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.13347", "ticker_sentiment_score": "0.096259", "ticker_sentiment_label": "Neutral"}]}, {"title": "Ginkgo Bioworks is Teaming Up With Alphabet For AI, But Does That Make It a Buy?", "url": "https://www.fool.com/investing/2023/09/20/ginkgo-bioworks-is-teaming-up-with-alphabet-for-ai/", "time_published": "20230920T135300", "authors": ["Alex Carchidi"], "summary": "The move is unsurprising, but it will be positive for shareholders.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.227962, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.058615", "ticker_sentiment_score": "0.09215", "ticker_sentiment_label": "Neutral"}, {"ticker": "DNA", "relevance_score": "0.116914", "ticker_sentiment_score": "0.077759", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.058615", "ticker_sentiment_score": "0.09215", "ticker_sentiment_label": "Neutral"}]}, {"title": "With New COVID-19 Boosters in Tow, Which Is the Better Buy: Pfizer, BioNtech, or Moderna Stock?", "url": "https://www.fool.com/investing/2023/09/20/with-new-covid-19-boosters-in-tow-which-is-the-bet/", "time_published": "20230920T114500", "authors": ["Jim Halley"], "summary": "All three companies should benefit from increased COVID-19 booster sales.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999862"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.54554"}], "overall_sentiment_score": 0.184775, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.254307", "ticker_sentiment_score": "0.092614", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.29485", "ticker_sentiment_score": "0.221283", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BNTX", "relevance_score": "0.29485", "ticker_sentiment_score": "0.19767", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "2 Unstoppable Growth Stocks to Buy in 2023 and Beyond", "url": "https://www.fool.com/investing/2023/09/20/2-unstoppable-growth-stocks-to-buy-in-2023-and-bey/", "time_published": "20230920T093000", "authors": ["Adria Cimino"], "summary": "These stocks could take off in the years to come.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999174"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.929393"}], "overall_sentiment_score": 0.143021, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.47672", "ticker_sentiment_score": "0.187026", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TDOC", "relevance_score": "0.16849", "ticker_sentiment_score": "-0.031286", "ticker_sentiment_label": "Neutral"}]}, {"title": "Uninsured Americans can still get free Covid boosters - here's how to find them", "url": "https://www.cnbc.com/2023/09/19/covid-vaccine-boosters-uninsured-americans-can-find-free-moderna-pfizer-shots.html", "time_published": "20230919T151953", "authors": ["Annika Kim Constantino"], "summary": "The new Covid vaccines from Pfizer and Moderna began to roll out last week after the CDC recommended them to all Americans ages six months and up.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107302559-1695065834466-gettyimages-1666316367-1348234-me-0914-new-covid-vaccine-015-ik.jpeg?v=1695136793&w=1920&h=1080", "source": "CNBC", "category_within_source": "Business", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}], "overall_sentiment_score": -0.004741, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CVS", "relevance_score": "0.382925", "ticker_sentiment_score": "-0.136703", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVAX", "relevance_score": "0.158519", "ticker_sentiment_score": "0.170861", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.158519", "ticker_sentiment_score": "0.039436", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.158519", "ticker_sentiment_score": "0.039436", "ticker_sentiment_label": "Neutral"}]}, {"title": "Check Out What Whales Are Doing With MRNA - Moderna  ( NASDAQ:MRNA ) ", "url": "https://www.benzinga.com/markets/options/23/09/34733490/check-out-what-whales-are-doing-with-mrna", "time_published": "20230919T150147", "authors": ["Benzinga Insights"], "summary": "A whale with a lot of money to spend has taken a noticeably bearish stance on Moderna. Looking at options history for Moderna MRNA we detected 11 strange trades. If we consider the specifics of each trade, it is accurate to state that 36% of the investors opened trades with bullish expectations ...", "banner_image": "https://www.benzinga.com/files/images/story/2023/1695135703_0.png", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.099306, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.846873", "ticker_sentiment_score": "0.201756", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Moderna to cut mRNA drug substance production at Lonza facility", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/moderna-ramp-down-mrna-drug-substance-production-switzerland-unit-2023-09-19/", "time_published": "20230919T150100", "authors": ["Reuters"], "summary": "A bottle containing multiple doses of the Moderna COVID-19 vaccine is pictured at the Hausaerzte Hegibachplatz doctors office as the spread of the coronavirus disease ( COVID-19 ) continues, in Zurich, Switzerland January 28, 2021. REUTERS/Arnd Wiegmann/File photo Acquire Licensing Rights", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/RF526O6VNNJUZHKZCN5NOCM7VY.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.086104, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.733479", "ticker_sentiment_score": "-0.17146", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Amazon, Moderna And 2 Other Stocks Insiders Are Selling - Electronic Arts  ( NASDAQ:EA ) , Amazon.com  ( NASDAQ:AMZN ) ", "url": "https://www.benzinga.com/news/23/09/34723585/amazon-moderna-and-2-other-stocks-insiders-are-selling", "time_published": "20230919T114459", "authors": ["Lisa Levin"], "summary": "The Nasdaq 100 closed slightly higher on Monday. Investors, meanwhile, focused on some notable insider trades. When insiders sell shares, it could be a preplanned sale, or could indicate their concern in the company's prospects or that they view the stock as being overpriced.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/19/amazon_-logo.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.090193, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PINS", "relevance_score": "0.410505", "ticker_sentiment_score": "0.191686", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "EA", "relevance_score": "0.410505", "ticker_sentiment_score": "0.016811", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.334008", "ticker_sentiment_score": "0.218201", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMZN", "relevance_score": "0.253866", "ticker_sentiment_score": "-0.037568", "ticker_sentiment_label": "Neutral"}]}, {"title": "You Can Pick Up These High-Risk, High-Reward Stocks for Less Than $10", "url": "https://www.fool.com/investing/2023/09/19/high-risk-high-reward-stocks-for-10-dollars/", "time_published": "20230919T093000", "authors": ["Adria Cimino"], "summary": "These stocks look cheap right now -- if the companies can meet their goals.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972756"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.929393"}], "overall_sentiment_score": 0.218466, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NVTA", "relevance_score": "0.390396", "ticker_sentiment_score": "0.1518", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVAX", "relevance_score": "0.434349", "ticker_sentiment_score": "0.15925", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.101582", "ticker_sentiment_score": "0.012198", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.050894", "ticker_sentiment_score": "-0.061", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pfizer expects 24 percent of Americans will get new Covid boosters", "url": "https://www.financialexpress.com/healthcare/covid-19/pfizer-expects-24-percent-of-americans-will-get-new-covid-boosters/3248414/", "time_published": "20230919T091130", "authors": ["Bloomberg"], "summary": "Pfizer Inc. is forecasting 24 percent of the US population recommended to take newly approved Covid-19 vaccinations will decide to roll up their sleeves, representing a slight increase in takeup from the previous round of boosters.", "banner_image": "https://www.financialexpress.com/wp-content/uploads/2023/05/2GZYFBYGOZMO3E5URJP6ZIZQ7M.jpg", "source": "The Financial Express", "category_within_source": "n/a", "source_domain": "www.financialexpress.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.133487, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.174587", "ticker_sentiment_score": "0.063164", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.174587", "ticker_sentiment_score": "0.210052", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.491878", "ticker_sentiment_score": "0.333503", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BNTX", "relevance_score": "0.174587", "ticker_sentiment_score": "0.063164", "ticker_sentiment_label": "Neutral"}]}, {"title": "Moderna faces tougher competition in its next chapter: Lisa Jarvis", "url": "https://www.financialexpress.com/healthcare/pharma-healthcare/moderna-faces-tougher-competition-in-its-next-chapter-lisa-jarvis/3248401/", "time_published": "20230919T085903", "authors": ["Bloomberg"], "summary": "Moderna Inc. made a pitch to investors this week at its annual R&D day that the unprecedented success of its Covid vaccine wasn't a one-off, and the company is well on the way to becoming a big biotech contender.", "banner_image": "https://www.financialexpress.com/wp-content/uploads/2023/09/thermometer-g9932653d8_1920-1.jpg", "source": "The Financial Express", "category_within_source": "n/a", "source_domain": "www.financialexpress.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.231718, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.326283", "ticker_sentiment_score": "0.321332", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.083833", "ticker_sentiment_score": "0.053688", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Stocks That Sank Hard on Monday", "url": "https://www.fool.com/investing/2023/09/18/2-stocks-that-sank-hard-on-monday/", "time_published": "20230918T224900", "authors": ["Dan Caplinger"], "summary": "Investors were generally in wait-and-see mode, but not with certain individual stocks.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.0, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.538389", "ticker_sentiment_score": "-0.190023", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "U", "relevance_score": "0.217508", "ticker_sentiment_score": "-0.090277", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.146025", "ticker_sentiment_score": "0.052411", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Moderna Stock Is Sinking Today - Moderna  ( NASDAQ:MRNA ) ", "url": "https://www.benzinga.com/news/23/09/34700390/why-moderna-stock-is-sinking-today", "time_published": "20230918T192948", "authors": ["Ryan Gustafson"], "summary": "Moderna, Inc. MRNA shares are trading lower Monday alongside other vaccine stocks amid a selloff after the sector gained amid rising cases. Weakness comes after Pfizer said it expects a 24% vaccination rate this year.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/18/injection-5722329_12801.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.858979"}], "overall_sentiment_score": 0.084075, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.976058", "ticker_sentiment_score": "0.16814", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.252987", "ticker_sentiment_score": "-0.152432", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Stocks making the biggest moves midday: Marathon Petroleum, Tesla, Moderna and more", "url": "https://www.cnbc.com/2023/09/18/stocks-making-biggest-midday-moves-marathon-tesla-moderna-and-more.html", "time_published": "20230918T161952", "authors": ["Hakyung Kim"], "summary": "These are the stocks posting the largest moves in midday trading.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107293159-1693311725077-gettyimages-1645360591-01-dji_fly_20230819_054408_896_1692444219662_photo-_eyke1mgw.jpeg?v=1695053992&w=1920&h=1080", "source": "CNBC", "category_within_source": "Market Insider", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.99793"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.614606"}], "overall_sentiment_score": 0.226417, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ENPH", "relevance_score": "0.051551", "ticker_sentiment_score": "0.017012", "ticker_sentiment_label": "Neutral"}, {"ticker": "MPC", "relevance_score": "0.051551", "ticker_sentiment_score": "0.102017", "ticker_sentiment_label": "Neutral"}, {"ticker": "TENB", "relevance_score": "0.051551", "ticker_sentiment_score": "0.321808", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "C", "relevance_score": "0.051551", "ticker_sentiment_score": "0.017012", "ticker_sentiment_label": "Neutral"}, {"ticker": "PARA", "relevance_score": "0.051551", "ticker_sentiment_score": "0.198156", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MS", "relevance_score": "0.102888", "ticker_sentiment_score": "0.067347", "ticker_sentiment_label": "Neutral"}, {"ticker": "MU", "relevance_score": "0.051551", "ticker_sentiment_score": "0.113468", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.051551", "ticker_sentiment_score": "-0.099998", "ticker_sentiment_label": "Neutral"}, {"ticker": "DASH", "relevance_score": "0.051551", "ticker_sentiment_score": "0.170483", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.051551", "ticker_sentiment_score": "0.058855", "ticker_sentiment_label": "Neutral"}, {"ticker": "IRDM", "relevance_score": "0.051551", "ticker_sentiment_score": "0.037001", "ticker_sentiment_label": "Neutral"}, {"ticker": "SMPL", "relevance_score": "0.102888", "ticker_sentiment_score": "-0.047879", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.051551", "ticker_sentiment_score": "-0.099998", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.051551", "ticker_sentiment_score": "0.115", "ticker_sentiment_label": "Neutral"}, {"ticker": "VLO", "relevance_score": "0.051551", "ticker_sentiment_score": "0.102017", "ticker_sentiment_label": "Neutral"}, {"ticker": "RL", "relevance_score": "0.051551", "ticker_sentiment_score": "0.176018", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.051551", "ticker_sentiment_score": "0.058855", "ticker_sentiment_label": "Neutral"}]}, {"title": "Canopy Growth, DocGo And Other Big Stocks Moving Lower On Monday - AMC Enter Hldgs  ( NYSE:AMC ) , ARM Holdings  ( NASDAQ:ARM ) ", "url": "https://www.benzinga.com/news/23/09/34694939/canopy-growth-docgo-and-other-big-stocks-moving-lower-on-monday", "time_published": "20230918T150835", "authors": ["Lisa Levin"], "summary": "U.S. stocks traded mostly flat on Monday. Here are some big stocks recording losses in today's session. Scilex Holding Company SCLX shares dipped 17.3% to $1.86. Scilex recently announced the completion of its SP-103 Phase 2 study to evaluate the safety and efficacy in subjects with acute LBP.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/18/canopy_growth_-_logo.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Real Estate & Construction", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}], "overall_sentiment_score": -0.342479, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "BFLY", "relevance_score": "0.272788", "ticker_sentiment_score": "-0.65515", "ticker_sentiment_label": "Bearish"}, {"ticker": "BASE", "relevance_score": "0.272788", "ticker_sentiment_score": "-0.65515", "ticker_sentiment_label": "Bearish"}, {"ticker": "LXRX", "relevance_score": "0.272788", "ticker_sentiment_score": "-0.176191", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "VKTX", "relevance_score": "0.272788", "ticker_sentiment_score": "-0.65515", "ticker_sentiment_label": "Bearish"}, {"ticker": "FNGR", "relevance_score": "0.272788", "ticker_sentiment_score": "-0.65515", "ticker_sentiment_label": "Bearish"}, {"ticker": "U", "relevance_score": "0.272788", "ticker_sentiment_score": "-0.032247", "ticker_sentiment_label": "Neutral"}, {"ticker": "APE", "relevance_score": "0.138464", "ticker_sentiment_score": "-0.45255", "ticker_sentiment_label": "Bearish"}, {"ticker": "DCGO", "relevance_score": "0.399204", "ticker_sentiment_score": "0.014453", "ticker_sentiment_label": "Neutral"}, {"ticker": "GCT", "relevance_score": "0.272788", "ticker_sentiment_score": "-0.65515", "ticker_sentiment_label": "Bearish"}, {"ticker": "MNSO", "relevance_score": "0.272788", "ticker_sentiment_score": "-0.78722", "ticker_sentiment_label": "Bearish"}, {"ticker": "NUVL", "relevance_score": "0.399204", "ticker_sentiment_score": "-0.280124", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "SCLX", "relevance_score": "0.399204", "ticker_sentiment_score": "0.398371", "ticker_sentiment_label": "Bullish"}, {"ticker": "TELLL", "relevance_score": "0.138464", "ticker_sentiment_score": "-0.45255", "ticker_sentiment_label": "Bearish"}, {"ticker": "EOSE", "relevance_score": "0.272788", "ticker_sentiment_score": "-0.65515", "ticker_sentiment_label": "Bearish"}, {"ticker": "MRNA", "relevance_score": "0.272788", "ticker_sentiment_score": "-0.65515", "ticker_sentiment_label": "Bearish"}, {"ticker": "CRBU", "relevance_score": "0.272788", "ticker_sentiment_score": "-0.65515", "ticker_sentiment_label": "Bearish"}, {"ticker": "CGC", "relevance_score": "0.272788", "ticker_sentiment_score": "-0.293044", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Pfizer expects 24% uptake of COVID vaccines in US - CFO", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-expects-24-uptake-covid-vaccines-us-cfo-2023-09-18/", "time_published": "20230918T110400", "authors": ["Reuters"], "summary": "Pfizer expects 24% uptake of COVID vaccines in US ...", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/H624DNNR3BL2VMEMBQNBQ7XOSE.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.043264, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.29234", "ticker_sentiment_score": "-0.388044", "ticker_sentiment_label": "Bearish"}, {"ticker": "PFE", "relevance_score": "0.546745", "ticker_sentiment_score": "0.156508", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GERN", "relevance_score": "0.29234", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here Are 15 New Reasons to Be Bullish About Moderna Stock", "url": "https://www.fool.com/investing/2023/09/18/15-new-reasons-bullish-about-moderna-stock/", "time_published": "20230918T091500", "authors": ["Alex Carchidi"], "summary": "With its first big successes drawing to a close, new products are on the horizon.", "banner_image": "https://media.ycharts.com/charts/cf3be820c03d184cfc23fff6842734ae.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.684621"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.1223, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.238718", "ticker_sentiment_score": "0.330541", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.060541", "ticker_sentiment_score": "-0.043235", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Top Trends to Invest $500 In Right Now", "url": "https://www.fool.com/investing/2023/09/18/2-top-trends-to-invest-500-in-right-now/", "time_published": "20230918T090000", "authors": ["Adria Cimino"], "summary": "Early investors in these trends may reap the rewards over time.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.818451"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.451494"}], "overall_sentiment_score": 0.344437, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMD", "relevance_score": "0.094204", "ticker_sentiment_score": "0.139544", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.047185", "ticker_sentiment_score": "0.018814", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.094204", "ticker_sentiment_score": "0.139544", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.094204", "ticker_sentiment_score": "0.229371", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NTLA", "relevance_score": "0.140896", "ticker_sentiment_score": "-0.021192", "ticker_sentiment_label": "Neutral"}]}, {"title": "Lonza CEO departure prompts concern over earnings prospects", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/lonza-ceo-leave-by-mutual-agreement-2023-09-18/", "time_published": "20230918T075900", "authors": ["Noele Illien", "Ludwig Burger"], "summary": "The logo of Swiss contract drug maker Lonza is seen at its headquarters in Basel, Switzerland October 1, 2020. REUTERS/Arnd Wiegmann/File photo Acquire Licensing Rights", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/ANR37X7AQVOAJJSDB7EIQS4QJY.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.127742, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.101154", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.101154", "ticker_sentiment_score": "0.183815", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Is the end of AIDS in sight?", "url": "https://www.economist.com/middle-east-and-africa/2023/09/17/is-the-end-of-aids-in-sight", "time_published": "20230917T231425", "authors": ["The Economist"], "summary": "The high-tech, low-tech struggle to end AIDS The Economist ...", "banner_image": "https://www.economist.com/cdn-cgi/image/width=1424,quality=80,format=auto/content-assets/images/20230923_MAM941.png", "source": "The Economist", "category_within_source": "BusinessGoogleRSS", "source_domain": "www.economist.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.137588, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.014867", "ticker_sentiment_score": "-0.074339", "ticker_sentiment_label": "Neutral"}, {"ticker": "HCSG", "relevance_score": "0.014867", "ticker_sentiment_score": "-0.036098", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.014867", "ticker_sentiment_score": "-0.074339", "ticker_sentiment_label": "Neutral"}]}, {"title": "The high-tech, low-tech struggle to end AIDS", "url": "https://www.economist.com/news/2023/09/17/the-high-tech-low-tech-struggle-to-end-aids", "time_published": "20230917T231425", "authors": ["The Economist"], "summary": "H cotton wool help in the fight against ? The answer is surprising, and illuminates how complicated it will be to beat the deadliest sexually transmitted sickness of all time. The struggle involves not only dazzling science but also old-fashioned insights into human behaviour, rational and ...", "banner_image": "https://www.economist.com/cdn-cgi/image/width=1424,quality=80,format=auto/content-assets/images/20230923_MAM941.png", "source": "The Economist", "category_within_source": "BusinessGoogleRSS", "source_domain": "www.economist.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.137588, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.014867", "ticker_sentiment_score": "-0.074339", "ticker_sentiment_label": "Neutral"}, {"ticker": "HCSG", "relevance_score": "0.014867", "ticker_sentiment_score": "-0.036098", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.014867", "ticker_sentiment_score": "-0.074339", "ticker_sentiment_label": "Neutral"}]}, {"title": "The high-tech, low-tech struggle to end AIDS", "url": "https://www.economist.com/middle-east-and-africa/2023/09/17/the-high-tech-low-tech-struggle-to-end-aids", "time_published": "20230917T231425", "authors": ["The Economist"], "summary": "H cotton wool help in the fight against ? The answer is surprising, and illuminates how complicated it will be to beat the deadliest sexually transmitted sickness of all time. The struggle involves not only dazzling science but also old-fashioned insights into human behaviour, rational and ...", "banner_image": "https://www.economist.com/cdn-cgi/image/width=1424,quality=80,format=auto/content-assets/images/20230923_MAM941.png", "source": "The Economist", "category_within_source": "BusinessGoogleRSS", "source_domain": "www.economist.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.137588, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.014867", "ticker_sentiment_score": "-0.074339", "ticker_sentiment_label": "Neutral"}, {"ticker": "HCSG", "relevance_score": "0.014867", "ticker_sentiment_score": "-0.036098", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.014867", "ticker_sentiment_score": "-0.074339", "ticker_sentiment_label": "Neutral"}]}, {"title": "Looking for Growth? These Companies' Revenue May Skyrocket", "url": "https://www.fool.com/investing/2023/09/17/these-companies-revenue-may-skyrocket/", "time_published": "20230917T093000", "authors": ["Adria Cimino"], "summary": "Catalysts on the horizon could drive gains in these top stocks.", "banner_image": "https://media.ycharts.com/charts/0860f3894a954ca09bca6721c87f1455.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Earnings", "relevance_score": "0.986714"}], "overall_sentiment_score": 0.301635, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CHWY", "relevance_score": "0.363009", "ticker_sentiment_score": "0.330634", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.21258", "ticker_sentiment_score": "0.195774", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.107255", "ticker_sentiment_score": "0.066468", "ticker_sentiment_label": "Neutral"}]}, {"title": "Chewy, Pfizer, Raytheon, Toro Make New 52-Week Lows List", "url": "https://www.forbes.com/sites/johnnavin/2023/09/16/chewy-pfizer-raytheon-toro-make-new-52-week-lows-list/", "time_published": "20230916T173436", "authors": ["John Navin"], "summary": "It's the heaviness of the selling volume in these big market capitalization stocks that stands out.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/6505e6d3990ebe27ee28ff09/0x0.jpg?format=jpg&width=1200", "source": "Forbes", "category_within_source": "Money", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}, {"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.002399, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "TTC", "relevance_score": "0.084127", "ticker_sentiment_score": "-0.01255", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.084127", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.084127", "ticker_sentiment_score": "0.118871", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.167322", "ticker_sentiment_score": "0.092348", "ticker_sentiment_label": "Neutral"}]}, {"title": "Moderna  ( MRNA )  Gains As Market Dips: What You Should Know", "url": "https://www.zacks.com/stock/news/2149830/moderna-mrna-gains-as-market-dips-what-you-should-know", "time_published": "20230915T215017", "authors": ["Zacks Equity Research"], "summary": "Moderna (MRNA) closed at $114.59 in the latest trading session, marking a +1.58% move from the prior day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default90.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.839681"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.18545, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.582526", "ticker_sentiment_score": "0.197326", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "More Than Half Of Americans Want New COVID-19 Booster, But Ron DeSantis Will Fight Virus With His Charisma Alone - Moderna  ( NASDAQ:MRNA ) , BioNTech  ( NASDAQ:BNTX ) ", "url": "https://www.benzinga.com/news/23/09/34628137/more-than-half-of-americans-want-new-covid-19-booster-but-ron-desantis-will-fight-virus-with-his-cha", "time_published": "20230915T201915", "authors": ["Chris Katje"], "summary": "New COVID-19 boosters have been approved by the U.S. FDA in the fight against new variants. A new survey showed how likely people are to get new boosters and if they will have their children get boosters.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/15/rondesantis.shutterstock_1355382881.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.139889, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "TRMNF", "relevance_score": "0.07446", "ticker_sentiment_score": "0.049669", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVAX", "relevance_score": "0.148273", "ticker_sentiment_score": "0.185979", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.148273", "ticker_sentiment_score": "0.197008", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.148273", "ticker_sentiment_score": "0.197008", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BNTX", "relevance_score": "0.148273", "ticker_sentiment_score": "0.197008", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "US NIH begins human trials of 'universal' flu vaccine", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/us-nih-begins-human-trials-universal-flu-vaccine-2023-09-15/", "time_published": "20230915T185800", "authors": ["Reuters"], "summary": "Sept 15 ( Reuters ) - The U.S. National Institutes of Health ( NIH ) said on Friday that it has begun an early-stage study on its experimental vaccine targeting six strains of influenza virus.", "banner_image": "https://www.reuters.com/pf/resources/images/reuters/reuters-default.webp?d=157", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.23968, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.183895", "ticker_sentiment_score": "-0.276137", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "For Thanksgiving, Have Cacio e Pepe in Rome", "url": "https://www.barrons.com/articles/for-thanksgiving-have-cacio-e-pepe-in-rome-1db09f00", "time_published": "20230915T181000", "authors": ["Shivani Vora"], "summary": "As a lifelong Roman and co-owner of Access Italy, a company that plans luxury experiences in Rome, Simone Amorico wants travelers to discover the city he loves and is proud to call home.", "banner_image": "https://images.barrons.com/im-96177267?width=639&height=958", "source": "Barrons", "category_within_source": "n/a", "source_domain": "www.barrons.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.334064, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.049221", "ticker_sentiment_score": "0.272284", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Moderna Unusual Options Activity For September 15 - Moderna  ( NASDAQ:MRNA ) ", "url": "https://www.benzinga.com/markets/options/23/09/34622019/moderna-unusual-options-activity-for-september-15", "time_published": "20230915T161837", "authors": ["Benzinga Insights"], "summary": "Someone with a lot of money to spend has taken a bullish stance on Moderna MRNA. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.154459, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.822984", "ticker_sentiment_score": "0.398215", "ticker_sentiment_label": "Bullish"}]}, {"title": "Florida Defies CDC - Telling Under-65s To Skip Covid Boosters - Though The State Leads In Covid Deaths Nationwide", "url": "https://www.forbes.com/sites/conormurray/2023/09/15/florida-defies-cdc---telling-under-65s-to-skip-covid-boosters---though-the-state-leads-in-covid-deaths-nationwide/", "time_published": "20230915T161203", "authors": ["Conor Murray"], "summary": "The Centers for Disease Control and Prevention slammed Florida's decision as \"dangerous.\" ...", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65048205fd99e7ca8d52ccdb/0x0.jpg?format=jpg&crop=2880,1620,x123,y45,safe&width=1200", "source": "Forbes", "category_within_source": "Business", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": -0.031287, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NYT", "relevance_score": "0.050359", "ticker_sentiment_score": "0.358752", "ticker_sentiment_label": "Bullish"}, {"ticker": "MRNA", "relevance_score": "0.050359", "ticker_sentiment_score": "-0.011984", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.050359", "ticker_sentiment_score": "-0.011984", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.050359", "ticker_sentiment_score": "-0.011984", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is Moderna Stock a Top Buy?", "url": "https://www.fool.com/investing/2023/09/15/is-moderna-stock-a-top-buy/", "time_published": "20230915T143000", "authors": ["George Budwell"], "summary": "Wall Street is bullish on the biotech's novel pipeline.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F747633%2Fgrowth.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.839681"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.459462"}], "overall_sentiment_score": 0.079808, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.360752", "ticker_sentiment_score": "0.049296", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.05339", "ticker_sentiment_score": "-0.024004", "ticker_sentiment_label": "Neutral"}]}, {"title": "Moderna  ( MRNA )  Receives CHMP Nod for Updated COVID Vaccine", "url": "https://www.zacks.com/stock/news/2149481/moderna-mrna-receives-chmp-nod-for-updated-covid-vaccine", "time_published": "20230915T133500", "authors": ["Zacks Equity Research"], "summary": "Clinical data from studies on Moderna's (MRNA) updated COVID vaccine shows improved antibody responses against multiple circulating variants, including BA.2.86, EG.5 and FL.1.5.1 variants.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/a1/7439.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.145002, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVAX", "relevance_score": "0.285526", "ticker_sentiment_score": "0.181726", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.670742", "ticker_sentiment_score": "0.212284", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.285526", "ticker_sentiment_score": "0.160024", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BNTX", "relevance_score": "0.192694", "ticker_sentiment_score": "0.006179", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pharma Stock Roundup: FDA Nod to Updated PFE, MRNA COVID Jabs, & More", "url": "https://www.zacks.com/stock/news/2149445/pharma-stock-roundup-fda-nod-to-updated-pfe-mrna-covid-jabs-more", "time_published": "20230915T133300", "authors": ["Kinjel Shah"], "summary": "The FDA authorizes Pfizer (PFE) and Moderna's (MRNA) updated mRNA-based COVID-19 vaccines. Novo Nordisk (NVO) conducts a two-for-one split of its shares and ADRs.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/66/1019.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.413559"}], "overall_sentiment_score": 0.059775, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ABBV", "relevance_score": "0.107736", "ticker_sentiment_score": "0.031869", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.315493", "ticker_sentiment_score": "0.13387", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.107736", "ticker_sentiment_score": "0.031869", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.265089", "ticker_sentiment_score": "0.093183", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.364529", "ticker_sentiment_score": "0.081749", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.107736", "ticker_sentiment_score": "0.036452", "ticker_sentiment_label": "Neutral"}]}, {"title": "Company News for Sep 15, 2023", "url": "https://www.zacks.com/stock/news/2149443/company-news-for-sep-15-2023", "time_published": "20230915T133000", "authors": ["Zacks Equity Research"], "summary": "Companies in The News Are: ...", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/72/1912.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Real Estate & Construction", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}], "overall_sentiment_score": 0.280894, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HPQ", "relevance_score": "0.595343", "ticker_sentiment_score": "0.156644", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.595343", "ticker_sentiment_score": "0.419895", "ticker_sentiment_label": "Bullish"}, {"ticker": "CWK", "relevance_score": "0.595343", "ticker_sentiment_score": "0.607392", "ticker_sentiment_label": "Bullish"}, {"ticker": "BRK-A", "relevance_score": "0.323078", "ticker_sentiment_score": "0.105586", "ticker_sentiment_label": "Neutral"}, {"ticker": "SMTC", "relevance_score": "0.595343", "ticker_sentiment_score": "0.428516", "ticker_sentiment_label": "Bullish"}]}, {"title": "We should all support Biden's war on Big Pharma", "url": "https://www.aljazeera.com/opinions/2023/9/15/we-should-all-support-bidens-war-on-big-pharma", "time_published": "20230915T123329", "authors": ["Nick Dearden"], "summary": "If we want cutting-edge medicines at a price we can afford, the US president will need to stand his ground. \"This time, we beat Big Pharma\", United States President Joe Biden tweeted, after finally giving his government the power to negotiate the price of 10 prescription drugs, including ...", "banner_image": "https://www.aljazeera.com/wp-content/uploads/2023/08/AP23241010218588-1693383279.jpg?resize=770%2C513&quality=80", "source": "Al Jareeza", "category_within_source": "n/a", "source_domain": "www.aljazeera.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.058017, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NFLX", "relevance_score": "0.034087", "ticker_sentiment_score": "-0.205373", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ABBV", "relevance_score": "0.034087", "ticker_sentiment_score": "0.084327", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.034087", "ticker_sentiment_score": "0.010668", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.034087", "ticker_sentiment_score": "-0.175942", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Covid, RSV and flu vaccines are now available - here's how to decide whether to get them together", "url": "https://www.cnbc.com/2023/09/15/covid-rsv-flu-vaccines-how-to-decide-whether-to-get-them-together.html", "time_published": "20230915T110724", "authors": ["Annika Kim Constantino"], "summary": "Public health officials are urging eligible Americans to take all three shots so the nation can avoid another \"tripledemic\" of Covid, flu and RSV.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107300978-1694711585325-gettyimages-1660859705-1347136-me-flu-shots-12-brv.jpeg?v=1694776044&w=1920&h=1080", "source": "CNBC", "category_within_source": "Business", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.040494, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.036812", "ticker_sentiment_score": "0.093697", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.110124", "ticker_sentiment_score": "0.037493", "ticker_sentiment_label": "Neutral"}]}, {"title": "Meet the Black students who were instrumental in developing the first Covid-19 shots", "url": "https://www.cnn.com/2023/09/15/health/covid-vaccines-black-student-scientists/index.html", "time_published": "20230915T103100", "authors": ["Jacqueline Howard"], "summary": "It was a meeting that changed their lives forever. The year was 2020, and reports had emerged from China that a never-before-seen coronavirus was spreading quickly, sickening hundreds of people and turning deadly.", "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/230914111624-02-covid-vaccine-black-students.jpg?c=16x9&q=h_720,w_1280,c_fill", "source": "CNN", "category_within_source": "Markets", "source_domain": "www.cnn.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.164109, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "WBD", "relevance_score": "0.026357", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.105141", "ticker_sentiment_score": "0.137944", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.026357", "ticker_sentiment_score": "0.083048", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.026357", "ticker_sentiment_score": "0.083048", "ticker_sentiment_label": "Neutral"}]}, {"title": "UK regulator approves Moderna's updated COVID vaccine", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/uk-regulator-approves-modernas-updated-covid-vaccine-2023-09-15/", "time_published": "20230915T102406", "authors": ["Reuters"], "summary": "A vial labelled \"Moderna COVID-19 Vaccine\" is seen in this illustration taken January 16, 2022. REUTERS/Dado Ruvic/Illustration Acquire Licensing Rights", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/TFL7EZY6HFL45DDKYNHCWW6NVI.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}], "overall_sentiment_score": 0.206051, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CVS", "relevance_score": "0.218817", "ticker_sentiment_score": "0.205099", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.421485", "ticker_sentiment_score": "0.135408", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.218817", "ticker_sentiment_score": "0.167276", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BNTX", "relevance_score": "0.218817", "ticker_sentiment_score": "0.167276", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WBA", "relevance_score": "0.218817", "ticker_sentiment_score": "0.205099", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "This 1 Number May Completely Change Your Opinion About Moderna", "url": "https://www.fool.com/investing/2023/09/15/this-1-number-may-change-your-opinion-of-moderna/", "time_published": "20230915T093000", "authors": ["Adria Cimino"], "summary": "Moderna shares look dirt cheap considering the company's prospects.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.94762"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.042892, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.693986", "ticker_sentiment_score": "0.019061", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.062761", "ticker_sentiment_score": "-0.039079", "ticker_sentiment_label": "Neutral"}]}, {"title": "Wall Street ends higher on economic data; Arm soars in debut", "url": "https://www.moneycontrol.com/news/business/markets/wall-street-ends-higher-on-economic-data-arm-soars-in-debut-11371811.html", "time_published": "20230915T004703", "authors": [], "summary": "SoftBank's Arm ( ARM.O ) was valued at nearly $60 billion in a strong Nasdaq debut, with the chip designer's shares soaring nearly 25% in their first day of trading.", "banner_image": "https://images.moneycontrol.com/static-mcnews/2020/08/wall-street-1.jpg?impolicy=website&width=168&height=118", "source": "Money Control", "category_within_source": "Markets", "source_domain": "www.moneycontrol.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "IPO", "relevance_score": "0.310843"}, {"topic": "Financial Markets", "relevance_score": "0.77141"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.181773, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.080188", "ticker_sentiment_score": "0.097632", "ticker_sentiment_label": "Neutral"}, {"ticker": "BRK-A", "relevance_score": "0.080188", "ticker_sentiment_score": "-0.043009", "ticker_sentiment_label": "Neutral"}, {"ticker": "C", "relevance_score": "0.159569", "ticker_sentiment_score": "0.110009", "ticker_sentiment_label": "Neutral"}]}, {"title": "DeSantis rips Trump for claiming not to know who gave Fauci presidential commendation: 'Is this the immaculate commendation?' | Politics", "url": "https://www.cnn.com/2023/09/14/politics/desantis-trump-fauci-commendation-covid/index.html", "time_published": "20230914T221300", "authors": ["Kit Maher"], "summary": "DeSantis rips Trump for claiming not to know who gave Fauci presidential commendation: 'Is this the immaculate commendation?' ...", "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/230831155318-04-ron-desantis-080623.jpg?c=16x9&q=w_800,c_fill", "source": "CNN", "category_within_source": "Markets", "source_domain": "www.cnn.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.034108, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.078099", "ticker_sentiment_score": "-0.011322", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.078099", "ticker_sentiment_score": "-0.011322", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.078099", "ticker_sentiment_score": "-0.011322", "ticker_sentiment_label": "Neutral"}]}, {"title": "Dow Jones Soars Amid Strong Arm IPO Gains; Cathie Wood Loads Up On This Stock After 43% Plunge", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-surges-amid-strong-arm-ipo-gains-cathie-wood-loads-up-on-this-stock-after-43-percent-plunge-roblox-stock-rblx-arm-stock-tesla-stock/", "time_published": "20230914T203800", "authors": ["MICHAEL LARKIN", "Investor's Business Daily"], "summary": "Dow Jones Soars Amid Strong Arm IPO Gains. Cathie Wood Loads ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2023/09/SMT-CathieWood-091423-news-.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}, {"topic": "IPO", "relevance_score": "0.576289"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.495866"}], "overall_sentiment_score": 0.295425, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MOS", "relevance_score": "0.078354", "ticker_sentiment_score": "0.303972", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVDA", "relevance_score": "0.078354", "ticker_sentiment_score": "0.169729", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AAPL", "relevance_score": "0.078354", "ticker_sentiment_score": "0.169729", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TSLA", "relevance_score": "0.155954", "ticker_sentiment_score": "0.133975", "ticker_sentiment_label": "Neutral"}, {"ticker": "V", "relevance_score": "0.078354", "ticker_sentiment_score": "-0.061633", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAT", "relevance_score": "0.117295", "ticker_sentiment_score": "0.116241", "ticker_sentiment_label": "Neutral"}, {"ticker": "SFTBF", "relevance_score": "0.039224", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "RBLX", "relevance_score": "0.155954", "ticker_sentiment_score": "0.061925", "ticker_sentiment_label": "Neutral"}, {"ticker": "CTAS", "relevance_score": "0.155954", "ticker_sentiment_score": "0.110023", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.078354", "ticker_sentiment_score": "0.002043", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.078354", "ticker_sentiment_score": "0.122806", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Moderna Stock Is Rising Today - Moderna  ( NASDAQ:MRNA ) ", "url": "https://www.benzinga.com/news/23/09/34590853/why-moderna-stock-is-rising-today", "time_published": "20230914T192125", "authors": ["Ryan Gustafson"], "summary": "Moderna, Inc. MRNA shares are trading higher after the EMA Committee for Medicinal Products for Human Use adopted an opinion recommending authorization of the company's updated COVID-19 vaccine in the EU. What To Know: The marketing authorization is for Spikevax, the company's updated COVID-19 ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/14/medical-5835701_12802.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.211875, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.762438", "ticker_sentiment_score": "0.521633", "ticker_sentiment_label": "Bullish"}]}, {"title": "Moderna's R&D Day Unveils Strategic Roadmap Beyond COVID Franchise: Goldman Sachs - Moderna  ( NASDAQ:MRNA ) ", "url": "https://www.benzinga.com/analyst-ratings/analyst-color/23/09/34585904/modernas-r-d-day-unveils-strategic-roadmap-beyond-covid-franchise-goldman-sachs", "time_published": "20230914T172345", "authors": ["Vandana Singh"], "summary": "On Wednesday, Moderna Inc MRNA conducted an R&D Day event outlining its strategic initiatives across four key areas - Respiratory Vaccines, Latent/Other Vaccines, Oncology Therapeutics, and Rare Disease Therapeutics.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/14/moderna_covid-19_vaccine_2021_g.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.153732, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GS", "relevance_score": "0.235823", "ticker_sentiment_score": "0.15009", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.34729", "ticker_sentiment_score": "0.122303", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.235823", "ticker_sentiment_score": "0.253799", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "MRNA: Moderna  ( MRNA )  Stock Analysis: Is the Biotech Stock a Buy at This Time?", "url": "https://stocknews.com/news/mrna-jazz-otsky-amgn-moderna-mrna-stock-analysis-is-the-biotech-stock-a-buy/", "time_published": "20230914T165016", "authors": ["StockNews.com Staff"], "summary": "MRNA: Moderna ( MRNA ) Stock Analysis: Is the Biotech Stock a Buy ... ...", "banner_image": "https://stocknews.com/wp-content/uploads/2022/06/Biotech-Lg_FB.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Earnings", "relevance_score": "0.993781"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}], "overall_sentiment_score": 0.131754, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.595794", "ticker_sentiment_score": "0.219381", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.045874", "ticker_sentiment_score": "0.171212", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JAZZ", "relevance_score": "0.045874", "ticker_sentiment_score": "0.171212", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Moderna  ( MRNA )  Posts '28 Biz View, Up 3% on Upbeat Flu Jab Data", "url": "https://www.zacks.com/stock/news/2149066/moderna-mrna-posts-28-biz-view-up-3-on-upbeat-flu-jab-data", "time_published": "20230914T152500", "authors": ["Zacks Equity Research"], "summary": "Moderna's (MRNA) reformulated influenza vaccine candidate meets the primary endpoint in a late-stage study. It expects to launch up to 15 new products in the next five years.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/db/3160.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.02387, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.604961", "ticker_sentiment_score": "-0.06737", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.122894", "ticker_sentiment_score": "0.039205", "ticker_sentiment_label": "Neutral"}]}, {"title": "EU regulator panel recommends authorizing Moderna's updated COVID shot", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/eu-regulator-panel-recommends-authorizing-modernas-updated-covid-shot-2023-09-14/", "time_published": "20230914T142910", "authors": ["Reuters"], "summary": "A vial of the Moderna coronavirus disease ( COVID-19 ) booster vaccine targeting BA.4 and BA.5 Omicron sub variants is pictured at Skippack Pharmacy in Schwenksville, Pennsylvania, U.S., September 8, 2022. REUTERS/Hannah Beier/File Photo Acquire Licensing Rights", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/PX4J23T4RJJ7PIOMCPRIW2NT4E.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.094439, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.360752", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Alnylam Crumbles On Dashed Hopes Of Rivaling Pfizer", "url": "https://www.investors.com/news/technology/alnylam-stock-tumbles-on-dashed-hopes-of-rivaling-pfizer-in-heart-disease-treatment/", "time_published": "20230914T142800", "authors": ["Investor's Business Daily", "ALLISON GATLIN"], "summary": "Alnylam Stock Tumbles On Dashes Hopes Of Rivaling Pfizer In ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2019/12/stock-Alnylam-01-shutter.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.999365"}], "overall_sentiment_score": 0.22653, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALNY", "relevance_score": "0.113597", "ticker_sentiment_score": "0.090759", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDGL", "relevance_score": "0.056943", "ticker_sentiment_score": "0.199995", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.056943", "ticker_sentiment_score": "-0.190991", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "SNY", "relevance_score": "0.056943", "ticker_sentiment_score": "-0.190991", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Biotech Stock Roundup: MRNAs Pipeline News, RCKT, BCYC Rally on Study Updates", "url": "https://www.zacks.com/stock/news/2148988/biotech-stock-roundup-mrnas-pipeline-news-rckt-bcyc-rally-on-study-updates", "time_published": "20230914T141200", "authors": ["Zacks Equity Research"], "summary": "Pipeline and regulatory updates from Moderna (MRNA) and Rocket Pharmaceuticals (RCKT) are in focus in the biotech sector.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.052524, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.057628", "ticker_sentiment_score": "-0.016084", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCYC", "relevance_score": "0.057628", "ticker_sentiment_score": "0.077171", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.227538", "ticker_sentiment_score": "0.056455", "ticker_sentiment_label": "Neutral"}, {"ticker": "RCKT", "relevance_score": "0.114956", "ticker_sentiment_score": "0.10906", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.057628", "ticker_sentiment_score": "0.117973", "ticker_sentiment_label": "Neutral"}]}, {"title": "Moderna  ( MRNA )  Surges 3.2%: Is This an Indication of Further Gains?", "url": "https://www.zacks.com/stock/news/2148987/moderna-mrna-surges-32-is-this-an-indication-of-further-gains", "time_published": "20230914T141000", "authors": ["Zacks Equity Research"], "summary": "Moderna (MRNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default188.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.95493"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.178728, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.610896", "ticker_sentiment_score": "0.278407", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RGEN", "relevance_score": "0.52706", "ticker_sentiment_score": "-0.105642", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why COVID Vaccine Demand Might Not Be That Strong", "url": "https://www.fool.com/investing/2023/09/14/why-covid-vaccine-demand-might-not-be-that-strong/", "time_published": "20230914T133700", "authors": ["David Jagielski"], "summary": "COVID hospitalizations are rising, but they're nowhere near the levels they were at a year or two ago.", "banner_image": "https://media.ycharts.com/charts/8ba6e8b921cc2a548c438926c5ee7ab5.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.103823, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.406901", "ticker_sentiment_score": "-0.01143", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.060848", "ticker_sentiment_score": "0.013029", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVAX", "relevance_score": "0.458593", "ticker_sentiment_score": "-0.024846", "ticker_sentiment_label": "Neutral"}]}, {"title": "COVID-19 Vaccine Market Predicted to Reach USD 9.9 billion by 2031, Garnering -13.6% CAGR: TMR Report", "url": "https://www.benzinga.com/pressreleases/23/09/g34581796/covid-19-vaccine-market-predicted-to-reach-usd-9-9-billion-by-2031-garnering-13-6-cagr-tmr-report", "time_published": "20230914T133000", "authors": ["Globe Newswire"], "summary": "Wilmington, Delaware, United States, Sept. 14, 2023 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The COVID-19 vaccine market was estimated to have acquired US$ 92.6 billion in 2021. It is anticipated to register a negative 13.6% CAGR from 2022 to 2031 and by 2031, the market is ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Mergers & Acquisitions", "relevance_score": "0.360215"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.212758, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.041901", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "HCSG", "relevance_score": "0.041901", "ticker_sentiment_score": "0.046561", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.041901", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.083687", "ticker_sentiment_score": "0.05209", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.041901", "ticker_sentiment_score": "0.183806", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Nvidia, Amgen back AI-driven drug firm Generate:Biomedicines' $273 mln fundraise", "url": "https://www.reuters.com/markets/deals/nvidia-amgen-back-ai-driven-drug-firm-generatebiomedicines-273-mln-fundraise-2023-09-14/", "time_published": "20230914T124043", "authors": ["Reuters"], "summary": "Sept 14 ( Reuters ) - Drug developer Generate:Biomedicines, which uses artificial intelligence ( AI ) to find new treatments, said on Thursday it has raised $273 million from investors including Nvidia's ( NVDA.O ) venture capital arm and Amgen ( AMGN.O ) .", "banner_image": "https://www.reuters.com/pf/resources/images/reuters/reuters-default.webp?d=157", "source": "Reuters", "category_within_source": "Markets", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.278841, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.149656", "ticker_sentiment_score": "0.328175", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "This Market Could Be Worth $10 Billion by 2030 -- 2 Stocks to Buy Now", "url": "https://www.fool.com/investing/2023/09/14/this-market-could-be-worth-10-billion-by-2030/", "time_published": "20230914T114500", "authors": ["Prosper Junior Bakiny"], "summary": "This market is currently in its infancy.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.538269"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}], "overall_sentiment_score": 0.2915, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SGEN", "relevance_score": "0.055881", "ticker_sentiment_score": "0.175082", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.055881", "ticker_sentiment_score": "0.143999", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.42503", "ticker_sentiment_score": "0.471183", "ticker_sentiment_label": "Bullish"}, {"ticker": "SNY", "relevance_score": "0.471856", "ticker_sentiment_score": "0.33848", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Novavax Is a Step Behind, Again. Should You Be Worried?", "url": "https://www.fool.com/investing/2023/09/14/novavax-is-a-step-behind-should-you-be-worried/", "time_published": "20230914T090000", "authors": ["Adria Cimino"], "summary": "The FDA still is reviewing Novavax's updated vaccine candidate.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.161647"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.031686, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.395012", "ticker_sentiment_score": "-0.131364", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.395012", "ticker_sentiment_score": "-0.131364", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVAX", "relevance_score": "0.663242", "ticker_sentiment_score": "0.086693", "ticker_sentiment_label": "Neutral"}]}, {"title": "'This Is Not a Covid Vaccine Company,' Moderna CEO Says", "url": "https://www.barrons.com/articles/moderna-ceo-covid-vaccine-ebad07a5", "time_published": "20230914T043000", "authors": ["Josh Nathan-Kazis"], "summary": "Moderna CEO Pledges 15 New Products. For Now It Has 1: Its Covid Vaccine. ...", "banner_image": "https://images.barrons.com/im-32307945?width=620&height=413", "source": "Barrons", "category_within_source": "n/a", "source_domain": "www.barrons.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.012024, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.682689", "ticker_sentiment_score": "-0.018976", "ticker_sentiment_label": "Neutral"}]}, {"title": "DeSantis warns against Covid-19 boosters for people under 65 contradicting CDC guidance | Politics", "url": "https://www.cnn.com/2023/09/13/politics/desantis-covid-booster-florida-2024/index.html", "time_published": "20230914T032500", "authors": ["Kit Maher", "Eric Bradner"], "summary": "DeSantis warns against Covid-19 boosters for people under 65 contradicting CDC guidance ...", "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/230913213239-ron-desantis-082323.jpg?c=16x9&q=w_800,c_fill", "source": "CNN", "category_within_source": "Markets", "source_domain": "www.cnn.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.064824, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.087503", "ticker_sentiment_score": "-0.00943", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.087503", "ticker_sentiment_score": "-0.00943", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.087503", "ticker_sentiment_score": "-0.00943", "ticker_sentiment_label": "Neutral"}]}, {"title": "Moderna poised to seek flu shot approval after trial results", "url": "https://www.financialexpress.com/healthcare/news-healthcare/moderna-poised-to-seek-flu-shot-approval-after-trial-results/3242674/", "time_published": "20230914T023000", "authors": ["Bloomberg"], "summary": "Moderna Inc. said a reformulated version of its messenger-RNA based flu shot met its primary goals in a final-stage trial - a result that could pave the way for the company to seek regulatory approval for the influenza vaccine.", "banner_image": "https://www.financialexpress.com/wp-content/uploads/2023/09/vaccination-inde.jpg", "source": "The Financial Express", "category_within_source": "n/a", "source_domain": "www.financialexpress.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.060625, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.566871", "ticker_sentiment_score": "-0.038282", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.056808", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "5 things to know about the new COVID-19 vaccine", "url": "https://www.marketwatch.com/story/five-things-to-know-about-the-new-covid-19-vaccine-96557794", "time_published": "20230913T204200", "authors": ["Charles Passy"], "summary": "The booster will be available starting later this week.", "banner_image": "https://images.mktw.net/im-851536/horizontal", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": 0.040778, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NYT", "relevance_score": "0.068896", "ticker_sentiment_score": "-0.067417", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.137278", "ticker_sentiment_score": "-0.072244", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.137278", "ticker_sentiment_score": "-0.072244", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.137278", "ticker_sentiment_score": "-0.072244", "ticker_sentiment_label": "Neutral"}]}, {"title": "FFF Enterprises Inc. Adds COVID-19 Vaccines and Respiratory Syncytial Virus  ( RSV )  Products to Its Comprehensive, Expanding Portfolio", "url": "https://www.benzinga.com/pressreleases/23/09/g34545441/fff-enterprises-inc-adds-covid-19-vaccines-and-respiratory-syncytial-virus-rsv-products-to-its-com", "time_published": "20230913T173400", "authors": ["Globe Newswire"], "summary": "TEMECULA, Calif., Sept. 13, 2023 ( GLOBE NEWSWIRE ) -- FFF Enterprises Inc., recognized as the nation's most trusted specialty drug distributor and diversified healthcare company, has partnered with the industry's top pharmaceutical manufacturers to carry Moderna and Novavax COVID-19 vaccines, ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.344439, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.086556", "ticker_sentiment_score": "0.20451", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "META", "relevance_score": "0.086556", "ticker_sentiment_score": "0.20451", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVAX", "relevance_score": "0.172097", "ticker_sentiment_score": "0.187023", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.172097", "ticker_sentiment_score": "0.187059", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Stocks making the biggest moves midday: Citigroup, Adobe, Corteva and more", "url": "https://www.cnbc.com/2023/09/13/stocks-making-the-biggest-moves-midday-c-adbe-ctva-and-more.html", "time_published": "20230913T165329", "authors": ["Pia Singh"], "summary": "These are the stocks posting the largest moves in midday trading.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107140421-1666715616730-gettyimages-143309378-ADOBE_CLOUD_LAUNCH.jpeg?v=1694624009&w=1920&h=1080", "source": "CNBC", "category_within_source": "Top News", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.538269"}], "overall_sentiment_score": 0.219743, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "XPEV", "relevance_score": "0.183895", "ticker_sentiment_score": "0.168515", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "C", "relevance_score": "0.183895", "ticker_sentiment_score": "0.037784", "ticker_sentiment_label": "Neutral"}, {"ticker": "CTVA", "relevance_score": "0.092569", "ticker_sentiment_score": "0.163738", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "F", "relevance_score": "0.092569", "ticker_sentiment_score": "0.118947", "ticker_sentiment_label": "Neutral"}, {"ticker": "GM", "relevance_score": "0.183895", "ticker_sentiment_score": "0.16561", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SAVE", "relevance_score": "0.092569", "ticker_sentiment_score": "0.019049", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAL", "relevance_score": "0.092569", "ticker_sentiment_score": "0.019049", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.183895", "ticker_sentiment_score": "0.085573", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.092569", "ticker_sentiment_score": "0.061397", "ticker_sentiment_label": "Neutral"}]}, {"title": "The latest Covid-19 vaccine is here. Here's where and when to get it - and RSV and flu shots, too", "url": "https://www.cnn.com/2023/09/13/health/updated-covid-vaccine-where-when-flu-rsv-wellness/index.html", "time_published": "20230913T163800", "authors": ["Amanda Musa"], "summary": "Now that the US Food and Drug Administration and Centers for Disease Control and Prevention have signed off, you won't have to wait long to get your updated Covid-19 shot. Major pharmacy chains have already started rolling out vaccine appointments.", "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/230831162545-04-cnn-news-quiz-083123.jpg?c=16x9&q=h_144,w_256,c_fill", "source": "CNN", "category_within_source": "Markets", "source_domain": "www.cnn.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}], "overall_sentiment_score": -0.007209, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CVS", "relevance_score": "0.161349", "ticker_sentiment_score": "0.058147", "ticker_sentiment_label": "Neutral"}, {"ticker": "RAD", "relevance_score": "0.027072", "ticker_sentiment_score": "0.048086", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.027072", "ticker_sentiment_score": "0.075894", "ticker_sentiment_label": "Neutral"}, {"ticker": "WBD", "relevance_score": "0.054114", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.054114", "ticker_sentiment_score": "0.085893", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.054114", "ticker_sentiment_score": "0.085893", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.027072", "ticker_sentiment_score": "0.183956", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Mainz Biomed Paves The Way For Early Colorectal Cancer Diagnosis And Even Prevention - Mainz Biomed  ( NASDAQ:MYNZ ) ", "url": "https://www.benzinga.com/markets/penny-stocks/23/09/34543332/mainz-biomed-paves-the-way-for-early-colorectal-cancer-diagnosis-and-even-prevention", "time_published": "20230913T163152", "authors": ["Upwallstreet"], "summary": "By the words of Dr. Ruediger Dahlke, cancer is a caricature of today's modern society as it reflects the dark side 'growth'. Our civilization is clearly more on the dark side of growth with technology advancing but not with our wellbeing in mind as everything seems to be thriving, besides our ...", "banner_image": "https://cdn.benzinga.com/files/view-yellow-ribbon-with-human-hands.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": -0.081385, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.292922", "ticker_sentiment_score": "-0.22843", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PFE", "relevance_score": "0.245835", "ticker_sentiment_score": "-0.008092", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARVN", "relevance_score": "0.049939", "ticker_sentiment_score": "-0.004015", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stock Market Not Too Rattled By Inflation Data; Trucking Stock Gets A Bounce", "url": "https://www.investors.com/market-trend/stock-market-today/stock-market-weighs-in-on-inflation-vaccine-maker-leads-sp-500/", "time_published": "20230913T163000", "authors": ["Investor's Business Daily", "KIMBERLEY KOENIG"], "summary": "Stock Market Weighs In On Inflation Data. Vaccine Maker Leads ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2020/04/Stock-JB-Hunt-02-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Economy - Monetary", "relevance_score": "0.769861"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.538269"}], "overall_sentiment_score": 0.159269, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "UAL", "relevance_score": "0.095327", "ticker_sentiment_score": "-0.037062", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRS", "relevance_score": "0.095327", "ticker_sentiment_score": "0.092326", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.047749", "ticker_sentiment_score": "0.081006", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.095327", "ticker_sentiment_score": "0.112985", "ticker_sentiment_label": "Neutral"}, {"ticker": "SAVE", "relevance_score": "0.095327", "ticker_sentiment_score": "-0.014957", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAL", "relevance_score": "0.095327", "ticker_sentiment_score": "0.013274", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.047749", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LUV", "relevance_score": "0.095327", "ticker_sentiment_score": "-0.037062", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.095327", "ticker_sentiment_score": "-0.082331", "ticker_sentiment_label": "Neutral"}, {"ticker": "RCKT", "relevance_score": "0.095327", "ticker_sentiment_score": "0.138345", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.142565", "ticker_sentiment_score": "0.145552", "ticker_sentiment_label": "Neutral"}]}, {"title": "This Stock Once Jumped 268% On FDA Action; Can It Do That Again?", "url": "https://www.investors.com/news/technology/mdgl-stock-jumps-as-its-nash-treatment-toes-the-long-awaited-finish-line/", "time_published": "20230913T160900", "authors": ["ALLISON GATLIN", "Investor's Business Daily"], "summary": "MDGL Stock Jumps As Its NASH Treatment Toes The Long-Awaiting ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2017/11/stock-biotech-05-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.962106"}], "overall_sentiment_score": 0.262821, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SLRN", "relevance_score": "0.068502", "ticker_sentiment_score": "0.11589", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSSMY", "relevance_score": "0.136499", "ticker_sentiment_score": "0.231953", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVO", "relevance_score": "0.136499", "ticker_sentiment_score": "0.159342", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LLY", "relevance_score": "0.136499", "ticker_sentiment_score": "0.159342", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MDGL", "relevance_score": "0.393977", "ticker_sentiment_score": "0.491279", "ticker_sentiment_label": "Bullish"}, {"ticker": "MRNA", "relevance_score": "0.068502", "ticker_sentiment_score": "-0.191908", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "SNY", "relevance_score": "0.068502", "ticker_sentiment_score": "-0.191908", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "US pharmacy chains gear up to administer updated COVID shots", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/us-pharmacy-chains-gear-up-administer-updated-covid-shots-2023-09-13/", "time_published": "20230913T160500", "authors": ["Reuters"], "summary": "Walgreens healthcare professional Luis S. Solano prepares a dose of the Pfizer-BioNTec vaccine against coronavirus disease ( COVID-19 ) at the Victor Walchirk Apartments in Evanston, Illinois, U.S. February 22, 2021. REUTERS/Kamil Krzaczynski/File Photo Acquire Licensing Rights", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/3U77DV7QDZPUPMDSMEYSJZOF6I.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}], "overall_sentiment_score": 0.009463, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CVS", "relevance_score": "0.227007", "ticker_sentiment_score": "0.054526", "ticker_sentiment_label": "Neutral"}, {"ticker": "RAD", "relevance_score": "0.114682", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "WBA", "relevance_score": "0.114682", "ticker_sentiment_score": "0.078804", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.114682", "ticker_sentiment_score": "0.051179", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.227007", "ticker_sentiment_score": "0.046958", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.114682", "ticker_sentiment_score": "0.051179", "ticker_sentiment_label": "Neutral"}, {"ticker": "WMT", "relevance_score": "0.114682", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "AI in agriculture Market Size is projected to reach USD 5.96 billion by 2031, growing at a CAGR of 25%: Straits Research", "url": "https://www.benzinga.com/pressreleases/23/09/g34540765/ai-in-agriculture-market-size-is-projected-to-reach-usd-5-96-billion-by-2031-growing-at-a-cagr-of-", "time_published": "20230913T151500", "authors": ["Globe Newswire"], "summary": "New York, United States, Sept. 13, 2023 ( GLOBE NEWSWIRE ) -- AI in farming has become widespread due to its apparent benefits in crop yield and quality.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}], "overall_sentiment_score": 0.205541, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.029839", "ticker_sentiment_score": "0.270131", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "META", "relevance_score": "0.029839", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TMO", "relevance_score": "0.059636", "ticker_sentiment_score": "0.147005", "ticker_sentiment_label": "Neutral"}]}, {"title": "Top Stories Wednesday, Sep 13: Europe Set To Launch Anti-Subsidy Probe Into Chinese EVs, American Airlines and Spirit Lower Profit Outlook, Manchester United's New Shirt Sponsor - Apple  ( NASDAQ:AAPL ) , American Airlines Group  ( NASDAQ:AAL ) ", "url": "https://www.benzinga.com/news/23/09/34537719/europe-set-to-launch-anti-subsidy-probe-into-chinese-evs-american-airlines-and-spirit-lower-profit-o", "time_published": "20230913T141520", "authors": ["Vandana Singh"], "summary": "Chinese electric vehicle company stocks, including XPeng Inc XPEV, NIO Inc NIO, and Li Auto Inc LI, are trading lower Wednesday after Brussels shared plans to launch an anti-subsidy investigation into Chinese EVs that are \"distorting\" the EU market.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/13/xpev_g6.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "IPO", "relevance_score": "0.451494"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.01682, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "XPEV", "relevance_score": "0.061081", "ticker_sentiment_score": "-0.035101", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.061081", "ticker_sentiment_score": "-0.006011", "ticker_sentiment_label": "Neutral"}, {"ticker": "REVG", "relevance_score": "0.061081", "ticker_sentiment_score": "-0.012051", "ticker_sentiment_label": "Neutral"}, {"ticker": "F", "relevance_score": "0.061081", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.030563", "ticker_sentiment_score": "0.111637", "ticker_sentiment_label": "Neutral"}, {"ticker": "BP", "relevance_score": "0.061081", "ticker_sentiment_score": "-0.125018", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.061081", "ticker_sentiment_score": "0.069001", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPR", "relevance_score": "0.061081", "ticker_sentiment_score": "-0.046375", "ticker_sentiment_label": "Neutral"}, {"ticker": "QCOM", "relevance_score": "0.061081", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SAVE", "relevance_score": "0.091509", "ticker_sentiment_score": "0.104012", "ticker_sentiment_label": "Neutral"}, {"ticker": "VIRT", "relevance_score": "0.061081", "ticker_sentiment_score": "-0.185266", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "GOOG", "relevance_score": "0.181819", "ticker_sentiment_score": "-0.137519", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.030563", "ticker_sentiment_score": "0.111637", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAL", "relevance_score": "0.091509", "ticker_sentiment_score": "0.24366", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GS", "relevance_score": "0.030563", "ticker_sentiment_score": "0.111637", "ticker_sentiment_label": "Neutral"}, {"ticker": "QUBSF", "relevance_score": "0.030563", "ticker_sentiment_score": "-0.098227", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSM", "relevance_score": "0.061081", "ticker_sentiment_score": "0.180071", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TMUS", "relevance_score": "0.061081", "ticker_sentiment_score": "0.132023", "ticker_sentiment_label": "Neutral"}, {"ticker": "NIO", "relevance_score": "0.061081", "ticker_sentiment_score": "-0.035101", "ticker_sentiment_label": "Neutral"}, {"ticker": "MANU", "relevance_score": "0.061081", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TM", "relevance_score": "0.061081", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CCZ", "relevance_score": "0.030563", "ticker_sentiment_score": "0.124145", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.181819", "ticker_sentiment_score": "-0.039078", "ticker_sentiment_label": "Neutral"}, {"ticker": "LI", "relevance_score": "0.061081", "ticker_sentiment_score": "-0.035101", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.061081", "ticker_sentiment_score": "0.126019", "ticker_sentiment_label": "Neutral"}, {"ticker": "DB", "relevance_score": "0.061081", "ticker_sentiment_score": "0.003025", "ticker_sentiment_label": "Neutral"}, {"ticker": "BA", "relevance_score": "0.061081", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Moderna, REV Group, Rocket Pharmaceuticals And Other Big Stocks Moving Higher On Wednesday - Carpenter Tech  ( NYSE:CRS ) , Amprius Technologies  ( NYSE:AMPX ) ", "url": "https://www.benzinga.com/news/23/09/34538669/moderna-rev-group-rocket-pharmaceuticals-and-other-big-stocks-moving-higher-on-wednesday", "time_published": "20230913T141359", "authors": ["Lisa Levin"], "summary": "U.S. stocks traded mixed, with the Dow Jones gaining around 10 points on Wednesday. Here are some big stocks recording gains in today's session. Rocket Pharmaceuticals, Inc.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/13/moderna_-_logo.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}], "overall_sentiment_score": 0.337143, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REVG", "relevance_score": "0.316846", "ticker_sentiment_score": "0.619509", "ticker_sentiment_label": "Bullish"}, {"ticker": "CRS", "relevance_score": "0.316846", "ticker_sentiment_score": "0.243382", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SGML", "relevance_score": "0.316846", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMPX", "relevance_score": "0.316846", "ticker_sentiment_score": "0.662736", "ticker_sentiment_label": "Bullish"}, {"ticker": "ECX", "relevance_score": "0.316846", "ticker_sentiment_score": "0.662736", "ticker_sentiment_label": "Bullish"}, {"ticker": "HRT", "relevance_score": "0.459624", "ticker_sentiment_score": "0.406511", "ticker_sentiment_label": "Bullish"}, {"ticker": "MRNA", "relevance_score": "0.316846", "ticker_sentiment_score": "0.164865", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RCKT", "relevance_score": "0.316846", "ticker_sentiment_score": "0.243382", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HAIN", "relevance_score": "0.459624", "ticker_sentiment_score": "0.37591", "ticker_sentiment_label": "Bullish"}, {"ticker": "NM", "relevance_score": "0.16171", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NMM", "relevance_score": "0.316846", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Up 20% in 1 Month, Is This Stock a Buy?", "url": "https://www.fool.com/investing/2023/09/13/up-20-in-1-month-is-this-stock-a-buy/", "time_published": "20230913T140700", "authors": ["Prosper Junior Bakiny"], "summary": "As Covid cases rise, Novavax is getting more attention again. But will the momentum last?", "banner_image": "https://media.ycharts.com/charts/dde93b99c1fa71813c4e3b1280a1678a.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.928769"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}], "overall_sentiment_score": 0.130798, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.112797", "ticker_sentiment_score": "0.185715", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVAX", "relevance_score": "0.47672", "ticker_sentiment_score": "0.174778", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Apple Shares Down While Consumer Prices Are Up", "url": "https://www.forbes.com/sites/jjkinahan/2023/09/13/apple-shares-down-while-consumer-prices-are-up/", "time_published": "20230913T133854", "authors": ["JJ Kinahan"], "summary": "An uninspiring Apple event and disappointing earnings from Oracle sent stocks lower Tuesday.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/6501ad8ca74117c5f14f3f1a/0x0.jpg?format=jpg&width=1200", "source": "Forbes", "category_within_source": "Markets", "source_domain": "www.forbes.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.838487"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.929393"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.614606"}], "overall_sentiment_score": 0.017001, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.057215", "ticker_sentiment_score": "0.015003", "ticker_sentiment_label": "Neutral"}, {"ticker": "GM", "relevance_score": "0.114137", "ticker_sentiment_score": "0.060094", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Is Moderna Stock Trading Higher Today? - Moderna  ( NASDAQ:MRNA ) ", "url": "https://www.benzinga.com/general/biotech/23/09/34534167/why-is-moderna-stock-trading-higher-today", "time_published": "20230913T131315", "authors": ["Vandana Singh"], "summary": "Moderna Inc MRNA announced its intentions to launch up to 15 new products and advance up to 50 mRNA medicines into clinical trials over the next five years. Up to four of those launches could come by 2025.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/13/moderna_covid-19_vaccine_2021_g.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.028231, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.720958", "ticker_sentiment_score": "-0.064807", "ticker_sentiment_label": "Neutral"}]}, {"title": "New Covid vaccines could reach Americans as soon as Thursday - here's what you need to know", "url": "https://www.cnbc.com/2023/09/13/new-covid-vaccines-from-pfizer-and-moderna-what-you-need-to-know.html", "time_published": "20230913T130314", "authors": ["Annika Kim Constantino"], "summary": "Updated Covid vaccines from Pfizer and Moderna will soon be administered at pharmacies, and many other locations across the U.S.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107261566-1687527023180-gettyimages-1252034687-US-NEWS-CORONAVIRUS-CHICAGO-VACCINATIONS-1-TB.jpeg?v=1694610194&w=1920&h=1080", "source": "CNBC", "category_within_source": "Top News", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}], "overall_sentiment_score": 0.068752, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CVS", "relevance_score": "0.090219", "ticker_sentiment_score": "0.065696", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVAX", "relevance_score": "0.067727", "ticker_sentiment_score": "0.026125", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.112638", "ticker_sentiment_score": "0.033408", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.112638", "ticker_sentiment_score": "0.033408", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stocks making the biggest moves premarket: Moderna, American, Spirit Air, Ford and more", "url": "https://www.cnbc.com/2023/09/13/stocks-making-biggest-premarket-moves-moderna-american-air-and-more.html", "time_published": "20230913T122332", "authors": ["Lisa Kailai Han"], "summary": "These are some of the stocks posting the largest moves in premarket trading.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107263506-1687890015984-AP21008694499981.jpg?v=1694607812&w=1920&h=1080", "source": "CNBC", "category_within_source": "Market Insider", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.166024, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "XPEV", "relevance_score": "0.246582", "ticker_sentiment_score": "0.12886", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAL", "relevance_score": "0.124809", "ticker_sentiment_score": "0.076102", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.246582", "ticker_sentiment_score": "0.292198", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NIO", "relevance_score": "0.246582", "ticker_sentiment_score": "0.12886", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.124809", "ticker_sentiment_score": "0.187214", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Moderna says flu vaccine showed promising results in phase three trial, paving path to approval", "url": "https://www.cnbc.com/2023/09/13/moderna-flu-vaccine-shows-promising-phase-three-trial-results.html", "time_published": "20230913T121900", "authors": ["Annika Kim Constantino"], "summary": "Moderna compared the flu vaccine, dubbed mRNA-1010, to a currently approved seasonal flu vaccine from GlaxoSmithKline called Fluarix.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107299908-1694606184669-gettyimages-1400632449-liflu211210_sp_2_of_659862.jpeg?v=1694607540&w=1920&h=1080", "source": "CNBC", "category_within_source": "Business", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.058477, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.733479", "ticker_sentiment_score": "-0.027807", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.088472", "ticker_sentiment_score": "-0.004192", "ticker_sentiment_label": "Neutral"}]}, {"title": "Say Goodbye to Free COVID-19 Shots: CDC Approves Priced Boosters for Omicron Subvariants - Moderna  ( NASDAQ:MRNA ) , Pfizer  ( NYSE:PFE ) ", "url": "https://www.benzinga.com/general/biotech/23/09/34527706/say-goodbye-to-free-covid-19-shots-cdc-approves-priced-boosters-for-omicron-subvariants", "time_published": "20230913T115240", "authors": ["Vandana Singh"], "summary": "The Centers for Disease Control and Prevention ( CDC ) has officially endorsed COVID-19 booster shots for individuals six months and older as we approach the fall season. Monday, the FDA cleared updated booster shots from Pfizer Inc PFE and Moderna Inc MRNA for individuals aged six months and ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/13/pfizer-biontech_covid-19_vaccine_2020_g.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.169884, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.672055", "ticker_sentiment_score": "0.481044", "ticker_sentiment_label": "Bullish"}, {"ticker": "PFE", "relevance_score": "0.585052", "ticker_sentiment_score": "0.53463", "ticker_sentiment_label": "Bullish"}]}, {"title": "ICON to partner with US govt agency to test COVID vaccine candidates", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/icon-partner-with-us-govt-agency-test-covid-19-vaccine-candidates-2023-09-13/", "time_published": "20230913T113919", "authors": ["Reuters"], "summary": "ICON to partner with US govt agency to test COVID-19 vaccine candidates ...", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/U5FW7I4CEZKB7IIE5MSDQQC7XY.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.113217, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ICLR", "relevance_score": "0.200688", "ticker_sentiment_score": "0.094462", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.200688", "ticker_sentiment_score": "-0.193573", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PFE", "relevance_score": "0.200688", "ticker_sentiment_score": "-0.193573", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "BNTX", "relevance_score": "0.200688", "ticker_sentiment_score": "-0.193573", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Moderna to scale down manufacturing of COVID vaccine", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/moderna-scale-down-manufacturing-covid-vaccine-2023-09-13/", "time_published": "20230913T104200", "authors": ["Patrick Wingrove"], "summary": "Sept 13 ( Reuters ) - Moderna ( MRNA.O ) on Wednesday announced it was scaling down manufacturing of its COVID-19 vaccine, an updated version of which was approved this week by U.S. regulators, to align with lower post-pandemic demand and help the company sooner hit its target of 75% to 80% ...", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/VPXRRSLRYRMXZAI5KF6OMXLVXQ.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.067606, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.663374", "ticker_sentiment_score": "0.015157", "ticker_sentiment_label": "Neutral"}, {"ticker": "CTLT", "relevance_score": "0.085022", "ticker_sentiment_score": "-0.107737", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.085022", "ticker_sentiment_score": "-0.107737", "ticker_sentiment_label": "Neutral"}]}, {"title": "Moderna aims to prove it's 'more than a COVID company'", "url": "https://www.marketwatch.com/story/moderna-aims-to-prove-its-more-than-a-covid-company-8681c064", "time_published": "20230913T103200", "authors": ["Eleanor Laise"], "summary": "As COVID vaccine sales fall, Moderna releases positive results from mRNA flu vaccine, adds new development programs ...", "banner_image": "https://images.mktw.net/im-828860/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.031389, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.55727", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GSK", "relevance_score": "0.101797", "ticker_sentiment_score": "0.078452", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.101797", "ticker_sentiment_score": "0.078452", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why A Moderna Exec Says Its Growth Story Is 'Misunderstood'", "url": "https://www.investors.com/news/technology/moderna-stock-why-moderna-executives-say-the-growth-story-is-misunderstood/", "time_published": "20230913T103000", "authors": ["ALLISON GATLIN", "Investor's Business Daily"], "summary": "Moderna Stock: Why Moderna Executives Say The Growth Story Is ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2020/12/Stock-moderna-04-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.962106"}], "overall_sentiment_score": -0.086091, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SLRN", "relevance_score": "0.047654", "ticker_sentiment_score": "0.113058", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.790514", "ticker_sentiment_score": "-0.221379", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PFE", "relevance_score": "0.095138", "ticker_sentiment_score": "-0.048123", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.095138", "ticker_sentiment_score": "-0.048123", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.095138", "ticker_sentiment_score": "-0.078581", "ticker_sentiment_label": "Neutral"}]}, {"title": "The Zacks Analyst Blog Highlights Pfizer, BioNTech, Moderna and Novavax", "url": "https://www.zacks.com/stock/news/2148101/the-zacks-analyst-blog-highlights-pfizer-biontech-moderna-and-novavax", "time_published": "20230913T085100", "authors": ["Zacks Investment Research"], "summary": "Pfizer, BioNTech, Moderna and Novavax are included in this Analyst Blog.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/6f/3484.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.094935, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVAX", "relevance_score": "0.355588", "ticker_sentiment_score": "0.047876", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.539766", "ticker_sentiment_score": "0.056557", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.48182", "ticker_sentiment_score": "0.03761", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.288044", "ticker_sentiment_score": "0.055237", "ticker_sentiment_label": "Neutral"}]}, {"title": "You can now get a new Covid booster shot. Should you?", "url": "https://theweek.com/health/you-can-now-get-a-new-covid-booster-shot-should-you", "time_published": "20230913T052105", "authors": ["Peter Weber"], "summary": "Covid-19 booster shots are now available. Should you get one? The Week ...", "banner_image": "https://cdn.mos.cms.futurecdn.net/pxzBXLiZJxyPC3pSHNhZFk-415-80.jpg", "source": "The Week News", "category_within_source": "n/a", "source_domain": "theweek.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": 0.101553, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NYT", "relevance_score": "0.053153", "ticker_sentiment_score": "0.091673", "ticker_sentiment_label": "Neutral"}, {"ticker": "FRNWF", "relevance_score": "0.053153", "ticker_sentiment_score": "0.058731", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.10607", "ticker_sentiment_score": "0.138324", "ticker_sentiment_label": "Neutral"}, {"ticker": "WLDS", "relevance_score": "0.053153", "ticker_sentiment_score": "-0.056057", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.10607", "ticker_sentiment_score": "0.138324", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:GBP", "relevance_score": "0.053153", "ticker_sentiment_score": "0.008003", "ticker_sentiment_label": "Neutral"}]}, {"title": "CDC Head Gives Final Approval For New Covid Boosters For Most Americans", "url": "https://www.forbes.com/sites/willskipworth/2023/09/12/cdc-head-gives-final-approval-for-new-covid-boosters-for-most-americans/", "time_published": "20230912T225920", "authors": ["William Skipworth"], "summary": "Vaccines are expected to be delivered to pharmacies and providers soon.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/6500cab6ff061865a33e675b/0x0.jpg?format=jpg&crop=1134,638,x0,y56,safe&width=1200", "source": "Forbes", "category_within_source": "Business", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.096152, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "TRMNF", "relevance_score": "0.162802", "ticker_sentiment_score": "0.031364", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.08183", "ticker_sentiment_score": "0.069955", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.08183", "ticker_sentiment_score": "0.069955", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.08183", "ticker_sentiment_score": "0.069955", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's how much the new COVID vaccines will cost", "url": "https://www.foxbusiness.com/healthcare/heres-how-much-new-covid-vaccines-will-cost", "time_published": "20230912T220331", "authors": ["Christine Rousselle"], "summary": "The updated COVID vaccine will be priced between $120 and $130 per dose, the vaccine manufacturers announced on Tuesday, Sept. 12. Speaking at an advisory panel meeting at the Centers for Disease Control and Prevention ( CDC ) , executives from Pfizer, BioNTech, Moderna and Novavax laid out the ...", "banner_image": "https://cf-images.us-east-1.prod.boltdns.net/v1/static/854081161001/b863cdd0-c6c7-4ea9-b686-25b4d058c476/8f2819c8-f0c0-4f36-85cf-a33bb1892bc3/1280x720/match/image.jpg", "source": "Fox Business News", "category_within_source": "n/a", "source_domain": "www.foxbusiness.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.092718, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVAX", "relevance_score": "0.272788", "ticker_sentiment_score": "-0.006097", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.439026", "ticker_sentiment_score": "0.161719", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.358152", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.183895", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Does The Future Of Healthcare Depend On AI?", "url": "https://www.benzinga.com/news/23/09/34505219/does-the-future-of-healthcare-depend-on-ai", "time_published": "20230912T203329", "authors": ["Chris Bibey"], "summary": "With each passing day, the significance of artificial intelligence ( AI ) in the healthcare sector's future is evident. From early detection of diseases and the creation of revolutionary medications to minimizing yearly healthcare expenses, AI's immense potential cannot be disregarded.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/Indian,Male,Serious,Doctor,Medical,Worker,In,Modern,Clinic,Wearing_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.173409, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.075397", "ticker_sentiment_score": "0.189338", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AAPL", "relevance_score": "0.075397", "ticker_sentiment_score": "0.158837", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABNB", "relevance_score": "0.150122", "ticker_sentiment_score": "0.134631", "ticker_sentiment_label": "Neutral"}]}, {"title": "CDC panel recommends updated COVID vaccines. Shots could be ready this week", "url": "https://apnews.com/article/covid-vaccines-shots-cdc-5bc4db844557120bcc50dc0838c0e044", "time_published": "20230912T202600", "authors": ["LAURAN NEERGAARD", "MIKE STOBBE"], "summary": "Americans may soon be able to get an updated COVID-19 vaccine. Advisers to the Centers for Disease Control and Prevention on Tuesday endorsed the new shots for everyone 6 months of age and older. The agency's director is expected to sign off on the panel's recommendation.", "banner_image": "https://dims.apnews.com/dims4/default/4c4ab7d/2147483647/strip/true/crop/1952x1300+24+0/resize/599x399!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2F59%2F66%2F52fa39d1a0a30e552f711ddbf172%2F5158223e9590446a97651439603968aa", "source": "Associated Press", "category_within_source": "Markets", "source_domain": "apnews.com", "topics": [{"topic": "Real Estate & Construction", "relevance_score": "0.5"}, {"topic": "Life Sciences", "relevance_score": "0.5"}], "overall_sentiment_score": 0.063002, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "HHC", "relevance_score": "0.049939", "ticker_sentiment_score": "0.166198", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVAX", "relevance_score": "0.049939", "ticker_sentiment_score": "0.096271", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.099683", "ticker_sentiment_score": "0.102992", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.149038", "ticker_sentiment_score": "0.118804", "ticker_sentiment_label": "Neutral"}]}, {"title": "CDC Panel Recommends New Covid Boosters For Most Americans", "url": "https://www.forbes.com/sites/willskipworth/2023/09/12/cdc-panel-recommends-new-covid-boosters-for-most-americans/", "time_published": "20230912T202038", "authors": ["William Skipworth"], "summary": "Now, the vaccines will need signoff from the CDC director.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/6500cab6ff061865a33e675b/0x0.jpg?format=jpg&crop=1134,638,x0,y56,safe&width=1200", "source": "Forbes", "category_within_source": "Business", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.091139, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "TRMNF", "relevance_score": "0.147818", "ticker_sentiment_score": "0.029451", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.07423", "ticker_sentiment_score": "0.046711", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.07423", "ticker_sentiment_score": "0.046711", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.07423", "ticker_sentiment_score": "0.046711", "ticker_sentiment_label": "Neutral"}]}, {"title": "US CDC panel recommends broad use of updated COVID-19 vaccines", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/us-cdc-panel-recommends-broad-use-updated-covid-19-vaccines-2023-09-12/", "time_published": "20230912T200300", "authors": ["Reuters"], "summary": "The word \"COVID-19\" is reflected in a drop on a syringe needle in this illustration taken November 9, 2020. REUTERS/Dado Ruvic/Illustration/File Photo Acquire Licensing Rights Sept 12 ( Reuters ) - A U.S.", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/JADKZUFW3ZPZPBEIIL6UXHIKEE.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.004724, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVAX", "relevance_score": "0.240489", "ticker_sentiment_score": "0.052874", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.240489", "ticker_sentiment_score": "0.052874", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.240489", "ticker_sentiment_score": "0.052874", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.240489", "ticker_sentiment_score": "0.052874", "ticker_sentiment_label": "Neutral"}]}, {"title": "CDC advisors recommend updated Covid vaccines for all Americans ages 6 months and up", "url": "https://www.cnbc.com/2023/09/12/new-covid-vaccines-cdc-advisors-recommend-pfizer-and-moderna-shots.html", "time_published": "20230912T200057", "authors": ["Annika Kim Constantino"], "summary": "CDC Director Mandy Cohen still has to sign off on the panel's recommendation before the new Pfizer and Moderna Covid vaccines become available nationwide.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107127491-16645571912022-09-30t164750z_1232329474_rc2bdw9yt2gh_rtrmadp_0_health-coronavirus-usa-vaccines.jpeg?v=1694548857&w=1920&h=1080", "source": "CNBC", "category_within_source": "Business", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.007226, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.236281", "ticker_sentiment_score": "0.080378", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.236281", "ticker_sentiment_score": "0.082187", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVAX", "relevance_score": "0.190043", "ticker_sentiment_score": "0.086859", "ticker_sentiment_label": "Neutral"}]}, {"title": "CDC advisers recommend updated COVID shots for people 6 months of age and older", "url": "https://www.marketwatch.com/story/cdc-advisers-recommend-updated-covid-shots-for-people-6-months-of-age-and-older-2a90e1b3", "time_published": "20230912T195900", "authors": ["Eleanor Laise"], "summary": "Newly approved Pfizer and Moderna vaccines to hit pharmacies for fall vaccination season.", "banner_image": "https://images.mktw.net/im-850942/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}], "overall_sentiment_score": 0.156604, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CVS", "relevance_score": "0.176502", "ticker_sentiment_score": "0.02299", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.176502", "ticker_sentiment_score": "0.081583", "ticker_sentiment_label": "Neutral"}, {"ticker": "HCSG", "relevance_score": "0.088799", "ticker_sentiment_score": "0.016652", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.176502", "ticker_sentiment_score": "0.081583", "ticker_sentiment_label": "Neutral"}, {"ticker": "WBA", "relevance_score": "0.176502", "ticker_sentiment_score": "0.02299", "ticker_sentiment_label": "Neutral"}]}, {"title": "CDC advisers recommend updated Covid-19 vaccines", "url": "https://www.cnn.com/2023/09/12/health/cdc-covid-19-vaccines/index.html", "time_published": "20230912T195900", "authors": ["Brenda Goodman"], "summary": "The US Centers for Disease Control and Prevention's independent vaccine advisers voted 13-1 on Tuesday to recommend updated Covid-19 vaccines for all Americans 6 months of age and older. The Advisory Committee on Immunization Practices, or ACIP, is a panel of experts that advises the CDC on its ...", "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/230712185157-covid-vaccine-file.jpg?c=16x9&q=h_144,w_256,c_fill", "source": "CNN", "category_within_source": "Markets", "source_domain": "www.cnn.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.095282, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "WBD", "relevance_score": "0.037504", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVAX", "relevance_score": "0.074926", "ticker_sentiment_score": "0.116718", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.112182", "ticker_sentiment_score": "0.083277", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.112182", "ticker_sentiment_score": "0.083277", "ticker_sentiment_label": "Neutral"}]}, {"title": "MODERNA RECEIVES HEALTH CANADA AUTHORIZATION FOR UPDATED COVID-19 VACCINE FOR AGES SIX ... - Canada NewsWire", "url": "https://www.newswire.ca/news-releases/moderna-receives-health-canada-authorization-for-updated-covid-19-vaccine-for-ages-six-months-and-older-849398298.html", "time_published": "20230912T185500", "authors": [], "summary": "MODERNA RECEIVES HEALTH CANADA AUTHORIZATION FOR UPDATED COVID-19 VACCINE FOR AGES SIX ... Canada ...", "banner_image": null, "source": "Canada Newswire", "category_within_source": "n/a", "source_domain": "www.newswire.ca", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.240824, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.609676", "ticker_sentiment_score": "0.352765", "ticker_sentiment_label": "Bullish"}]}, {"title": "COVID vaccine manufacturers set list price between $120-$130 per dose", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/covid-vaccine-manufacturers-set-list-price-between-120-130-per-dose-2023-09-12/", "time_published": "20230912T180500", "authors": ["Reuters"], "summary": "A patient receives their coronavirus disease ( COVID-19 ) vaccine booster during a Pfizer-BioNTech vaccination clinic in Southfield, Michigan, U.S., September 29, 2021. REUTERS/Emily Elconin/File photo Acquire Licensing Rights Sept 12 ( Reuters ) - U.S.", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/LK57GUEPHRNRFIRMNHON6C567M.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.117406, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVAX", "relevance_score": "0.306963", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.306963", "ticker_sentiment_score": "0.184446", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.570165", "ticker_sentiment_score": "0.307379", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BNTX", "relevance_score": "0.570165", "ticker_sentiment_score": "0.307379", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Will A Jump To An 8-Month High Erase This Biotech's Recent Setbacks?", "url": "https://www.investors.com/news/technology/nbix-stock-why-neurocrine-shares-surged-within-striking-distance-of-a-breakout/", "time_published": "20230912T161200", "authors": ["ALLISON GATLIN", "Investor's Business Daily"], "summary": "NBIX Stock: Why Neurocrine Shares Surged Within Striking ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2022/08/Stock-neurocrinebio-01-shutt.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.177048, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NVAX", "relevance_score": "0.091162", "ticker_sentiment_score": "-0.174067", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "SLRN", "relevance_score": "0.091162", "ticker_sentiment_score": "0.12313", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.091162", "ticker_sentiment_score": "-0.174067", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PFE", "relevance_score": "0.091162", "ticker_sentiment_score": "-0.174067", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "NBIX", "relevance_score": "0.43303", "ticker_sentiment_score": "0.091486", "ticker_sentiment_label": "Neutral"}]}, {"title": "Moderna  ( MRNA ) , Immatics Ink Deal to Develop New Cancer Therapies", "url": "https://www.zacks.com/stock/news/2147964/moderna-mrna-immatics-ink-deal-to-develop-new-cancer-therapies", "time_published": "20230912T155600", "authors": ["Zacks Equity Research"], "summary": "The deal will combine Moderna (MRNA) and Immatics' (IMTX) proprietary platforms to develop innovative immunotherapies for cancer.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/db/3160.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.576289"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.086321, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ANVS", "relevance_score": "0.256989", "ticker_sentiment_score": "0.074638", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.674691", "ticker_sentiment_score": "0.167847", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Top Stories Tuesday, Sep 12: DraftKings Apologizes For 9/11 'Never Forget' Parlay Promotion, Apple Set For Selling 'Made In India' iPhone 15 on Launch Day, MGM Resorts Faces Ongoing Cyber Incident - Apple  ( NASDAQ:AAPL ) , Amazon.com  ( NASDAQ:AMZN ) ", "url": "https://www.benzinga.com/news/23/09/34490786/draftkings-apologizes-for-911-never-forget-parlay-promotion-apple-set-for-selling-made-in-india-ipho", "time_published": "20230912T143257", "authors": ["Vandana Singh"], "summary": "DraftKings Inc DKNG has apologized for a parlay that the app featured on Sunday night. DraftKings shares featured parlays on its app, such as the current offerings of the \"Shay Shay Parlay,\" which includes three betting picks from Shannon Sharpe, or the \"Hard Knocks\" parlay, which includes four ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/12/dkng.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Real Estate & Construction", "relevance_score": "0.166667"}], "overall_sentiment_score": 0.185815, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DKNG", "relevance_score": "0.12546", "ticker_sentiment_score": "0.058281", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.083833", "ticker_sentiment_score": "0.164876", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AAPL", "relevance_score": "0.12546", "ticker_sentiment_score": "-0.01539", "ticker_sentiment_label": "Neutral"}, {"ticker": "F", "relevance_score": "0.083833", "ticker_sentiment_score": "-0.071567", "ticker_sentiment_label": "Neutral"}, {"ticker": "GM", "relevance_score": "0.083833", "ticker_sentiment_score": "-0.071567", "ticker_sentiment_label": "Neutral"}, {"ticker": "SMFTF", "relevance_score": "0.041975", "ticker_sentiment_score": "0.248837", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.083833", "ticker_sentiment_score": "0.097902", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.083833", "ticker_sentiment_score": "0.097902", "ticker_sentiment_label": "Neutral"}, {"ticker": "STLA", "relevance_score": "0.083833", "ticker_sentiment_score": "-0.071567", "ticker_sentiment_label": "Neutral"}, {"ticker": "WRK", "relevance_score": "0.166743", "ticker_sentiment_score": "0.348271", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MGM", "relevance_score": "0.166743", "ticker_sentiment_score": "0.041884", "ticker_sentiment_label": "Neutral"}, {"ticker": "SLRN", "relevance_score": "0.083833", "ticker_sentiment_score": "-0.135273", "ticker_sentiment_label": "Neutral"}, {"ticker": "GFS", "relevance_score": "0.083833", "ticker_sentiment_score": "0.039696", "ticker_sentiment_label": "Neutral"}, {"ticker": "QCOM", "relevance_score": "0.083833", "ticker_sentiment_score": "-0.005158", "ticker_sentiment_label": "Neutral"}, {"ticker": "CDNS", "relevance_score": "0.083833", "ticker_sentiment_score": "0.164876", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "UPS", "relevance_score": "0.083833", "ticker_sentiment_score": "-0.093113", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVAX", "relevance_score": "0.083833", "ticker_sentiment_score": "0.126524", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.083833", "ticker_sentiment_score": "0.097902", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.12546", "ticker_sentiment_score": "0.178332", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "FDA Approves Pfizer & Moderna's New COVID Booster Vaccines", "url": "https://www.zacks.com/stock/news/2147828/fda-approves-pfizer-modernas-new-covid-booster-vaccines", "time_published": "20230912T142600", "authors": ["Kinjel Shah"], "summary": "Pfizer (PFE)/ BioNTech (BNTX), and Moderna's (MRNA) updated mRNA vaccines are now approved for individuals 12 years of age and older and are authorized under emergency use for individuals 6 months through 11 years of age.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/96/702.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.104685, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVAX", "relevance_score": "0.316846", "ticker_sentiment_score": "0.060752", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.524949", "ticker_sentiment_score": "0.062714", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.459624", "ticker_sentiment_score": "0.045984", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.240489", "ticker_sentiment_score": "0.08638", "ticker_sentiment_label": "Neutral"}]}, {"title": "What to Know About the New Covid Booster Shots", "url": "https://www.nytimes.com/2023/09/11/well/live/covid-vaccine-booster-fall.html", "time_published": "20230912T134700", "authors": ["Knvul Sheikh"], "summary": "Two new Covid shots have received the green light from the Food and Drug Administration. The Centers for Disease Control and Prevention is expected to follow up with guidance on eligibility as soon as Tuesday, making the new vaccines from Pfizer-BioNTech and Moderna available as Covid cases ...", "banner_image": "https://static01.nyt.com/images/2023/09/12/multimedia/12WELL-COVID-BOOSTER1-zfck/12WELL-COVID-BOOSTER1-zfck-articleLarge.jpg?quality=75&auto=webp&disable=upscale", "source": "New York Times", "category_within_source": "GoogleRSS", "source_domain": "www.nytimes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}], "overall_sentiment_score": 0.083964, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CVS", "relevance_score": "0.048523", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVAX", "relevance_score": "0.048523", "ticker_sentiment_score": "0.121952", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.144853", "ticker_sentiment_score": "0.112765", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.144853", "ticker_sentiment_score": "0.112765", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.048523", "ticker_sentiment_score": "0.110986", "ticker_sentiment_label": "Neutral"}]}, {"title": "The Surprising News That Sent One Biotech Up 19% And Another Down 59%", "url": "https://www.investors.com/news/technology/mltx-stock-flirts-with-new-record-on-unexpected-setback-for-rival-acelyrin/", "time_published": "20230912T133700", "authors": ["Investor's Business Daily", "ALLISON GATLIN"], "summary": "MLTX Stock Flirts With New Record On Unexpected Setback For ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2017/12/Stock-biotech-12-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.955357"}], "overall_sentiment_score": 0.084541, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVAX", "relevance_score": "0.140896", "ticker_sentiment_score": "-0.204993", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "SLRN", "relevance_score": "0.522333", "ticker_sentiment_score": "-0.066246", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.140896", "ticker_sentiment_score": "-0.204993", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PFE", "relevance_score": "0.140896", "ticker_sentiment_score": "-0.204993", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MLTX", "relevance_score": "0.522333", "ticker_sentiment_score": "0.085909", "ticker_sentiment_label": "Neutral"}]}, {"title": "10 things you need to know today: September 12, 2023", "url": "https://theweek.com/digest/round-up/10-things-you-need-to-know-today-september-12-2023", "time_published": "20230912T121450", "authors": ["Harold Maass"], "summary": "1. US to release $6 billion to Iran under prisoner swap 2. Kim arrives in Russia for talks with Putin 4. Morocco earthquake death toll rises as frantic rescue efforts continue 5. UK says Russia attacked civilian cargo ship in Black Sea port", "banner_image": "https://cdn.mos.cms.futurecdn.net/FNuYBSupizjMBzkFwi6gGU-415-80.jpg", "source": "The Week News", "category_within_source": "n/a", "source_domain": "theweek.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": -0.043765, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "FRNWF", "relevance_score": "0.02241", "ticker_sentiment_score": "0.052075", "ticker_sentiment_label": "Neutral"}, {"ticker": "WBD", "relevance_score": "0.02241", "ticker_sentiment_score": "-0.133207", "ticker_sentiment_label": "Neutral"}, {"ticker": "CHTR", "relevance_score": "0.02241", "ticker_sentiment_score": "0.10059", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.02241", "ticker_sentiment_score": "-0.017796", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOX", "relevance_score": "0.02241", "ticker_sentiment_score": "0.049379", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.02241", "ticker_sentiment_score": "-0.017796", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.02241", "ticker_sentiment_score": "-0.017796", "ticker_sentiment_label": "Neutral"}]}, {"title": "The New Stakes in Pay-TV Battles to Come", "url": "https://www.nytimes.com/2023/09/12/business/dealbook/disney-charter-pay-tv.html", "time_published": "20230912T121340", "authors": ["Andrew Ross Sorkin", "Lauren Hirsch", "Ephrat Livni", "Sarah Kessler", "Michael J. de la Merced", "Bernhard Warner", "Ravi Mattu"], "summary": "Disney's deal with Charter will give it more streaming customers, but it also reflects concessions that other content providers will have to make in the future.", "banner_image": "https://static01.nyt.com/images/2023/09/12/multimedia/12db-rodgers-lcbz/12db-rodgers-lcbz-articleLarge.jpg?quality=75&auto=webp&disable=upscale", "source": "New York Times", "category_within_source": "Dealbook", "source_domain": "www.nytimes.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.769861"}, {"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.026769, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.167758", "ticker_sentiment_score": "0.067849", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.167758", "ticker_sentiment_score": "0.063849", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.021124", "ticker_sentiment_score": "0.198006", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PARA", "relevance_score": "0.021124", "ticker_sentiment_score": "0.015481", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.021124", "ticker_sentiment_score": "0.006728", "ticker_sentiment_label": "Neutral"}, {"ticker": "SFTBF", "relevance_score": "0.021124", "ticker_sentiment_score": "0.080465", "ticker_sentiment_label": "Neutral"}, {"ticker": "YELP", "relevance_score": "0.021124", "ticker_sentiment_score": "0.020459", "ticker_sentiment_label": "Neutral"}, {"ticker": "CHTR", "relevance_score": "0.021124", "ticker_sentiment_score": "-0.0445", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.021124", "ticker_sentiment_score": "-0.014921", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.021124", "ticker_sentiment_score": "-0.014921", "ticker_sentiment_label": "Neutral"}, {"ticker": "BA", "relevance_score": "0.021124", "ticker_sentiment_score": "0.058781", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.021124", "ticker_sentiment_score": "-0.014921", "ticker_sentiment_label": "Neutral"}]}, {"title": "US CDC contemplates who should get the new COVID shots", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/us-cdc-contemplates-who-should-get-new-covid-shots-2023-09-12/", "time_published": "20230912T100600", "authors": ["Julie Steenhuysen", "Bhanvi Satija"], "summary": "Syringes ready to be administrated to residents who are over 50 years old and immunocompromised and are eligible to receive their second booster shots of the coronavirus disease ( COVID-19 ) vaccines are seen in Waterford, Michigan, U.S., April 8, 2022. REUTERS/Emily Elconin/File Photo Acquire ...", "banner_image": "https://s3.amazonaws.com/arc-authors/reuters/24e53264-190b-4097-835a-edeca236a9f4.png", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.030992, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVAX", "relevance_score": "0.174167", "ticker_sentiment_score": "0.142584", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.174167", "ticker_sentiment_score": "0.142584", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.116631", "ticker_sentiment_score": "0.114184", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.116631", "ticker_sentiment_score": "0.114184", "ticker_sentiment_label": "Neutral"}]}, {"title": "What to know about the updated Pfizer, Moderna COVID vaccines", "url": "https://www.aljazeera.com/news/2023/9/12/fda-approves-updated-pfizer-moderna-covid-vaccines-here-is-what-to-know", "time_published": "20230912T092948", "authors": ["Al Jazeera"], "summary": "FDA approves updated Pfizer, Moderna COVID vaccines: Here is what to know Al Jazeera English ...", "banner_image": "https://www.aljazeera.com/wp-content/uploads/2021/08/AP21215544491116.jpg?resize=730%2C410&quality=80", "source": "Al Jareeza", "category_within_source": "n/a", "source_domain": "www.aljazeera.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.029101, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.164468", "ticker_sentiment_score": "0.147968", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.164468", "ticker_sentiment_score": "0.147968", "ticker_sentiment_label": "Neutral"}]}, {"title": "C.D.C. Advisers to Decide Who Should Receive New Covid Vaccines", "url": "https://www.nytimes.com/2023/09/12/health/covid-cdc-vaccines.html", "time_published": "20230912T090207", "authors": ["Apoorva Mandavilli"], "summary": "Americans may be able to receive the next Covid shots as early as Wednesday, the last of a trifecta of vaccines intended to prevent respiratory infections this fall and winter. On Monday, the Food and Drug Administration authorized updated Covid vaccines by Pfizer and Moderna.", "banner_image": "https://static01.nyt.com/images/2023/09/12/multimedia/12covid-vaccines-hlvt/12covid-vaccines-hlvt-articleLarge.jpg?quality=75&auto=webp&disable=upscale", "source": "New York Times", "category_within_source": "GoogleRSS", "source_domain": "www.nytimes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.014543, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.072876", "ticker_sentiment_score": "0.046276", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.072876", "ticker_sentiment_score": "0.046276", "ticker_sentiment_label": "Neutral"}]}, {"title": "2024 GOP contenders clash over Covid-19 records as they warn against future mandates | Politics", "url": "https://edition.cnn.com/2023/09/12/politics/covid-republican-president-candidates-warning/index.html", "time_published": "20230912T090100", "authors": ["Eric Bradner"], "summary": "2024 GOP contenders clash over Covid-19 records as they warn against future mandates CNN International ...", "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/230908185231-01-trump-sd-rally-0908.jpg?c=16x9&q=h_144,w_256,c_fill", "source": "CNN", "category_within_source": "Economy", "source_domain": "edition.cnn.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.007171, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.041039", "ticker_sentiment_score": "0.060071", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOX", "relevance_score": "0.08197", "ticker_sentiment_score": "-0.086752", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.041039", "ticker_sentiment_score": "0.060071", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.041039", "ticker_sentiment_score": "0.060071", "ticker_sentiment_label": "Neutral"}]}, {"title": "2024 GOP contenders clash over Covid-19 records as they warn against future mandates | Politics", "url": "https://www.cnn.com/2023/09/12/politics/covid-republican-president-candidates-warning/index.html", "time_published": "20230912T090100", "authors": ["Eric Bradner"], "summary": "2024 GOP contenders clash over Covid-19 records as they warn against future mandates ...", "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/230908185231-01-trump-sd-rally-0908.jpg?c=16x9&q=h_144,w_256,c_fill", "source": "CNN", "category_within_source": "Economy", "source_domain": "www.cnn.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.007171, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.041039", "ticker_sentiment_score": "0.060071", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOX", "relevance_score": "0.08197", "ticker_sentiment_score": "-0.086752", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.041039", "ticker_sentiment_score": "0.060071", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.041039", "ticker_sentiment_score": "0.060071", "ticker_sentiment_label": "Neutral"}]}, {"title": "TSLA, ORCL, NVAX, DKNG, PFE: Top 5 Trending Stocks - DraftKings  ( NASDAQ:DKNG ) , Tesla  ( NASDAQ:TSLA ) , Oracle  ( NYSE:ORCL ) , Novavax  ( NASDAQ:NVAX ) , Pfizer  ( NYSE:PFE ) ", "url": "https://www.benzinga.com/markets/equities/23/09/34466205/tesla-oracle-novavax-draftkings-pfizer-why-these-five-stocks-are-tending-today", "time_published": "20230912T022651", "authors": ["Benzinga Neuro"], "summary": "U.S. stocks showcased a positive momentum as the trading day approached its end. The Nasdaq Composite exhibited a notable rise, gaining more than 1% on Monday. The tech-heavy index closed at 13,917.89 for the day. The Dow Jones Industrial Average also reflected an upward trend, increasing by ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/Stocks_Photo_by_Phongphan_on_Shutterstock_9.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.5855"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.108179"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.15598, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DKNG", "relevance_score": "0.173333", "ticker_sentiment_score": "0.09081", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.087185", "ticker_sentiment_score": "0.10299", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.087185", "ticker_sentiment_score": "0.10299", "ticker_sentiment_label": "Neutral"}, {"ticker": "ORCL", "relevance_score": "0.173333", "ticker_sentiment_score": "0.09472", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVAX", "relevance_score": "0.173333", "ticker_sentiment_score": "0.008775", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.087185", "ticker_sentiment_score": "0.006315", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.173333", "ticker_sentiment_score": "-0.029058", "ticker_sentiment_label": "Neutral"}]}, {"title": "The F.D.A. Approved New Covid Shots", "url": "https://www.nytimes.com/2023/09/11/briefing/fda-covid-shots-elon-musk-book.html", "time_published": "20230911T214219", "authors": ["Matthew Cullen"], "summary": "The F.D.A. gave the green light today to a new round of Covid boosters, the first to be approved since the public health emergency ended in May. The move comes as the Biden administration is preparing a campaign to convince Americans to get immunized, and as Covid cases tick up.", "banner_image": "https://static01.nyt.com/images/2023/09/11/science/11evening-nl-FDA/11evening-nl-FDA-articleLarge-v2.jpg?quality=75&auto=webp&disable=upscale", "source": "New York Times", "category_within_source": "GoogleRSS", "source_domain": "www.nytimes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": 0.002424, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NFLX", "relevance_score": "0.032602", "ticker_sentiment_score": "0.250339", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.032602", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.032602", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TWNK", "relevance_score": "0.032602", "ticker_sentiment_score": "0.166199", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Moderna, Pfizer Get FDA Nod For Omicron COVID Boosters While Novavax Waits - Novavax  ( NASDAQ:NVAX ) , Moderna  ( NASDAQ:MRNA ) , Pfizer  ( NYSE:PFE ) ", "url": "https://www.benzinga.com/general/biotech/23/09/34457751/moderna-pfizer-get-fda-nod-for-omicron-covid-boosters-while-novavax-waits", "time_published": "20230911T205735", "authors": ["AJ Fabino"], "summary": "The U.S. Food and Drug Administration on Monday approved and authorized updated COVID-19 vaccines by Moderna Inc MRNA and partners Pfizer Inc PFE and BioNTech SE BNTX aimed at better countering circulating viral strains, including the omicron variant XBB.1.5.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/11/shutterstock_1690179541.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.14556, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVAX", "relevance_score": "0.280615", "ticker_sentiment_score": "0.25343", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.52759", "ticker_sentiment_score": "0.159456", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.52759", "ticker_sentiment_score": "0.159456", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BNTX", "relevance_score": "0.280615", "ticker_sentiment_score": "0.237319", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Arbutus Announces Pipeline Updates and Dosing of the First Subject in the Phase 1a/1b Clinical Trial with AB-101; Cash Runway Extended - Arbutus Biopharma  ( NASDAQ:ABUS ) ", "url": "https://www.benzinga.com/pressreleases/23/09/g34456832/arbutus-announces-pipeline-updates-and-dosing-of-the-first-subject-in-the-phase-1a1b-clinical-tria", "time_published": "20230911T201500", "authors": ["Globe Newswire"], "summary": "WARMINSTER, Pa., Sept. 11, 2023 ( GLOBE NEWSWIRE ) -- Arbutus Biopharma Corporation ABUS ( \"Arbutus\" or the \"Company\" ) , a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}], "overall_sentiment_score": 0.024373, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ABUS", "relevance_score": "0.087583", "ticker_sentiment_score": "0.008458", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.065745", "ticker_sentiment_score": "0.047539", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.087583", "ticker_sentiment_score": "0.049805", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.043858", "ticker_sentiment_score": "0.046865", "ticker_sentiment_label": "Neutral"}]}, {"title": "Arbutus Announces Pipeline Updates and Dosing of the First Subject in the Phase 1a/1b Clinical Trial with AB-101; Cash Runway Extended", "url": "https://www.globenewswire.com/news-release/2023/09/11/2741168/14025/en/Arbutus-Announces-Pipeline-Updates-and-Dosing-of-the-First-Subject-in-the-Phase-1a-1b-Clinical-Trial-with-AB-101-Cash-Runway-Extended.html", "time_published": "20230911T201500", "authors": ["Arbutus Biopharma Corporation"], "summary": "Progressing development of hepatitis B virus ( HBV ) compounds imdusiran ( AB-729 ) and AB-101, an oral PD-L1 inhibitor ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/be474abd-3f6d-4270-a58e-1e6ee5c80bb2", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.019531, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ABUS", "relevance_score": "0.087027", "ticker_sentiment_score": "0.009514", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.065327", "ticker_sentiment_score": "0.047512", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.087027", "ticker_sentiment_score": "0.049728", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.043579", "ticker_sentiment_score": "0.046852", "ticker_sentiment_label": "Neutral"}]}, {"title": "US Approves Updated Covid Vaccines For Fall", "url": "https://www.barrons.com/news/us-approves-updated-covid-vaccines-for-fall-3ceceedc", "time_published": "20230911T193700", "authors": ["Issam AHMED"], "summary": "The United States on Monday approved Covid vaccines with formulations that more closely target currently circulating variants, as infections are once more on the rise. The new approvals relate to updated vaccines produced by Moderna and Pfizer that correspond to an Omicron sublineage.", "banner_image": "https://www.barrons.com/asset/external-media/afp/AFP6178447553491632108684283300315864673912---1.jpg", "source": "Barrons", "category_within_source": "n/a", "source_domain": "www.barrons.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.134776, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.227716", "ticker_sentiment_score": "0.037935", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.152983", "ticker_sentiment_score": "-0.006775", "ticker_sentiment_label": "Neutral"}]}, {"title": "Novavax Dives As Pfizer, Moderna Snag First Nods For Covid Boosters", "url": "https://www.investors.com/news/technology/novavax-stock-dives-as-pfizer-moderna-win-first-fda-ok-for-covid-boosters/", "time_published": "20230911T191000", "authors": ["ALLISON GATLIN", "Investor's Business Daily"], "summary": "Novavax Dives As Pfizer, Moderna Snag First Nods For Covid ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2021/10/Stock-covidshotdistribute-02-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.990999"}], "overall_sentiment_score": 0.089781, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVAX", "relevance_score": "0.694113", "ticker_sentiment_score": "0.201562", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.587278", "ticker_sentiment_score": "0.135554", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.587278", "ticker_sentiment_score": "0.135554", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.081552", "ticker_sentiment_score": "0.094784", "ticker_sentiment_label": "Neutral"}]}, {"title": "Explainer: Who should get a COVID vaccine this year?", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/who-should-get-covid-vaccine-this-year-2023-09-11/", "time_published": "20230911T190403", "authors": ["Michael Erman"], "summary": "A nurse fills up syringes with the coronavirus disease ( COVID-19 ) vaccines for residents who are over 50 years old and immunocompromised and are eligible to receive their second booster shots in Waterford, Michigan, U.S., April 8, 2022. REUTERS/Emily Elconin/File Photo Acquire Licensing Rights", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/6PQ2MLKOTJJRBAO7ILLTDEUPZY.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.019173, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVAX", "relevance_score": "0.11123", "ticker_sentiment_score": "0.024564", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.11123", "ticker_sentiment_score": "0.024564", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.11123", "ticker_sentiment_score": "0.024564", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.11123", "ticker_sentiment_score": "0.024564", "ticker_sentiment_label": "Neutral"}]}, {"title": "Check Out What Whales Are Doing With MRNA - Moderna  ( NASDAQ:MRNA ) ", "url": "https://www.benzinga.com/markets/options/23/09/34454328/check-out-what-whales-are-doing-with-mrna", "time_published": "20230911T190149", "authors": ["Benzinga Insights"], "summary": "A whale with a lot of money to spend has taken a noticeably bullish stance on Moderna. Looking at options history for Moderna MRNA we detected 14 strange trades. If we consider the specifics of each trade, it is accurate to state that 57% of the investors opened trades with bullish expectations ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.155079, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.818966", "ticker_sentiment_score": "0.419649", "ticker_sentiment_label": "Bullish"}]}, {"title": "New Pfizer and Moderna COVID shots approved by FDA", "url": "https://www.marketwatch.com/story/pfizer-and-moderna-updated-covid-vaccines-approved-by-fda-449108b", "time_published": "20230911T190100", "authors": ["Eleanor Laise"], "summary": "CDC is set to vote on the new shots Tuesday, but questions remain about costs for uninsured people.", "banner_image": "https://images.mktw.net/im-834406/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.08481, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVAX", "relevance_score": "0.194242", "ticker_sentiment_score": "0.203977", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.433877", "ticker_sentiment_score": "0.175596", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.433877", "ticker_sentiment_score": "0.175596", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BNTX", "relevance_score": "0.194242", "ticker_sentiment_score": "0.054908", "ticker_sentiment_label": "Neutral"}]}, {"title": "FDA Approves New Covid Vaccines To Target Latest Strains", "url": "https://www.forbes.com/sites/willskipworth/2023/09/11/fda-approves-new-covid-vaccines-to-target-latest-strains/", "time_published": "20230911T183327", "authors": ["William Skipworth"], "summary": "The updated booster shots arrive as new coronavirus variants circulate.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/64ff6920eb033e3b7f6445b8/0x0.jpg?format=jpg&crop=2516,1414,x0,y104,safe&width=1200", "source": "Forbes", "category_within_source": "Business", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": -0.02156, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "TRMNF", "relevance_score": "0.097259", "ticker_sentiment_score": "-0.048751", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVAX", "relevance_score": "0.04872", "ticker_sentiment_score": "-0.014868", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.193078", "ticker_sentiment_score": "-0.024636", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.375016", "ticker_sentiment_score": "0.031565", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.286082", "ticker_sentiment_score": "0.025632", "ticker_sentiment_label": "Neutral"}]}, {"title": "US approves updated COVID vaccines to rev up protection this fall", "url": "https://apnews.com/article/covid-vaccines-coronavirus-234f27c74438fb4812a014dbd98ddbde", "time_published": "20230911T180500", "authors": ["LAURAN NEERGAARD"], "summary": "WASHINGTON ( AP ) - The U.S. approved updated COVID-19 vaccines Monday, hoping to rev up protection against the latest coronavirus strains and blunt any surge this fall and winter.", "banner_image": "https://dims.apnews.com/dims4/default/a2de2bc/2147483647/strip/true/crop/3000x1998+0+1/resize/599x399!/quality/90/?url=https%3A%2F%2Fstorage.googleapis.com%2Fafs-prod%2Fmedia%2F60513dc5f5934044a4c5ab2fcbcf4344%2F3000.jpeg", "source": "Associated Press", "category_within_source": "Markets", "source_domain": "apnews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Real Estate & Construction", "relevance_score": "0.5"}], "overall_sentiment_score": -0.048863, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "HHC", "relevance_score": "0.098659", "ticker_sentiment_score": "0.177423", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.098659", "ticker_sentiment_score": "-0.039894", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.098659", "ticker_sentiment_score": "-0.039894", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.098659", "ticker_sentiment_score": "-0.039894", "ticker_sentiment_label": "Neutral"}]}, {"title": "US FDA authorizes updated COVID vaccines", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-authorizes-updated-covid-vaccines-2023-09-11/", "time_published": "20230911T175500", "authors": ["Reuters"], "summary": "Sept 11 ( Reuters ) - The U.S. health regulator on Monday authorized updated COVID-19 vaccines that closely match the Omicron variants that are circulating, starting the process to deploy the shots this month.", "banner_image": "https://www.reuters.com/pf/resources/images/reuters/reuters-default.webp?d=156", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.0, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.595343", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.595343", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.595343", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "FDA signs off on updated Covid-19 vaccines to target circulating variants", "url": "https://www.cnn.com/2023/09/11/health/fda-signs-off-on-updated-covid-19-vaccines/index.html", "time_published": "20230911T175005", "authors": ["Jacqueline Howard"], "summary": "FDA signs off on updated Covid-19 vaccines that target circulating variants ...", "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/230827052600-exp-covid-cases-rising-dr-chris-t-pernell-intv-082703aseg3-cnni-health-00002001.png?c=16x9&q=h_144,w_256,c_fill", "source": "CNN", "category_within_source": "Markets", "source_domain": "www.cnn.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}], "overall_sentiment_score": 0.076476, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "WBD", "relevance_score": "0.047465", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CVS", "relevance_score": "0.047465", "ticker_sentiment_score": "0.061733", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.094762", "ticker_sentiment_score": "0.041718", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.188193", "ticker_sentiment_score": "0.050965", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.141726", "ticker_sentiment_score": "0.079143", "ticker_sentiment_label": "Neutral"}]}, {"title": "FDA approves updated Covid vaccines from Pfizer and Moderna as hospitalizations rise", "url": "https://www.cnbc.com/2023/09/11/covid-vaccines-fda-approves-new-shots-from-pfizer-moderna.html", "time_published": "20230911T174948", "authors": ["Annika Kim Constantino"], "summary": "The Biden administration said it expects the new Pfizer and Moderna vaccines targeting the omicron variant XBB.1.5 to be available in mid-September.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107007489-1643303810715-gettyimages-1238021606-MASSACHUSETTS_VACCINES.jpeg?v=1694454588&w=1920&h=1080", "source": "CNBC", "category_within_source": "Business", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.050262, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.288214", "ticker_sentiment_score": "0.119534", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.342487", "ticker_sentiment_score": "0.216679", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVAX", "relevance_score": "0.175433", "ticker_sentiment_score": "0.127808", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stocks making the biggest moves midday: Tesla, Qualcomm, Meta, Moderna and more", "url": "https://www.cnbc.com/2023/09/11/stocks-making-the-biggest-moves-midday-tesla-qualcomm-meta-moderna-and-more.html", "time_published": "20230911T154848", "authors": ["Hakyung Kim"], "summary": "These are the stocks posting the largest moves in midday trading.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107274568-1689896482590-gettyimages-1543385301-cfoto-teslaq2r230720_np5tD.jpeg?v=1694447328&w=1920&h=1080", "source": "CNBC", "category_within_source": "Market Insider", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.186247, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BABA", "relevance_score": "0.145145", "ticker_sentiment_score": "-0.018558", "ticker_sentiment_label": "Neutral"}, {"ticker": "TENB", "relevance_score": "0.072876", "ticker_sentiment_score": "0.066294", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.072876", "ticker_sentiment_score": "0.120255", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.216215", "ticker_sentiment_score": "0.178306", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MS", "relevance_score": "0.072876", "ticker_sentiment_score": "0.120255", "ticker_sentiment_label": "Neutral"}, {"ticker": "NU", "relevance_score": "0.216215", "ticker_sentiment_score": "0.214883", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TWNK", "relevance_score": "0.072876", "ticker_sentiment_score": "0.153785", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "KVUE", "relevance_score": "0.145145", "ticker_sentiment_score": "0.27573", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CHTR", "relevance_score": "0.072876", "ticker_sentiment_score": "0.156639", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.145145", "ticker_sentiment_score": "-0.146497", "ticker_sentiment_label": "Neutral"}]}, {"title": "Longeveron  ( NASDAQ: LGVN )  Reports 100% 5-Year Survival In Trial For Rare Pediatric Disease HLHS  ( Compared To 80% Survival In Historical Trials )  To Market - Longeveron  ( NASDAQ:LGVN ) , Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/general/biotech/23/09/34436783/longeveron-nasdaq-lgvn-reports-100-5-year-survival-in-trial-for-rare-pediatric-disease-hlhs-compa", "time_published": "20230911T120509", "authors": ["David Willey"], "summary": "Advancements in healthcare and medicine have helped contribute to the reduction in child mortality rates, plummeting from 185 per 1,000 births a century ago to just 7 per 1,000 births in 2020. However, some serious pediatric conditions continue to pose a threat.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/11/screenshot_2023-09-11_at_5.33.52_pm.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.223302, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LGVN", "relevance_score": "0.254307", "ticker_sentiment_score": "0.328893", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.128822", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.128822", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Covid vaccine rollout begins early in the UK with new variant under watch", "url": "https://www.cnbc.com/2023/09/11/uk-begins-covid-vaccine-rollout-early-with-new-variant-under-watch.html", "time_published": "20230911T113826", "authors": ["Jenni Reid"], "summary": "The National Health Service wants to avoid another \"twindemic\" of Covid and flu putting strain on hospitals.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107296311-16940025401694002533-31077960630-1080pnbcnews.jpg?v=1694007496&w=750&h=422&vtcrop=y", "source": "CNBC", "category_within_source": "Top News", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.02668, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVAX", "relevance_score": "0.070517", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.070517", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.070517", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.070517", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.070517", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Moderna, Immatics to work jointly on cancer vaccines", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/moderna-immatics-work-jointly-cancer-vaccines-2023-09-11/", "time_published": "20230911T113200", "authors": ["Reuters"], "summary": "Syringes with needles are seen in front of a displayed Moderna logo in this illustration taken, November 27, 2021. REUTERS/Dado Ruvic/Illustration/File Photo Acquire Licensing Rights", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/3VLHFOFHNVNINLQQJJP6V3KH44.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.188638, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.913524", "ticker_sentiment_score": "-0.32742", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer - PR Newswire", "url": "https://www.prnewswire.com/news-releases/flagship-pioneering-announces-appointment-of-amanda-kay-as-chief-business-development-officer-301922352.html", "time_published": "20230911T103000", "authors": [], "summary": "Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer PR ...", "banner_image": null, "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.292631, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MCRB", "relevance_score": "0.091335", "ticker_sentiment_score": "0.150011", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FHTX", "relevance_score": "0.091335", "ticker_sentiment_score": "0.150011", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DNLI", "relevance_score": "0.091335", "ticker_sentiment_score": "0.150011", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SANA", "relevance_score": "0.091335", "ticker_sentiment_score": "0.150011", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SYBX", "relevance_score": "0.136629", "ticker_sentiment_score": "0.052078", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.091335", "ticker_sentiment_score": "0.150011", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "OMGA", "relevance_score": "0.091335", "ticker_sentiment_score": "0.150011", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Covid Vaccines May Roll Out Within Days", "url": "https://www.nytimes.com/2023/09/11/health/covid-vaccines-may-roll-out-within-days.html", "time_published": "20230911T090235", "authors": ["Christina Jewett"], "summary": "The F.D.A. is expected to approve a new round of shots by Pfizer and Moderna as early as Monday to prepare Americans for the fall and winter season when infections usually tick upward.", "banner_image": "https://static01.nyt.com/images/2023/09/11/science/11FDA-VACCINE/11FDA-VACCINE-articleLarge.jpg?quality=75&auto=webp&disable=upscale", "source": "New York Times", "category_within_source": "Business", "source_domain": "www.nytimes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}], "overall_sentiment_score": -0.053036, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CVS", "relevance_score": "0.049577", "ticker_sentiment_score": "-0.013996", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVAX", "relevance_score": "0.024801", "ticker_sentiment_score": "0.073064", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.172272", "ticker_sentiment_score": "0.001421", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.123526", "ticker_sentiment_score": "0.004639", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.049577", "ticker_sentiment_score": "0.040549", "ticker_sentiment_label": "Neutral"}]}, {"title": "Covid Vaccines May Roll Out Within Days", "url": "https://www.nytimes.com/2023/09/11/health/covid-vaccine-boosters-fda-pfizer-moderna.html", "time_published": "20230911T090235", "authors": ["Christina Jewett"], "summary": "The F.D.A. is expected to approve a new round of shots by Pfizer and Moderna as early as Monday to prepare Americans for the fall and winter season when infections usually tick upward.", "banner_image": "https://static01.nyt.com/images/2023/09/11/science/11FDA-VACCINE/11FDA-VACCINE-articleLarge.jpg?quality=75&auto=webp&disable=upscale", "source": "New York Times", "category_within_source": "Business", "source_domain": "www.nytimes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}], "overall_sentiment_score": -0.053036, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CVS", "relevance_score": "0.049577", "ticker_sentiment_score": "-0.013996", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVAX", "relevance_score": "0.024801", "ticker_sentiment_score": "0.073064", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.172272", "ticker_sentiment_score": "0.001421", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.123526", "ticker_sentiment_score": "0.004639", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.049577", "ticker_sentiment_score": "0.040549", "ticker_sentiment_label": "Neutral"}]}, {"title": "Will Mask Mandates Return? Fauci Doesn't Expect More Federal Mandates As Covid Deaths Rise", "url": "https://www.forbes.com/sites/mollybohannon/2023/09/10/will-mask-mandates-return-fauci-doesnt-expect-more-federal-mandates-as-covid-deaths-rise/", "time_published": "20230910T165724", "authors": ["Molly Bohannon"], "summary": "The former chief medical advisor to the White House said he'd be \"extremely surprised\" to see another federal mask mandate.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/64fdf46664710e83a76445c0/0x0.jpg?format=jpg&crop=3910,2198,x0,y201,safe&width=1200", "source": "Forbes", "category_within_source": "Business", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.100899, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.138066", "ticker_sentiment_score": "0.130221", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.138066", "ticker_sentiment_score": "0.130221", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVAX", "relevance_score": "0.069294", "ticker_sentiment_score": "0.128553", "ticker_sentiment_label": "Neutral"}]}, {"title": "Italy's PM Meloni champions 'family values.' But critics say she's doing little to protect women from violence", "url": "https://www.cnn.com/2023/09/10/europe/italy-giorgia-meloni-sexual-violence-intl-cmd/index.html", "time_published": "20230910T065800", "authors": ["Barbie Latza Nadeau"], "summary": "When Italy's Prime Minister Giorgia Meloni made an official visit to the crime-ridden Neapolitan suburb of Caivano last week, she promised a \"radical reclamation\" of a territory she admitted \"the state had failed.\"", "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/230908161320-03-italy-meloni-women.jpg?c=16x9&q=h_720,w_1280,c_fill", "source": "CNN", "category_within_source": "Markets", "source_domain": "www.cnn.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.096884, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.028798", "ticker_sentiment_score": "0.033768", "ticker_sentiment_label": "Neutral"}]}, {"title": "Updated Covid-19 shots are coming soon, to be part of trio of vaccines", "url": "https://www.business-standard.com/india-news/updated-covid-19-shots-are-coming-soon-to-be-part-of-trio-of-vaccines-123090900529_1.html", "time_published": "20230909T100851", "authors": ["AP"], "summary": "Updated COVID-19 vaccines are coming soon, just in time to pair them with flu shots. And this fall, the first vaccines for another scary virus called RSV are rolling out to older adults and pregnant women.", "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2023-01/19/full/1674097211-0177.jpg?im=FeatureCrop,size=(826,465)", "source": "Business Standard", "category_within_source": "GoogleRSS", "source_domain": "www.business-standard.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.014692, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVAX", "relevance_score": "0.045655", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.045655", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.045655", "ticker_sentiment_score": "0.159168", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.091162", "ticker_sentiment_score": "0.072647", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.045655", "ticker_sentiment_score": "0.159168", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Updated COVID shots are coming. They're part of a trio of vaccines to block fall viruses", "url": "https://apnews.com/article/covid-flu-rsv-vaccines-tripledemic-2a55728638c1c0879ce58deeeb0196bf", "time_published": "20230909T042900", "authors": ["LAURAN NEERGAARD"], "summary": "WASHINGTON ( AP ) - Updated COVID-19 are coming soon, just in time to pair them with flu shots. And this fall, the first vaccines for another scary virus called RSV are rolling out to and .", "banner_image": "https://dims.apnews.com/dims4/default/2d6c9d5/2147483647/strip/true/crop/5184x3453+0+1/resize/599x399!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2F9a%2F49%2F3c605305504dfd887c1d87622bc8%2Fdec49713a1d44ba8a82f79c577d7d6f1", "source": "Associated Press", "category_within_source": "Markets", "source_domain": "apnews.com", "topics": [{"topic": "Real Estate & Construction", "relevance_score": "0.5"}, {"topic": "Life Sciences", "relevance_score": "0.5"}], "overall_sentiment_score": 0.022031, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "HHC", "relevance_score": "0.04531", "ticker_sentiment_score": "0.165054", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVAX", "relevance_score": "0.04531", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.04531", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.04531", "ticker_sentiment_score": "0.159067", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.090474", "ticker_sentiment_score": "0.072535", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.04531", "ticker_sentiment_score": "0.159067", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Moderna  ( MRNA )  Stock Sinks As Market Gains: What You Should Know", "url": "https://www.zacks.com/stock/news/2146834/moderna-mrna-stock-sinks-as-market-gains-what-you-should-know", "time_published": "20230908T215019", "authors": ["Zacks Equity Research"], "summary": "In the latest trading session, Moderna (MRNA) closed at $107.64, marking a -0.66% move from the previous day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default44.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.858979"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.230409, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.601928", "ticker_sentiment_score": "0.382356", "ticker_sentiment_label": "Bullish"}]}, {"title": "China Is Full of Risks. So Why Can't Corporate America Leave?", "url": "https://www.nytimes.com/2023/09/08/business/china-us-business.html", "time_published": "20230908T153213", "authors": ["Alexandra Stevenson"], "summary": "Doing business in China, once seen as a can't-miss opportunity, poses a troubling dilemma: Reasons to stay can be as compelling as the reasons to retreat.", "banner_image": "https://static01.nyt.com/images/2023/09/08/multimedia/00China-LongGame-jvfk/00China-LongGame-jvfk-articleLarge.jpg?quality=75&auto=webp&disable=upscale", "source": "New York Times", "category_within_source": "Business", "source_domain": "www.nytimes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.77141"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": -0.045799, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.088363", "ticker_sentiment_score": "0.03151", "ticker_sentiment_label": "Neutral"}, {"ticker": "F", "relevance_score": "0.029508", "ticker_sentiment_score": "0.012198", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.058976", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biotech Stock Roundup: MRNA's Vaccine Update, AMGN & HZNP Clear FTC Lawsuit & More", "url": "https://www.zacks.com/stock/news/2146657/biotech-stock-roundup-mrnas-vaccine-update-amgn-hznp-clear-ftc-lawsuit-more", "time_published": "20230908T135800", "authors": ["Zacks Equity Research"], "summary": "Pipeline and regulatory updates from (MRNA) and Amgen (AMGN) are in focus in the biotech sector.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default115.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.136858, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALNY", "relevance_score": "0.090816", "ticker_sentiment_score": "0.039966", "ticker_sentiment_label": "Neutral"}, {"ticker": "BHVN", "relevance_score": "0.224487", "ticker_sentiment_score": "0.180294", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.310283", "ticker_sentiment_score": "0.018387", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.224487", "ticker_sentiment_score": "0.133694", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.18046", "ticker_sentiment_score": "0.113277", "ticker_sentiment_label": "Neutral"}]}, {"title": "COVID Vaccine Sales Are Declining. But Here's How They're Still Driving Growth at Moderna.", "url": "https://www.fool.com/investing/2023/09/08/vaccine-sales-fall-still-drive-moderna-growth/", "time_published": "20230908T100000", "authors": ["Adria Cimino"], "summary": "Moderna expects to launch several products over the next few years.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.839681"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.28196, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.505737", "ticker_sentiment_score": "0.389824", "ticker_sentiment_label": "Bullish"}]}, {"title": "2 Nasdaq 100 Stocks That Are Surefire Buys in September and 1 to Avoid Like the Plague", "url": "https://www.fool.com/investing/2023/09/08/2-nasdaq-100-stocks-buy-and-1-to-avoid-like-plague/", "time_published": "20230908T092100", "authors": ["Sean Williams"], "summary": "Two high-growth Nasdaq 100 stocks are phenomenal businesses hiding in plain sight, while another Nasdaq 100 component comes with outsize risk.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F746450%2Fstock-chart-crash-correction-plunge-bounce-bear-market-bar-trend-invest-crypto-getty.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.5855"}, {"topic": "Earnings", "relevance_score": "0.650727"}], "overall_sentiment_score": 0.102765, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVAX", "relevance_score": "0.030064", "ticker_sentiment_score": "0.11464", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.321545", "ticker_sentiment_score": "0.133089", "ticker_sentiment_label": "Neutral"}, {"ticker": "ISRG", "relevance_score": "0.208081", "ticker_sentiment_score": "0.121112", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.236972", "ticker_sentiment_score": "0.13131", "ticker_sentiment_label": "Neutral"}]}, {"title": "Nobel Trust Family Joins BIOHK2023 - Unveiling Key Announcement", "url": "https://www.prnewswire.com/apac/news-releases/nobel-trust-family-joins-biohk2023---unveiling-key-announcement-301921752.html", "time_published": "20230908T083000", "authors": ["Hong Kong Biotechnology Organization (HKBIO)"], "summary": "HONG KONG, Sept. 8, 2023 /PRNewswire/ -- BIOHK2023 garnered widespread acclaim featuring an exceptional lineup of speakers, including a Nobel Laureate, world-renowned scientists who have won distinguished awards, and accomplished biotech C-level venture capitalists taking the stage on 13th to ...", "banner_image": "https://mma.prnewswire.com/media/2205352/V3_0_Sponsored_Program_Poster.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.373473, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.146025", "ticker_sentiment_score": "0.122009", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.146025", "ticker_sentiment_score": "0.122009", "ticker_sentiment_label": "Neutral"}]}, {"title": "Jets' Aaron Rodgers shows support for unvaccinated tennis star Novak Djokovic", "url": "https://apnews.com/article/aaron-rodgers-novak-djokovic-us-open-29aea36eb153384855052ba6f767ada6", "time_published": "20230907T213600", "authors": ["DENNIS WASZAK Jr."], "summary": "FLORHAM PARK, N.J. ( AP ) - Aaron Rodgers crossed an item off his sports bucket list - and then made a statement with a more visible crossout. The attended the U.S. Open on Sunday, something he said he'd like to do for the first time since he's playing in the New York/New Jersey area after 18 ...", "banner_image": "https://dims.apnews.com/dims4/default/cc61016/2147483647/strip/true/crop/3017x2010+0+1/resize/599x399!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2F98%2F17%2F06618e970df4ca8f36dc44d4b4ec%2F74e4cdceb5fe49cda74fdeb1b029a3c6", "source": "Associated Press", "category_within_source": "Markets", "source_domain": "apnews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.165702, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.220809", "ticker_sentiment_score": "0.112673", "ticker_sentiment_label": "Neutral"}]}, {"title": "Don't Get Your Next Covid Booster Quite Yet", "url": "https://www.nytimes.com/article/covid-booster-fall.html", "time_published": "20230907T161559", "authors": ["Dana G. Smith"], "summary": "Should You Get Another Covid Booster Now, or Wait Until the Fall? The New York Times ...", "banner_image": "https://static01.nyt.com/images/2023/08/07/multimedia/WELL-2023-BOOSTER1-qkml/WELL-2023-BOOSTER1-qkml-articleLarge.jpg?quality=75&auto=webp&disable=upscale", "source": "New York Times", "category_within_source": "GoogleRSS", "source_domain": "www.nytimes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.132549, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.063258", "ticker_sentiment_score": "0.103056", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.063258", "ticker_sentiment_score": "0.103056", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVAX", "relevance_score": "0.063258", "ticker_sentiment_score": "0.103056", "ticker_sentiment_label": "Neutral"}]}, {"title": "Moderna  ( MRNA )  Updated COVID Jab Effective Against Pirola Variant", "url": "https://www.zacks.com/stock/news/2146191/moderna-mrna-updated-covid-jab-effective-against-pirola-variant", "time_published": "20230907T152000", "authors": ["Zacks Equity Research"], "summary": "Clinical study data shows Moderna's (MRNA) updated COVID-19 vaccine generates a robust immune response against newer circulating variants, including Pirola and Eris.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/db/3160.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.087771, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVAX", "relevance_score": "0.317254", "ticker_sentiment_score": "0.043677", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.538084", "ticker_sentiment_score": "0.06009", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.317254", "ticker_sentiment_score": "0.070961", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.256314", "ticker_sentiment_score": "0.059825", "ticker_sentiment_label": "Neutral"}]}, {"title": "Explainer: Do I need to worry about COVID again?", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/do-i-need-worry-about-covid-again-2023-09-07/", "time_published": "20230907T101000", "authors": ["Deena Beasley", "Julie Steenhuysen"], "summary": "[1/3] A nurse fills up syringes with the coronavirus disease ( COVID-19 ) vaccines for residents who are over 50 years old and immunocompromised and are eligible to receive their second booster shots in Waterford, Michigan, U.S., April 8, 2022. REUTERS/Emily Elconin/File Photo Acquire Licensing ...", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/ZVHZKD4JKRJOBLJTOPWJXKQKTY.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.030686, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.120431", "ticker_sentiment_score": "-0.039448", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.120431", "ticker_sentiment_score": "-0.078938", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.060388", "ticker_sentiment_score": "-0.10008", "ticker_sentiment_label": "Neutral"}]}, {"title": "Giant Food pharmacies roll out seasonal flu vaccinations ahead of fall season", "url": "https://www.foxbusiness.com/healthcare/giant-food-pharmacies-seasonal-flu-vaccinations-fall-season", "time_published": "20230906T221759", "authors": ["Andrea Vacchiano"], "summary": "Giant Food, a supermarket chain with stores in Maryland, Virginia, Delaware and Washington, D.C., is officially rolling out its seasonal vaccines. The chain announced Wednesday that seasonal flu vaccines are ready and available in all 153 of their in-store pharmacies.", "banner_image": "https://cf-images.us-east-1.prod.boltdns.net/v1/static/854081161001/2ed80d18-1ffd-42d9-9777-73abfcde866a/2a6b44b0-ca46-43fd-817a-90d763c7a490/1280x720/match/image.jpg", "source": "Fox Business News", "category_within_source": "n/a", "source_domain": "www.foxbusiness.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.029149, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.154455", "ticker_sentiment_score": "-0.065027", "ticker_sentiment_label": "Neutral"}]}, {"title": "Non-Disappearing COVID Creates Another Chapter For The Pharmaceutical Industry - Pfizer  ( NYSE:PFE ) ", "url": "https://www.benzinga.com/news/small-cap/23/09/34294328/non-disappearing-covid-creates-another-chapter-for-the-pharmaceutical-industry", "time_published": "20230906T203939", "authors": ["Upwallstreet"], "summary": "On Tuesday, UK regulators joined their US and European peers in approving an updated COVID-19 vaccine by Pfizer Inc PFE and its German partner BioNTech BNTX that targets only the Omicron XBB.1.5 subvariant.", "banner_image": "https://cdn.benzinga.com/files/covid-still-life-with-vaccine.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.038227, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "TRMNF", "relevance_score": "0.095138", "ticker_sentiment_score": "-0.027725", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVAX", "relevance_score": "0.188928", "ticker_sentiment_score": "-0.077832", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.526707", "ticker_sentiment_score": "0.071884", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.526707", "ticker_sentiment_score": "-0.026244", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.367412", "ticker_sentiment_score": "-0.056578", "ticker_sentiment_label": "Neutral"}]}, {"title": "Covid hospitalizations spike with new variant as school returns, U.S. readies vaccines", "url": "https://www.cnbc.com/2023/09/06/covid-hospitalizations-spike-with-new-variant-as-us-readies-vaccines.html", "time_published": "20230906T203023", "authors": ["Spencer Kimball"], "summary": "The late summer Covid spike comes after a quiet year in which hospitalizations and deaths had declined week after week since January.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107295691-16939162131693916210-31063473254-1080pnbcnews.jpg?v=1693918022&w=750&h=422&vtcrop=y", "source": "CNBC", "category_within_source": "Top News", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.18515, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.092036", "ticker_sentiment_score": "-0.153458", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PFE", "relevance_score": "0.046095", "ticker_sentiment_score": "-0.193273", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "NVAX", "relevance_score": "0.046095", "ticker_sentiment_score": "-0.193273", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Pfizer says updated COVID shot generated strong reaction vs new variant in mice", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-says-updated-covid-shot-generated-strong-reaction-vs-new-variant-mice-2023-09-06/", "time_published": "20230906T181000", "authors": ["Reuters"], "summary": "Vials with a sticker reading, \"COVID-19 / Coronavirus vaccine / Injection only\" and a medical syringe are seen in front of a displayed Pfizer logo in this illustration taken October 31, 2020. REUTERS/Dado Ruvic/File Photo Acquire Licensing Rights", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/R7KF5PKLJ5OADHUMOEIJTQTUA4.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.065936, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.266828", "ticker_sentiment_score": "0.239492", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.693563", "ticker_sentiment_score": "0.048776", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.266828", "ticker_sentiment_score": "0.046203", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stocks on the Mend: A Mean Reversion Duo", "url": "https://www.zacks.com/commentary/2145594/stocks-on-the-mend-a-mean-reversion-duo", "time_published": "20230906T171600", "authors": ["Andrew Rocco"], "summary": "September is starting in classic, historically weak form. However, if the market finds it's footing, two stocks have explosive, reversion to the mean potential.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/8a/2449.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.197817, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMD", "relevance_score": "0.708432", "ticker_sentiment_score": "0.522995", "ticker_sentiment_label": "Bullish"}, {"ticker": "NVDA", "relevance_score": "0.274834", "ticker_sentiment_score": "0.218445", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVAX", "relevance_score": "0.360752", "ticker_sentiment_score": "0.099524", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.185306", "ticker_sentiment_score": "0.054842", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.185306", "ticker_sentiment_score": "0.054842", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.185306", "ticker_sentiment_score": "0.054842", "ticker_sentiment_label": "Neutral"}]}, {"title": "How Moderna Stacks Up Against Highly Mutated 'Pirola' Variant", "url": "https://www.investors.com/news/technology/moderna-stock-new-vaccine-takes-on-highly-mutated-covid-virus-and-wins/", "time_published": "20230906T142400", "authors": ["ALLISON GATLIN", "Investor's Business Daily"], "summary": "Moderna Stock: New Vaccine Takes On Highly Mutated Covid Virus ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2020/11/Stock-moderna-02-shutt.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.929393"}], "overall_sentiment_score": 0.007245, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVAX", "relevance_score": "0.166743", "ticker_sentiment_score": "-0.012818", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.600271", "ticker_sentiment_score": "0.068084", "ticker_sentiment_label": "Neutral"}, {"ticker": "INSM", "relevance_score": "0.083833", "ticker_sentiment_score": "0.139392", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.166743", "ticker_sentiment_score": "-0.012818", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.166743", "ticker_sentiment_score": "-0.012818", "ticker_sentiment_label": "Neutral"}]}, {"title": "Top Stories Wednesday, Sep 6: iPhone 15 May Face Hurdle In China, FTC Could Prosecute Amazon.com Over Antitrust Claims, United Airlines Planes Back In Air - Apple  ( NASDAQ:AAPL ) , Albertsons Companies  ( NYSE:ACI ) ", "url": "https://www.benzinga.com/news/23/09/34279089/iphone-15-may-face-hurdle-in-china-ftc-could-prosecute-amazon-com-over-antitrust-claims-united-airli", "time_published": "20230906T134339", "authors": ["Vandana Singh"], "summary": "The Chinese government has banned its officials from using Apple Inc.'s AAPL iPhones and other foreign-branded devices at work, dealing a blow to the company just days ahead of its 'Wonderlust' iPhone 15 launch event. Chinese government officials have been banned from using iPhones and other ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/06/us-china_tatiana_popova_and_rawf8_by_shuttterstock.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Manufacturing", "relevance_score": "0.2"}], "overall_sentiment_score": 0.045494, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.129749", "ticker_sentiment_score": "-0.128088", "ticker_sentiment_label": "Neutral"}, {"ticker": "ROKU", "relevance_score": "0.086713", "ticker_sentiment_score": "0.021089", "ticker_sentiment_label": "Neutral"}, {"ticker": "UAL", "relevance_score": "0.129749", "ticker_sentiment_score": "-0.021618", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.214557", "ticker_sentiment_score": "0.081528", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPOT", "relevance_score": "0.129749", "ticker_sentiment_score": "0.043528", "ticker_sentiment_label": "Neutral"}, {"ticker": "GM", "relevance_score": "0.086713", "ticker_sentiment_score": "0.237574", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ACI", "relevance_score": "0.129749", "ticker_sentiment_score": "0.031507", "ticker_sentiment_label": "Neutral"}, {"ticker": "KR", "relevance_score": "0.129749", "ticker_sentiment_score": "0.031507", "ticker_sentiment_label": "Neutral"}, {"ticker": "WMG", "relevance_score": "0.214557", "ticker_sentiment_score": "0.039752", "ticker_sentiment_label": "Neutral"}, {"ticker": "SFBQF", "relevance_score": "0.086713", "ticker_sentiment_score": "0.051357", "ticker_sentiment_label": "Neutral"}, {"ticker": "SFTBF", "relevance_score": "0.129749", "ticker_sentiment_score": "0.094917", "ticker_sentiment_label": "Neutral"}, {"ticker": "TM", "relevance_score": "0.086713", "ticker_sentiment_score": "0.068868", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.086713", "ticker_sentiment_score": "0.064745", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.086713", "ticker_sentiment_score": "-0.096955", "ticker_sentiment_label": "Neutral"}]}, {"title": "What's Going On With Moderna  ( MRNA )  Stock Today - Moderna  ( NASDAQ:MRNA ) ", "url": "https://www.benzinga.com/general/biotech/23/09/34275845/is-modernas-new-vaccine-the-answer-to-the-highly-mutated-ba-2-86-covid-19-variant", "time_published": "20230906T131104", "authors": ["Vandana Singh"], "summary": "Moderna Inc's MRNA clinical trial data from its research assay confirm that its updated COVID-19 vaccine generates an 8.7-fold increase in neutralizing antibodies in humans against BA.2.86 ( Pirola ) , a variant under monitoring.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/06/moderna_covid-19_vaccine_2021_g.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.088533, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.56415", "ticker_sentiment_score": "0.345027", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Moderna says updated COVID vaccine is effective against newer variant", "url": "https://www.financialexpress.com/healthcare/covid-19/moderna-says-updated-covid-vaccine-is-effective-against-newer-variant/3235157/", "time_published": "20230906T113812", "authors": ["Reuters"], "summary": "Moderna on Wednesday said clinical trial data showed its updated COVID-19 vaccine will likely be effective against the highly-mutated BA.2.86 subvariant of the coronavirus that has raised fears of a resurgence of infections.", "banner_image": "https://www.financialexpress.com/wp-content/uploads/2023/09/COVID-1.jpg", "source": "The Financial Express", "category_within_source": "n/a", "source_domain": "www.financialexpress.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.040898, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVAX", "relevance_score": "0.109956", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.419733", "ticker_sentiment_score": "0.181143", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.321673", "ticker_sentiment_score": "0.058081", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.217834", "ticker_sentiment_score": "0.030337", "ticker_sentiment_label": "Neutral"}]}, {"title": "Moderna says updated COVID vaccine is effective against newer variant", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/moderna-says-updated-covid-vaccine-is-effective-against-newer-variant-2023-09-06/", "time_published": "20230906T111300", "authors": ["Patrick Wingrove"], "summary": "[1/2] A vial and sryinge are seen in front of a displayed Moderna logo in this illustration taken January 11, 2021. REUTERS/Dado Ruvic/Illustration/File Photo Acquire Licensing Rights", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/3E24FDHNT5NBJLN4GWK2FUWNPA.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.040766, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVAX", "relevance_score": "0.09989", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.469744", "ticker_sentiment_score": "0.164122", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.293506", "ticker_sentiment_score": "0.054031", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.198221", "ticker_sentiment_score": "0.028181", "ticker_sentiment_label": "Neutral"}]}, {"title": "Moderna's Updated Covid Vaccine Is Effective Against Pirola Variant-As Concern Over New Strain Grows", "url": "https://www.forbes.com/sites/roberthart/2023/09/06/modernas-updated-covid-vaccine-is-effective-against-pirola-variant-as-concern-over-new-strain-grows/", "time_published": "20230906T110350", "authors": ["Robert Hart"], "summary": "Experts are worried the highly mutated variant, a relative of omicron formally called BA.2.86, could trigger a new wave of cases.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/64f85c1b88709d61e23849ff/0x0.jpg?format=jpg&crop=3000,1688,x0,y149,safe&width=1200", "source": "Forbes", "category_within_source": "Business", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.061066, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.22421", "ticker_sentiment_score": "0.097187", "ticker_sentiment_label": "Neutral"}, {"ticker": "TRMNF", "relevance_score": "0.075635", "ticker_sentiment_score": "-0.190044", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Moderna says updated Covid vaccine was effective against highly mutated BA.2.86 variant in trial", "url": "https://www.cnbc.com/2023/09/06/moderna-says-new-covid-vaccine-effective-against-bapoint2point86-variant.html", "time_published": "20230906T110201", "authors": ["Annika Kim Constantino"], "summary": "Moderna, Pfizer and Novavax are slated to roll out new vaccines targeting XBB.1.5 within weeks, pending approvals from the FDA.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107261603-1687528289059-gettyimages-1237672961-widak-covid19s220112_npv5n.jpeg?v=1693998121&w=1920&h=1080", "source": "CNBC", "category_within_source": "Business", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.016671, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.380012", "ticker_sentiment_score": "0.026599", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.098659", "ticker_sentiment_score": "-0.024251", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVAX", "relevance_score": "0.098659", "ticker_sentiment_score": "-0.024251", "ticker_sentiment_label": "Neutral"}]}, {"title": "This Down-on-Its-Luck Biotech Could Surge 150%, Wall Street Says. Should You Buy the Stock?", "url": "https://www.fool.com/investing/2023/09/06/this-down-on-its-luck-biotech-could-surge-150-wall/", "time_published": "20230906T093000", "authors": ["Adria Cimino"], "summary": "Today, Novavax is getting ready to compete in the fall vaccine market -- one that's in transition.", "banner_image": "https://media.ycharts.com/charts/29008821ecf149aa15f634c7ca78f5cc.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.796627"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.413559"}], "overall_sentiment_score": 0.106401, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.159218", "ticker_sentiment_score": "0.025676", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.159218", "ticker_sentiment_score": "0.025676", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVAX", "relevance_score": "0.796741", "ticker_sentiment_score": "0.157719", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "New Covid Variant Might Not Be That Bad", "url": "https://www.barrons.com/articles/new-covid-19-variant-boosters-2e77dd0", "time_published": "20230905T203000", "authors": ["Josh Nathan-Kazis"], "summary": "New Covid-19 Variant Might Not Be That Bad. More Boosters Are Coming Soon. ...", "banner_image": "https://images.barrons.com/im-54505212?width=639&height=426", "source": "Barrons", "category_within_source": "n/a", "source_domain": "www.barrons.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": 0.092681, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NYT", "relevance_score": "0.062271", "ticker_sentiment_score": "0.02002", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVAX", "relevance_score": "0.124164", "ticker_sentiment_score": "0.023254", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.360752", "ticker_sentiment_score": "0.131596", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.245339", "ticker_sentiment_score": "0.097341", "ticker_sentiment_label": "Neutral"}]}, {"title": "Novavax  ( NVAX )  Stock Increases 9% in a Month: Here's Why", "url": "https://www.zacks.com/stock/news/2145017/novavax-nvax-stock-increases-9-in-a-month-heres-why", "time_published": "20230905T161000", "authors": ["Zacks Equity Research"], "summary": "This growth in Novavax (NVAX) is likely due to the rising COVID-19 infection cases in the United States. Management claims its updated vaccine is effective against the newly emerged virus variants.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/8a/2449.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.122343, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVAX", "relevance_score": "0.533241", "ticker_sentiment_score": "0.229279", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.253646", "ticker_sentiment_score": "0.119646", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.314017", "ticker_sentiment_score": "0.210562", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BNTX", "relevance_score": "0.314017", "ticker_sentiment_score": "0.210562", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Cancer Remains Pharma's Biggest Challenge And Mainz Biomed Has The Tool To Help Win The Battle - Pfizer  ( NYSE:PFE ) ", "url": "https://www.benzinga.com/markets/penny-stocks/23/09/34242725/cancer-remains-pharmas-biggest-challenge-and-mainz-biomed-has-the-tool-to-help-win-the-battl", "time_published": "20230905T160610", "authors": ["Upwallstreet"], "summary": "Last week, The European Commission authorizing Comirnaty, a third version of the updated COVID-19 vaccine from Pfizer Inc PFE and BioNTech SE BNTX to be used in EU countries' vaccination campaigns this autumn to combat yet another Covid-19 variant.", "banner_image": "https://cdn.benzinga.com/files/covid-recovery-center-female-doctor-holding-older-patient-s-hands.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": -0.002482, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GRTS", "relevance_score": "0.112008", "ticker_sentiment_score": "-0.061869", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.112008", "ticker_sentiment_score": "-0.061869", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.221819", "ticker_sentiment_score": "-0.094989", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.221819", "ticker_sentiment_score": "-0.056252", "ticker_sentiment_label": "Neutral"}]}, {"title": "Peering Into Moderna's Recent Short Interest - Moderna  ( NASDAQ:MRNA ) ", "url": "https://www.benzinga.com/short-sellers/23/09/34239987/peering-into-modernas-recent-short-interest", "time_published": "20230905T150030", "authors": ["Benzinga Insights"], "summary": "Moderna's MRNA short percent of float has risen 9.06% since its last report. The company recently reported that it has 17.22 million shares sold short, which is 6.02% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.77 days to cover their ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.26961, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.224903", "ticker_sentiment_score": "0.158881", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "UK regulator approves updated Pfizer-BioNTech COVID vaccine", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/uk-regulator-approves-updated-pfizer-biontech-covid-vaccine-2023-09-05/", "time_published": "20230905T140700", "authors": ["Reuters"], "summary": "[1/2] Pfizer company logo is seen at a Pfizer office in Puurs, Belgium, December 2, 2022. REUTERS/Johanna Geron/File Photo Acquire Licensing Rights", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/PMN2KSP6HZIKBEGKPN77OEIWBU.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.091184, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GERN", "relevance_score": "0.18967", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVAX", "relevance_score": "0.18967", "ticker_sentiment_score": "-0.05287", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.368773", "ticker_sentiment_score": "-0.127809", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.769861", "ticker_sentiment_score": "-0.007894", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.528475", "ticker_sentiment_score": "-0.006572", "ticker_sentiment_label": "Neutral"}]}, {"title": "Legal Twist In Drug Price Negotiation: Federal Judge Quits Case Amid Allegations Of Stock Ownership - AstraZeneca  ( NASDAQ:AZN ) , Johnson & Johnson  ( NYSE:JNJ ) ", "url": "https://www.benzinga.com/general/biotech/23/09/34228654/legal-twist-in-drug-price-negotiation-federal-judge-quits-case-amid-allegations-of-stock-ownershi", "time_published": "20230905T123832", "authors": ["Vandana Singh"], "summary": "On Friday, Judge Thomas Rose, serving in the U.S. District Court for the Southern District of Ohio, opted to step down from the case on the same day the Revolving Door Project, a nonprofit organization, revealed his ownership of stocks in Johnson & Johnson JNJ and AstraZeneca Plc AZN.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/05/pharma-photo_by_pina_messina_on_unsplash.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.085977, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.118647", "ticker_sentiment_score": "0.194566", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.449503", "ticker_sentiment_score": "0.14674", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.234684", "ticker_sentiment_score": "-0.025921", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.345674", "ticker_sentiment_score": "-0.017137", "ticker_sentiment_label": "Neutral"}]}, {"title": "McDonald's, Moderna And 2 Other Stocks Insiders Are Selling - Moderna  ( NASDAQ:MRNA ) , McDonald's  ( NYSE:MCD ) ", "url": "https://www.benzinga.com/news/23/09/34231238/mcdonalds-moderna-and-2-other-stocks-insiders-are-selling", "time_published": "20230905T115747", "authors": ["Lisa Levin"], "summary": "The Nasdaq 100 closed slightly lower on Friday. Investors, meanwhile, focused on some notable insider trades. When insiders sell shares, it could be a preplanned sale, or could indicate their concern in the company's prospects or that they view the stock as being overpriced.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/05/mcdonalds_-_logo_0.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}], "overall_sentiment_score": 0.196178, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "X", "relevance_score": "0.436009", "ticker_sentiment_score": "0.601306", "ticker_sentiment_label": "Bullish"}, {"ticker": "MDNDF", "relevance_score": "0.355588", "ticker_sentiment_score": "0.305261", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.436009", "ticker_sentiment_score": "-0.183506", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "SNAP", "relevance_score": "0.182506", "ticker_sentiment_score": "0.123555", "ticker_sentiment_label": "Neutral"}, {"ticker": "MCD", "relevance_score": "0.182506", "ticker_sentiment_score": "0.112584", "ticker_sentiment_label": "Neutral"}]}, {"title": "Coronavirus Cases Are on the Rise -- Should You Buy Vaccine Stocks?", "url": "https://www.fool.com/investing/2023/09/05/coronavirus-rising-should-you-buy-vaccine-stocks/", "time_published": "20230905T093000", "authors": ["Adria Cimino"], "summary": "Investors have worried about vaccine revenue in a post-pandemic world.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F746253%2Fpaper-certificate-shares-invest-stock-split-market-reverse-getty.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.94762"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.085663, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.399734", "ticker_sentiment_score": "0.055471", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.444487", "ticker_sentiment_score": "0.083107", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVAX", "relevance_score": "0.155786", "ticker_sentiment_score": "0.035317", "ticker_sentiment_label": "Neutral"}]}, {"title": "Aaron Rodgers achieves bucket list dream of watching Novak Djokovic play", "url": "https://www.cnn.com/2023/09/04/sport/aaron-rodgers-novak-djokovic-us-open-spt-intl/index.html", "time_published": "20230904T181200", "authors": ["Thomas Schlachter"], "summary": "Aaron Rodgers was among those in the crowd to watch Novak Djokovic advance to the US Open quarterfinals with a straight sets win against Borna Gojo. The New York Jets' star quarterback made the short trip to Flushing Meadows and admitted it was a dream of his to watch the world No. 2 in the flesh.", "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/230904093606-02-aaron-rodgers-novak-djokovic-us-open.jpg?c=16x9&q=h_720,w_1280,c_fill", "source": "CNN", "category_within_source": "Markets", "source_domain": "www.cnn.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.344153, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.12165", "ticker_sentiment_score": "0.021164", "ticker_sentiment_label": "Neutral"}]}, {"title": "Will Covid Mask Mandates Return? Here's Where They're Making A Comeback", "url": "https://www.forbes.com/sites/brianbushard/2023/09/02/will-covid-mask-mandates-return-heres-where-theyre-making-a-comeback/", "time_published": "20230902T155810", "authors": ["Brian Bushard"], "summary": "A rise in Covid-19 cases over the past month has prompted several colleges and hospitals to reimplement mask mandates.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/64f35b55764e0549a11e813e/0x0.jpg?format=jpg&width=1200", "source": "Forbes", "category_within_source": "Business", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.033453, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "WBD", "relevance_score": "0.057767", "ticker_sentiment_score": "0.035002", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVAX", "relevance_score": "0.057767", "ticker_sentiment_score": "0.021024", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.057767", "ticker_sentiment_score": "0.021024", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.057767", "ticker_sentiment_score": "0.021024", "ticker_sentiment_label": "Neutral"}]}, {"title": "Surprise! This Potential AI Winner Isn't a Tech Stock.", "url": "https://www.fool.com/investing/2023/09/02/surprise-this-potential-ai-winner-isnt-tech-stock/", "time_published": "20230902T093000", "authors": ["Adria Cimino"], "summary": "I'll give you a hint: You've probably heard of this company's big product.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.682689"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.263897, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMD", "relevance_score": "0.055621", "ticker_sentiment_score": "0.052986", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.055621", "ticker_sentiment_score": "0.052986", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.055621", "ticker_sentiment_score": "0.138892", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.857111", "ticker_sentiment_score": "0.45811", "ticker_sentiment_label": "Bullish"}, {"ticker": "IBM", "relevance_score": "0.055621", "ticker_sentiment_score": "0.141895", "ticker_sentiment_label": "Neutral"}]}, {"title": "MRNA: Which of These 3 Biotech Stocks Are a Buy, Sell, or Hold?", "url": "https://stocknews.com/news/mrna-fold-mgnx-mrk-incy-which-of-these-3-biotech-stocks-are-a-buy-sell/", "time_published": "20230901T174349", "authors": ["StockNews.com Staff"], "summary": "While the first few months of the year witnessed volatility driven by increasing interest rates, an economic downturn, ongoing geopolitical uncertainties, regulatory changes under the Inflation Reduction Act, and persistent supply chain disruptions, biotech manufacturers are steadily regaining ...", "banner_image": "https://stocknews.com/wp-content/uploads/2022/04/shutterstock_149136044-scaled.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.99977"}, {"topic": "Earnings", "relevance_score": "0.918141"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.291632, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "FOLD", "relevance_score": "0.173958", "ticker_sentiment_score": "0.207306", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MGNX", "relevance_score": "0.173958", "ticker_sentiment_score": "0.158036", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "INCY", "relevance_score": "0.087503", "ticker_sentiment_score": "0.18513", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NHPEF", "relevance_score": "0.02922", "ticker_sentiment_score": "0.097347", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.230509", "ticker_sentiment_score": "0.124273", "ticker_sentiment_label": "Neutral"}]}, {"title": "When to wear masks as Covid cases rise, new variants emerge in the U.S.", "url": "https://www.cnbc.com/2023/09/01/covid-when-to-wear-masks-as-cases-rise-new-variants-emerge-in-us-.html", "time_published": "20230901T161334", "authors": ["Annika Kim Constantino"], "summary": "The decision to mask depends on a few things: you personal risk level, Covid rates in your region and who you might make contact with, experts say.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107295066-1693580190658-gettyimages-1636806457-1342525-me-covid-19-continues-to-rise-in-calif-011-fo.jpeg?v=1693584814&w=1920&h=1080", "source": "CNBC", "category_within_source": "Business", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.024141, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.040011", "ticker_sentiment_score": "0.157174", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.040011", "ticker_sentiment_score": "0.157174", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVAX", "relevance_score": "0.040011", "ticker_sentiment_score": "0.157174", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Here's Why the Next 4 Months May Be Critical for Pfizer", "url": "https://www.fool.com/investing/2023/09/01/why-next-4-months-may-be-critical-for-pfizer/", "time_published": "20230901T093000", "authors": ["Adria Cimino"], "summary": "The pharmaceutical giant's stock has dropped by around 30% year to date.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.986714"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.007099, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.057767", "ticker_sentiment_score": "-0.149991", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.615462", "ticker_sentiment_score": "-0.095743", "ticker_sentiment_label": "Neutral"}]}, {"title": "What's Going On With Moderna  ( MRNA )  Stock? - Moderna  ( NASDAQ:MRNA ) ", "url": "https://www.benzinga.com/news/23/08/34153212/whats-going-on-with-moderna-mrna-stock", "time_published": "20230831T180300", "authors": ["Henry Khederian"], "summary": "Moderna Inc MRNA shares are trading lower by 2.4% to $113.80 Thursday afternoon. The stock has seen volatility in recent sessions amid rising COVID-19 cases in the U.S. Rising COVID-19 cases might lead to increased demand for vaccines, including Moderna's.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/08/31/vaccine-4892059.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.177709, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.465196", "ticker_sentiment_score": "-0.123018", "ticker_sentiment_label": "Neutral"}]}, {"title": "Moderna Unusual Options Activity For August 31 - Moderna  ( NASDAQ:MRNA ) ", "url": "https://www.benzinga.com/markets/options/23/08/34151709/moderna-unusual-options-activity-for-august-31", "time_published": "20230831T164745", "authors": ["Benzinga Insights"], "summary": "Someone with a lot of money to spend has taken a bullish stance on Moderna MRNA. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.180213, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.781119", "ticker_sentiment_score": "0.294923", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MS", "relevance_score": "0.097854", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "MEDIA ALERT: Robert De Niro and Jane Rosenthal to Headline Cisco's WebexOne Event - Cisco Systems  ( NASDAQ:CSCO ) ", "url": "https://www.benzinga.com/pressreleases/23/08/n34147753/media-alert-robert-de-niro-and-jane-rosenthal-to-headline-ciscos-webexone-event", "time_published": "20230831T150000", "authors": ["PRNewswire"], "summary": "Speakers Include Robert De Niro and Jane Rosenthal, Co-Founders of the Tribeca Festival; Neil deGrasse Tyson, Renowned Astrophysicist; the CEO of Matthew Berry's Fantasy Life; along with Cisco Leaders, Partners and Customers", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.279296, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.047371", "ticker_sentiment_score": "0.180625", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "UAL", "relevance_score": "0.047371", "ticker_sentiment_score": "0.180625", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CSCO", "relevance_score": "0.594412", "ticker_sentiment_score": "0.360858", "ticker_sentiment_label": "Bullish"}, {"ticker": "MRNA", "relevance_score": "0.047371", "ticker_sentiment_score": "0.180625", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Should You Buy Novavax's Stock Before the FDA Approves Its New COVID Shot?", "url": "https://www.fool.com/investing/2023/08/31/should-you-buy-novavaxs-stock-before-the-fda/", "time_published": "20230831T140700", "authors": ["David Jagielski"], "summary": "The vaccine's approval could come within weeks.", "banner_image": "https://media.ycharts.com/charts/3a4491de5ccc1780f9083e27009d266e.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.266143"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.007291, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.067158", "ticker_sentiment_score": "0.088406", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.067158", "ticker_sentiment_score": "0.088406", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVAX", "relevance_score": "0.600602", "ticker_sentiment_score": "0.028846", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pfizer  ( PFE )  & BioNTech Get CHMP Nod for Updated Covid-19 Jab", "url": "https://www.zacks.com/stock/news/2143047/pfizer-pfe-biontech-get-chmp-nod-for-updated-covid-19-jab", "time_published": "20230831T132700", "authors": ["Zacks Equity Research"], "summary": "Pfizer (PFE) and partner BioNTech receive a positive recommendation from the CHMP for its Omicron XBB.1.5-adapted Covid-19 vaccine.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ce/3721.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.104362, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVAX", "relevance_score": "0.234006", "ticker_sentiment_score": "0.058919", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.234006", "ticker_sentiment_score": "0.088781", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.448316", "ticker_sentiment_score": "0.24081", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BNTX", "relevance_score": "0.366061", "ticker_sentiment_score": "0.20125", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Vertex  ( VRTX )  Outperforms Industry Year to Date: Here's Why", "url": "https://www.zacks.com/stock/news/2142369/vertex-vrtx-outperforms-industry-year-to-date-heres-why", "time_published": "20230830T132700", "authors": ["Zacks Equity Research"], "summary": "Vertex Pharmaceuticals (VRTX) is expected to benefit from several catalysts this year. The company is likely to achieve multiple clinical milestones in 2023 and 2024, both in its CF and non-CF portfolio.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/07/905.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.682689"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.045394, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.21258", "ticker_sentiment_score": "-0.175302", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "VRTX", "relevance_score": "0.21258", "ticker_sentiment_score": "0.127966", "ticker_sentiment_label": "Neutral"}, {"ticker": "CORT", "relevance_score": "0.160277", "ticker_sentiment_score": "0.173384", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Fomento Economico Mexicano and Delek Logistics Partners have been highlighted as Zacks Bull and Bear of the Day", "url": "https://www.zacks.com/stock/news/2142305/fomento-economico-mexicano-and-delek-logistics-partners-have-been-highlighted-as-zacks-bull-and-bear-of-the-day", "time_published": "20230830T115000", "authors": ["Zacks Equity Research"], "summary": "Fomento Economico Mexicano and Delek Logistics Partners are part of the Zacks Bull and Bear of the Day article.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/dd/1894.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.199333, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "R", "relevance_score": "0.055621", "ticker_sentiment_score": "0.092868", "ticker_sentiment_label": "Neutral"}, {"ticker": "DLKGF", "relevance_score": "0.092569", "ticker_sentiment_score": "-0.085544", "ticker_sentiment_label": "Neutral"}, {"ticker": "DKL", "relevance_score": "0.255259", "ticker_sentiment_score": "-0.110571", "ticker_sentiment_label": "Neutral"}, {"ticker": "KO", "relevance_score": "0.037098", "ticker_sentiment_score": "0.12901", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.018554", "ticker_sentiment_score": "0.044552", "ticker_sentiment_label": "Neutral"}, {"ticker": "AL-P-A", "relevance_score": "0.074115", "ticker_sentiment_score": "0.10086", "ticker_sentiment_label": "Neutral"}, {"ticker": "TRTN", "relevance_score": "0.147592", "ticker_sentiment_score": "0.166155", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Bull of the Day: Fomento Economico Mexicano  ( FMX ) ", "url": "https://www.zacks.com/commentary/2142188/bull-of-the-day-fomento-economico-mexicano-fmx", "time_published": "20230830T100000", "authors": ["Bryan Hayes"], "summary": "This defensive staple has been widely outperforming this year.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default305.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.980922"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.998287"}], "overall_sentiment_score": 0.368823, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "KO", "relevance_score": "0.112269", "ticker_sentiment_score": "0.142331", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.056275", "ticker_sentiment_score": "0.051913", "ticker_sentiment_label": "Neutral"}]}, {"title": "Want to diversify your stock-market investments away from top-heavy indexes? Here's another easy way.", "url": "https://www.marketwatch.com/story/want-to-diversify-your-stock-market-investments-away-from-top-heavy-indexes-heres-another-easy-way-cdcde04e", "time_published": "20230829T134900", "authors": ["Philip van Doorn"], "summary": "The Invesco S&P 500 GARP ETF selects rapidly growing companies that are trading at lower valuations than the tech highfliers that dominate the stock market.", "banner_image": "https://images.mktw.net/im-843610?width=700&height=615", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.999499"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.838487"}], "overall_sentiment_score": 0.117623, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.114682", "ticker_sentiment_score": "0.06665", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.076602", "ticker_sentiment_score": "-0.0576", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.076602", "ticker_sentiment_score": "0.113961", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.114682", "ticker_sentiment_score": "0.06665", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.189968", "ticker_sentiment_score": "0.089878", "ticker_sentiment_label": "Neutral"}, {"ticker": "MORN", "relevance_score": "0.038345", "ticker_sentiment_score": "0.062408", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.076602", "ticker_sentiment_score": "0.107604", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.076602", "ticker_sentiment_score": "-0.030617", "ticker_sentiment_label": "Neutral"}, {"ticker": "SBNY", "relevance_score": "0.076602", "ticker_sentiment_score": "-0.067725", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.076602", "ticker_sentiment_score": "0.060056", "ticker_sentiment_label": "Neutral"}]}, {"title": "Beaten Down COVID-19 Vaccine Partner Stock Catalent Finalizes Deal With Activist Investor, Reports Mixed Q4 Earnings - Catalent  ( NYSE:CTLT ) ", "url": "https://www.benzinga.com/general/biotech/23/08/34086113/beaten-down-covid-19-vaccine-partner-stock-catalent-finalizes-deal-with-activist-investor-reports", "time_published": "20230829T121743", "authors": ["Vandana Singh"], "summary": "Catalent Inc CTLT, valued at around $8 billion, has finalized a deal with activist investor Elliott Investment Management. The board has recommended and approved the appointment of four new independent directors. With these appointments, Catalent's Board of Directors will consist of 16 directors, ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/08/29/ctlt.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.093729, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ABCM", "relevance_score": "0.202366", "ticker_sentiment_score": "0.13723", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.202366", "ticker_sentiment_score": "0.364349", "ticker_sentiment_label": "Bullish"}, {"ticker": "CTLT", "relevance_score": "0.694939", "ticker_sentiment_score": "0.082982", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.299478", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.202366", "ticker_sentiment_score": "0.364349", "ticker_sentiment_label": "Bullish"}, {"ticker": "MRNA", "relevance_score": "0.202366", "ticker_sentiment_score": "0.364349", "ticker_sentiment_label": "Bullish"}, {"ticker": "DHR", "relevance_score": "0.202366", "ticker_sentiment_score": "0.13723", "ticker_sentiment_label": "Neutral"}]}, {"title": "Flagship Pioneering Announces Appointment of David Khougazian as Growth Partner - PR Newswire", "url": "https://www.prnewswire.com/news-releases/flagship-pioneering-announces-appointment-of-david-khougazian-as-growth-partner-301911946.html", "time_published": "20230829T120000", "authors": [], "summary": "Flagship Pioneering Announces Appointment of David Khougazian as Growth Partner PR ...", "banner_image": null, "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.360032, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "MCRB", "relevance_score": "0.129866", "ticker_sentiment_score": "0.169401", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FHTX", "relevance_score": "0.129866", "ticker_sentiment_score": "0.169401", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DNLI", "relevance_score": "0.129866", "ticker_sentiment_score": "0.169401", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SANA", "relevance_score": "0.129866", "ticker_sentiment_score": "0.169401", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.129866", "ticker_sentiment_score": "0.169401", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "OMGA", "relevance_score": "0.129866", "ticker_sentiment_score": "0.169401", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNY", "relevance_score": "0.586322", "ticker_sentiment_score": "0.221079", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Global Lipids Market is Likely to Reach US$ 29.9 billion by 2031, Expanding at a 4.3% CAGR: TMR Report", "url": "https://www.benzinga.com/pressreleases/23/08/g34084320/global-lipids-market-is-likely-to-reach-us-29-9-billion-by-2031-expanding-at-a-4-3-cagr-tmr-report", "time_published": "20230829T103000", "authors": ["Globe Newswire"], "summary": "Wilmington, Delaware, United States, Aug. 29, 2023 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The global market for lipids was estimated to be worth US$ 19.4 billion in 2021. The market is anticipated to advance with a 4.3% CAGR from 2022 to 2031 and by 2031, the market is likely ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": 0.228853, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.048425", "ticker_sentiment_score": "0.014924", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADM", "relevance_score": "0.048425", "ticker_sentiment_score": "-0.100011", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Novavax Stock Was So Healthy on Monday", "url": "https://www.fool.com/investing/2023/08/28/why-novavax-stock-was-so-healthy-on-monday/", "time_published": "20230828T221603", "authors": ["Eric Volkman"], "summary": "As the coronavirus threat rises, so too does the vaccine maker's value to investors.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.011977, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.150592", "ticker_sentiment_score": "0.010687", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.150592", "ticker_sentiment_score": "0.010687", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVAX", "relevance_score": "0.431065", "ticker_sentiment_score": "0.101272", "ticker_sentiment_label": "Neutral"}]}, {"title": "What's Going On With Moderna Stock Monday? - Moderna  ( NASDAQ:MRNA ) ", "url": "https://www.benzinga.com/news/23/08/34072092/whats-going-on-with-moderna-stock-monday", "time_published": "20230828T160337", "authors": ["Henry Khederian"], "summary": "Moderna Inc MRNA shares are trading higher by roughly 2% to $114.12 Monday morning. The stock is rising amid rising COVID-19 cases in the U.S. Rising COVID-19 cases might lead to increased demand for vaccines, including Moderna's.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/08/28/vaccine-4892048.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.222057, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.470894", "ticker_sentiment_score": "0.139977", "ticker_sentiment_label": "Neutral"}]}, {"title": "COVID is evolving quickly in white-tailed deer, study finds", "url": "https://www.marketwatch.com/story/covid-is-evolving-quickly-in-white-tailed-deer-study-finds-a7027d3b", "time_published": "20230828T155300", "authors": ["Eleanor Laise"], "summary": "Mutated virus can jump from animals back to humans, researchers say.", "banner_image": "https://images.mktw.net/im-843082/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.009536, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.144275", "ticker_sentiment_score": "0.185227", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.144275", "ticker_sentiment_score": "0.185227", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVAX", "relevance_score": "0.144275", "ticker_sentiment_score": "0.185227", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Ross Stores, Vertex Pharmaceuticals And 2 Other Stocks Insiders Are Selling - Moderna  ( NASDAQ:MRNA ) , DXC Technology  ( NYSE:DXC ) ", "url": "https://www.benzinga.com/news/23/08/34066417/ross-stores-vertex-pharmaceuticals-and-2-other-stocks-insiders-are-selling", "time_published": "20230828T121711", "authors": ["Lisa Levin"], "summary": "The Nasdaq 100 closed higher on Friday. Investors, meanwhile, focused on some notable insider trades. When insiders sell shares, it could be a preplanned sale, or could indicate their concern in the company's prospects or that they view the stock as being overpriced.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/08/28/ross_stores_-_logo.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.0695, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ROST", "relevance_score": "0.425746", "ticker_sentiment_score": "0.329398", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.425746", "ticker_sentiment_score": "0.017448", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.425746", "ticker_sentiment_score": "-0.137067", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRTHF", "relevance_score": "0.089462", "ticker_sentiment_score": "-0.132682", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXC", "relevance_score": "0.425746", "ticker_sentiment_score": "0.084265", "ticker_sentiment_label": "Neutral"}]}, {"title": "COVID Is Making a Comeback: Should You Buy These 2 Stocks?", "url": "https://www.fool.com/investing/2023/08/27/covid-is-making-a-comeback-should-you-buy-these-2/", "time_published": "20230827T101000", "authors": ["Prosper Junior Bakiny"], "summary": "Can these companies keep up their recent momentum?", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F745407%2Fai-android-black-robot-head.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.538269"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.053059, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVAX", "relevance_score": "0.350564", "ticker_sentiment_score": "0.048029", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.090474", "ticker_sentiment_score": "-0.009538", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.223659", "ticker_sentiment_score": "0.06077", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.468029", "ticker_sentiment_score": "0.112923", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is Alexandria Real Estate Equities a Buy?", "url": "https://www.fool.com/investing/2023/08/26/is-alexandria-real-estate-equities-a-buy/", "time_published": "20230826T091800", "authors": ["Brent Nyitray", "CFA"], "summary": "Great company, attractive valuation, lousy sector.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F745252%2Flaboratory-space.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.413559"}, {"topic": "Earnings", "relevance_score": "0.744043"}, {"topic": "Real Estate & Construction", "relevance_score": "0.5"}], "overall_sentiment_score": 0.190154, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.126784", "ticker_sentiment_score": "0.045025", "ticker_sentiment_label": "Neutral"}, {"ticker": "BXP", "relevance_score": "0.126784", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARE", "relevance_score": "0.31006", "ticker_sentiment_score": "0.173989", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.126784", "ticker_sentiment_score": "0.045025", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.126784", "ticker_sentiment_score": "0.045025", "ticker_sentiment_label": "Neutral"}]}, {"title": "Joe Biden says he will request more funding for a new coronavirus vaccine", "url": "https://www.business-standard.com/world-news/joe-biden-says-he-will-request-more-funding-for-a-new-coronavirus-vaccine-123082600057_1.html", "time_published": "20230826T012312", "authors": ["AP"], "summary": "President Joe Biden said Friday that he is planning to request more money from Congress to develop another new coronavirus vaccine, as scientists track new waves and hospitalizations rise, though not like before.", "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2023-08/25/full/1692962686-212.jpg?im=FeatureCrop,size=(826,465)", "source": "Business Standard", "category_within_source": "GoogleRSS", "source_domain": "www.business-standard.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.113936, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.115787", "ticker_sentiment_score": "-0.020719", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.115787", "ticker_sentiment_score": "-0.020719", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVAX", "relevance_score": "0.115787", "ticker_sentiment_score": "-0.020719", "ticker_sentiment_label": "Neutral"}]}, {"title": "President Joe Biden says he will request more funding for a new coronavirus vaccine", "url": "https://apnews.com/article/covid-biden-pandemic-79d8b3004009a1560744dfc116c4af0a", "time_published": "20230825T213700", "authors": ["SEUNG MIN KIM"], "summary": "SOUTH LAKE TAHOE, California ( AP ) - President Joe Biden said Friday that he is planning to request more money from Congress to develop another new coronavirus vaccine, as scientists track new waves and hospitalizations rise, though not like before.", "banner_image": "https://dims.apnews.com/dims4/default/dd0e23f/2147483647/strip/true/crop/6000x3375+0+312/resize/1440x810!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2Fd2%2Fd1%2Fd11cc2197f56bf5924061aaba41a%2Fd2ebd0aa66fb4efc8b750c778f51bbaf", "source": "Associated Press", "category_within_source": "Business", "source_domain": "apnews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.078371, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.116348", "ticker_sentiment_score": "-0.020762", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.116348", "ticker_sentiment_score": "-0.020762", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVAX", "relevance_score": "0.116348", "ticker_sentiment_score": "-0.020762", "ticker_sentiment_label": "Neutral"}]}, {"title": "Some Older Adults Are Being Charged Over $300 for the New R.S.V. Vaccine", "url": "https://www.nytimes.com/2023/08/25/well/live/rsv-vaccines-health-insurance-medicare.html", "time_published": "20230825T195521", "authors": ["Dana G. Smith"], "summary": "New RSV Vaccines Aren't Covered by Some Health Insurance Plans The New York Times ...", "banner_image": "https://static01.nyt.com/images/2023/08/24/well/WELL-MEDICARE-VACCINE/WELL-MEDICARE-VACCINE-articleLarge.jpg?quality=75&auto=webp&disable=upscale", "source": "New York Times", "category_within_source": "GoogleRSS", "source_domain": "www.nytimes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": 0.116347, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.051999", "ticker_sentiment_score": "-0.015002", "ticker_sentiment_label": "Neutral"}, {"ticker": "NYT", "relevance_score": "0.103778", "ticker_sentiment_score": "0.060009", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.051999", "ticker_sentiment_score": "-0.015026", "ticker_sentiment_label": "Neutral"}]}, {"title": "Moderna Unusual Options Activity - Moderna  ( NASDAQ:MRNA ) ", "url": "https://www.benzinga.com/markets/options/23/08/34047223/moderna-unusual-options-activity", "time_published": "20230825T171556", "authors": ["Benzinga Insights"], "summary": "Someone with a lot of money to spend has taken a bearish stance on Moderna MRNA. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.10833, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.832645", "ticker_sentiment_score": "0.250324", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MS", "relevance_score": "0.09989", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "MRNA: Is Now the Time to Buy Into Moderna, Inc.  ( MRNA ) ?", "url": "https://stocknews.com/news/mrna-alks-gild-otsky-is-now-the-time-to-buy-into-moderna-inc-mrna/", "time_published": "20230825T164132", "authors": ["StockNews.com Staff"], "summary": "COVID-19-related hospitalizations are once again on the rise due to the onslaught of new subvariants. Vaccine-maker Moderna, Inc. ( MRNA ) announced that an initial study shows that its updated vaccine is effective against the EG.5 ( Eris ) and FL 1.5.1 ( Fornax ) subvariants.", "banner_image": "https://stocknews.com/wp-content/uploads/2022/03/shutterstock_745024336-scaled.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Earnings", "relevance_score": "0.890401"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.105101, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.597862", "ticker_sentiment_score": "0.078067", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALKS", "relevance_score": "0.051386", "ticker_sentiment_score": "0.166452", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.051386", "ticker_sentiment_score": "0.166452", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Market Suffers Big Reversal Amid Nvidia, Powell: Weekly Review", "url": "https://www.investors.com/news/market-rally-attempt-suffers-big-reversal-nvidia-earnings-powell-speech/", "time_published": "20230825T151600", "authors": ["IBD STAFF", "Investor's Business Daily"], "summary": "A stock market rally attempt gained momentum to start the week, but then suffered an ugly reversal Thursday after initially gaining as Nvidia ( NVDA ) crushed views and sharply raised guidance yet again. NVDA erased post-earnings gains but was up sharply for the week, although many AI plays fell ...", "banner_image": "https://www.investors.com/wp-content/uploads/2021/09/Stock-nvidia-bluefield-01-company.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.99793"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Real Estate & Construction", "relevance_score": "0.2"}], "overall_sentiment_score": -0.061164, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVDA", "relevance_score": "0.226477", "ticker_sentiment_score": "-0.140539", "ticker_sentiment_label": "Neutral"}, {"ticker": "INTU", "relevance_score": "0.057352", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADSK", "relevance_score": "0.057352", "ticker_sentiment_score": "0.110961", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNOW", "relevance_score": "0.114409", "ticker_sentiment_score": "-0.01592", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADI", "relevance_score": "0.057352", "ticker_sentiment_score": "0.019005", "ticker_sentiment_label": "Neutral"}, {"ticker": "FL", "relevance_score": "0.142734", "ticker_sentiment_score": "-0.282805", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "BIDU", "relevance_score": "0.085936", "ticker_sentiment_score": "0.269697", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DKS", "relevance_score": "0.114409", "ticker_sentiment_score": "-0.253749", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "M", "relevance_score": "0.057352", "ticker_sentiment_score": "-0.219811", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "WDAY", "relevance_score": "0.085936", "ticker_sentiment_score": "-0.01458", "ticker_sentiment_label": "Neutral"}, {"ticker": "URBN", "relevance_score": "0.085936", "ticker_sentiment_score": "0.147398", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTES", "relevance_score": "0.057352", "ticker_sentiment_score": "-0.051436", "ticker_sentiment_label": "Neutral"}, {"ticker": "TOL", "relevance_score": "0.057352", "ticker_sentiment_score": "0.353129", "ticker_sentiment_label": "Bullish"}, {"ticker": "ZM", "relevance_score": "0.085936", "ticker_sentiment_score": "0.154459", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GES", "relevance_score": "0.085936", "ticker_sentiment_score": "0.147398", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPR", "relevance_score": "0.085936", "ticker_sentiment_score": "-0.278118", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ANF", "relevance_score": "0.114409", "ticker_sentiment_score": "0.14178", "ticker_sentiment_label": "Neutral"}, {"ticker": "MNSO", "relevance_score": "0.114409", "ticker_sentiment_score": "0.180558", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SPLK", "relevance_score": "0.057352", "ticker_sentiment_score": "0.138316", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.085936", "ticker_sentiment_score": "-0.103865", "ticker_sentiment_label": "Neutral"}, {"ticker": "BA", "relevance_score": "0.142734", "ticker_sentiment_score": "-0.204153", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MRVL", "relevance_score": "0.057352", "ticker_sentiment_score": "0.019005", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:USD", "relevance_score": "0.028695", "ticker_sentiment_score": "0.121177", "ticker_sentiment_label": "Neutral"}]}, {"title": "US CDC advisers set to vote on updated COVID vaccines next month", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/us-cdc-advisers-set-vote-updated-covid-vaccines-next-month-2023-08-25/", "time_published": "20230825T145900", "authors": ["Reuters"], "summary": "[1/2] A vial labelled \"VACCINE Coronavirus COVID-19\" is seen in front of a stock graph in this illustration taken on January 17, 2022. REUTERS/Dado Ruvic/Illustration/File Photo Acquire Licensing Rights", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/IAGIIZRW2JKQHJPYYR3W4J26UA.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.037513, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVAX", "relevance_score": "0.231332", "ticker_sentiment_score": "-0.059775", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.231332", "ticker_sentiment_score": "-0.059775", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.231332", "ticker_sentiment_score": "-0.059775", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.231332", "ticker_sentiment_score": "-0.059775", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pfizer's  ( PFE )  RSV Vaccine Abrysvo Gets Approval in EU", "url": "https://www.zacks.com/stock/news/2140757/pfizers-pfe-rsv-vaccine-abrysvo-gets-approval-in-eu", "time_published": "20230825T134300", "authors": ["Zacks Equity Research"], "summary": "Pfizer's (PFE) RSV vaccine, Abrysvo, gets approval in Europe to protect infants through maternal immunization as well as for older adults.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/5d/2633.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.261592, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.135347", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.201803", "ticker_sentiment_score": "0.26956", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.390904", "ticker_sentiment_score": "0.312051", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNY", "relevance_score": "0.135347", "ticker_sentiment_score": "0.209151", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Gilead Sciences, Novavax, Apellis Pharmaceuticals and Fulcrum Therapeutics", "url": "https://www.zacks.com/stock/news/2140807/the-zacks-analyst-blog-highlights-regeneron-pharmaceuticals-gilead-sciences-novavax-apellis-pharmaceuticals-and-fulcrum-therapeutics", "time_published": "20230825T131600", "authors": ["Zacks Equity Research"], "summary": "Regeneron Pharmaceuticals, Gilead Sciences, Novavax, Apellis Pharmaceuticals and Fulcrum Therapeutics are part of the Zacks top Analyst Blog.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c9/2325.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.148916, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "APLS", "relevance_score": "0.10087", "ticker_sentiment_score": "0.038774", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.10087", "ticker_sentiment_score": "0.054348", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVAX", "relevance_score": "0.200134", "ticker_sentiment_score": "0.040362", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.067347", "ticker_sentiment_score": "0.030389", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.10087", "ticker_sentiment_score": "0.059516", "ticker_sentiment_label": "Neutral"}, {"ticker": "FULC", "relevance_score": "0.10087", "ticker_sentiment_score": "0.062715", "ticker_sentiment_label": "Neutral"}]}, {"title": "Updated Covid-19 vaccines are coming mid-September, officials say", "url": "https://www.cnn.com/2023/08/25/health/covid-vaccine-release/index.html", "time_published": "20230825T122500", "authors": ["Brenda Goodman"], "summary": "Covid-19 vaccines that have been tweaked to teach the body how to fend off the current crop of circulating variants are now expected to land in drugstores and clinics in mid-September, CDC and FDA officials said.", "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/230817230825-covid-vaccine-arm-wellness.jpg?c=16x9&q=h_144,w_256,c_fill", "source": "CNN", "category_within_source": "Markets", "source_domain": "www.cnn.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}], "overall_sentiment_score": 0.134321, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "WBD", "relevance_score": "0.092569", "ticker_sentiment_score": "0.067661", "ticker_sentiment_label": "Neutral"}, {"ticker": "CVS", "relevance_score": "0.046363", "ticker_sentiment_score": "0.081761", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVAX", "relevance_score": "0.138464", "ticker_sentiment_score": "0.010039", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.092569", "ticker_sentiment_score": "0.008502", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.092569", "ticker_sentiment_score": "0.008502", "ticker_sentiment_label": "Neutral"}, {"ticker": "WMT", "relevance_score": "0.046363", "ticker_sentiment_score": "0.081761", "ticker_sentiment_label": "Neutral"}]}, {"title": "CDC expects new Covid vaccines from Pfizer, Moderna and Novavax to be available in mid-September", "url": "https://www.cnbc.com/2023/08/25/covid-vaccines-cdc-expects-new-shots-to-be-available-in-mid-september.html", "time_published": "20230825T090602", "authors": ["Annika Kim Constantino"], "summary": "The updated Covid vaccines from Pfizer, Moderna and Novavax still need green lights from the FDA and the CDC before they roll out to the public.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107154198-1668785334763-gettyimages-1243314474-20090101220918-99-802870.jpeg?v=1692954362&w=1920&h=1080", "source": "CNBC", "category_within_source": "Top News", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.004822, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.158519", "ticker_sentiment_score": "-0.00816", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.158519", "ticker_sentiment_score": "-0.00816", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVAX", "relevance_score": "0.158519", "ticker_sentiment_score": "-0.00816", "ticker_sentiment_label": "Neutral"}]}, {"title": "Catalent  ( CTLT )  to Report Q4 Earnings: What's in the Cards?", "url": "https://www.zacks.com/stock/news/2140444/catalent-ctlt-to-report-q4-earnings-whats-in-the-cards", "time_published": "20230824T162800", "authors": ["Zacks Equity Research"], "summary": "Catalent's (CTLT) Q4 results are likely to be affected by soft segmental performances.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/df/34747.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.999994"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.074034, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AEO", "relevance_score": "0.131884", "ticker_sentiment_score": "0.107564", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.044141", "ticker_sentiment_score": "0.097135", "ticker_sentiment_label": "Neutral"}, {"ticker": "PDCO", "relevance_score": "0.175221", "ticker_sentiment_score": "0.057319", "ticker_sentiment_label": "Neutral"}, {"ticker": "SRPT", "relevance_score": "0.044141", "ticker_sentiment_score": "0.097135", "ticker_sentiment_label": "Neutral"}, {"ticker": "CTLT", "relevance_score": "0.45738", "ticker_sentiment_score": "0.139936", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMWD", "relevance_score": "0.131884", "ticker_sentiment_score": "0.096869", "ticker_sentiment_label": "Neutral"}]}, {"title": "With Healthier Finances, Clover Bio Shifts To Flu And RSV Vaccines - Moderna  ( NASDAQ:MRNA ) , Sanofi  ( NASDAQ:SNY ) ", "url": "https://www.benzinga.com/23/08/34027210/with-healthier-finances-clover-bio-shifts-to-flu-and-rsv-vaccines", "time_published": "20230824T153318", "authors": ["The Bamboo Works"], "summary": "Clover Biopharmaceuticals posted a surge in first-half earnings after a $384 million grant for Covid vaccine development was belatedly folded into its accounts The company has turned its attention to flu vaccines after being hit by waning demand in the crowded Covid market", "banner_image": "https://cdn.benzinga.com/files/clover-bio.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.99676"}, {"topic": "Earnings", "relevance_score": "0.838487"}], "overall_sentiment_score": 0.06027, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "HUATF", "relevance_score": "0.03463", "ticker_sentiment_score": "-0.087412", "ticker_sentiment_label": "Neutral"}, {"ticker": "SZIHF", "relevance_score": "0.03463", "ticker_sentiment_score": "-0.056907", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.069194", "ticker_sentiment_score": "-0.110432", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.069194", "ticker_sentiment_score": "-0.026287", "ticker_sentiment_label": "Neutral"}]}, {"title": "Michigan Teen Who Died 3 Days After Covid Vaccination Actually Killed By Bacterial Infection, CDC Reportedly Finds", "url": "https://www.forbes.com/sites/maryroeloffs/2023/08/24/michigan-teen-who-died-3-days-after-covid-vaccination-actually-killed-by-bacterial-infection-cdc-reportedly-finds/", "time_published": "20230824T150121", "authors": ["Mary Whitfill Roeloffs"], "summary": "A CDC report says Jacob Clynick did not die of vaccine-related causes, the Detroit Free Press reported Thursday, but the medical examiner who performed his autopsy stands by his findings.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/64e76f877a8284c8340f2e72/0x0.jpg?format=jpg&width=1200", "source": "Forbes", "category_within_source": "Business", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}], "overall_sentiment_score": -0.218761, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.047749", "ticker_sentiment_score": "-0.182723", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "TSLA", "relevance_score": "0.047749", "ticker_sentiment_score": "-0.182723", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MRNA", "relevance_score": "0.047749", "ticker_sentiment_score": "-0.066", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.095327", "ticker_sentiment_score": "-0.072826", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biotech Stock Roundup: REGN Up on Approval, APLS, NVAX Gain on Updates & More", "url": "https://www.zacks.com/stock/news/2140318/biotech-stock-roundup-regn-up-on-approval-apls-nvax-gain-on-updates-more", "time_published": "20230824T141500", "authors": ["Zacks Equity Research"], "summary": "Regulatory updates from Regeneron (REGN) and Apellis (APLS) are in focus in the biotech sector.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/88/898.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.153817, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "APLS", "relevance_score": "0.071463", "ticker_sentiment_score": "0.075322", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.071463", "ticker_sentiment_score": "0.112486", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVAX", "relevance_score": "0.17741", "ticker_sentiment_score": "0.058468", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.071463", "ticker_sentiment_score": "0.030591", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.071463", "ticker_sentiment_score": "0.143951", "ticker_sentiment_label": "Neutral"}, {"ticker": "FULC", "relevance_score": "0.071463", "ticker_sentiment_score": "0.136884", "ticker_sentiment_label": "Neutral"}]}, {"title": "PM360 Announces 2023 Trailblazer Award Finalists", "url": "https://www.prnewswire.com/news-releases/pm360-announces-2023-trailblazer-award-finalists-301907769.html", "time_published": "20230824T130000", "authors": ["PM360"], "summary": "Top Companies, Marketers, CEOs, Products, and Initiatives to be Honored During Gala on October 3rd NEW YORK, Aug. 24, 2023 /PRNewswire/ -- PM360 has announced the finalists for its 15th annual Trailblazer Awards.", "banner_image": "https://mma.prnewswire.com/media/545940/PM360_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.284744, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GDRX", "relevance_score": "0.027747", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "OPRX", "relevance_score": "0.013876", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.04161", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NBIX", "relevance_score": "0.027747", "ticker_sentiment_score": "0.27629", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SUPN", "relevance_score": "0.013876", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SYNH", "relevance_score": "0.013876", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TARS", "relevance_score": "0.027747", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CDNA", "relevance_score": "0.013876", "ticker_sentiment_score": "-0.066083", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRTX", "relevance_score": "0.013876", "ticker_sentiment_score": "-0.24502", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PFE", "relevance_score": "0.04161", "ticker_sentiment_score": "0.075016", "ticker_sentiment_label": "Neutral"}, {"ticker": "UTHR", "relevance_score": "0.013876", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVCR", "relevance_score": "0.013876", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SLGC", "relevance_score": "0.013876", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVAX", "relevance_score": "0.027747", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.04161", "ticker_sentiment_score": "0.080752", "ticker_sentiment_label": "Neutral"}, {"ticker": "TVTX", "relevance_score": "0.027747", "ticker_sentiment_score": "0.23749", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MCRB", "relevance_score": "0.027747", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MAYNF", "relevance_score": "0.013876", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALNY", "relevance_score": "0.013876", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "APLS", "relevance_score": "0.013876", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.027747", "ticker_sentiment_score": "-0.073367", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLCO", "relevance_score": "0.013876", "ticker_sentiment_score": "0.273432", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DVAX", "relevance_score": "0.013876", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.013876", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.027747", "ticker_sentiment_score": "-0.071498", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.027747", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.083107", "ticker_sentiment_score": "-0.072498", "ticker_sentiment_label": "Neutral"}, {"ticker": "SSUMF", "relevance_score": "0.013876", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CHRS", "relevance_score": "0.04161", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.013876", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARGX", "relevance_score": "0.05546", "ticker_sentiment_score": "0.086858", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.013876", "ticker_sentiment_score": "0.202947", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TXMD", "relevance_score": "0.013876", "ticker_sentiment_score": "0.349415", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NSRGF", "relevance_score": "0.027747", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TAK", "relevance_score": "0.013876", "ticker_sentiment_score": "-0.187445", "ticker_sentiment_label": "Somewhat-Bearish"}]}]}